0001144204-13-019057.txt : 20130401 0001144204-13-019057.hdr.sgml : 20130401 20130401151309 ACCESSION NUMBER: 0001144204-13-019057 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20121231 FILED AS OF DATE: 20130401 DATE AS OF CHANGE: 20130401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADHEREX TECHNOLOGIES INC CENTRAL INDEX KEY: 0001211583 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32295 FILM NUMBER: 13730740 BUSINESS ADDRESS: STREET 1: 4620 CREEKSTONE DRIVE STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-484-8484 MAIL ADDRESS: STREET 1: 4620 CREEKSTONE DRIVE STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 10-K 1 v337350_10k.htm 10-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 10-K

 

 

 

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2012

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from____ to ____

Commission File Number: 001-32295

 

 

 

ADHEREX TECHNOLOGIES INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Canada 20-0442384
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization Identification No.)
   
PO Box 13628, 68 TW Alexander Drive  
Research Triangle Park, NC 27709
(Address of Principal Executive Offices) (Zip Code)

(919) 636-4530

(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act:  None

 

 

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  YES ¨   NO x

 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  YES ¨   NO x

 

Indicate by check mark whether the Registrant:  (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES x   NO ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x   No¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.   x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): 

 

Large accelerated filer  ¨   Accelerated filer  ¨  

Non-accelerated filer  ¨

(Do not check if a smaller

reporting company)

   Smaller reporting company  x

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES ¨   NO x

 

The aggregate market value of the voting stock held by non-affiliates of the Registrant, computed by reference to the closing sales price of the Common Shares as reported by the OTCQB on June 30, 2012 (the last business day of the Registrant’s most recently completed second fiscal quarter) was $1,401,073 based upon a total of 9,340,489 sharesheld as of June 30, 2012 by persons believed to be non-affiliates of the Registrant (for purposes of this calculation, all of the Registrant’s officers, directors and 10% owners known to the Company are deemed to be affiliates of the Registrant).

 

As of March 16, 2013, there were 25,157,618 shares of Adherex Technologies Inc. common stock outstanding.

 

 
 

 

ADHEREX TECHNOLOGIES INC.

2012 FORM 10-K ANNUAL REPORT

TABLE OF CONTENTS

 

    Page
PART I    
Item 1. Business 1
Item 1A. Risk Factors 8
Item 1B. Unresolved Staff Comments 16
Item 2. Properties 17
Item 3. Legal Proceedings 17
Item 4. Mine Safety Disclosures 17
     
PART II    
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities 18
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 22
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 28
Item 8. Financial Statements and Supplementary Data 28
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 28
Item 9A. Controls and Procedures 28
Item 9B. Other Information 29
     
PART III    
Item 10. Directors, Executives Officers and Corporate Governance 30
Item 11. Executive Compensation 32
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 35
Item 13. Certain Relationships and Related Transactions, and Director Independence 36
Item 14. Principal Accounting Fees and Services 37
     
PART IV    
Item 15. Exhibits and Financial Statement Schedules 38
     
SIGNATURES   40

 

 
 

 

NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements that involve significant risks and uncertainties.  Our actual results, performance or achievements may be materially different from any results, performance or achievements expressed or implied by such forward-looking statements.  Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “project,” “plan,” and other similar words are one way to identify such forward-looking statements.  Forward-looking statements in this Annual Report include, but are not limited to, statements with respect to (1) our anticipated sources and uses of cash and cash equivalents; (2) our anticipated commencement dates, completion dates and results of clinical trials; (3) our efforts to pursue collaborations with the government, industry groups or other companies; (4) our anticipated progress and costs of our clinical and preclinical research and development programs; (5) our corporate and development strategies; (6) our expected results of operations; (7) our anticipated levels of expenditures; (8) our ability to protect our intellectual property; (9) our ability to fully comply with domestic and international governmental regulation; (10) the anticipated applications and efficacy of our drug candidates; (11) the nature and scope of potential markets for our drug candidates; (12) future legal liability; and (13) our ability to attract and retain key employees.   All statements, other than statements of historical fact, included in this Annual Report that address activities, events or developments that we expect or anticipate will or may occur in the future are forward-looking statements.  We include forward-looking statements because we believe that it is important to communicate our expectations to our investors.  However, all forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties, including specifically our need to raise money in the very near term and others, as discussed below in Item 1.A., “Risk Factors.”  Although we believe the expectations reflected in the forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be attained, and we caution you not to place undue reliance on such statements.

 

Our periodic and current reports are available, free of charge, after the material is electronically filed with, or furnished to, the SEC and EDGAR at http://www.sec.gov/edgar and the Canadian securities regulators on SEDAR, at www.sedar.com .  The information provided on our website is not part of this annual report and is therefore not incorporated herein by reference.

 

Item 1.   Business.

Overview

 

Adherex Technologies Inc. is a biopharmaceutical company focused on cancer therapeutics. We incorporated under the Canada Business Corporations Act ("CBCA”) in September 1996. Effective on August 25, 2011, the Company continued from the Canada Business Corporations Act to the Business Corporations Act (British Columbia) (the “Continuance”), which Continuance was approved by the shareholders of Adherex at the Company's June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have three wholly-owned subsidiaries: Oxiquant, Inc. and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc., a Canadian company.With the exception of Adherex Inc. all subsidiaries are inactive.

 

On August 25, 2011, Adherex filed Articles of Amendment under the CBCA to implement an eighteen-for-one reverse stock split of our common stock (defined herein as the “Share Consolidation”). As a result of the Share Consolidation, every eighteen shares of common stock outstanding on August 25, 2011 were combined into one share of common stock. Our common stock began trading on the Toronto Stock Exchange and the OTC market (on the OTCQB tier) on a post-Share Consolidation basis on August 30, 2011. The Share Consolidation reduced the number of shares of the Company's outstanding common stock from approximately 452.8 million, to approximately 25.2 million as of August 25, 2011, the effective date of the Share Consolidation. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis.

 

In the Annual Report, unless otherwise indicated, (i) the number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and our March 11, 2011 rights offering (the “Rights Offering”)) have not been adjusted to reflect the Share Consolidation, (ii) the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding) and (iii) the number of shares outstanding, common stock issuable upon exercise or conversion of our warrants, options and other derivative securities (including the Warrant Shares), all exercise or conversion prices with respect thereto, and all market prices and over-the-counter quotations of our common stock have been adjusted to reflect the Share Consolidation.

 

Eniluracil

 

Eniluracil was previously under development by GlaxoSmithKline. GlaxoSmithKline advanced Eniluracil into a comprehensive Phase III clinical development program that did not produce positive results and GlaxoSmithKline terminated further development. We developed a hypothesis as to why the GlaxoSmithKline Phase III trials were not successful and licensed the compound from GlaxoSmithKline in July 2005. We believe that Eniluracil might enhance and expand the therapeutic spectrum of activity of 5-FU, reduce the occurrence of a disabling side effect known as hand foot syndrome and allow 5-FU to be given orally. In April of 2011, we commenced a Phase II trial comparing the anti-tumor activity and safety of completely oral Eniluracil plus 5-FU and leucovorin regimen (treatment Arm 1) versus Xeloda® (capecitabine) (treatment Arm 2) for Metastatic Breast Cancer. Patients who have disease progression in Arm 2 may crossover to take Eniluracil plus 5-FU and leucovorin (Treatment Arm X).We expect results from the trial to be indicative of the future viability of Eniluracil and will allow us to assess whether further development and testing of enliuracil is warranted. The Phase II trial completed enrollment in Russia and the United States at the end of December 2012 after having enrolled 153 patients. Adherex anticipates final efficacy and safety data to be available during the second or third quarter of 2013.

 

1
 

 

Eniluracil is an irreversible inhibitor of DPD, the enzyme primarily responsible for the rapid breakdown of 5-FU in the body. Eniluracil is being developed by Adherex to improve the therapeutic value of 5-FU by making it more effective in cancers while reducing the debilitating side effects.

 

While 5-FU is a current mainstay of contemporary oncology treatment, it has some therapeutic drawbacks and limitations; including that 5-FU:

 

ϖis given by vein (intravenously) and often by prolonged, multi-day infusions;

 

ϖproduces highly variable blood levels in patients. Low levels can reduce its effectiveness and high levels can increase its side effects; and

 

ϖis broken down (catabolized) to form α-fluoro-β-alanine, or F-BAL. This compound appears to cause neurotoxicity and “hand-foot syndrome” which are debilitating and dose-limiting side effects of 5-FU therapy. Importantly, F-BAL also decreases the antitumor activity of 5-FU in lab animals.

 

Eniluracil: Mechanism of Action

 

By inactivating DPD, Eniluracil prevents the breakdown of 5-FU to F-BAL. Eniluracil also greatly prolongs exposure of the tumor cells to 5-FU. When Eniluracil is properly used in combination with 5-FU, it resolves many of the therapeutic drawbacks and limitations of 5-FU noted above. For instance, we believe Eniluracil: 

 

ϖenables 5-FU to be dosed orally;

 

ϖconverts highly variable blood levels of 5-FU to highly consistent and predictable levels;

 

ϖextends the elimination half-life of 5-FU from about 10 minutes to about 5 hours; and

 

ϖprevents the formation of F-BAL, which is the apparent causative agent for hand-foot syndrome and for 5-FU-induced neurotoxicity. F-BAL also decreases the antitumor efficacy of 5-FU in lab animals.

 

Thus, Eniluracil has the potential to make 5-FU more effective and better tolerated.

 

Eniluracil: Clinical Development

 

Eniluracil plus 5-FU was previously being developed by GlaxoSmithKline. Although the therapy was successful in Phase I and Phase II clinical trials, it tended to produce less antitumor activity than the control therapy in two Phase III trials. Development was subsequently stopped.

 

We believe that the dose and schedule used in the previous GlaxoSmithKline Phase III trials may not have been optimal. Preclinical studies have shown that when Eniluracil is present in high ratios to 5-FU, it decreases the antitumor activity. In the GlaxoSmithKline Phase III trials, the ratio of Eniluracil to 5-FU was 10 to 1.

 

Our Chief Scientific Officer, Dr. Spector, is the principal inventor of Eniluracil/5-FU treatment and has over 20 years of experience with Eniluracil. Dr. Spector has created a revised protocol designed to avoid the problems of the earlier GlaxoSmithKline Phase III trials as well as those encountered in our more recent trials.

 

Sodium Thiosulfate (STS)

 

STS is currently marketed for use in humans as part of a treatment for cyanide poisoning. We have licensed from Oregon Health & Science University intellectual property rights for the use of STS as a chemoprotectant, and are developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. Preclinical and clinical studies conducted by Oregon Health & Science University and others have indicated that STS can effectively reduce the incidence of hearing loss caused by platinum-based anti-cancer agents. We have received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients.

 

Hearing loss among children receiving platinum-based chemotherapy is frequent, permanent and often severely disabling. The incidence of hearing loss in these children depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. In addition, adults undergoing chemotherapy for several common malignancies, including ovarian cancer, testicular cancer, and particularly head and neck cancer and brain cancer, often receive intensive platinum-based therapy and may experience severe, irreversible hearing loss, particularly in the high frequencies.

 

Investigators at Oregon Health & Science University have conducted Phase I and Phase II studies which have shown STS reduces the hearing loss associated with platinum-based chemotherapy. In one study at Oregon Health & Science University, the need for hearing aids to correct high frequency hearing loss was reduced from about 50% to less than 5%.

 

2
 

 

In October 2007, we announced that our collaborative partner, the International Childhood Liver Tumour Strategy Group, known as SIOPEL, a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology, had launched a randomized Phase III clinical trial to investigate whether STS reduces hearing loss in children receiving cisplatin, a platinum-based chemotherapy often used in children. The study initially opened in the United Kingdom and now includes SIOPEL centers in several additional countries. The clinical trial is expected to enroll approximately 100 children with liver (hepatoblastoma) cancer. Patients will receive cisplatin alone or cisplatin plus STS. The study, which is being coordinated through the Children’s Cancer and Leukemia Group in the United Kingdom, is intended to compare the level of hearing loss associated with cisplatin alone versus the combination of cisplatin plus STS, as well as the safety, tolerability and anti-tumor activity in both arms of the study. Under the terms of our agreement, SIOPEL will conduct and fund the clinical activity and we will provide drug, drug distribution and pharmacovigilance, or safety monitoring, for the study. Since the commencement of the study in 2007, the study has enrolled 69 patients.

 

In March 2008, we announced the activation of a Phase III trial with STS to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children’s Oncology Group. The goal of this Phase III study is to evaluate in a multi-centered, randomized trial whether STS is an effective and safe means of preventing hearing loss in children receiving cisplatin-based chemotherapy for newly diagnosed germ cell, liver (hepatoblastoma), brain (medulloblastoma), nerve tissue (neuroblastoma) or bone (osteosarcoma) cancers. Eligible children, one to eighteen years of age, who are to receive cisplatin according to their disease-specific regimen and, upon enrollment in this study, will be randomized to receive STS or not. Efficacy of STS will be determined through comparison of hearing sensitivity at follow-up relative to baseline measurements using standard audiometric techniques. The Children’s Oncology Group will fund the clinical activities for the study and we will be responsible for providing the drug, drug distribution and pharmacovigilance, or safety monitoring, for the study.The Company's Children Oncology Group study completed enrollment of 135 pediatric patients in the first half of 2012. Final efficacy and safety data is expected during the second or third quarter of 2013.

 

Intellectual Property

 

Patents are important to developing and protecting our competitive position. Our general policy is to seek patent protection in the United States, major European countries, Japan, Canada and other jurisdictions as appropriate for our compounds and methods. U.S. patents, as well as most foreign patents, are generally effective for 20 years from the date the earliest (priority) application was filed; however, U.S. patents that issue on applications filed before June 8, 1995 may be effective until 17 years from the issue date, if that is later than the 20 year date. In some cases, the patent term may be extended to recapture a portion of the term lost during FDA regulatory review or because of U.S. Patent and Trademark Office, or USPTO, delays in prosecuting the application. The duration of foreign patents varies similarly, in accordance with local law.

 

Currently, we own or have licensed 16 issued patents world-wide. We have been issued 6 U.S. and 10 foreign patents, and we have 26 patents pending throughout the world. In regards to Eniluracil, we have licensed from GlaxoSmithKline 4 U.S. patents. In addition, not covered by the licensing agreement with GlaxoSmithKline, we have been issued 1 U.S. patent and 2 foreign patents and are currently prosecuting 3 U.S. and an additional 20 foreign patents. In regards to STS, we have licensed from Oregon Health and Science University 1 U.S. and 8 foreign patents, with an additional 3 patents pending.

 

In addition, periods of marketing exclusivity for STS may also be possible in the United States under orphan drug status. We obtained U.S. Orphan Drug Designation for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients in 2004.

 

Our success is significantly dependent on our ability to obtain and maintain patent protection for our product candidates, both in the United States and abroad. The patent position of biotechnology and pharmaceutical companies, in general, is highly uncertain and involves complex legal and factual questions, which often results in apparent inconsistencies regarding the breadth of claims allowed and general uncertainty as to their legal interpretation and enforceability. Further, some of our principal candidates, including STS, are based on previously known compounds, and candidates or products that we develop in the future may include or be based on the same or other compounds owned or produced by other parties, some or all of which may not be subject to effective patent protection. In addition, regimens that we may develop for the administration of pharmaceuticals, such as specifications for the frequency, timing and amount of dosages, may not be patentable. Accordingly, our patent applications may not result in patents being issued and issued patents may not afford effective protection. In addition, products or processes that we develop may turn out to be covered by third party patents, in which case we may require a license under such patents if we intend to continue the development of those products or processes.

 

Our patent position and proprietary rights are subject to certain risks and uncertainties. Please read the “Risk Factors” section of this Annual Report for information about certain risks and uncertainties that may affect our patent position and proprietary rights.

 

We also rely upon unpatented confidential information to remain competitive. We protect such information principally through confidentiality agreements with our employees, consultants, outside scientific collaborators, and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment shall be our exclusive property.

 

3
 

 

Corporate Relationships

 

License Agreement with Oregon Health & Science University

 

On February 20, 2013, Adherex entered into a new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans (the "New OHSU Agreement"). Under the New OHSU Agreement, OHSU will receive certain milestone payments, a 2.5 percent royalty on net sales for licensed products which can be reduced to 1.0 percent upon a $150,000 buy down and a 5 percent royalty on any consideration received from sublicensing of the licensed technology. Milestone payment fees payable to OHSU under the New OHSU Agreement include $100,000 upon our first commercial sale of STS.

 

On February 20, 2013, Adherex terminated the previous exclusive license agreement with Oregon Health & Science University and Oxiquant a wholly owned subsidiary of Adherex, dated September 26, 2002 (the "Previous OHSU Agreement"). Pursuant to the Previous OHSU Agreement, OHSU granted Oxiquant an exclusive worldwide license to intellectual property directed to thiol-based compounds including STS and their use in oncology. In consideration, Oregon Health & Science University was issued 13,902 shares of common stock of Oxiquant that were subsequently converted upon the acquisition of Oxiquant into 21,250 shares of Adherex common stock, and warrants to purchase shares of Adherex common stock that subsequently expired in 2007. In addition under the Previous OHSU Agreement, the following milestone payments were included in the agreement: (i) $50,000 upon completion of Phase I clinical trials, (ii) $200,000 upon completion of Phase II clinical trials, (iii) $500,000 upon completion of Phase III clinical trials. Also, Oxiquant was to be liable for an additional milestone payment of $250,000 upon the first commercial sale for any licensed product. Further, the Previous OHSU Agreement required Adherex to pay Oregon Health & Science University a 2.5% royalty on net sales of any licensed products and a 15% royalty on any consideration received from sublicensing of the licensed technology.

 

The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to us, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that we exclusively licensed from OHSU that expire in Europe, Canada and Australia in 2021 and are currently pending in the United States and Japan. The New OHSU Agreement is terminable by either Adherex or Oregon Health & Science University in the event of a material breach of the agreement by either party after 45 days prior written notice. Adherex has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

 

Development and License Agreement with GlaxoSmithKline

 

On July 14, 2005, we entered into a development and license agreement with GlaxoSmithKline, or GSK.  The agreement included the in-license by our Company of GSK’s oncology product, Eniluracil, and an option for GSK to license ADH-1, a compound we are no longer developing.  As part of the transaction, GSK invested $3.0 million in our Company's common stock.  On October 11, 2006, the GSK option to license ADH-1 expired unexercised.  Under the terms of the agreement relating to Eniluracil, we received an exclusive license to develop Eniluracil for all indications and GSK retained options to buy-back and assume development of the compound at various points in time.

 

On March 1,2007, the GSK agreement was amended and we purchased all of GSK’s remaining buy-back options for a fee of $1.0 million.  As a resultof the amendment to the GSK agreement, we now may be required to pay GSK development and sales milestones and royalties until the last applicable licensed GSK patent expires.  Specifically, if we file a New Drug Application, or NDA, with the Food and Drug Administration, or FDA, we may be required to pay development milestones of $5.0 million to GSK.  Additionally, depending upon whether the NDA is approved by the FDA and whether Eniluracil becomes a commercial success, we may be required to pay up to an additional $70.0 million in development and sales milestones for the initially approved indication, plus royalties in the low-double digit range based on annual net sales. If we pursue other indications, we may also be required to pay up to an additional $15.0 million to GSK for each FDA-approved indication. The GSK agreement continues until the earliest of (i) the licensed patents expire or (ii) is terminated by either party in the event of an uncured breach by the breaching party after 60 days prior written notice.

 

Collaboration Agreement with McGill University

 

In February 2001, we entered into a general collaboration agreement with McGill University. Pursuant to the terms of the agreement, McGill granted us a 27-year exclusive worldwide license to develop, use and market certain cell adhesion technology and compounds. In particular, McGill granted us an exclusive worldwide license to U.S. Patent 6,031,072 covering specific compounds including ADH-1 (composition of matter), U.S. Patent 6,551,994 covering alpha-catenin and beta-catenin inhibiting compounds, related international filings under the Patent Cooperation Treaty, or PCT, continuations and certain other patents and patent applications.

 

In consideration, we issued 28,245 shares of our common stock to McGill. We also agreed to pay to McGill future royalties of 2% of any gross revenues from the use of the technology and compounds. In addition, we agreed to fund research at McGill over a period of 10 years totaling CAD$3.3 million. Annual funding commenced in 2001, the first year of the agreement, for a total of CAD$200,000, and increased annually by 10% through 2010, when the required annual funding reached CAD$500,000.

 

The general collaboration agreement with McGill University was terminated on November 19, 2009. All remaining costs were forgiven, and we returned all licenses granted in the agreement to McGill. We continue to hold various ADH-1 method of use and small molecule patents that are property of Adherex.

 

4
 

 

Competition

 

Competition in the biotechnology and pharmaceutical industries is intense. We expect that if any of our product candidates achieve regulatory approval for sale, they will compete on the basis of drug efficacy, safety, patient convenience, reliability, ease of manufacture, price, marketing, distribution and patent protection, among other variables. Our competitors may develop technologies or drugs that are more effective, safer or more affordable than any we may develop.

 

There are a number of different approaches to the development of therapeutics for the treatment of cancer that are currently being used and studied. These approaches include: (i) surgery to excise the cancerous tissue; (ii) radiation therapy, which attacks cancerous cells but does not easily distinguish between healthy and diseased cells; (iii) chemotherapy, which works by preventing a cancerous cell from dividing or by killing cells that quickly divide; (iv) immunotherapy, which stimulates the body’s immune system to respond to the disease; and (v) hormone therapy, which may slow the growth of cancer cells or even kill them.

 

We are aware of a number of companies engaged in the research, development and testing of new cancer therapies or means of increasing the effectiveness of existing therapies, including, among many others, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Eisai, Merck KGaA, Novartis, Johnson & Johnson, Onyx, Pfizer, Roche, Taiho and Sanofi-Aventis. Some of these companies have products that have already received, or are in the process of receiving, regulatory approval or are in later stages of clinical development than our products. Many of them have much greater financial resources than we do. Many of these companies have marketed drugs or are developing targeted cancer therapeutics which, depending upon the mechanism of action of such agents, could be viewed as competitors.

 

There are several potential therapies that may be competitive to Eniluracil, including capecitabine (Xeloda®) which is an oral pro-drug of 5-FU marketed by Roche that is converted to 5-FU following absorption from the gastrointestinal tract. Capecitabine is approved by the FDA and many other regulatory agencies worldwide for use in breast and colorectal cancer, but Eniluracil/5-FU has a potential competitive advantage in having minimal hand foot syndrome compared to the up to 60% incidence with Xeloda®. Hand foot syndrome is a major complication of the use of Xeloda® and there is currently no adequate treatment, with most physicians resorting to reducing the starting dosage of Xeloda®.

 

5-FU is normally rapidly metabolized and broken down by the enzyme DPD. Eniluracil is an irreversible inhibitor of DPD and its use with 5-FU leads to prolonged and elevated levels of 5-FU. Uracil is a competitive inhibitor of DPD. Although not FDA approved as a therapeutic agent, uracil has been used with 5-FU and tegafur, a reversible DPD inhibitor (5-chloro-2, 4-dihydrozypyidine, or CDHP) for the treatment of certain cancers. UFT is an orally active combination of uracil and tegafur that is available in some international markets through Merck KGaA.

 

S-1, which is marketed by Taiho in Japan for gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, and inoperable or recurrent breast cancer, is an orally active combination of tegafur and oxonic acid, an inhibitor of phosphoribosyl pyrophosphate transferase, an enzyme that reduces the incorporation of 5-FU into RNA. Both S-1 and UFT have been shown to have very low levels of hand foot syndrome, but because they are reversible inhibitors of DPD, these products would not be expected to be as successful at targeting new product indications where DPD levels are intrinsically high, such as hepatocellular cancer, compared to an irreversible DPD inhibitor like Eniluracil. Other reversible DPD inhibitors in development include a Roche molecule, Ro 09-4889, which has completed a Phase I clinical study. To our knowledge, no other irreversible DPD inhibitors are currently in development.

 

We are not aware of any commercially available agents that reduce the incidence of hearing loss associated with the use of platinum-based anti-cancer agents, for which purpose we are developing STS. There are several potential competitive agents with activity in preclinical or limited clinical settings. These include: D-methionine, an amino acid that has been shown to protect against hearing loss in experimental settings but was demonstrated to be inferior to STS in comparative studies; SPI-3005, an oral agent primarily being developed by Sound Pharmaceuticals for noise and age-related hearing loss but in early Phase II trials for chemotherapy related hearing loss, which mimics glutathione peroxidase and induces the intracellular induction of glutathione; N-acetylcysteine and amifostine, which have shown effectiveness (but less than STS) in experimental systems; and Vitamin E, salicylate and tiopronin, which have all demonstrated moderate activity in rat models to protect against cisplatin-induced ototoxicity, but no clinical trials have been performed. Cochlear implants, which are small electronic devices that are surgically placed in the inner ear to assist with certain types of deafness, are utilized to offer some relief but are often suboptimal.

 

Many chemotherapeutic agents are currently available and numerous others are being developed. Any chemotherapeutic products that we develop may not be able to compete effectively with existing or future chemotherapeutic agents. Our competitors might obtain regulatory approval for their drug candidates sooner than we do, or their drugs may prove to be more effective than ours. However, cancer as a disease is not currently controlled by any one anti-cancer agent, and there is typically a need for several agents at any one time and over time.

 

Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market products. In addition, many of these competitors have extensive experience with preclinical testing and human clinical trials and in obtaining regulatory approvals. In addition, many of the smaller companies that compete with us have formed collaborative relationships with large, established companies to support the research, development, clinical trials and commercialization of any products that they may develop . We may rely on third parties to commercialize the products we develop, and our success will depend in large part on the efforts and competitive merit of these collaborative partners. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for research, clinical development and marketing of products similar to those we seek to develop. These companies and institutions compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our projects. The existence of competitive products, including products or treatments of which we are not aware, or products or treatments that may be developed in the future, may adversely affect the marketability of any products that we may develop.

 

5
 

 

Government Regulation

 

The production and manufacture of our product candidates and our research and development activities are subject to significant regulation for safety, efficacy and quality by various governmental authorities around the world. Before new pharmaceutical products may be sold in the U.S. and other countries, clinical trials of the products must be conducted and the results submitted to appropriate regulatory agencies for approval. Clinical trial programs must establish efficacy, determine an appropriate dose and regimen, and define the conditions for safe use. This is a high-risk process that requires stepwise clinical studies in which the candidate product must successfully meet predetermined endpoints. In the U.S., the results of the preclinical and clinical testing of a product are then submitted to the FDA in the form of a Biologics License Application or a New Drug Application. In response to these submissions, the FDA may grant marketing approval, request additional information or deny the application if it determines the application does not provide an adequate basis for approval. Similar submissions are required by authorities in other jurisdictions who independently assess the product and may reach the same or different conclusions.

 

The receipt of regulatory approval often takes a number of years, involves the expenditure of substantial resources and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments and the risks and benefits demonstrated in clinical trials. On occasion, regulatory authorities may require larger or additional studies, leading to unanticipated delay or expense. Even after initial approval from the FDA or other regulatory agencies has been obtained, further clinical trials may be required to provide additional data on safety and effectiveness. Additional trials are required to gain clearance for the use of a product as a treatment for indications other than those initially approved. Furthermore, the FDA and other regulatory agencies require companies to disclose clinical trial results. Failure to disclose such results within applicable time periods could result in penalties, including civil monetary penalties.

 

In Canada, these activities are subject to regulation by Health Canada’s Therapeutic Products Directorate, or TPD, and the rules and regulations promulgated under the Food and Drug Act. In the United States, drugs and biological products are subject to regulation by the FDA. The FDA requires licensing of manufacturing and contract research facilities, carefully controlled research and testing of products and governmental review and approval of results prior to marketing therapeutic products. Additionally, the FDA requires adherence to “Good Laboratory Practices” as well as “Good Clinical Practices” during clinical testing and “Good Manufacturing Practices” and adherence to labeling and supply controls. The systems of new drug approvals in Canada and the United States are substantially similar, and are generally considered to be among the most rigorous in the world.

 

Generally, the steps required for drug approval in Canada and the United States, specifically in cancer related therapies, include:

 

·Preclinical Studies : Preclinical studies, also known as non-clinical studies, primarily involve evaluations of pharmacology, toxic effects, pharmacokinetics and metabolism of a drug in animals to provide evidence of the relative safety and bioavailability of the drug prior to its administration to humans in clinical studies. A typical program of preclinical studies takes 18 to 24 months to complete. The results of the preclinical studies as well as information related to the chemistry and comprehensive descriptions of proposed human clinical studies are then submitted as part of the Investigational New Drug, application to the FDA, a Clinical Trial Application to the TPD, or similar submission to other foreign regulatory bodies. This is necessary in Canada, the United States and most other countries prior to undertaking clinical studies. Additional preclinical studies are conducted during clinical development to further characterize the toxic effects of a drug prior to submitting a marketing application.

 

·Phase I Clinical Trials : Most Phase I clinical trials take approximately one year to complete and are usually conducted on a small number of healthy human subjects to evaluate the drug’s safety, tolerability and pharmacokinetics. In some cases, such as cancer indications, Phase I clinical trials are conducted in patients rather than healthy volunteers.

 

·Phase II Clinical Trials : Phase II clinical trials typically take one to two years to complete and are generally carried out on a relatively small number of patients, generally between 15 and 50, in a specific setting of targeted disease or medical condition, in order to provide an estimate of the drug’s effectiveness in that specific setting. This phase also provides additional safety data and serves to identify possible common short-term side effects and risks in a somewhat larger group of patients. Phase II testing frequently relates to a specific disease, such as breast or lung cancer. Some contemporary methods of developing drugs, particularly molecularly targeted therapies, do not require broad testing in specific diseases, and instead permit testing in subsets of patients expressing the particular marker. In some cases, such as cancer indications, the company sponsoring the new drug may submit a marketing application to seek accelerated approval of the drug based on evidence of the drug’s effect on a “surrogate endpoint” from Phase II clinical trials. A surrogate endpoint is a laboratory finding or physical sign that may not be a direct measurement of how a patient feels, functions or survives, but is still considered likely to predict therapeutic benefit for the patient. If accelerated approval is received, the company sponsoring the new drug must continue testing to demonstrate that the drug indeed provides therapeutic benefit to the patient.

 

6
 

 

·Phase III Clinical Trials : Phase III clinical trials typically take two to four years to complete and involve tests on a much larger population of patients suffering from the targeted condition or disease. These studies involve conducting controlled testing and/or uncontrolled testing in an expanded patient population, numbering several hundred to several thousand patients, at separate test sites, known as multi-center trials, to establish clinical safety and effectiveness. These trials also generate information from which the overall benefit-risk relationship relating to the drug can be determined and provide a basis for drug labeling. Phase III trials are generally the most time consuming and expensive part of a clinical trial program. In some instances, governmental authorities, such as the FDA, will allow a single Phase III clinical trial to serve as a pivotal efficacy trial to support a Marketing Application.

 

·Marketing Application : Upon completion of Phase III clinical trials, the pharmaceutical company sponsoring the new drug assembles all the chemistry, preclinical and clinical data and submits it to the TPD or the FDA as part of a New Drug Submission in Canada or a New Drug Application, in the United States. The marketing application is then reviewed by the regulatory body for approval to market the product. The review process generally takes twelve to eighteen months.

 

Any clinical trials that we conduct may not be successfully completed, either in a satisfactory time period or at all. The typical time periods described above may vary substantially and may be materially longer. In addition, the FDA and its counterparts in other countries have considerable discretion to discontinue trials if they become aware of any significant safety issues or convincing evidence that a therapy is not effective for the indication being tested. It is possible the FDA and its counterparts in other countries may not (i) allow clinical trials to proceed at any time after receiving an Investigational New Drug, (ii) allow further clinical development phases after authorizing a previous phase, or (iii) approve marketing of a drug after the completion of clinical trials.

 

While European, U.S. and Canadian regulatory systems require that medical products be safe, effective, and manufactured according to high quality standards, the drug approval process in Europe differs from that in the United States and Canada and may require us to perform additional preclinical or clinical testing regardless of whether FDA or TPD approval has been obtained. The amount of time required to obtain necessary approvals may be longer or shorter than that required for FDA or TPD approval. European Union Regulations and Directives generally classify health care products either as medicinal products, medical devices or in vitro diagnostics. For medicinal products, marketing approval may be sought using either the centralized procedure of the European Agency for the Evaluation of Medicinal Products, or EMEA, or the decentralized, mutual recognition process. The centralized procedure, which is mandatory for some biotechnology derived products, results in an approval recommendation from the EMEA to all member states, while the European Union mutual recognition process involves country by country approval.

 

Good Clinical Practices

 

The FDA and other regulatory agencies promulgate regulations and standards, commonly referred to as current Good Clinical Practices for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the trial participants are adequately protected. The FDA and other regulatory agencies enforce Good Clinical Practices through periodic inspections of trial sponsors, principal investigators and trial sites. If our study sites fail to comply with applicable Good Clinical Practices, the clinical data generated in our clinical trials may be deemed unreliable and relevant regulatory agencies may require us to perform additional clinical trials before approving our marketing applications.

 

Good Manufacturing Practices

 

The FDA and other regulatory agencies regulate and inspect equipment, facilities and processes used in the manufacture of pharmaceutical and biologic products prior to approving a product. If, after receiving approval from regulatory agencies, a company makes a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required. All facilities and manufacturing techniques that may be used for the manufacture of our products must comply with applicable regulations governing the production of pharmaceutical products known as "Good Manufacturing Practices."

 

Orphan Drug Act

 

Under the U.S. Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a “rare disease or condition,” which generally is a disease or condition that affects fewer than 200,000 individuals in the U.S. If a product which has an orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, i.e., the FDA may not approve any other applications to market the same drug for the same indication for a period of seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Legislation similar to the U.S. Orphan Drug Act has been enacted in other countries, including within the European Union.

 

Other Laws

 

Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights may be subject to national or supranational antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.

 

7
 

 

Research and Development

 

Our research and development efforts have been focused on the development of cancer therapeutics and our cadherin technology platform and currently focus on Eniluracil and STS.

 

We have established relationships with contract research organizations, universities and other institutions, which we utilize to perform many of the day-to-day activities associated with our drug development.  Where possible, we have sought to include leading scientific investigators and advisors to enhance our internal capabilities.  Research and development issues are reviewed internally by our executive management and supporting scientific staff.

 

Research and development expenses totaled $2.1 million and $1.5 million for the fiscal years ended December 31, 2012 and 2011, respectively.

 

Our product candidates are in various stages of development and still require significant, time-consuming and costly research and development, testing and regulatory clearances.  In developing our product candidates, we are subject to risks of failure that are inherent in the development of products based on innovative technologies.  For example, it is possible that any or all of these products will be ineffective or toxic, or will otherwise fail to receive the necessary regulatory clearances. There is a risk that our product candidates will be uneconomical to manufacture or market or will not achieve market acceptance. There is also a risk that third parties may hold proprietary rights that preclude us from marketing our product candidates or that others will market a superior or equivalent product.  As a result of these factors, we are unable to accurately estimate the nature, timing and future costs necessary to complete the development of these product candidates. In addition, we are unable to reasonably estimate the period when material net cash inflows could commence from the sale, licensing or commercialization of such product candidates, if ever.

 

Item 1A.  Risk Factors.

 

An investment in our common stock involves a significant risk of loss.  You should carefully read this entire report and should give particular attention to the following risk factors.  You should recognize that other significant risks may arise in the future, which we cannot reasonably foresee at this time.  Also, the risks that we now foresee might affect us to a greater or different degree than currently expected.  There are a number of important factors that could cause our actual results to differ materially from those expressed or implied by any of our forward-looking statements in this report.  These factors include, without limitation, the risk factors listed below and other factors presented throughout this report and any other documents filed by us with the Securities and Exchange Commission, or the SEC, and the Canadian securities regulators on SEDAR which can be accessed at www.sedar.com.

 

Risks Related to Our Business

 

We have a history of significant losses and have had no revenues to date through the sale of our products. If we do not generate significant revenues, we will not achieve profitability.

 

To date, we have been engaged primarily in research and development activities. We have had no revenues through the sale of our products, and we do not expect to have significant revenues until we are able to either sell our product candidates after obtaining applicable regulatory approvals or we establish collaborations that provide us with up-front payments, licensing fees, milestone payments, royalties or other revenue. We have incurred significant operating losses every year since our inception on September 3, 1996. We had a net loss of approximately$5.2 million (including a non-cash loss on derivatives of $1.6 million) in the twelve months ended December 31, 2012, and reported a gain of approximately $4.7 million (which included a $8.1 million non-cash gain on derivatives) for the twelve months ended December 31, 2011. At December 31, 2012, we had an accumulated deficit of approximately $110.5 million. We anticipate incurring substantial additional losses due to the need to spend substantial amounts on our current clinical trials, anticipated research and development activities, and general and administrative expenses, among other factors. We have not commercially introduced any product and our product candidates are in varying stages of development and testing. Our ability to attain profitability will depend upon our ability to fund and develop products that are safe, effective and commercially viable, to obtain regulatory approval for the manufacture and sale of our product candidates and to license or otherwise market our product candidates successfully. Any revenues generated from such products, assuming they are successfully developed, marketed and sold, may not be realized for a number of years. We may never achieve or sustain profitability on an ongoing basis.

 

There is no assurance that we will successfully develop a commercially viable product.

 

Since our formation in September 1996, we have engaged in research and development programs. We have generated no revenue from product sales, do not have any products currently available for sale, and none are expected to be commercially available for sale until we have completed additional clinical trials, if at all. There can be no assurance that the research we fund and manage will lead to commercially viable products.We are currently completing a Phase II study for Eniluracil and STS is currently in a Phase III study.Our products must still undergo substantial additional regulatory review prior to commercialization.

 

8
 

 

We do not presently have the financial or human resources to complete Phase III trials for our lead product candidates.

 

We do not presently have the financial or human resources to complete Phase III trials for any of our lead product candidates. We are currently completing a Phase II trial for Eniluracil and a Phase III trial for STS. If these trials are successful, and if we decide to continue to develop Eniluracil, we will need additional funding, or we will need to enlist a partner to conduct future trials.

 

We have agreements with the International Childhood Liver Tumour Strategy Group, known as SIOPEL, and the Children's Oncology Group to further develop STS in Phase III trials. It is possible SIOPEL and the Children's Oncology Group may not conduct or complete the clinical trials with STS as currently planned. Such collaborators might not commit sufficient resources to the development of our product candidates, which may lead to significant delays. We have already experienced significant delays in the activation of the Children's Oncology Group trial and subsequent accrual of patients into the Children's Oncology Group and SIOPEL clinical trials. We do not have the resources to independently develop or conduct such trials ourselves.

 

We continue to seek a licensing or funding partner for the further development of one or all of our product candidates. If a partner for one or all of these technologies is not found, we may not be able to further advance these products. If a partner is found, the financial terms that they propose may not be acceptable to us.

 

We anticipate the need for additional capital in the future and if we cannot raise additional capital, we will not be able to fulfill our business plan.

 

We need to obtain additional funding in the future in order to finance our business strategy, operations and growth. We may not be able to obtain additional financing in sufficient amounts or on acceptable terms when needed. If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing. Debt financing must be repaid regardless of whether or not we generate profits or cash flows from our business activities. Equity financing may result in dilution to existing stockholders and may involve securities that have rights, preferences, or privileges that are senior to our common stock or other securities. If we cannot raise sufficient capital when necessary, we will likely have to curtail operations and you may lose part or all of your investment.

 

If we do not maintain current or enter into new collaborations with other companies, we might not successfully develop our product candidates or generate sufficient revenues to expand our business.

 

We currently rely on scientific and research and development collaboration arrangements with academic institutions and other third party collaborators, including our agreement for Eniluracil with GlaxoSmithKline and an exclusive worldwide license from Oregon Health & Science University for STS. We also rely on collaborators for testing STS, including SIOPEL and the Children’s Oncology Group.

 

The agreements with GlaxoSmithKline and Oregon Health & Science University are terminable by either party in the event of an uncured breach by the other party. We may also terminate our agreement with Oregon Health & Science University at any time upon prior written notice of specified durations to the licensor. Termination of any of our collaborative arrangements could materially adversely affect our business. For example, if we are unable to make the appropriate payments under these agreements, the licensor might terminate the agreement which might have a material adverse impact. In addition, our collaborators might not perform as agreed in the future.

 

Since we conduct a significant portion of our research and development through collaborations, our success may depend significantly on the performance of such collaborators, as well as any future collaborators. Collaborators might not commit sufficient resources to the research and development or commercialization of our product candidates. Economic or technological advantages of products being developed by others, or other factors could lead our collaborators to pursue other product candidates or technologies in preference to those being developed in collaboration with us. The commercial potential of, development stage of and projected resources required to develop our drug candidates will affect our ability to maintain current collaborations or establish new collaborators. There is a risk of dispute with respect to ownership of technology developed under any collaboration. Our management of any collaboration will require significant time and effort as well as an effective allocation of resources. We may not be able to simultaneously manage a large number of collaborations.

 

Our product candidates are still in development. Due to the long, expensive and unpredictable drug development process, we might not ever successfully develop and commercialize any of our product candidates.

 

In order to achieve profitable operations, we, alone or in collaboration with others, must successfully fund, develop, manufacture, introduce and market our product candidates. The time necessary to achieve market success for any individual product is long and uncertain. Our product candidates and research programs are in various stages of clinical development and require significant, time-consuming and costly research, testing and regulatory clearances. In developing our product candidates, we are subject to risks of failure that are inherent in the development of therapeutic products based on innovative technologies. For example, our product candidates might be ineffective, as Eniluracil was shown to be in earlier clinical trials conducted by GlaxoSmithKline, or may be overly toxic, or otherwise might fail to receive the necessary regulatory clearances. The results of preclinical and initial clinical trials are not necessarily predictive of future results. Our product candidates might not be economical to manufacture or market or might not achieve market acceptance. In addition, third parties might hold proprietary rights that preclude us from marketing our product candidates or others might market equivalent or superior products.

 

9
 

 

We must conduct human clinical trials to assess our product candidates. If these trials are delayed or are unsuccessful, our development costs will significantly increase and our business prospects may suffer.

 

Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate, through preclinical studies with animals and clinical trials with humans, that our product candidates are safe and effective for use in each target indication. To date, we have performed only limited clinical trials, and we have only done so with some of our product candidates. Much of our testing has been conducted on animals or on human cells in the laboratory, and the benefits of treatment seen in animals may not ultimately be obtained in human clinical trials. As a result, we will need to perform significant additional research and development and extensive preclinical and clinical testing prior to any application for commercial use. We may suffer significant setbacks in clinical trials, and the trials may demonstrate our product candidates to be unsafe or ineffective. We may also encounter problems in our clinical trials that will cause us to delay, suspend or terminate those clinical trials, which would increase our development costs and harm our financial results and commercial prospects. Identifying and qualifying patients to participate in clinical trials of our potential products is critically important to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. We have experienced delays in some of our clinical trials and we may experience significant delays in the future. If patients are unwilling to participate in our trials because of competitive clinical trials for similar patient populations, perceived risk or any other reason, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of potential products will be delayed. Other factors that may result in significant delays include obtaining regulatory or ethics review board approvals for proposed trials, reaching agreement on acceptable terms with prospective clinical trial sites, and obtaining sufficient quantities of drug for use in the clinical trials. Such delays could result in the termination of the clinical trials altogether.

 

Regulatory approval of our product candidates is time-consuming, expensive and uncertain, and could result in unexpectedly high expenses and delay our ability to sell our products.

 

Development, manufacture and marketing of our products are subject to extensive regulation by governmental authorities in the United States and other countries. This regulation could require us to incur significant unexpected expenses or delay or limit our ability to sell our product candidates. Our clinical studies might be delayed or halted, or additional studies might be required, for various reasons, including:

 

·lack of funding;
·the drug is not effective;
·patients experience severe side effects during treatment;
·appropriate patients do not enroll in the studies at the rate expected;
·drug supplies are not sufficient to treat the patients in the studies; or
·we decide to modify the drug during testing.

 

If regulatory approval of any product is granted, it will be limited to those indications for which the product has been shown to be safe and effective, as demonstrated to the FDA’s satisfaction through clinical studies. Furthermore, approval might entail ongoing requirements for post-marketing studies. Even if regulatory approval is obtained, labeling and promotional activities are subject to continual scrutiny by the FDA and state regulatory agencies and, in some circumstances, the Federal Trade Commission. FDA enforcement policy prohibits the marketing of approved products for unapproved, or off-label, uses. These regulations and the FDA’s interpretation of them might impair our ability to effectively market our products.

 

We and our third-party manufacturers are also required to comply with the applicable current FDA Good Manufacturing Practices regulations, which include requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation. Further, manufacturing facilities must be approved by the FDA before they can be used to manufacture our products, and they are subject to additional FDA inspection. If we fail to comply with any of the FDA’s continuing regulations, we could be subject to reputational harm and sanctions, including:

 

·delays, warning letters and fines;
·product recalls or seizures and injunctions on sales;
·refusal of the FDA to review pending applications;
·total or partial suspension of production;
·withdrawals of previously approved marketing applications; and
·civil penalties and criminal prosecutions.

 

In addition, identification of side effects after a drug is on the market or the occurrence of manufacturing problems could cause subsequent withdrawal of approval, reformulation of the drug, additional testing or changes in labeling of the product.

 

We may be unable to effectively deploy the proceeds from our recent financings for the development of Eniluracil.

 

In April 2010, we announced the closing of a private placement for proceeds of CAD $7.2 million and in March 2011, we announced the closing of a rights offering for proceeds of approximately $2.5 million. Any inability on our part to manage effectively the deployment of this capital could limit our ability to successfully develop Eniluracil.

 

10
 

 

If our licenses to proprietary technology owned by others are terminated or expire, we may suffer increased development costs and delays, and we may not be able to successfully develop our product candidates.

 

The development of our drug candidates and the manufacture and sale of any products that we develop will involve the use of processes, products and information, some of the rights to which are owned by others. Our product candidates are licensed under agreements with GlaxoSmithKline and Oregon Health & Science University. Although we have obtained licenses or rights with regard to the use of certain processes, products and information, the licenses or rights could be terminated or expire during critical periods and we may not be able to obtain, on favorable terms or at all, licenses or other rights that may be required. Some of these licenses provide for limited periods of exclusivity that may be extended only with the consent of the licensor, which may not be granted.

 

If we are unable to adequately protect or maintain our patents and licenses related to our product candidates, or we infringe upon the intellectual property rights of others, we may not be able to successfully develop and commercialize our product candidates.

 

The value of our technology will depend in part upon our ability, and those of our collaborators, to obtain patent protection or licenses to patents, maintain trade secret protection and operate without infringing on the rights of third parties. Although we have successfully pursued patent applications in the past, it is possible that:

 

·some of all of our pending patent applications, or those we have licensed, may not be allowed;
·proprietary products or processes that we develop in the future may not be patentable;
·any issued patents that we own or license may not provide us with any competitive advantages or may be successfully challenged by third parties; or
·the patents of others may have an adverse effect on our ability to do business.

 

It is not possible for us to be certain that we are the original and first creator of inventions encompassed by our pending patent applications or that we were the first to file patent applications for any such inventions. Further, any of our patents, once issued, may be declared by a court to be invalid or unenforceable.

 

Eniluracil is currently protected in the US under an issued method of use patent that we own and expires in 2025 as well as 2 international jurisdictionsunder an issued method of use patent that we own and expire in 2025. We have also exclusively licensed from GlaxoSmithKline method of use patents that expire in 2014 and 2015. STS is currently protected by methods of use patents that we exclusively licensed from Oregon Health & Science University that expire in Europe in 2021 and are currently pending in the United States. None of the above expiry dates take into consideration additional and pending patent applications for Eniluracil that, if issued, could provide additional patent protection nor possible patent term extensions or periods of data exclusivity that may be available upon marketing approval in the various countries worldwide. In addition, periods of marketing exclusivity for STS may also be possible in the United States under orphan drug status. We obtained Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients in 2004, if approved, will have seven years of exclusivity in the United States from the approval date. Refer to the “Description of Business” section of this report for a further description of the United States Orphan Drug Designation.

 

We may be required to obtain licenses under patents or other proprietary rights of third parties but the extent to which we may wish or need to do so is unknown. Any such licenses may not be available on terms acceptable to us or at all. If such licenses are obtained, it is likely they would be royalty bearing, which would reduce any future income. If licenses cannot be obtained on an economical basis, we could suffer delays in market introduction of planned products or their introduction could be prevented, in some cases after the expenditure of substantial funds. If we do not obtain such licenses, we would have to design around patents of third parties, potentially causing increased costs and delays in product development and introduction or precluding us from developing, manufacturing or selling our planned products, or our ability to develop, manufacture or sell products requiring such licenses could be foreclosed.

 

Litigation may also be necessary to enforce or defend patents issued or licensed to us or our collaborators or to determine the scope and validity of a third party’s proprietary rights. We could incur substantial costs if litigation is required to defend ourselves in patent suits brought by third parties, if we participate in patent suits brought against or initiated by our collaborators, or if we initiate such suits. We might not prevail in any such action. An adverse outcome in litigation or an interference to determine priority or other proceeding in a court or patent office could subject us to significant liabilities, require disputed rights to be licensed from other parties or require us or our collaborators to cease using certain technology or products. Any of these events would likely have a material adverse effect on our business, financial condition and results of operations.

 

Much of our technological know-how that is not patentable may constitute trade secrets. Our confidentiality agreements might not provide for meaningful protection of our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure of information. In addition, others may independently develop or obtain similar technology and may be able to market competing products and obtain regulatory approval through a showing of equivalency to our product that has obtained regulatory approvals, without being required to undertake the same lengthy and expensive clinical studies that we would have already completed.

 

11
 

 

The vulnerability to off-label use or sale of our product candidates that are covered only by “method of use” patents may cause downward pricing pressure on these product candidates if they are ever commercialized and may make it more difficult for us to enter into collaboration or partnering arrangements for the development of these product candidates.

 

STS, one of our product candidates, is currently only covered by “method of use” patents, which covers the use of certain compounds to treat specific conditions, and not by “composition of matter” patents, which would cover the chemical composition of the compound. Method of use patents provides less protection than composition of matter patents because of the possibility of off-label competition if other companies develop or market the compound for other uses. If another company markets a drug that we expect to market under the protection of a method of use patent, physicians may prescribe the other company’s drug for use in the indication for which we obtain approval and have a patent, even if the other company’s drug is not approved for such an indication. Off-label use and sales could limit our sales and exert pricing pressure on any products we develop covered only by method of use patents. Also, it may be more difficult to find a collaborator to license or support the development of our product candidates that are only covered by method of use patents.

 

If our third party manufacturers breach or terminate their agreements with us, or if we are unable to secure arrangements with third party manufacturers on acceptable terms as needed in the future, we may suffer significant delays and additional costs.

 

We have no experience manufacturing products and do not currently have the resources to manufacture any products that we may develop. We currently have agreements with contract manufacturers for clinical supplies of STS, Eniluracil and 5-FU, including drug substance providers and drug product suppliers, but they might not perform as agreed in the future or may terminate our agreement with them before the end of the required term. Significant additional time and expense would be required to effect a transition to a new contract manufacturer.

 

We plan to continue to rely on contract manufacturers for the foreseeable future to produce quantities of products and substances necessary for research and development, preclinical trials, human clinical trials and product commercialization, and to perform their obligations in a timely manner and in accordance with applicable government regulations. If we develop any products with commercial potential, we will need to develop the facilities to independently manufacture such products or secure arrangements with third parties to manufacture them. We may not be able to independently develop manufacturing capabilities or obtain favorable terms for the manufacture of our products. While we intend to contract for the commercial manufacture of our product candidates, we may not be able to identify and qualify contractors or obtain favorable contracting terms. We or our contract manufacturers may also fail to meet required manufacturing standards, which could result in delays or failures in product delivery, increased costs, injury or death to patients, product recalls or withdrawals and other problems that could significantly hurt our business. We intend to maintain a second source for back-up commercial manufacturing, wherever feasible. However, if a replacement to our future internal or contract manufacturers were required, the ability to establish second-sourcing or find a replacement manufacturer may be difficult due to the lead times generally required to manufacture drugs and the need for FDA compliance inspections and approvals of any replacement manufacturer, all of which factors could result in production delays and additional commercialization costs. Such lead times would vary based on the situation, but might be twelve months or longer.

 

We lack the resources necessary to effectively market our product candidates, and we may need to rely on third parties over whom we have little or no control and who may not perform as expected.

 

We do not have the necessary resources to market our product candidates. If we develop any products with commercial potential, we will either have to develop a marketing capability, including a sales force, which is difficult and expensive to implement successfully, or attempt to enter into a collaboration, merger, joint venture, license or other arrangement with third parties to provide a substantial portion of the financial and other resources needed to market such products. We may not be able to do so on acceptable terms, if at all. If we rely extensively on third parties to market our products, the commercial success of such products may be largely outside of our control.

 

We conduct our business internationally and are subject to laws and regulations of several countries which may affect our ability to access regulatory agencies and may affect the enforceability and value of our licenses.

 

We have conducted clinical trials in the United States, Canada, Europe and the Pacific Rim and intend to, or may, conduct future clinical trials in these and other jurisdictions. There can be no assurance that any sovereign government will not establish laws or regulations that will be deleterious to our interests. There is no assurance that we, as a British Columbia corporation, will continue to have access to the regulatory agencies in any jurisdiction where we might want to conduct clinical trials or obtain regulatory approval, and we might not be able to enforce our license or patent rights in foreign jurisdictions. Foreign exchange controls may have a material adverse effect on our business and financial condition, since such controls may limit our ability to flow funds into or out of a particular country to meet obligations under licenses, clinical trial agreements or other collaborations.

 

Our cash invested in money market funds might be subject to loss.

 

Even though we believe we take a conservative approach to investing our funds, the volatility of the current financial markets exposes us to increased investment risk, including the risks that the value and liquidity of our money market investments could deteriorate significantly and the issuers of the investments we hold could be subject to credit rating downgrades. While we have not experienced any loss or write down of our money market investments in the past, we cannot guarantee that such losses will not occur in future periods.

 

12
 

 

Risks Related to Our Industry

 

If we are unable to obtain applicable U.S. and/or foreign regulatory approvals, we will be unable to develop and commercialize our drug candidates.

 

The preclinical studies and clinical trials of our product candidates, as well as the manufacturing, labeling, sale and distribution, export or import, marketing, advertising and promotion of our product candidates are subject to various regulatory frameworks in the United States, Canada and other countries. Any products that we develop must receive all relevant regulatory approvals and clearances before any marketing, sale or distribution. The regulatory process, which includes extensive preclinical studies and clinical testing to establish product safety and efficacy, can take many years and cost substantial amounts of money. As a result of the length of time, many challenges and costs associated with the drug development process, the historical rate of failures for drug candidates is extremely high. For example, prior development of our compound Eniluracil by GlaxoSmithKline was not successful. Varying interpretations of the data obtained from studies and tests could delay, limit or prevent regulatory approval or clearance. Changes in regulatory policy could also cause delays or affect regulatory approval. Any regulatory delays may increase our development costs and negatively impact our competitiveness and prospects. It is possible that we may not be able to obtain regulatory approval of any of our drug candidates or approvals may take longer and cost more to obtain than expected.

 

Regulatory approvals, if granted, may entail limitations on the uses for which any products we develop may be marketed, limiting the potential sales for any such products. The granting of product approvals can be withdrawn at any time, and manufacturers of approved products are subject to regular reviews, including for compliance with FDA Good Manufacturing Practices regulations. Failure to comply with any applicable regulatory requirement, which may change from time to time, can result in warning letters, fines, sanctions, penalties, recalling or seizing products, suspension of production, or even criminal prosecution.

 

Future sales of our product candidates may suffer if they fail to achieve market acceptance.

 

Even if our product candidates are successfully developed and achieve appropriate regulatory approval, they may not enjoy commercial acceptance or success. Product candidates may compete with a number of new and traditional drugs and therapies developed by major pharmaceutical and biotechnology companies. Market acceptance is dependent on product candidates demonstrating clinical efficacy and safety, as well as demonstrating advantages over alternative treatment methods. In addition, market acceptance is influenced by government reimbursement policies and the ability of third parties to pay for such products. Physicians, patients, the medical community or patients may not accept or utilize any products we may develop.

 

We face a strong competitive environment. Other companies may develop or commercialize more effective or cheaper products, which may reduce or eliminate the demand for our product candidates.

 

The biotechnology and pharmaceutical industry, and in particular the field of cancer therapeutics where we are focused, is very competitive. Many companies and research organizations are engaged in the research, development and testing of new cancer therapies or means of increasing the effectiveness of existing therapies, including, among many others, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Eisai, Merck KGaA, Novartis, Johnson & Johnson, Onyx, Pfizer, Roche, Taiho and Sanofi-Aventis. Many of these companies have marketed drugs or are developing targeted cancer therapeutics which, depending upon the mechanism of action of such agents could thus be competitors.

 

Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market products. In addition, many of these competitors have extensive experience with preclinical testing and human clinical trials and in obtaining regulatory approvals. Also, some of the smaller companies that compete with us have formed collaborative relationships with large, established companies to support the research, development, clinical trials and commercialization of any products that they may develop. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for research, clinical development and marketing of products similar to those we seek to develop. These companies and institutions compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our projects.

 

We are likely to face competition in the areas of product efficacy and safety, ease of use and adaptability, as well as pricing, product acceptance, regulatory approvals and intellectual property. Competitors could develop more effective, safer and more affordable products than we do, and they may obtain patent protection or product commercialization before we do or even render our product candidates obsolete. The existence of competitive products, including products or treatments of which we are not aware, or products or treatments that may be developed in the future, may adversely affect the marketability of any products that we develop.

 

We may face product liability claims that could require us to defend costly lawsuits or incur substantial liabilities that could adversely impact our financial condition, receipt of regulatory approvals for our product candidates and our results of operation.

 

The use of our product candidates in clinical trials and for commercial applications, if any, may expose us to liability claims in the event that such product candidates cause injury or death or result in other adverse effects. These claims could be made by health care institutions, contract laboratories, and subjects participating in our clinical studies, patients or others using our product candidates. In addition to liability claims, certain serious adverse events could require interruption, delay and/or discontinuation of a clinical trial and potentially prevent further development of the product candidate. We carry clinical trial insurance but the coverage may not be sufficient to protect us from legal expenses and liabilities we might incur. Litigation is very expensive, even if we defend successfully against possible litigation. In addition, our existing coverage may not be adequate if we further develop products, and future coverage may not be available in sufficient amounts or at reasonable cost. In addition, we might reduce the amount of this coverage due to our limited financial resources. Adverse liability claims may also harm our ability to obtain or maintain regulatory approvals.

 

13
 

 

We used hazardous material and chemicals in our research and development, and our failure to comply with laws related to hazardous materials could materially harm us.

 

In the past, our research and development processes involved the controlled use of hazardous materials, such as flammable organic solvents, corrosive acids and corrosive bases. Accordingly, we are subject to federal, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. The risk of accidental contamination or injury from these materials cannot be completely eliminated. We could be held liable for any damages that result and any such liability could exceed our resources and may not be covered by our general liability insurance. We currently do not carry insurance specifically for hazardous materials claims. We may be required to incur significant costs to comply with environmental laws and regulations, which may change from time to time. Our current practice is to outsource these activities.

 

Efforts to reduce product pricing and health care reimbursement and changes to government policies could negatively affect the commercialization of our product candidates.

 

If any of our product candidates achieve regulatory approval, we may be materially adversely affected by the continuing efforts of governmental and third-party payers to contain or reduce health care costs. For example, if we succeedin bringing one or more products to market, such products may not be considered cost-effective and the availability of consumer reimbursement may not exist or be sufficient to allow the sale of such products on a competitive basis. The constraints on pricing and availability of competitive products may further limit our pricing and reimbursement policies as well as adversely impact market acceptance and commercialization for the products.

 

In many markets, the pricing or profitability of healthcare products is subject to government control. In recent years, federal, state, provincial and local officials and legislators have proposed or are proposing a variety of price-based reforms to the healthcare systems in the United States, Canada and elsewhere. Some proposals include measures that would limit or eliminate payments from third-party payors to the consumer for certain medical procedures and treatments or allow government control of pharmaceutical pricing. The adoption of any such proposals or reforms could adversely affect the commercial viability of our product candidates.

 

In the U.S., there have been numerous proposals considered at the federal and state levels for comprehensive reforms of health care and its cost, and it is likely that federal and state legislatures and health agencies will continue to focus on health care reform in the future. Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products.

 

Any significant changes in the healthcare system in the United States, Canada or abroad would likely have a substantial impact on the manner in which we conduct business and could have a material adverse effect on our ability to raise capital and the viability of product commercialization.

 

Risks Related to Owning Our Common Shares

 

Our common stock has been delisted from NYSE Alternext US LLC (formerly the American Stock Exchange), which may make it more difficult for stockholders to dispose of their shares.

 

In December 2008, we received notice from the NYSE Alternext US, LLC (formerly the American Stock Exchange), or AMEX, that we were not in compliance with Section 1003(a)(ii) of its Company Guide, because our stockholders’ equity was below $6 million and we had incurred losses from continued operations and net losses in the five most recent fiscal years. On January 20, 2009, we voluntarily filed to delist our common stock from the AMEX and effective January 30, 2009, our common stock no longer traded on the AMEX. As a result, any trading of our common stock in the U.S. will need to be conducted in the over-the-counter market, on the Pink Sheets. In addition, our common stock is also subject to the SEC’s penny stock rules, which impose additional requirements on broker-dealers who effect trades. As a result, stockholders might have difficulty selling our common stock.

 

We may be unable to maintain the listing of our common stock on the TSX and that would make it more difficult for stockholders to dispose of their common stock.

 

Our common stock is currently listed on the TSX. The TSX has rules for continued listing, including minimum market capitalization and other requirements, that we might not meet in the future, particularly if the price of our common stock does not increase or we are unable to raise additional capital to continue operations. In January 2009, our common stock was delisted from the AMEX as we did not meet the continued listing requirements of that exchange. On September 8, 2012, the Toronto Stock Exchange issued an official delisting review of our common stock. The remedial delisting review was initiated because the value of the shares of our common stock that are held by “public shareholders” had been below the CAD$2.0 million threshold required under the TSX continuing listing standards for a period of 30 consecutive trading days. On January 7, 2013, the Toronto Stock Exchange completed its review of the Company and determined that the Company met TSX's continued listing requirements.

 

14
 

 

Delisting from the TSX would make it more difficult for stockholders to dispose of their common stock and more difficult to obtain accurate quotations on our common stock. This could have an adverse effect on the price of our common stock. There can be no assurances that a market maker will make a market in our common stock on the OTCQB or any other stock quotation system after delisting. Furthermore, securities quoted on the Pink Sheets generally have significantly less liquidity than securities traded on a national securities exchange, not only in the number of shares that can be bought and sold, but also through delays in the timing of transactions and lower market prices than might otherwise be obtained. As a result, stockholders might find it difficult to resell shares at prices quoted in the market or at all. Furthermore, because of the limited market and generally low volume of trading in our common stock, our common stock is more likely to be affected by broad market fluctuations, general market conditions, fluctuations in our operating results, changes in the market’s perception of our business, and announcements made by us, our competitors or parties with whom we have business relationships. Our ability to issue additional securities for financing or other purposes, or to otherwise arrange for any financing we may need in the future, may also be materially and adversely affected by the fact that our securities are not traded on a national securities exchange.

 

The market price of our common stock is highly volatile and could cause the value of your investment to significantly decline.

 

Historically, the market price of our common stock has been highly volatile and the market for our common stock has from time to time experienced significant price and volume fluctuations, some of which are unrelated to our operating performance. From July 1, 2008 to March 16, 2013, the trading price of our stock fluctuated from a high closing price of CAD$3.60 per share to a low closing price of CAD$0.08 per share on the TSX. From July 1, 2008 until our delisting on January 30, 2009, the trading price of our stock fluctuated from a high closing price of $4.14 per share to a low closing price of $0.18 per share on the AMEX. Historically, our common stock has had a low trading volume, and may continue to have a low trading volume in the future. This low volume may contribute to the volatility of the market price of our common stock. It is likely that the market price of our common stock will continue to fluctuate significantly in the future.

 

The market price of our stock may be significantly affected by many factors, including without limitation:

 

·the need to raise additional capital and the terms of any transaction we are able to enter into;
·other external factors generally or stock market trends in the pharmaceutical or biotechnology industries specifically;
·announcements of licensing agreements, joint ventures, collaborations or other strategic alliances that involve our products or those of our competitors;
·innovations related to our or our competitors’ products;
·actual or potential clinical trial results related to our or our competitors’ products;
·our financial results or those of our competitors;
·reports of securities analysts regarding us or our competitors;
·developments or disputes concerning our licensed or owned patents or those of our competitors;
·developments with respect to the efficacy or safety of our products or those of our competitors; and
·health care reforms and reimbursement policy changes nationally and internationally.

 

Our common stock is deemed to be a “penny stock,” which may make it more difficult for investors to sell their shares due to suitability requirements.

 

Our common stock is subject to Rule 15g-1 through 15g-9 under the Exchange Act, which imposes certain sales practice requirements on broker-dealers which sell our common stock to persons other than established customers and “accredited investors” who are generally individuals with a net worth in excess of $1,000,000 (excluding their principal residence)   or annual incomes exceeding $200,000, or $300,000 together with their spouses. For transactions covered by this rule, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to the sale. This rule adversely affects the ability of broker-dealers to sell our common stock and the ability of our stockholders to sell their shares of common stock.

 

Additionally, our common stock is subject to the SEC regulations for “penny stock.” Penny stock includes any equity security that is not listed on a national exchange and has a market price of less than $5.00 per share, subject to certain exceptions. The regulations require that prior to any non-exempt buy/sell transaction in a penny stock, a disclosure schedule set forth by the SEC relating to the penny stock market must be delivered to the purchaser of such penny stock. This disclosure must include the amount of commissions payable to both the broker-dealer and the registered representative and current price quotations for the common stock. The regulations also require that monthly statements be sent to holders of penny stock that disclose recent price information for the penny stock and information of the limited market for penny stocks. These requirements adversely affect the market liquidity of our common stock.

 

15
 

 

Our existing principal stockholders hold a substantial number of shares of our common stock and may be able to exercise influence in matters requiring approval of stockholders.

 

At March 16, 2013, our current stockholders separately representing more than 5% ownership in our Company collectively represented beneficial ownership of approximately 60% of our common stock. In particular, Southpoint Capital Advisors LP owns or exercises control over 11 million shares of common stock, representing approximately 45% of the issued and outstanding common stock. In addition, Mr. Robert Butts, individually owns approximately 2.3 million shares, or 9% of our common stock, and he served as Chairman of our Board of Directors until June 2011. Further, 683 Capital LLC, owns approximately 2.1 million shares, or 9% of our common stock. Southpoint Capital, our other 5% stockholders, and other insiders, acting alone or together, might be able to influence the outcomes of matters that require the approval of our stockholders, including but not limited to certain equity transactions (such as a financing), an acquisition or merger with another company, a sale of substantially all of our assets, the election and removal of directors, or amendments to our incorporating documents. These stockholders might make decisions that are adverse to your interests. The concentration of ownership could have the effect of delaying, preventing or deterring a change of control of our company, which could adversely affect the market price of our common stock or deprive our other stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company.

 

There are a large number of shares of our common stock underlying outstanding warrants and options, and reserved for issuance under our stock option plan, that may be sold in the market, which could depress the market price of our stock and result in substantial dilution to the holders of our common stock.

 

Sale or issuance of a substantial number of shares of our common stock in the future could cause the market price of our common stock to decline. It may also impair our ability to obtain additional financing. At March 16, 2013, we had outstanding warrants to purchase approximately 18.1 million shares of our common stock which had a weighted average exercise price of $1.44. In addition, at March 16, 2013, there were approximately 5.5 million shares issuable upon the exercise of stock options granted by us of which approximately 4.2 million were denominated in Canadian dollars and had a weighted average exercise price of CAD$0.78 per common share and approximately 1.3 million were denominated in U.S. dollars and had a weighted average exercise price of $0.67 per common share. We may also issue further warrants as part of any future financings as well as the additional 0.7 million options to acquire our common stock currently remaining available for issuance under our stock option plan.

 

We may need to raise substantial additional funds in the near future to continue our operations. Any equity offering could result in significant dilution to the ownership interests of shareholders and may result in dilution of the value of such interests and any debt offering will increase financial risk.

 

In order to satisfy our anticipated capital requirements to develop our products, we may need to raise substantial additional funds through either the sale of additional equity, the issue of securities convertible into equity, the issuance of debt, the establishment of collaborations that provide us with funding, the out-license or sale of certain aspects of our intellectual property portfolio, or from other sources. The most likely sources of financing that may be available to us in the near term are the sale of shares of common stock and/or securities convertible into common stock and the issuance of debt.

 

We cannot predict the size of future issues of common stock or the issue of securities convertible into common stock or the effect that any such future issues and sales of common stock will have on the market price of our common stock. However, given the current market price of our common stock, any transaction involving the issue of common stock, or securities convertible into common stock, will likely result in immediate and substantial dilution to present and prospective holders of common stock. Alternatively, we may rely on debt financing and assume debt obligations that require us to make substantial interest and capital payments and to pledge some or all of our assets as collateral to secure such debt obligations.

 

We have not paid any dividends since incorporation and do not anticipate declaring any dividends in the foreseeable future. As a result, you will not be able to recoup your investment through the payment of dividends on your common stock and the lack of a dividend payable on our common stock might depress the value of your investment.
 

We will use all available funds to finance the development of our product candidates and operation of our business. Our directors will determine if and when dividends should be declared and paid in the future based on our financial position at the relevant time, but since we have no present plans to pay dividends, you should not expect receipt of dividends either for your cash needs or to enhance the value of your common stock.

 

Item 1B.  Unresolved Staff Comments

 

None.

 

16
 

 

Item 2.  Properties

 

We lease approximately 350 square feet of office space in Research Triangle Park, North Carolina. The current monthly lease payments are approximately $1,100 and the lease is terminable with 30 days notice.

 

Item 3.  Legal Proceedings

 

None.

 

Item 4.  Mine Safety Disclosures

 

Not applicable.

 

17
 

 

Part II

 

Item 5.  Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities

 

Our common stock traded on currently trades on the OTCQBMarket under the trading symbol “ADHXF”, and has traded on the TSX under the trading symbol “AHX” since June 5, 2001.  The following table sets forth the quarterly high and low market closing prices, and average daily trading volume on the OTCQB and the TSX, for the two most recent full fiscal years:

 

   OTC Market: OTCQB (1)
(in U.S. dollars)		   Toronto Stock Exchange (1)
(in Canadian dollars)		 
   High $   Low $   Volume   High $   Low $   Volume 
Fiscal 2012:                              
Quarter ended 12/31/12  $0.66   $0.13    81,994   $0.65   $0.12    17,423 
Quarter ended 09/30/12   0.18    0.11    4,943    0.30    0.11    2,787 
Quarter ended 06/30/12   0.15    0.18    1,162    0.20    0.15    1,814 
Quarter ended 03/31/12   0.17    0.33    7,722   $0.40   $0.18    5,733 
Fiscal 2011:                              
Quarter ended 12/31/11  $0.60   $0.32    5,784   $0.70   $0.35    3,789 
Quarter ended 09/30/11   0.77    0.54    4,786    0.75    0.51    5,158 
Quarter ended 06/30/11   0.90    0.54    6,590    0.90    0.54    12,278 
Quarter ended 03/31/11   1.26    0.36    3,969   $1.26   $0.54    7,713 

 

  (1) All above market quotations and trading prices for our common stock included above have been adjusted to give retroactive effect to the 1-for-18 Share Consolidation effected on August 25, 2011.

 

As of March 16, 2013, the last reported sale on the TSX was CAD$0.85 per share and the last reported sale on the over the counter markets in the U.S. was $0.85 per share.

 

Record Holders

 

As of March 16, 2013, there were approximately 83 shareholders of record of our common stock, one of which was Cede & Co., a nominee for Depository Trust Company, or DTC, and one of which was The Canadian Depository for Securities Limited, or CDS.  All of our common shares held by brokerage firms, banks and other financial institutions in the U.S. or Canada as nominees for beneficial owners are considered to be held of record by Cede & Co. in respect of brokerage firms, banks and other financial institutions located in Canada.  Cede & Co. and CDS are each considered to be one shareholder of record.

 

Dividend Policy

 

We have never declared or paid cash dividends on our common stock.  We currently expect to retain future earnings, if any, for use in the operation and expansion of business and do not anticipate paying any cash dividends in the foreseeable future.

 

Recent Sales of Unregistered Securities

 

On April 5, 2012, May 18, 2012, August 20, 2012, November 20, 2012 and December 18, 2012 the Company issued 254,335, 61,111, 33,333, 688,571 and 100,000 stock options, respectively, to certain consultants and board members of the Company. The options were issued in a private placement exempt under Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"). The options were issued in USD dollar denominated grants at an exercise price equal to the market price on the date of issue,at $0.20,$0.18, $0.15, $0.35 and $0.56 per share, respectively, and are exercisable for a period of 7 years from the grant date.

 

18
 

 

Material United States Federal and Canadian Income Tax Consequences

 

This section summarizes the material U.S. federal and Canadian federal income tax consequences of the ownership and disposition of the common stock. Nothing contained herein shall be construed as tax advice; you must rely only on the advice of your own tax advisor.  We make no assurances as to the applicability of any tax laws with respect to any individual investment.

 

This summary relating to the common stock applies to the beneficial owners who are individuals, corporations, trusts and estates that:

 

  · at all relevant times are: (i) U.S. persons for purposes of the U.S. Internal Revenue Code of 1986, as amended through the date hereof, or the Code, (ii) nonresidents of Canada for purposes of the Income Tax Act (Canada), or the Income Tax Act, and (iii) residents of the United States for purposes of, and entitled to all the benefits under, the Canada-United States Income and Capital Tax Convention (1980), as amended through the date hereof, or the Tax Treaty;
  · hold common stock as a capital asset for purposes of the Code and capital property for the purposes of the Income Tax Act;
  · deal at arm’s length with, and are not affiliated with, the Company for purposes of the Income Tax Act; and
  · do not and will not use or hold the common stock in carrying on a business in Canada.

 

Persons who satisfy the above conditions are referred to as U.S. Shareholders.

 

The tax consequences of an investment in common stock by persons who are not U.S. Shareholders may differ materially from the tax consequences discussed in this section. The Income Tax Act contains rules relating to securities held by some financial institutions. This Annual Report does not discuss these rules, and holders that are financial institutions should consult their own tax advisors. This discussion is based upon the following, all as currently in effect:

 

  · the Income Tax Act and regulations under the Income Tax Act;
  · the Code and Treasury regulations under the Code;
  · the Tax Treaty;
  · the administrative policies and practices published by the Canada Revenue Agency, formerly Revenue Canada;
  · all specific proposals to amend the Income Tax Act and the regulations under the Income Tax Act that have been publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date of this report;
  · the administrative policies and rulings published by the U.S. Internal Revenue Service, or the IRS; and
  · judicial decisions.

 

All of the foregoing are subject to change either prospectively or retroactively. This summary does not take into account estate or gift tax laws, the tax laws of the various provinces or territories of Canada or the tax laws of the various state and local jurisdictions of the United States or foreign jurisdictions.

 

This discussion summarizes the material U.S. federal and Canadian federal income tax considerations of the ownership and disposition of common stock. This discussion does not address all possible tax consequences relating to an investment in common stock. No account has been taken of your particular circumstances, and this summary does not address consequences peculiar to you if you are subject to special provisions of U.S. or Canadian income tax law (including, without limitation, dealers in securities or foreign currency, tax-exempt entities, banks, insurance companies or other financial institutions, persons that hold common stock as part of a “straddle,” “hedge” or “conversion transaction,” persons acquiring shares upon exercise of stock options or in other compensatory transactions, and U.S. Shareholders that have a “functional currency” other than the U.S. dollar or that own common stock through a partnership, persons that hold common stock other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes) or other pass-through entity). Therefore, you should consult your own tax advisor regarding the tax consequences of purchasing and owning common stock.

 

Material U.S. Federal Income Tax Considerations

 

Subject to the discussion below regarding Passive Foreign Investment Companies and Controlled Foreign Corporations, this section summarizes U.S. federal income tax consequences of ownership and disposition of the common stock.

 

U.S. Shareholders are generally required to include in income dividend distributions, if any, paid by a corporation to the extent of a corporation’s current or accumulated earnings and profits attributable to the distribution as computed based on U.S. income tax principles. The amount of any cash distribution paid in Canadian dollars will be equal to the U.S. dollar value of the Canadian dollars on the date of distribution based on the exchange rate on such date, regardless of whether the payment is in fact converted to U.S. dollars, and without reduction for Canadian withholding tax. For a discussion of Canadian withholding taxes applicable to dividends paid by the Company, see “Material Canadian Federal Income Tax Considerations.” You will generally be entitled to a foreign tax credit or deduction for U.S. federal income tax purposes in an amount equal to the Canadian tax withheld. To the extent distributions paid by the Company on the common stock exceed the Company’s current or accumulated earnings and profits, they will be treated first as a return of capital up to your adjusted tax basis in the shares and then as capital gain from the sale or exchange of the shares.

 

19
 

 

For 2012, under current law, U.S. federal income tax on qualified dividends paid to non-corporate U.S. holders are taxed at a reduced rates of either 0% or 15%. In 2013 rates will be 0%, 15% or 20%. In both years the rate would depend upon the amount of such shareholder’s taxable income. Distributions paid on common stock to a U.S. holder that do not constitute qualified dividends will be treated as ordinary income for U.S. federal income tax purposes. In order to qualify for the reduced tax rates on dividends, a non-corporate shareholder must satisfy certain holding period requirements and must not be under an obligation (whether pursuant to a short sale or otherwise) to make related payments with respect to positions in substantially similar or related property. In some circumstances, this holding period may be increased. If a non-corporate U.S. holder does not hold common stock for more than 60 days during the 120 day period beginning 60 days before an ex-dividend date, dividends received on common stock are not eligible for reduced rates. Additionally, the reduced tax rates do not apply to dividends that a non-corporate shareholder elects to treat as investment income for purposes of Section 163(d)(4) of the Code.

 

Qualified dividend income includes dividends received from a “qualified foreign corporation”, which are eligible for the reduced dividends tax rates for non-corporate shareholders. In general, a Canadian corporation entitled to all the benefits of the Tax Treaty will be treated as a qualified foreign corporation. In addition, a foreign corporation will be treated as a qualified foreign corporation with respect to any dividend paid by that corporation if the stock with respect to which the dividend is paid is readily tradable on an established securities market in the United States. Regardless of the above rules, however, a foreign corporation will not be treated as a qualified foreign corporation if, for the taxable year of the corporation in which the dividend was paid, or the preceding taxable year, the corporation is classified for U.S. tax purposes as a passive foreign investment company, or PFIC (as defined below). Accordingly, any dividends paid by us in a year that we are a PFIC or in the next taxable year would not qualify for the reduced tax rates on dividends paid to non-corporate U.S. holders.

 

Dividends paid by the Company generally will constitute foreign source dividend income and “passive income” for purposes of the foreign tax credit, which could affect the amount of foreign tax credits available to you. The Code applies various limitations on the amount of foreign tax credits that may be available to a U.S. taxpayer.

 

Because of the complexity of those limitations, you should consult your own tax advisor with respect to the availability of foreign tax credits.

 

Dividends paid by the Company on the common stock generally will not be eligible for the “dividends received” deduction available to corporate shareholders, because the Company is a foreign corporation. Note, however, that if a corporate shareholder owns at least 10 percent of our stock and we are not a PFIC (see “Tax Consequences if we are a Passive Foreign Investment Company” below) for a particular year, a dividends received deduction may be available under Section 245 of the Code for any dividends paid by the Company to that shareholder attributable to our U.S.-source earnings.

 

If you sell the common stock, you generally will recognize gain or loss in an amount equal to the difference between the amount realized on the sale and your adjusted tax basis in the shares. Any such gain or loss will be long-term or short-term capital gain or loss, depending on whether the shares have been held by you for more than one year, and will generally be U.S.-source gain or loss, except as otherwise provided in an applicable income tax treaty and if an election is properly made under the Code. Long-term capital gains generally are taxed at lower rates than items of ordinary income. The deductibility of capital losses is subject to limitations.

 

Certain individuals, estates and trusts whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surtax on “net investment income” including, among other things, dividends and net gain from dispositions of property (other than property held in certain trades or businesses).

 

A non-corporate U.S. holder may, under certain circumstances, be subject to information reporting requirements and “backup withholding” at a 28% rate on payments in the United States of dividends on, and the proceeds of disposition of, common stock. Backup withholding with respect to such amounts may apply unless you furnish the paying agent or middleman with a duly completed and signed Form W-9. You will be allowed a refund or a credit equal to any amount withheld under the U.S. backup withholding rules against your U.S. federal income tax liability, provided you furnish the required information to the IRS.

 

Under U.S. federal income tax law and Treasury Regulations, certain categories of U.S. holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. holders that hold certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. holders may be subject to these reporting requirements unless their common stock is held in an account at a domestic financial institution. Penalties for failure to file certain of these information returns are substantial.

 

Tax Consequences if We Are A Passive Foreign Investment Company

 

A foreign corporation generally will be treated as a “passive foreign investment company” (“PFIC”) if, after applying certain “look-through” rules, either (i) 75% or more of its gross income is passive income or (ii) 50% or more of the average value of its assets is attributable to assets that produce or are held to produce passive income. Passive income for this purpose generally includes dividends, interest, rents, royalties and gains from securities and commodities transactions. The look-through rules require a foreign corporation that owns at least 25% by value, of the stock of another corporation to treat a proportionate amount of assets and income as held or received directly by the foreign corporation.

 

20
 

 

The Company has not made the analysis necessary to determine whether or not it is currently a PFIC or whether it has ever been a PFIC.  There can be no assurance that the Company is not, has never been or will not in the future be a PFIC. If the Company were to be treated as a PFIC, any gain recognized by a U.S. holder upon the sale (or certain other dispositions) of common stock (or the receipt of certain distributions) generally would be treated as ordinary income, and a U.S. holder may be required, in certain circumstances, to pay an interest charge together with tax calculated at maximum rates on certain “excess distributions,” including any gain on the sale or certain dispositions of common stock. In order to avoid this tax consequence, a U.S. holder (i) may be permitted to make a “qualified electing fund” election, in which case, in lieu of such treatment, such holder would be required to include in its taxable income certain undistributed amounts of the Company’s income or (ii) may elect to mark-to-market the common stock and recognize ordinary income (or possible ordinary loss) each year with respect to such investment and on the sale or other disposition of the common stock. Additionally, if the Company is deemed to be a PFIC, a U.S. holder who acquires common stock in the Company from a decedent will be denied the normally available step-up in tax basis to fair market value for the common stock at the date of the death and instead will have a tax basis equal to the decedent’s tax basis if lower than fair market value. Neither the Company nor its advisors have the duty to or will undertake to inform U.S. holders of changes in circumstances that would cause the Company to become a PFIC. U.S. holders should consult their own tax advisors regarding the application of the PFIC rules including eligibility for and the manner and advisability of making certain elections in the event the Company is determined to be a PFIC at any point in time after the date of this report. The Company does not currently intend to take the action necessary for a U.S. holder to make a “qualified electing fund” election in the event the Company is determined to be a PFIC.

 

Tax Consequences if We are a Controlled Foreign Corporation

 

A foreign corporation will be treated as a “controlled foreign corporation” (“CFC”) for United States federal income tax purposes if, on any day during the taxable year of such foreign corporation, more than 50% of the equity interests in such corporation, measured by reference to the combined voting power or value of the equity of the corporation, is owned directly or by application of the attribution and constructive ownership rules of Sections 958(a) and 958(b) of the Code by United States Shareholders. For this purpose, a “United States Shareholder” is any United States person that possesses directly, or by application of the attribution and constructive ownership rules of Sections 958(a) and 958(b) of the Code, 10% or more of the combined voting power of all classes of equity in such corporation. If a foreign corporation is a CFC for an uninterrupted period of 30 days or more during any taxable year, each United States Shareholder of the corporation who owns, directly or indirectly, shares in the corporation on the last day of the taxable year on which it is a CFC will be required to include in its gross income for United States federal income tax purposes its pro rata share of the CFC’s “Subpart F income,” even if the Subpart F income is not distributed. Subpart F income generally includes passive income but also includes certain related party sales, manufacturing and services income.

 

United States persons who might, directly, indirectly or constructively, acquire 10% or more of the shares of the Company or any of its non-U.S. subsidiaries, and therefore might be a United States Shareholder, should consider the possible application of the CFC rules, and consult a tax advisor with respect to such matter.

 

Material Canadian Federal Income Tax Considerations

 

This section summarizes the material anticipated Canadian federal income tax considerations relevant to the ownership and disposition of the common stock.

 

Under the Income Tax Act, assuming you are a U.S. Shareholder, and provided the common stock is listed on a designated stock exchange, which includes the TSX, you will generally not be subject to Canadian tax on a capital gain realized on an actual or deemed disposition of the common stock unless: (A) you alone or together with persons with whom you did not deal at arm’s length owned or had rights to acquire 25% or more of our issued shares of any class at any time during the sixty (60) month period before the actual or deemed disposition; and (B) more than 50% of the fair market value of the common stock is derived directly or indirectly from (i) real or immovable property situated in Canada; (ii) Canadian resource properties; (iii) timber resource properties; and (iv) options in respect of (i), (ii) or (iii) during the sixty (60) month period that precedes the disposition. Based upon our review of our financial data for the current and prior fiscal years, we have determined that the common stock does not currently derive, and has not derived during the past sixty (60) months, more than 50% of its fair market value from the property listed above, and this characterization of the common stock will likely continue.

 

Dividends paid, credited or deemed to have been paid or credited on the common stock to U.S. Shareholders will be subject to a Canadian withholding tax under the Income Tax Act at a rate of 25% of the gross amount of the dividends. Under the Tax Treaty, the rate of withholding tax on dividends generally applicable to U.S. Shareholders who beneficially own the dividends is reduced to 15%. In the case of U.S. Shareholders that are corporations that beneficially own at least 10% of the Company’s voting shares, the rate of withholding tax on dividends generally is reduced to 5%. So-called "fiscally transparent" entities, such as United States limited liability companies, or LLCs, are not entitled to rely on the terms of the Tax Treaty, and therefore do not benefit from these reduced rates, however, reduced rates under the Tax Treaty apply to members of fiscally transparent entities who would be entitled to rely on the Tax Treaty if they held the common stock directly. Members of such entities are regarded as holding their proportionate share of the common stock held by the entity for the purposes of the Tax Treaty.

 

Canada does not currently impose any federal estate taxes or succession duties. However, if you die, there is a deemed disposition of the common stock held at that time for proceeds of disposition generally equal to the fair market value of the common stock immediately before your death. Capital gains realized on the deemed disposition, if any, will have the income tax consequences described above.

 

21
 

 

Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

CAUTIONARY STATEMENT

 

The discussion below contains forward-looking statements regarding our financial condition and our results of operations that are based upon our annual consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles within the United States, or U.S. GAAP, and applicable U.S. Securities and Exchange Commission, or SEC, regulations for financial information. The preparation of these financial statements requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based on historical experience and on various other assumptions that we believe to be reasonable.

 

Overview

 

In December 2008 we received notice from the American Stock Exchange that we were not in compliance with Section 1003(a)(ii) of its Company Guide, because our stockholders’ equity was below $6 million and we incurred losses from continued operation and net losses in the five most recent fiscal years. On January 29, 2009, we voluntarily filed to delist our common stock from the American Stock Exchange and effective January 29, 2009 our common stock was no longer traded on the American Stock Exchange. As a result, any trading of our common stock in the U.S. must now be conducted in the over-the-counter markets. Our common stock continues to trade on the Toronto Stock Exchange. The Toronto Stock Exchange also has continued listing standards, including minimum market capitalization and other requirements, that we might not meet in the future, particularly if the price of our common stock does not increase or we are unable to raise capital to continue our operations. On September 18, 2012, the Toronto Stock Exchange issued an official delisting review of our common stock. On January 7, 2013, the Toronto Stock Exchange announced that it had completed its review of the common shares of the Company and had determined that the Company meets TSX's continued listing requirements.

 

On August 25, 2011,Adherex filed Articles of Amendment under the Canada Business Corporations Act to implement a one-for-eighteen reverse split of our common stock (defined herein as the “Share Consolidation”). As a result of the Share Consolidation, every eighteen shares of common stock outstanding on August 25, 2011 were combined into one share of common stock. Our common stock began trading on the Toronto Stock Exchange and the OTC market (on the OTCQB tier) on a post-Share Consolidation basis on August 30, 2011.The share consolidation reduced the number of shares of the Company's outstanding common stock from approximately 452.8 million, to approximately 25.2 million effective as of August 25, 2011, the effective date of the Share Consolidation.Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis.

 

Our current prioritization initiative focuses primarily on our clinical activities with Eniluracil, as well as logistical and product support of ongoing clinical programs. Eniluracil was previously under development by GlaxoSmithKline. GlaxoSmithKline advanced Eniluracil into a comprehensive Phase III clinical development program that did not produce positive results and GlaxoSmithKline terminated further development. We developed a hypothesis as to why the GlaxoSmithKline Phase III trials were not successful and licensed the compound from GlaxoSmithKline in July 2005. We believe that Eniluracil might enhance and expand the therapeutic spectrum of activity of 5-FU, reduce the occurrence of a disabling side effect known as hand foot syndrome and allow 5-FU to be given orally. In April of 2011, we commenced a Phase II trial comparing the anti-tumor activity and safety of Eniluracil plus 5-FU and leucovorin regimen (treatment Arm 1) versus Xeloda® (capecitabine) (treatment Arm 2) for Metastatic Breast Cancer. Patients who have disease progression in Arm 2 may crossover to take Eniluracil plus 5-FU and leucovorin (Treatment Arm X).We expect the proceeds we received from the April 2010 Private Placement and the Rights Offering completed in March 2011 will be sufficient to fund the Phase II trial. We expect results from those trials to be indicative of the future viability of Eniluracil and will allow us to assess whether further development and testing of Eniluracil is warranted. The Phase II trial completed enrollment at the end of 2012. The Company enrolled 153 patients and anticipates that final safety and efficacy data will be available during the second or third quarter of 2013. We do not presently have the financial or human resources to complete Phase III trials for Eniluracil. If our Phase II trial for Eniluracil is successful, and if we decide to continue to develop Eniluracil, we will need additional funding, or we will need to enlist a partner to conduct future trials.

 

Patient enrollment is continuing in the Phase III trials of STS conducted by the International Childhood LiverTumour Strategy Group, known as SIOPEL and the Children's Oncology Group. Each of these trials is managed by SIOPEL and the Children’s Oncology Group, respectively, and each group is responsible for the costs of the trial. We continue to hold STS patents and our responsibility in the testing is limited to providing the drug, drug distribution and pharmacovigilance, or safety monitoring, for the study. The SIOPEL trial is expected to enroll approximately 100 pediatric patients with liver (hepatoblastoma) cancer at participating SIOPEL centers worldwide and the Children's Oncology Group study is expected to enroll up to 135 pediatric patients worldwide in five different disease indications. The Company's Children Oncology Group study completed during the first half of 2012 with the final results expected during the second or third quarter of 2013. The SIOPEL trial has enrolled 69 patients as of March 16, 2013.

 

In addition to our current development efforts with Eniluracil, we continue to pursue collaborations with other pharmaceutical and biotechnology companies, governmental agencies, academic or other corporate collaborators with respect to these candidate molecules. Some of these preclinical candidates are currently being tested under agreements with third parties that may help to advance these products into future clinical development, either by us or under investigator-initiated studies.

 

22
 

 

We have not received and do not expect to have significant revenues from our product candidates until we are either able to sell our product candidates after obtaining applicable regulatory approvals or we establish collaborations that provide us with up-front payments, licensing fees, milestone payments, royalties or other revenue. We experienced net losses of approximately$5.2 million for the twelve months ended December 31, 2012 and generated net income of $4.7 million for the twelve months ended December 31, 2011 (as a result of a non-cash gain on derivatives of $8.1 million). As of December 31, 2012, our deficit accumulated during development stage was approximately $110.5 million.

 

As a result of our limited financial resources we have postponed or terminated many of our previously planned or ongoing clinical development programs including our cadherin technology platform. We continue to pursue various strategic alternatives, including collaborations with other pharmaceutical and biotechnology companies. As a result, there is uncertainty of our ability to continue as a going concern. Our projections of our capital requirements are subject to substantial uncertainty. More capital than we anticipated may be requiredthereafter. To finance our continuing operations we will need to raise substantial additional funds through either the sale of additional equity, the issuance of debt, the establishment of collaborations that provide us with funding, the out-license or sale of certain aspects of our intellectual property portfolio or from other sources. Given current economic conditions, we might not be able to raise the necessary capital or such funding may not be available on financially acceptable terms if at all. If we cannot obtain adequate funding in the future, we might be required to further delay, scale back or eliminate certain research and development studies, consider business combinations or even shut down some, or all, of our operations.

 

Our operating expenses will depend on many factors, including the progress of our drug development efforts and the implementation of further cost reduction measures. Our research and development expenses, which include expenses associated with our clinical trials, drug manufacturing to support clinical programs, salaries for research and development personnel, stock-based compensation, consulting fees, sponsored research costs, toxicology studies, license fees, milestone payments, and other fees and costs related to the development of product candidates, will depend on the availability of financial resources, the results of our clinical trials and any directives from regulatory agencies, which are difficult to predict. Our general and administration expenses include expenses associated with the compensation of employees, stock-based compensation, professional fees, consulting fees, insurance and other administrative matters associated in support of our drug development programs.

 

Results of Operations

 

Fiscal 2012 versus Fiscal 2011

 

In thousands of U.S. Dollars  Fiscal
 2012		   %   Fiscal 
2011		   %   Increase
(Decrease)		 
                          
Revenue  $-        $-        $- 
Operating expenses:                         
Research and development   2,075    57%   1,494    43%   581 
General and administration   1,545    43%   1,944    57%   (399)
Total operating expense   3,620    100%   3,438    100%   182 
                          
Other (Loss) Income   (1,563)        8,071         (9,634)
Interest income   20         52         (32)
                          
Net (loss) income  $(5,163)       $4,685        $(9,848)

 

  · Research and development expenses were higher in fiscal 2012, as compared to fiscal 2011 primarily due to higher average patient participation in the Phase 2 study with Eniluracil and related costs. In fiscal 2012, 83 patients were enrolled in the Phase 2 study with Eniluracil compared with 70 patients enrolled in fiscal 2011.  In fiscal 2012, 112 patients participated in the Phase 2 study with Eniluracil compared with 70 patients participating in fiscal 2011.
  · General and administrative expenses decreased primarily as a result of the approximately $0.3 million in costs related to the 2011 rights offering which did not recur in 2012.
  · Other income decreased $9.6million as a result of change in the fair value of derivatives.
  · Interest income decreased in fiscal 2012, as compared to 2011 due to a lower average cash balance for the comparable periods.

 

Quarterly Information

 

The following table presents selected consolidated financial data for each of the last eight quarters through December 31, 2012, as prepared under U.S. GAAP (dollars in thousands, except per share information). Share information has been restated to reflect the share consolidation in 2012:

 

Period  Net (Loss)/Income for
the
Period		   Basic and Diluted
Net (Loss)/Income per
Common Share		 
March 31, 2011  $4,669   $0.23 
June 30, 2011  $(348)  $(0.01)
September 30, 2011  $(3,144)  $(0.17)
December 31, 2011  $3,508   $0.14 
March 31, 2012  $2,715   $0.11 
June 30, 2012  $(602)  $(0.02)
September 30, 2012  $(764)  $(0.03)
December 31, 2012  $(6,511)  $(0.26)

 

23
 

 

   December
31,		   December
31,		 
Dollars in thousands  2012   2011 
Selected Asset and Liability Data:          
Cash and cash equivalents  $2,303   $5,297 
Other current assets   62    54 
Capital assets   —    — 
Current liabilities excluding derivative warrant liability   682    394 
Derivative warrant liability   6,640    5,077 
Long term liabilities   -    - 
Working capital[Current Assets – Current Liabilities excluding derivative liability]   1,683    4,957 
           
Selected Equity:          
Common stock  $65,952   $65,952 
Accumulated deficit   (110,543)   (105,380)
Shareholders’ (deficit)   (4,957)   (120)

 

Liquidity and Capital Resources

 

·The decrease in cash and cash equivalents between December 31, 2011 and December 31, 2012 is due to clinical trial expenses related to our Phase II study of Eniluracil and our general and administrative expenses.
·The increase in other current assets between December 31, 2011 and December 31, 2012 is a result of an increase in prepaid insurance expenses.
·Our liabilities increased $1.9 million between December 31, 2011 and December 31, 2012. The increase was primarily a result of the valuation of the derivative liability at the two valuation dates as well as an increase in accrued liabilities from costs related to the Phase 2 study of Eniluracil.
·Current liabilities excluding derivative warrant liability increased between December 31, 2011 and December 31, 2012. The increase was due to a December 31, 2012 accrual for research and development expenses which reflects a timing difference in invoicing as compared to December 31, 2011.
·At December 31, 2012, our working capital decreased by approximately $3.3 million from December 31, 2011 due to operating expenses for the year.

 

   12 Months
Ended
December
31,		   12 Months
Ended
December
31,		 
Dollars and shares in thousands  2012   2011 
Selected Cash Flow Data:          
Net cash used in operating activities  $(2,994)  $(3,226)
Net cash provided from financing activities   -    2,566 
 Net cash provided from investing activities   -    - 
Number of shares of common stock outstanding   25,158    25,158 

 

The net cash flow used in operating activities for the year ended December 31, 2012 was approximately $3.0 million as compared to $3.2 million during the same period in 2011. This decrease is due to adecrease in our overall administrative activities during the fiscal year ended December 31, 2012, as compared to the same period in 2011.  Our administrative activities decreased from fiscal year 2012 to fiscal year 2011 due to $0.3 million in costs incurred related to the 2011 rights offering during fiscal 2011. During fiscal 2012 our average monthly cash burn was $0.25 million, as compared to $0.26 million for fiscal 2011.  
 

24
 

 

On July 7, 2009, we announced that we intended to primarily focus our remaining financial resources on the development of Eniluracil.  In 2009, we terminated our Eniluracil study using our topical formulation and decided to focus our resources on the development of a redesigned study combining Eniluracil and 5-fluorouracil, or 5-FU, targeting anti-cancer indications. We continue to pursue various strategic alternatives including collaborations with other pharmaceutical and biotechnology companies. Our projections of further capital requirements are subject to substantial uncertainty. Our working capital requirements may fluctuate in future periods depending upon numerous factors, including: our ability to obtain additional financial resources; our ability to enter into collaborations that provide us with up-front payments, milestones or other payments; results of our research and development activities; progress or lack of progress in our preclinical studies or clinical trials; unfavorable toxicology in our clinical programs, our drug substance requirements to support clinical programs; change in the focus, direction, or costs of our research and development programs; headcount expense; the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our patent claims; competitive and technological advances; the potential need to develop, acquire or license new technologies and products; our business development activities; new regulatory requirements implemented by regulatory authorities; the timing and outcome of any regulatory review process; and commercialization activities, if any.

 

We had cash and cash equivalents of approximately $2.3 million as of December 31, 2012. On April 30, 2010, we announced that we had completed a first closing of a non-brokered private placement of 240,066,664 Units, at a price of CAD$0.03 per Unit for gross proceeds of CAD$7.2 million. On March 29, 2011 we completed a Rights Offering to our shareholders for an aggregate of 84,559,178 Units, representing total proceeds of approximately $2.5 million. These financings allowed for the development of our Phase II trial of Eniluracil and the Phase III trials of STS.

 

Financial Instruments

 

We invest excess cash and cash equivalents in high credit quality investments held by financial institutions in accordance with our investment policy designed to protect the principal investment. At December 31, 2012, we had approximately $0.1 million in our cash accounts and $2.2 million in our money market accounts. We have not experienced any loss or write down of our money market investments for the year ended December 31, 2012 or for any other year since the inception of the company.

 

Our investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments may be made in U.S. or Canadian obligations and bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted average time to maturity of twelve months. This policy applies to all of our financial resources. The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As our main purpose is research and development, we have chosen to avoid investments of a trading or speculative nature.

 

We classify investments with original maturities at the date of purchase greater than three months which mature at or less than twelve months as current. We carry investments at their fair value with unrealized gains and losses included in other comprehensive income (loss); however we have not held any instruments that were classified as short term investments during the periods presented in this Annual Report.

 

Off-Balance Sheet Arrangements

 

Since our inception, we have not had any material off-balance sheet arrangements.

 

Contractual Obligations and Commitments

 

Since our inception, inflation has not had a material impact on our operations. We had no material commitments for capital expenses or contractual obligations beyond 3 years as of December 31, 2012.  The following table represents our contractual obligations and commitments at December 31, 2012 (in thousands of U.S. dollars):

 

   Less than
1 year		   1-3
years		   Total 
OCT Clinical Service Agreement (1)   402    -    402 
Oregon Health & Science University (2), excluding potential royalty payments   -    -    - 
Life Sci Advisors, LLC (3)   55    -    55 
Total  $457   $-   $457 

 

(1) Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia.  The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients.  The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled.
(2) Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million.  Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included.

  

25
 

  

(3) Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of a six month agreement.  Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.  

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. These estimates are based on assumptions and judgments that may be affected by commercial, economic and other factors. Actual results could differ from these estimates.

 

An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact the financial statements. The following description of critical accounting policies, judgments and estimates should be read in conjunction with our December 31, 2012 consolidated financial statements.

 

Stock-based Compensation

 

The calculation of the fair values of our stock-based compensation plans requires estimates that require management‘s judgments.  Under ASC 718, the fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model. The valuation models require assumptions and estimates to determine expected volatility, expected life, expected dividends and expected risk-free interest rates. The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. The risk-free interest rate assumption was based on the yield on zero-coupon U.S. Treasury strips at the award grant date. We also used historical data to estimate forfeiture experience.  In valuing options granted in the year ended December 31, 2012 and fiscal year ended December 31, 2011 we used the following weighted average assumptions:

 

   

Year Ended

December

31, 2012

    

Year Ended

December

31, 2011

  
Expected dividend     0 %     0 %
Risk-free interest rate     1.09-1.26 %     1.85-2.5 %
Expected volatility     118-133 %     121-132 %
Expected life   7 years     7 years  

 

Common stock and warrants

 

Common stock is recorded as the net proceeds received on issuance after deducting all share issuance costs and the value of investor warrants.  Warrants are recorded at fair value and are deducted from the proceeds of common stock and recorded on the consolidated statements of stockholders’ equity as additional paid-in capital.

 

Derivative Instruments

 

Effective January 1, 2009, the Company adopted ASC Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in shareholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' deficiency.

 

The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:

 

·Warrants to purchase 13,337 shares at CAD$1.44 per whole share that expire on April 30, 2015; and
·Warrants to purchase 4,698 shares exercisable at CAD$1.44 per whole share that expire on March 29, 2016.

 

26
 

 

These warrants have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.

As of December 31, 2012, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $4,698 and $1,847, respectively (December 31, 2011 – warrants expiring April 30, 2015, fair value of $3,672, March 29, 2016, fair value of $1,340), and the loss on these warrants for the twelve months ended December 31, 2012 was $1,026 and $507, respectively (December 31, 2011 - warrants expiring April 30, 2015, gain of $6,778; March 29,2016, gain of $643). There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.

 

Gain/(Loss) on Derivative Instruments   Twelve months ended December 31, 2012    Twelve months ended December 31, 2011 
Warrant expiring April 15, 2015   (1,026)   6,778 
Warrant expiring March 29, 2016   (507)   643 
Rights offering derivative   -    613 
Options to contractors   (30)   37 
Total   (1,563)   8,071 

 

Outstanding Share Information

 

Our outstanding share data at December 31, 2012 follows (in thousands):

 

   December 31,
2012		 
Common shares   25,158 
Warrants   18,035 
Stock options   5,498 
Total   48,684 

 

New Accounting Pronouncements Adopted

 

On May 12, 2011, the FASB issued ASU 2011-04 “Fair Value Measurement Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. Specifically, this update will require (a) an entity to disclose separately the amounts of significant transfers into and out of Level 1 and 2 fair value measurements and to describe the reasons for the transfers; and (b) information about purchases, sales, issuances, and settlements to be presented separately on a gross basis in the reconciliation of Level 3 fair value measurements. Level 3 reconciliation disclosures are effective for annual and interim periods beginning after December 15, 2011. The adoption of the guidance to has not had a significant impact on the Company’s consolidated financial position and results of operations.

 

In June 2011, the FASB released ASU 2011-05, “Comprehensive Income (Topic 220) – Presentation of Comprehensive Income”. This update requires and entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income in either a single continuous statement or two separate but consecutive statements. This guidance does not change the items that must be reported in other comprehensive income. Subsequently, in December 2011, the FASB issued ASU 2011-12 which deferred some aspects of the June guidance that relate to the presentation of reclassification adjustments. ASU 2011-05 is now effective for fiscal years and interim periods within those years, beginning after December 15, 2012. The adoption of this standard to has not had a significant impact on the Company’s consolidated financial position or results of operations.

 

Recent Accounting Pronouncements

 

In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company is required to adopt this ASU in the first quarter for fiscal 2013.

 

27
 

 

Item7A.  Quantitative and Qualitative Disclosures About Market Risk

 

Money Market Investments

 

We maintain an investment portfolio consisting of U.S. or Canadian obligations and bank securities and money market investments in compliance with our investment policy. We do not hold any mortgaged-backed investments in our investment portfolio. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted average time to maturity of twelve months. This policy applies to all of our financial resources.

 

At December 31, 2012, we had $2.2 million in money market investments as compared to $5.1 million at December 31, 2011; these investments typically have minimal risk. The financial markets had been volatile resulting in concerns regarding the recoverability of money market investments, but those conditions have stabilized. We have not experienced any loss or write down of our money market investments for the years ended December 31, 2012 and 2011.

 

Our investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Our risk associated with fluctuating interest rates on our investments is minimal and not significant to the results of operations. We currently do not use interest rate derivative instruments to manage exposure to interest rate changes. As the main purpose is research and development, we have chosen to avoid investments of a trade or speculative nature.

 

Foreign Currency Exposure

 

We are subject to foreign currency risks as we conduct certain clinical development activities in Canada, the United Kingdom, Europe and the Pacific Rim. To date, we have not employed the use of derivative instruments; however, we do hold Canadian dollars which we use to pay certain clinical development activities conducted in Canada and research, and other corporate obligations. At December 31, 2012 we held less than one thousand Canadian dollars.

 

Item 8.  Financial Statements and Supplementary Data

 

The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K.  A list of the financial statements filed herewith is found at “Index to Financial Statements” on Page F-1.

 

Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A.  Controls and Procedures

 

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

 

In connection with the preparation of this report, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”)) as of December 31, 2012. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were not effective as a result of having identified one material weakness in our internal control over financial reporting, as described in further detail below under “Management’s Annual Report on Internal Control over Financial Reporting.”

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended.  The Company’s internal control over financial reporting is a process, under the supervision of the Chief Executive Officer and the Chief Financial Officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). The Company’s management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2012, based on the criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on the aforementioned criteria, our management concluded in its assessment of internal control over financial reporting that our internal control procedures, as of December 31, 2012, were not effective, as a result of having identified one material weakness in our internal control over financial reporting, as described in further detail below.

 

28
 

 

Our management has identified a control deficiency because we lack sufficient staff to segregate accounting duties.  We believe the control deficiency results primarily because we have one full time employee performing all accounting and financial reporting duties. As a result, we do not maintain adequate segregation of duties within our critical financial reporting applications, the related modules and financial reporting processes. This control deficiency could result in a misstatement of balance sheet and income statement accounts in our interim or annual financial statements that would not be detected.  Accordingly, management has determined that this control deficiency constitutes a material weakness.

 

After the Company filed its Current Report on Form 8-K under Item 4.02 on November 2, 2010, the Company took remedial actions for our previously reported internal control weakness of not maintaining sufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of U.S. GAAP commensurate with our complexity and our financial accounting and reporting requirements. In 2012, the Company has contracted additional personnel with experience in the application of U.S. GAAP financial accounting and reporting requirements in order to assist management in its financial accounting and reporting functions. As a result, the Company believes that this added experience and knowledge has remediated the previously disclosed material internal control weakness described above.

 

Further, the Company believes that this has helped remedy, but has not eliminated, the control deficiency described above regarding lack of sufficient staff to segregate accounting duties. To finance our continuing operations, we will need to raise additional funds beyond those from our April 2010 private placement and the Rights Offering and, as disclosed elsewhere in this report, there remains substantial uncertainty of our ability to continue as a going concern and the failure to obtain such funds might require us to further delay, scale back or eliminate certain research and development studies, consider business combinations, or even shut down some, or all, of our operations. Once we are able to secure such additional financing, we anticipate hiring additional personnel with appropriate technical accounting knowledge, experience, and training in the application of U.S. GAAP to supplement our current accounting staff.

 

Changes in Internal Control over Financial Reporting

 

 There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control over financial reporting that occurred during the last fiscal quarter covered by this Annual Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B.  Other Information

 

None.

 

29
 

 

PART III

 

Item 10.  Directors, Executive Officers and Corporate Governance

 

 The following table sets forth the name of each of our executive officers and directors, such person’s principal occupation or employment, all other positions with Adherex and any significant affiliate thereof now held by such person, if any, the year in which such person became a director of Adherex and such person’s age.

 

The Corporation has an Audit Committee, a Compensation Committee, and a Governance Committee. The current members of such committees are noted below:

 

Name and Province/State and Country of

Residence, Position

  

Current Principal Occupation

and Principal Occupation

For Previous Five Years

   Director Since   Age
             

Robert Andrade

Texas, USA

Chief Financial Officer, Director

   Co-Founder and Manager, DCML LLC; previously Portfolio Manager Millennium Partners; previously analyst Caxton Associates   July 2009   37
             

David Lieberman (1)(2)(3)

New York, USA

Director, Chairman of Board

   Analyst Southpoint Capital Advisors LP; previously analyst Tiedemann Investment Group.   June 2010   36
             

Chris A. Rallis (1)(2)(3)

North Carolina, USA

Director

   Executive in-residence at Pappas Ventures; previously, CEO of ImmunoBiosciences   August 2011   59
             

Rostislav Raykov

New Jersey, USA

Chief Executive Officer, Director

   Co-Founder and Manager, DCML LLC; previously Portfolio Manager Alchem Partners; previously Portfolio Manager John Levin & Associates   July 2009   37
             

Steven D. Skolsky (1)(2)(3)

North Carolina, USA

Director

   Global Head of Clinical and Data Operations at Quintiles Transnational; previously CEO of Sequoia Pharmaceuticals   August 2011   57
             

Dr. Thomas Spector

Chief Scientific Officer

   President of Spector Consulting Services   N/A   69

 

(1)         Member of the Audit Committee

(2)         Member of the Compensation Committee

(3)         Member of the Governance Committee

 

Robert C. Andrade

 

Mr. Andrade has served as a director of Adherex since July 2009 and Chief Financial Officer since September 2009.  Mr. Andrade is a General Partner at DCML, a private investment partnership.  Prior to DCML, Mr. Andrade was a portfolio manager for Millennium Partners from November 2005 until December 2007 and a securities analyst for Caxton Associates from March 2003 until November 2005. Prior to Caxton Associates LLC, Mr. Andrade was a private equity associate at Trimaran Capital Partners (2000-2003) and an investment banking analyst at  Bear Stearns (1997-1999).  Mr. Andrade graduated from University of Southern California, where he earned a Masters of Arts degree and Bachelor of Arts degree in economics. As a result of these and other professional experiences, Mr. Andrade possesses particular knowledge and experience in financial analysis and capital markets that strengthen the Board’s collective qualifications, skills, and experience.

 

David Lieberman

 

Since February, 2002, Mr. Lieberman has been an analyst at Southpoint Capital Advisors LP, a private investment partnership with more than $1 billion in assets under management.  Prior to Southpoint, Mr. Lieberman was an analyst for Tiedemann Investment Group.  Mr. Lieberman graduated from University of Pennsylvania, The Wharton School, where he earned a Bachelor of Science degree in economics. In addition to his financial and investment background, as a designee of one of the Company’s largest investors, he brings to the Board the perspective of a major stakeholder.

 

30
 

 

Chris A. Rallis

 

Mr. Chris A. Rallis has served as a director of Adherex since August 2011. Mr. Rallis has been an executive-in-residence at Pappas Ventures, a life science venture capital firm since January 2008. Previously, Mr. Rallis was the President and Chief Executive Officer of ImmunoBiosciences, Inc. (“IBI”), a vaccine technology company formerly located in Raleigh, North Carolina from April 2006 through June 2007.  Prior to joining IBI, Mr. Rallis served as an executive in residence (part time) for Pappas Ventures, and as a consultant for Duke   University and Panacos Pharmaceuticals, Inc.  Mr. Rallis is the former President and Chief Operating Officer and director of Triangle Pharmaceuticals, Inc.,  which was acquired by Gilead Sciences in January 2003 for approximately $465  million. Prior to assuming the role of President and COO in March 2000, he was Executive Vice President, Business Development and General Counsel.  While at Triangle, Mr. Rallis  participated in 11 equity financings generating gross proceeds of approximately $500 million. He was also primarily responsible for all business development activities which included a worldwide alliance with Abbott Laboratories and the in-licensing of ten compounds.  Before joining Triangle in 1995, Mr. Rallis served in various business development and legal management roles with Burroughs Wellcome Co. over a 13-year period, including Vice President of Strategic Planning and Business Development.  Mr. Rallis also serves on the boards of Aeolus Pharmaceuticals, a biopharmaceutical company located in Mission Viejo, California and Oxygene Biotherapeutics, a biopharmaceutical company located in Morrisville, North Carolina. Mr. Rallis received his A.B. degree in economics from Harvard College and a J.D. from Duke University. As a result of these and other professional experiences, Mr. Rallis possesses particular healthcare industry knowledge and experience which strengthens the Board’s collective qualifications, skills, and experience.

 

Rostislav Raykov

 

Mr. Raykov has served as a director of Adherex since July 2009 and as Chief Executive Officer since July 2009.  Since May 2007, Mr. Raykov has been a General Partner at DCML, a private investment partnership. Prior to DCML, from January 2006 to December 2007, Mr. Raykov was a portfolio manager for Alchem Investment Partners and John Levin & Co Prior to founding Alchem, Mr. Raykov was a portfolio manager and securities analyst for John A. Levin & Co. Event Driven Fund (2002-2005). Prior to joining John A. Levin & Co., Mr. Raykov was a securities analyst for the Merger Fund at Tiedemann Investment Group (1999-2002) and an investment banking analyst at Bear Stearns (1998-1999).  Mr. Raykov earned a B.S. in Business Administration from the University of North Carolina at Chapel Hill. As a result of these and other professional experiences, Mr. Raykov has financial expertise and experience with the Company as it has developed within the drug development industry and, as such, is able to provide the Company with unique insight and guidance.

 

Steven D. Skolsky

 

Mr. Steven D. Skolsky has served as a director since August 2011. With a distinguished career spanning 30 years in the life sciences, Mr. Skolsky is a recognized industry leader who has held numerous international general management and executive leadership roles in the pharmaceutical and biotech sectors with a principal emphasis on commercialization, product strategy, and new product development. He was recently appointed to the position of Global Head of Clinical and Data Operations at Quintiles Transnational after serving as Principal of EXPIS Partners, a strategic life science consultancy. Mr. Skolsky also currently serves on the Board of BasileaPharmaceutica, a Swiss based biopharmaceutical company where he previously served as Vice Chairman of the Board. Mr. Skolsky is the former President and Chief Executive Officer of Sequoia Pharmaceuticals, a privately held company specializing in novel antiviral therapeutics. Prior to his appointment at Sequoia, he held the position of Chief Executive Officer at Trimeris, Inc., a publicly held company that discovered and commercialized Fuzeon®, a first- in-class HIV therapeutic in collaboration with partner F. Hoffmann-La Roche. Previously, Mr. Skolsky served over 20 years at GlaxoSmithKline in a range of senior leadership roles, including Senior Vice President of Global Product Strategy and Clinical Development, Managing Director of GSK’s operations in Australia and New Zealand and Head of GlaxoWellcome’s Division of HIV/Oncology. Mr. Skolsky received his Bachelor’s Degree in Biology from the University of North Carolina at Chapel Hill. As a result of these and other professional experiences, Mr. Skolsky possesses particular healthcare industry knowledge and experience which strengthens the Board’s collective qualifications, skills, and experience.

 

Dr. Thomas Spector, PhD.

 

Dr. Spector was appointed Chief Scientific Officer at Adherex in July 2009.  He is President of Spector Consulting Services.  Dr. Spector is the principal inventor of the Eniluracil / 5-fluorouracil treatment. In 2004, he discovered why the dosing regimen in Glaxo’s Phase III clinical trial was not optimal. Dr. Spector has authored and co-authored over 100 scientific articles, including 25 manuscripts on Eniluracil / 5-fluorouracil. He has over 35 years of experience in drug discovery and development and was the Assoc. Division Director of Experimental Therapy at Burroughs Wellcome and The International Vice President of Cancer Research at GlaxoWellcome (now GSK). Dr. Spector received a Ph.D. in Pharmacology from Yale University.

 

Audit Committee

 

On behalf of the Board, the Audit Committee of the Board retains, oversees and evaluates Adherex’s independent auditors, reviews the financial reports and other financial information provided by Adherex, including audited financial statements, and discusses the adequacy of disclosure with management and the auditors. The Audit Committee also reviews the performance of the independent auditors in the annual audit and in assignments unrelated to the audit, assesses the independence of the auditors, and reviews their fees. The Audit Committee is also responsible for reviewing Adherex’s internal controls over financial reporting and disclosure. The Audit Committee operates under a written charter adopted by the Board.

 

31
 

 

The directors have appointed an Audit Committee consisting of three directors; Chris A. Rallis, David Lieberman and Steven Skolsky, all of whom are independent and financially literate within the meaning of National Instrument 52-110 – Audit Committees. In addition, the Board has determined that Mr. Rallis qualifies as an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K promulgated by the SEC.Mr. Rallis has been an executive-in-residence at Pappas Ventures, a life science venture capital firm since January 2008.  Previously, Mr. Rallis was the President and Chief Executive Officer of ImmunoBiosciences, Inc. (“IBI”), a vaccine technology company formerly located in Raleigh, North Carolina from April 2006 through June 2007. Mr. Lieberman has been an analyst at Southpoint Capital Advisors LP, a private investment partnership with more than $1 billion in assets under management. Prior to Southpoint, Mr. Lieberman was an analyst for Tiedemann Investment Group. Mr. Skolsky was recently appointed to the position of Global Head of Clinical and Data Operations at Quintiles Transnational after serving as Principal of EXPIS Partners, a strategic life science consultancy. Mr. Skolsky also currently serves on the Board of BasileaPharmaceutica, a Swiss based biopharmaceutical company where he previously served as Vice Chairman of the Board. Several of these directors has held various director and/or executive officer positions with private and public companies and/or community organizations and has had responsibility for the supervision of the preparation of financial materials and disclosure documents for public and private corporations.

 

Code of Ethics

 

In February 2004, Adherex’s Board adopted a Mandate of the Board of Directors, Corporate Governance Guidelines and a Code of Business Conduct and Ethics (the “Code”) applicable to all officers, directors and employees of Adherex. Adherex is committed to adhering to applicable legal requirements and maintaining the highest standards of conduct and integrity. The Code sets out the legal and ethical standards of conduct for personnel of Adherex and addresses topics such as: reporting obligations and procedures; honest and ethical conduct and conflicts of interest; compliance with applicable laws and Corporation policies and procedures; confidentiality of corporate information; use of corporate assets and opportunities; public disclosure and books and records; and non-retaliation. Adherex undertakes to provide to any person without charge, upon request, a copy of such Code by writing to Attn: Code of Ethics Request, Adherex Technologies Inc., 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, North Carolina 27709.

 

Item 11.  Executive Compensation

 

Summary Compensation Table

 

The following table sets out certain information respecting the compensation paid to our Chief Executive Officer, as well as Chief Financial Officer and any executive officer of the Company whose total compensation for the fiscal years ended December 31, 2012 and December 31, 2011 exceeded $100,000.

 

Name and Principal Position  Year  Salary
($)		   Bonus
($)		   Option
Awards
($)(1)		   Non-Equity
Incentive Plan
Compensation
($)(2)		   All Other
Compensation
($)(3)		   Total
($)		 
Rostislav Raykov, Chief  2012   140,000    -    48,012    -    -    188,012 
Executive Officer  2011   140,000    -    32,226    -    -    172,226 
                                  
Robert Andrade, Chief  2012   140,000    -    48,012    -    -    188,012 
Financial Officer  2011   140,000    -    32,226    -    -    172,226 
                                  
Dr. Thomas Spector  2012   150,000    -    48,012    -    -    198,012 
Chief Scientific Officer  2011   150,000    -    32,226    -    -    182,226 

 

(1) Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718.  Dollar value amounts are based on individual grants to each of  Mr. Andrade, Mr. Raykov and Dr. Spector of 51,152 options on August 19, 2011 at an exercise price of $0.63, which options expire on August 19, 2018 and 150,000 options on November 20, 2012 at an exercise price of $0.35, which options expire on November 20, 2019.  All options vestedin full on the date of grant.
(2) The term “incentive plan” means any plan providing compensation intended to serve as incentive for performance to occur over a specified period, whether such performance is measured by reference to financial performance of the Corporation, the Corporation's stock price, or any other performance measure.  An “equity incentive plan” is an incentive plan or portion of an incentive plan under which awards are granted that fall within the scope of SFAS 123(R).  A “non-equity incentive plan” is an incentive plan or portion of an incentive plan that is not an equity incentive plan.
(3) Consists of the taxable benefit for premiums paid for group term life insurance, long term disability and long term care insurance.

 

32
 

 

 

Rostislav Raykov

Mr. Raykov has been employed by Adherex since July 2009.  Pursuant to an employment agreement dated May 3, 2010 between Rostislav Raykov and Adherex, Mr. Raykov is employed as Adherex’s Chief Executive Officer. Pursuant to this agreement, Mr. Raykov (a) receives an initial annual salary in the amount of $140,000, (b) upon approval by shareholders of the amended Stock Option Plan was granted options to purchase up to 5.0% of our common stock outstanding estimated by us to be outstanding upon completion of the Rights Offering, and (c) may receive annual bonuses at the sole discretion of the Board. If Mr. Raykov’semployment terminates due to a change of control of Adherex, any then remaining unvested shares under his options shall immediately vest and be fully exercisable. On August 18, 2010, Mr. Raykov was granted 971,885 options and on August 19, 2011 Mr. Raykov was granted 51,152 optionspursuant to his employment agreement.Further, on November 20, 2019, Mr. Raykov was granted 150,000 options. If Mr. Raykov is dismissed from employment by us for any reason other than “cause,” we are obligated to pay Mr. Raykov severance compensation equal to twelve months of salary.

 

Robert Andrade

Mr. Andrade has been employed by Adherex since July 2009, when he initially agreed to be compensated at the minimum wage. Pursuant to an employment agreement dated May 3, 2010 between Robert Andrade and Adherex, Mr. Andrade is employed as Adherex’s Chief Financial Officer. Pursuant to this agreement, Mr. Andrade (a) receives an initial annual salary in the amount of $140,000, (b) upon approval by shareholders of the amended Stock Option Plan was granted options to purchase up to 5.0% of our common stock outstanding estimated by us to be outstanding upon completion of the Rights Offering, and (c) may receive annual bonuses at the sole discretion of the Board.  If Mr. Andrade’s employment terminates due to a change of control of Adherex, any then remaining unvested shares under his options shall immediately vest and be fully exercisable. On August 18, 2010, Mr. Andrade was granted 971,885 options and on August 19, 2011 Mr. Andrade was granted 51,152 options pursuant to his employment agreement. Further, on November 20, 2019, Mr. Andrade was granted 150,000 options. If Mr. Andrade is dismissed from employment by us for any reason other than “cause,” we are obligated to pay Mr. Andrade severance compensation equal to twelve months of salary.

 

Dr. Thomas Spector

Dr. Spector has been employed by Adherex since July 2009, when he was initially paid a salary of $80,000 per year. Pursuant to an employment agreement dated May 3, 2010 between Dr. Thomas Spector and Adherex, Dr. Spector is employed as Adherex’s Chief Scientific Officer. Pursuant to this agreement, Dr. Spector (a) receives an annual salary in the amount of $150,000, (b) upon approval by shareholders of the amended Stock Option Plan was granted options to purchase up to 5.0% of our common stock outstanding estimated by us to be outstanding upon completion of the Rights Offering, and (c) may receive annual bonuses at the sole discretion of the Board.  If Dr. Spector’s employment terminates due to a change of control of Adherex, any then remaining unvested shares under his options shall immediately vest and be fully exercisable. On August 18, 2010, Dr. Spector was granted 971,885 options and on August 19, 2011 was granted 51,152 options pursuant to his employment agreement. Further, on November 20, 2019, Dr. Spector was granted 150,000 options. If Dr. Spector is dismissed from employment by us for any reason other than “cause,” we are obligated to pay Dr. Spector’s severance compensation equal to twelve months of salary.

 

In addition to such employment agreements, Dr. Spector and Messrs. Andrade and Raykov, are each a party to a confidentiality and intellectual property agreement with us.

 

In the employment agreements for each of Dr. Spector and Messrs. Andrade and Raykov “cause” is generally defined as (1) material breach of the terms of the employment or intellectual property agreements; (2) failure to perform the duties inherent in Employee’s position in good faith and in a reasonable and appropriate manner; or (3) acts of fraud or embezzlement or other intentional misconduct which adversely affects the Company's business.

 

33
 

 

Equity Grants, Exercises and Holdings

 

The following table sets forth information concerning the number and value of unexercised options held by each Named Executive Officer as of December 31, 2012.

 

Outstanding Equity Awards at December 31, 2012

 Name  

Number of Securities

Underlying Unexercised

Options (#) Exercisable

       

Number of Securities

Underlying Unexercised

Options (#)

Unexercisable

       

Option

Exercise Price ($)(1)

     

Option

Expiration Date

Rostislav Raykov     971,885 (2)     —   CAD$ 0.81   08/18/2017
      51,152 (3)     —   CAD$ 0.63   08/19/2018
      150,000 (4)     —   USD$ 0.35   11/20/2019
Robert Andrade     971,885 (2)     —   CAD$ 0.81   08/18/2017
      51,152 (3)     —   CAD$ 0.63   08/19/2018
      150,000 (4)     —   USD$ 0.35   11/20/2019
Dr. Thomas Spector     971,885 (2)     —   CAD$ 0.81   08/18/2017
      51,152 (3)     —   CAD$ 0.63   08/19/2018
      150,000 (4)     —   USD$ 0.35   11/20/2019

 

(1)The current Stock Option Plan provides for grants denominated in US and CAD dollars.
(2)971,885 options were granted on 08/18/2010 with all 971,885 immediately exercisable.
(3)51,152 options were granted on 08/19/2011 with all 51,152 immediately exercisable.
(4)150,000 options were granted on 11/20/2012 with all 150,000 immediately exercisable.

 

Termination Benefits

 

In the event of his termination with us other than for cause, we will pay Rostislav Raykov $140,000 severance. In the event of his termination with us other than for cause, we will pay Robert Andrade $140,000 severance. In the event of his termination with us other than for cause, we will pay Dr. Thomas Spector $150,000 severance.

 

Compensation of Directors

 

 Director Compensation Table

 

The following table summarizes the compensation earned by or paid to the Company's non-executive directors for the year ended December 31, 2012.

 

Name  

Fees Earned

or Paid

in Cash ($)

    

Stock

Awards ($)

    

Option

Awards ($)(1)

    

Non-equity

incentive plan

compensation ($)

    

Nonqualified

deferred

compensation

earnings ($)

    

All other

compensation ($)

     Total ($)  
Mr. Lieberman     —       —       —       —       —       —       —  
Mr. Rallis     16,500       —       16,507(2)       —       —       —       $33,007  
Mr. Skolsky     7,500       —       13,290(2)       —       —       —       $20,790  

 

(1) Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718.

(2) Dollar value amounts are based on individual grants of 25,000 options on April 5, 2012and 27,778 options on May 18, 2012at an exercise price of $0.18, and 14,286 options on November 20, 2012 at an exercise price of $0.35 to both Chris Rallis and Steve Skolsy and a grant of 33,333 options to Chris Rallis on August 20, 2012 at an exercise price of CAD$0.11 vested in full on the date of grant. All options expire 7 years from the date of grant.

 

The annual compensation considerations for non-executive directors also include the awarding of stock options. The granting of options to the non-executive directors under the Stock Option Plan serves three primary purposes: (1) to recognize the significant time and effort commitments during the past year; (2) to provide long-term incentives for future efforts since the value of the options is directly dependent on the market valuation of the Corporation; and (3) to retain quality individuals as the options typically vest over time. When determining whether and how many new option grants will be made, the Compensation Committee takes into account the amount and terms of any outstanding options. Adherex does not require its non-executive directors to own a specific amount of common stock.

 

34
 

 

 

Each of the Chris A. Rallis and Steven D. Skolsky has entered into an Independent Director Agreement with the Company, dated as of August 25, 2011, which provides for (i) cash compensation in the form of USD$ 1,500 per board meeting attended, and (ii) non-cash compensation in the form of a grant of options to purchase shares of the Company’s common stock having an aggregate value equal to USD $5,000 (with price per share and exercise price based on the value of the Company’s common stock as of the date of grant) per board meeting attended.  The options immediately vest when granted and are otherwise subject to the terms and conditions of the Company’s stock option plan, as amended. The Independent Director Agreement also provides for the reimbursement of such director’s reasonable travel and related expenses incurred in the course of attending board meetings.

 

Mr. Lieberman currently does not accept cash fees or stock for his participation on the Board.

 

Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters

 

The following table sets forth information regarding shares of our common stock beneficially owned as of March 16, 2013 by: (i) each of our officers and directors; (ii) all officers and directors as a group; and (iii) each person known by us to beneficially own five percent or more of the outstanding shares of our common stock. Except as indicated below, the security holders listed possess sole voting and investment power with respect to the shares beneficially owned by that person. Except as otherwise indicated below, the address for each listed shareholder is c/o Adherex Technologies Inc., 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, North Carolina 27709.

 

Name  

Common

Stock

    

Common

Stock

Options

Exercisable

Within

60 Days

    

Common

Stock

Purchase

Warrants

Exercisable

Within 60

Days

    

Total Stock

and Stock

Based

Holdings (1)

    

%

Ownership

(1)

  
                                         
Robert Andrade     82,228       1,173,037       38,889       1,294,154       4.9 %
                                         
David Lieberman (2)     11,111,111               8,805,333       19,916,444       58.6 %
                                         
Chris A. Rallis     -       110,397       -       110,397       * %
                                         
Rostislav Raykov     122,222       1,173,037       66,667       1,361,926       5.2 %
                                         
Steven D. Skolsky     -       77,063       -       77,063       * %
                                         
Thomas Spector     33,333       1,173,037       33,333       1,239,703       4.7 %
                                         
All officers and directors as a group (6 persons)     11,348,894       3,706,571       8,944,222       23,999,687       63.5 %
                                         
Southpoint Capital Advisors LP (2)     11,111,111       -       8,805,333       19,916,444       58.6 %
                                         
683 Capital  Management LLC(3)     2,162,457       -       1,997,902       4,160,359       15.3 %
                                         
Robert Butts     2,305,778               2,305,778       4,611,556       16.8 %

  * Percentage of shares beneficially owned does not exceed one percent.

 

(1)For purposes of this table “beneficial ownership” is determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, pursuant to which a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person or group has the right to acquire within 60 days after March 16, 2013.  For purposes of computing the percentage of outstanding shares of common stock held by each person or group of persons named above, any shares that such person or group has the right to acquire within 60 days after March 16, 2013 are deemed outstanding but are not deemed to be outstanding for purposes of computing the percentage ownership of any other person or group. As of March 16, 2013, there were 25,157,618 shares of our common stock issued and outstanding.

 

(2)David Lieberman an employee of Southpoint Capital Advisors, LP, 623 Fifth Avenue, Suite 2503, New York, New York 10022.  John S. Clark, II holds dispositive power over the shares owned by Southpoint Capital Advisors, LP.

 

(3)683 Capital Management, LLC, 595 Madison Avenue, 17th Floor, New York, New York 10025.  Ari Zweiman holds dispositive power over the shares owned by 683 Capital Management LLC.

 

35
 

 

Equity Compensation Plan Information

 

The following table provides certain information with respect to securities authorized for issuance under equity incentive plans as of December 31, 2012:

 

Plan Category  

(a)

Number of securities to be issued

upon exercise of outstanding

options warrants and rights (*)

    

(b)

Weighted-average exercise price of

outstanding options, warrants and

rights

    

(c)

Number of securities remaining

available for future issuance under

equity compensation plans

(excluding securities reflected in

Column (a))

  
Equity compensation plans     1,327     $  USD $0.67       789  
approved by security holders     4,171     CAD $ 0.78          
Equity compensation plans not approved by security holders     -       -       -  
Total     5,498       -       789  

 

* The Company’s current stock option plans allows for the issuance of stock options denominated in both United States, or U.S., dollars and Canadian, or CAD, dollars.  This table presents the number and weighted-average exercise price of outstanding options by the currency associated with the original grants  At December 31, 2012 we had 1,327 stock options denominated in U.S. dollars with a weighted-average exercise price of $0.67 and 4,171 stock options denominated in CAD dollars with a weighted-average exercise price of CAD$0.78.  At December 31, 2012, we had 789 stock options available for future issuance.

 

Item 13.  Certain Relationships and Related Transactions, and Director Independence

 

D. Scott Murray, a former executive officer, and Adherex entered into a Separation and Mutual Release Agreement, dated as of March 8, 2011, pursuant to which (a) each party thereto agreed to a mutual release of claims by such party and (b) we made a separation payment of $50,000 to Mr. Murray and granted Mr. Murray a three year period commencing July 10, 2009 to exercise any vested but unexpired stock options previously granted to him.

 

Except for the foregoing, there were no related party transactions in the last two years that were required to be reported under Item 404(d) of Regulation S-K.

 

Director Independence

 

The Board of Directors is composed of a majority of independent directors. The Board applies the definition of independence found in the rules of the SEC and in Canadian National Instrument 58-101 and National Policy 58-201. The Board has determined that three of the current five directors are “independent”, including the Chair of the Board, being Messrs. Lieberman, Rallis, and Skolsky. Only two current directors have material relationships with the Corporation and are therefore not independent. Mr. Raykov, Chief Executive Officer of the Corporation, and Mr. Andrade, Chief Financial Officer of the Corporation, are considered to have a material relationship with the Corporation by virtue of their executive officer positions. Adherex is of the view that the composition of its Board reflects a diversity of background and experience that are important for effective corporate governance. Other directorships held by Board members are described in this Annual Report under the heading “Directors and Executive Officers.”

  

36
 

 

Item 14. Principal Accounting Fees and Services

 

The following table presents the aggregate fees for professional services and other services rendered by our independent auditors, Deloitte LLP in fiscal year 2012 and 2011 (in US dollars):

 

   Fiscal Year 
2012		   Fiscal Year 
2011		 
Audit Fees (1)   100,020    95,201 
Audit-Related Fees (2)   -    81,446 
Tax Fees (3)   14,980    19,688 
All Other Fees (4)   -    - 
Total  $115,000   $196,335 

 

(1)Audit Fees include fees for the standard audit work that needs to be performed each year in order to issue an opinion on the consolidated financial statements of the Corporation and to issue reports on the local statutory and regulatory financial statements.  It also includes fees for services that can only be provided by the Corporation’s auditor such as auditing of non-recurring transactions and application of new accounting policies.
(2)Audit-Related Fees include fees for those other assurance services provided by auditors but not restricted to those that can only be provided by the auditor signing the audit report, which includes consents and comfort letters and any other audit services required for U.S. Securities and Exchange Commission or other regulatory filings.
(3)Tax Fees include fees for periodic tax consultations and compliance services in various local, regional and national tax jurisdictions.
(4)All Other Fees include fees for products and services other than Audit Fees, Audit Related Fees and Tax Fees.

 

The Audit Committee does not have formal pre-approval policies and procedures; however, prior to the engagement by the registrant, the Audit Committee approved all of the services performed by Deloitte LLP as required by SEC regulation.

 

37
 

 

PART IV

 

Item 15.  Exhibits, Financial Statement Schedules

 

(a) The following documents are included as part of this Annual Report filed on Form 10-K:

 

1.  Financial Statements – See Index to Financial Statements on page F-1.

 

2.  All schedules are omitted as the information required is inapplicable or the information is presented in the financial statements.

 

3.  Exhibits:

Exhibit

No.

   Description   Location
         
3.1   Notice of Articles dated August 25, 2011   Exhibit 3.2I to the Form 8-K of Adherex, filed August 26, 2011
         
3.2   Articles dated August 25, 2011   Exhibit 3.2II to the Form 8-K of Adherex, filed August 26, 2011
         
10.1   Exclusive License Agreement, dated as of September 26, 2002, by and between Oregon Health & Science University and Oxiquant, Inc.   Exhibit 4.5 to the Form 20-F Registration Statement (No. 001-32295) of Adherex, filed September 17, 2004
         
10.2   Development and License Agreement dated July 14, 2005 between Adherex Technologies Inc. and Glaxo Group Limited**   Exhibit 4.30 to Form 6-K of Adherex, filed July 22, 2005
         
10.3   Amendment No. 1 to Development and License Agreement dated December 20, 2005 between Glaxo Group Limited and Adherex Technologies Inc.**   Exhibit 4.36 to the Form 20-F Annual Report (No. 001-32295) of Adherex for the fiscal year ended December 31, 2005, filed on March 31, 2006
         
10.4   Amendment No. 2 to Development and License Agreement dated June 23, 2006 between Glaxo Group Limited and Adherex Technologies Inc.**   Exhibit 4.41 to Form 6-K of Adherex, filed August 9, 2006
         
10.5   Amendment No. 3 to Development and License Agreement dated January 17, 2007 between Adherex Technologies Inc. and Glaxo Group Limited   Exhibit 4.42 to Form 6-K of Adherex, filed January 19, 2007
         
10.6   Amendment No. 4 to Development and License Agreement dated May 23, 2007  between Adherex Technologies Inc. and Glaxo Group Limited   Exhibit 10.1 to Form 8-K of Adherex, filed June 19, 2007
         
10.7   Amended and Restated Stock Option Plan   Exhibit 10.19 to Form 10-K of Adherex, filed March 28, 2008
         
10.8   Lease Termination and Release   Exhibit 10.24 to Form 10-Q of Adherex, filed November 16, 2009
         
10.9   Amended and Restated Employment Agreement - Robin J. Norris*   Exhibit 10.23 to Form 10-Qof Adherex, filed  November 16, 2009
         
10.10   Lease agreement dated January 1, 2010, between Adherex and Valfern Holdings, Inc.   Exhibit 10.27 to the Form 10-Q of Adherex, filed on May 14, 2010
         
10.11   Executive Employment Agreement dated May 3, 2010 by and between Adherex and Rostislav Raykov*   Exhibit 10.28 to the Form 10-Q of Adherex, filed on May 14, 2010
         
10.12   Executive Employment Agreement dated May 3, 2010 by and between Adherex and Robert Andrade*   Exhibit 10.29 to the Form 10-Q of Adherex, filed on May 14, 2010

 

 

38
 

 

10.13   Executive Employment Agreement dated May 3, 2010 by and between Adherex and Dr. Thomas Spector*   Exhibit 10.30 to the Form 10-Q of Adherex, filed on May 14, 2010
         
10.14   Form of Independent Director Agreement, dated May 3, 2010   Exhibit 10.31 to the Form 10-Q of Adherex, filed on May 14, 2010
10.15   Master Service Agreement with OCT Group LLC   Exhibit 10.1 to the Form 10-Q of Adherex filed on November 15, 2010
10.16   Amendment No. 2 to Master Service Agreement with OCT Group LLC, dated August 16, 2011   Exhibit 10.1 to the Form 10-Q of Adherex filed on November 14, 2011
         
10.17   Amendment No. 3 to Master Service Agreement with OCT Group LLC, dated June 4, 2012   Exhibit 10.1 to the Form 10-Q of Adherex filed on August 2, 2012
         
10.18   Amendment No. 4 to Master Service Agreement with OCT Group LLC, dated October 29, 2012   Exhibit 10.1 to the Form 10-Q of Adherex filed on November 14, 2012
         
21   Subsidiaries   Exhibit 8 to the Form 20-F Registration Statement (No. 001-32295) of Adherex, filed September 17, 2004
         
31.1   Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002   Filed herewith
         
31.2   Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002   Filed herewith

 

32.1   Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002   Filed herewith
         
101.1   Interactive Data File   Filed herewith

  

*  Indicates a management contract or compensatory plan.

 

** The Company has received confidential treatment with respect to certain portions of this exhibit. Those portions have been omitted from this exhibit and are filed separately with the U.S. Securities and Exchange Commission.

 

39
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 of 15(d) the Securities Exchange Act of 1934, the registrant has duly causes this report to be signed on its behalf by the undersigned, thereunto authorized.

 

Adherex Technologies Inc.
By:  /s/ Rostislav Raykov
  Rostislav Raykov
  Chief Executive Officer and Director
  Date:  March 28, 2013

 

Pursuant to the requirement of the Securities and Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures   Title   Date
         
/s/     Rostislav Raykov   Chief Executive Officer   March 28, 2013
Rostislav Raykov   (principal executive officer) and Director    
         
/s/     Robert Andrade   Chief Financial Officer, Director   March 28, 2013
Robert Andrade  

(principal financial officer and principal

accounting officer)

    
         
/s/     Chris A. Rallis   Director   March 28, 2013
Chris A. Rallis        
         
/s/     Steven D. Skolsky   Director   March 28, 2013
Steven D. Skolsky        
         
/s/    David Lieberman   Director   March 28, 2013
David Lieberman        

 

Supplemental Information to be Furnished With Reports Filed Pursuant to Section 15(d) of the Act by Registrants Which Have Not Registered Securities Pursuant to Section 12 of the Act

 

The registrant intends to furnish proxy materials to its security holders subsequent to the filing of this annual report on Form 10-K and shall furnish copies of such proxy materials to the Commission when such materials are sent to security holders.

  

40
 

  

ADHEREX TECHNOLOGIES INC.

INDEX TO FINANCIAL STATEMENTS

 

  Page
Report of Independent Registered Chartered Accountants F-2
Consolidated Balance Sheets F-4
Consolidated Statements of Operations F-5
Consolidated Statements of Cash Flows F-6
Consolidated Statements of Stockholders’ Equity F-7
Notes to Consolidated Financial Statements F-11

 

F-1
 

 

REPORT OF INDEPENDENT REGISTERED CHARTERED ACCOUNTANTS

 

Report of Independent Registered Chartered Accountants

 

To the Board of Directors and Shareholders of Adherex Technologies Inc.

 

We have audited the accompanying consolidated balance sheets of Adherex Technologies Inc. and subsidiaries (a development stage company) (the "Company") as of December 31, 2012 and 2011, and the related consolidated statements of operations, stockholders' equity, and cash flows for the years then ended, and cumulatively for the period from September 3, 1996 (date of inception) to December 31, 2012.  These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the financial statements based on our audits. The Company's financial statements for the period September 3, 1996 (date of inception) to December 31, 2008, before the effects of the adjustments to retrospectively give effect of the stock split as described in Note 2 and Note 7 to the consolidated financial statements, were audited by other auditors whose report, dated March 30, 2009, expressed an unqualified opinion on those statements.  The financial statements for the period September 3, 1996 (date of inception) to December 31, 2008 reflect a net loss of $97,979,000. The other auditors' report has been furnished to us, and our opinion, insofar as it relates to the amounts included for such prior period, is based solely on the report of such other auditors.

 

We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits and the report of other auditors provide a reasonable basis for our opinion.

 

In our opinion, based on our audits and the report of other auditors, such financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the years then ended, and for the period from September 3, 1996 (date of inception) to December 31, 2012, in conformity with accounting principles generally accepted in the United States of America.

 

We have also audited the adjustments to the consolidated financial statements for the period from September 3, 1996 (date of inception) to December 31, 2008 to retrospectively give effect of the stock split as described in Note 2 and Note 7 to the consolidated financial statements. In our opinion, such retrospective adjustments are appropriate and have been properly applied. However, we were not engaged to audit, review, or apply any procedures to the financial statements of the Company for the period from September 3, 1996 (date of inception) to December 31, 2008 other than with respect to the retrospective adjustments and, accordingly, we do not express an opinion or any other form of assurance on the financial statements for the period from September 3, 1996 (date of inception) to December 31, 2008 taken as a whole.

  

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer, as discussed in Note 1 to the consolidated financial statements. During the year ended December 31, 2012, the Company incurred a loss from operations of $3,620,000. At December 31, 2012, it had an accumulated deficit of $110,543,000 and had experienced negative cash flows from operating activities since inception in the amount of $85,037,000. In addition, it had a deficiency in working capital at December 31, 2012 and the Company's operating losses since inception raise substantial doubt about its ability to continue as a going concern. Management's plans concerning these matters are also discussed in Note 1 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

  

/s/ Deloitte LLP  
Independent Registered Chartered Accountants  
Licensed Public Accountants  
Ottawa, Canada  

 

March 21, 2013

 

F-2
 

 

Report of Independent Auditors


To the Shareholders of Adherex Technologies Inc.

In our opinion, the consolidated statements of operations and cash flows, not separately presented herein, and statement of stockholders’ equity, present fairly, in all material respects the results of operations and cash flows for the period from September 3, 1996 (date of inception) to December 31, 2008, before the adjustments to retrospectively give effect of the reverse stock split as described in Notes 2 and 7 of Adherex Technologies Inc. (a development stage company) (the “Company”) in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

We were not engaged to audit, review, or apply any procedures to the adjustments to retrospectively give effect of the reverse stock split as described in Notes 2 and 7 and accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by other auditors.

/s/ PricewaterhouseCoopers LLP

Chartered Accountants, Licensed Public Accountants
Ottawa, Canada
March 30, 2009

 

F-3
 

 

Adherex Technologies Inc.

(a development stage company)

Consolidated Balance Sheets

(U.S. Dollars and shares in thousands, except per share amounts)

 

   December 
31,2012		   December
31, 2011		 
Assets          
           
Current assets          
Cash and cash equivalents  $2,303   $5,297 
Prepaid expense   56    35 
Other current assets   6    19 
           
Total assets  $2,365   $5,351 
           
Liabilities and stockholders’ equity          
           
Current liabilities          
Accounts payable  $259   $342 
Accrued liabilities   423    52 
Derivative liabilities   6,640    5,077 
Total current liabilities   7,322    5,471 
           
Total liabilities   7,322    5,471 
           
Commitments and contingencies (Note 10 and 11)          
           
Stockholders’ (deficit) equity          
           
Common stock, no par value; unlimited shares authorized; (2012 - 25,158, 2011 - 25,158 shares issued and outstanding)   65,952    65,952 
Additional paid-in capital   38,391    38,065 
Deficit accumulated during development stage   (110,543)   (105,380)
Accumulated other comprehensive income   1,243    1,243 
Total stockholders’ (deficit) equity   (4,957)   (120)
Total liabilities and stockholders’ (deficit) equity  $2,365   $5,351 

 

 (The accompanying notes are an integral part of these consolidated financial statements)

 

F-4
 

 

Adherex Technologies Inc.

(a development stage company)

Consolidated Statements of Operations

(U.S. dollars and shares in thousands, except per share information)

 

   Year Ended
December 31,
2012		   Year Ended
December 31,
2011		   Cumulative From
September 3, 1996
to
December 31, 2012		 
             
Revenue  $-   $-   $- 
                
Operating expenses:               
Research and development   2,075    1,494    69,168 
Impairment of capital assets   -    -    386 
Gain on deferred lease inducements   -    -    (497)
Acquired in-process research and development   -    -    13,094 
General and administration   1,545    1,944    32,094 
Loss from operations   (3,620)   (3,438)   (114,245)
                
Other income (expense):               
(Loss)/Gain on derivative warrants   (1,563)   8,071    3,257 
Settlement of Cadherin Biomedical Inc. litigation   -    -    (1,283)
Interest expense   -    -    (19)
Other income/(expense)   (5)   9    259 
Interest income   25    43    2,897 
Total other (expense)/ income   (1,543)   8,123    5,111 
                
Net (loss)/income and total comprehensive loss  $(5,163)  $4,685   $(109,134)
                
(Loss)/earnings per share of common stock, basic  $(0.21)  $0.20      
                
(loss)/earnings per share of common stock, diluted  $(0.21)  $0.19      
                
Weighted-average number of shares of common stock outstanding, basic   25,158    23,983      
                
Weighted-average number of shares of common stock outstanding, diluted   25,158    24,050      

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

F-5
 

 

Adherex Technologies Inc.

(a development stage company)

Consolidated Statements of Cash Flows

(U.S. Dollars and shares in thousands, except per share amounts)

 

   Year Ended
December 31,
2012		   Year Ended
December 31,
2011		   Cumulative
From
September 3, 1996 to
December 31,2012		 
Cash flows from (used in):               
Operating activities:               
Net (loss)/income  $(5,163)  $4,685   $(109,134)
Adjustments for non-cash items:               
Loss/(gain) on derivative warrants   1,563    (8,071)   (3,257)
Depreciation and amortization   -    -    1,404 
Non-cash Cadherin Biomedical Inc. litigation expense   -    -    1,187 
Unrealized foreign exchange (gain)/loss        (9)   36 
Loss on impairment of capital assets   -    -    386 
Amortization of and gain on lease inducements   -    -    (412)
Non-cash severance expense   -    -    168 
Stock options issued to consultants   152    121    1,048 
Stock options issued to employees   174    129    10,269 
Acquired in-process research and development   -    -    13,094 
Changes in non-cash working capital   280    (81)   174 
Net cash used in operating activities   (2,994)   (3,226)   (85,037)
                
Investing activities:               
Purchase of capital assets   -    -    (1,440)
Disposal of capital assets   -    -    115 
Proceeds from sale of assets   -    -    24 
Release of restricted cash   -    -    190 
Restricted cash   -    -    (209)
Purchase of short-term investments   -    -    (22,148)
Redemption of short-term investments   -    -    22,791 
Investment in Cadherin Biomedical Inc.   -    -    (166)
Acquired intellectual property rights   -    -    (640)
Net cash used in investing activities   -    -    (1,483)
                
Financing activities:               
Conversion of long-term debt to equity   -    -    68 
Long-term debt repayments   -    -    (65)
Capital lease repayments   -    -    (8)
Issuance of common stock   -    2,566    86,443 
Registration expense   -    -    (465)
Financing expenses   -    -    (544 
Proceeds from convertible note   -    -    3,017 
Other liability repayments   -    -    (87)
Security deposits received   -    -    35 
Proceeds from exercise of stock options   -    -    51 
Net cash provided from financing activities   -    2,566    88,445 
                
Effect of exchange rate changes on cash and cash equivalents   -    10    378 
                
Net change in cash and cash equivalents   (2,994)   (650)   2,303 
Cash and cash equivalents - Beginning of period   5,297    5,947    - 
Cash and cash equivalents - End of period  $2,303   $5,297    2,303 

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

F-6
 

 

Adherex Technologies Inc.

(a development stage company)

Consolidated Statements of Stockholders' Equity

(U.S. dollars and shares in thousands, except per share information)

 

   Common Stock  

Non-redeemable

Preferred Stock

  

Additional

Paid-in

  

Accumulated

Other
 Comprehensive

  

Deficit 

Accumulated

During 

Development

  

Total 

Shareholders’

 
   Number   Amount   of Subsidiary   Capital   Income   Stage   (Deficit)/Equity 
Balance as at Sept. 3 1996   -   $-   $-   $-   $-   $-   $- 
Issuance of common stock   89    -    -    -    -    -    - 
Net loss   -    -    -    -    -    (37)   (37)
Balance at June 30, 1997   89    -    -    -    -    (37)   (37)
Net loss   -    -    -    -    -    (398)   (398)
Balance at June 30, 1998   89    -    -    -    -    (435)   (435)
Exchange of Adherex Inc. shares for Adherex Technologies Inc. shares   (89)   -    -    -    -    -    - 
Issuance of common stock   239    1,615    -    -    -    -    1,615 
Cumulative translation adjustment   -    -    -    -    20    -    20 
Net loss   -    -    -    -    -    (958)   (958)
Balance at June 30, 1999   239    1,615    -    -    20    (1,393)   242 
Issuance of common stock   16    793    -    -    -    -    793 
Issuance of equity rights   -    -    -    171    -    -    171 
Issuance of special warrants   -    -    -    255    -    -    255 
Settlement of advances:                                   
Issuance of common stock   16    175    -    -    -    -    175 
Cancellation of common stock   (7)   -    -    -    -    -    - 
Cumulative translation adjustment   -    -    -    -    16    -    16 
Net loss   -    -    -    -    -    (1,605)   (1,605)
Balance at June 30, 2000   264    2,583    -    426    36    (2,998)   47 
Issuance of common stock:                                   
Initial Public Offering (“IPO”)   74    5,727    -    -    -    (38)   5,689 
Other   5    341    -    -    -    -    341 
Issuance of special warrants   -    -    -    1,722    -    -    1,722 
Conversion of special warrants   30    1,977    -    (1,977)   -    -    - 
Issuance of Series A special warrants   -    -    -    4,335    -    -    4,335 
Conversion of Series A special warrants   69    4,335    -    (4,335)   -    -    - 
Conversion of equity rights   4    171    -    (171)   -    -    - 
Cumulative translation adjustment   -    -    -    -    182    -    182 
Net loss   -    -    -    -    -    (2,524)   (2,524)
Balance at June 30, 2001   446    15,134    -    -    218    (5,560)   9,792 
Cumulative translation adjustment   -    -    -    -    11    -    11 
Net loss   -    -    -    -         (3,732)   (3,732)
Balance at June 30, 2002   446    15,134    -    -    229    (9,292)   6,071 

(The accompanying notes are an integral part of these consolidated financial statements)

(continued on next page)

 

F-7
 

 

Adherex Technologies Inc.

(a development stage company)

Consolidated Statements of Stockholders' Equity (continued)

(U.S. dollars and shares in thousands, except per share information)

 

   Common Stock  

Non-redeemable

Preferred Stock

  

Additional

Paid-in

  

 

Accumulated

Other

Comprehensive

  

Deficit 

Accumulated 

During 

Development

  

Total

Shareholders’

 
   Number   Amount   of Subsidiary   Capital   Income   Stage   (Deficit)/Equity 
Balance at June 30, 2002   446    15,134    -    -    229    (9,292)   6,071 
Common stock issued for Oxiquant acquisition   446    11,077    -    543    -    -    11,620 
Exercise of stock options   1    4    -    -    -    -    4 
Distribution to shareholders   -    -    -    -    -    (158)   (158)
Stated capital reduction   -    (9,489)   -    9,489    -    -    - 
Stock options issued to consultants   -    -    -    4    -    -    4 
Equity component of June convertible notes   -    -    -    1,058    -    -    1,058 
Financing warrants   -    -    -    53    -    -    53 
Cumulative translation adjustment   -    -    -    -    (159)   -    (159)
Net loss   -    -    -    -    -    (17,795)   (17,795)
Balance at June 30, 2003   893    16,726    -    11,147    70    (27,245)   698 
Stock options issued to consultants   -    -    -    148    -    -    148 
Repricing of warrants related to financing   -    -    -    18    -    -    18 
Equity component of December convertible notes   -    -    -    1,983    -    -    1,983 
Financing warrants   -    -    -    54    -    -    54 
Conversion of June convertible notes   96    1,216    -    (93)   -    -    1,123 
Conversion of December convertible notes   60    569    -    (398)   -    -    171 
Non-redeemable preferred stock   -    -    1,045    -    -    -    1,045 
December private placement   640    8,053    -    5,777    -    -    13,830 
May private placement   259    6,356    -    2,118    -    -    8,474 
Exercise of stock options   1    23    -    -    -    -    23 
Amalgamation of 2037357 Ontario Inc.   44    660    (1,045)   363    -    -    (22)
Cumulative translation adjustment   -    -    -    -    (219)   -    (219)
Net loss   -    -    -    -    -    (6,872)   (6,872)
Balance at June 30, 2004   1,993    33,603    -    21,117    (149)   (34,117)   20,454 
Stock options issued to consultants   -    -    -    39    -    -    39 
Stock options issued to employees   -    -    -    604    -    -    604 
Cost related to SEC registration   -    (493)   -    -    -    -    (493)
Acquisition of Cadherin Biomedical Inc.   37    1,252    -    -    -    -    1,252 
Cumulative translation adjustment   -    -    -    -    1,392    -    1,392 
Net loss – six months ended December 31, 2004   -    -    -    -    -    (6,594)   (6,594)
Balance at December 31, 2004   2,030    34,362    -    21,760    1,243    (40,711)   16,654 

  

(The accompanying notes are an integral part of these consolidated financial statements)

(continued on next page)

 

F-8
 

  

Adherex Technologies Inc.

(a development stage company)

Consolidated Statements of Stockholders' Equity (continued)

(U.S. dollars and shares in thousands, except per share information)

 

   Common Stock  

Non-redeemable

Preferred Stock

  

Additional

Paid-in

  

 

Accumulated

Other

Comprehensive

  

Deficit 

Accumulated 

During 

Development

  

Total

Shareholders’

 
   Number   Amount   of Subsidiary   Capital   Income   Stage   (Deficit)/Equity 
Balance at December 31, 2004   2,030    34,362    -    21,760    1,243    (40,711)   16,654 
Financing costs   -    (141)   -    -    -    -    (141)
Exercise of stock options   1    25    -    -    -    -    25 
Stock options issued to consultants   -    -    -    276    -    -    276 
July private placement   337    7,060    -    1,074    -    -    8,134 
Net loss   -    -    -    -    -    (13,871)   (13,871)
Balance at December 31, 2005   2,368    41,306    -    23,110    1,243    (54,582)   11,077 
Stock options issued to consultants   -    -    -    100    -    -    100 
Stock options issued to employees   -    -    -    491    -    -    491 
May private placement   431    5,218    -    822    -    -    6,040 
Net loss   -    -    -    -    -    (16,440)   (16,440)
Balance at December 31, 2006   2,799    46,524    -    24,523    1,243    (71,022)   1,268 
Stock options issued to consultants   -    -    -    59    -    -    59 
Stock options issued to employees   -    -    -    2,263    -    -    2,263 
February financing   4,209    17,842    -    5,379    -    -    23,221 
Exercise of warrants   116    563    -    131    -    -    694 
Net loss   -    -    -    -    -    (13,357)   (13,357)
Balance at December 31, 2007   7,124    64,929    -    32,355    1,243    (84,379)   14,148 
Stock options issued to consultants   -    -    -    88    -    -    88 
Stock options issued to employees   -    -    -    2,417    -    -    2,417 
Net loss   -    -    -    -    -    (13,600)   (13,600)
Balance at December 31, 2008   7,124   $64,929   $-   $34,860   $1,243   $(97,979)  $3,053 
Stock options issued to consultants   -    -    -    10    -    -    10 
Stock options issued to employees   -    -    -    355    -    -    355 
Net loss   -    -    -    -    -    (3,012)   (3,012)
Balance at December 31, 2009   7,124   $64,929   $-   $35,225   $1,243   $(100,991)  $406 
Stock options issued to consultants   -    -    -    53    -    -    53 
Stock options issued to employees   -    -    -    2,439    -    -    2,439 
April Financing   13,337    -    -    -    -    -    - 
Net loss   -    -    -    -    -    (7,823)   (7,823)
Balance at December 31, 2010   20,461   $64,929   $-   $37,717   $1,243   $(108,815)  $(4,924)
Stock options issued to consultants   -    -    -    20    -    -    20 
Stock options issued to employees   -    -    -    129    -    -    129 
Rights Offering   4,697    1,023    -    199    -    (1,250)   (28)
Net income   -    -    -    -    -    4,685    4,685 
Balance at December 31, 2011   25,158   $65,952   $-   $38,065   $1,243   $(105,380)  $(120)

 

(The accompanying notes are an integral part of these consolidated financial statements)

(continued on next page)

 

F-9
 

 

 Adherex Technologies Inc.

(a development stage company)

Consolidated Statements of Stockholders' Equity (continued)

(U.S. dollars and shares in thousands, except per share information)

   Common Stock   Non-redeemable
Preferred Stock		   Additional
Paid-in		  

 

Accumulated

Other

Comprehensive

   Deficit 
Accumulated 
During 
Development		   Total
Shareholders’		 
   Number   Amount   of Subsidiary   Capital   Income   Stage   (Deficit)/ Equity 
                             
Stock options issued to consultants   -    -    -    152    -    -    152 
Stock options issued to employees   -    -    -    174    -    -    174 
Net income   -    -    -    -    -    (5,163)   (5,163)
Balance at December 31, 2012   25,158   $65,952   $-   $38,391   $1,243   $(110,543)  $(4,957)

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

F-10
 

 

Adherex Technologies Inc.

(a development stage company)

Notes to the Consolidated Financial Statements

(U.S. dollars and shares in thousands, except per share information)

 

1.         Going Concern

 

Adherex Technologies Inc. (“Adherex”), a British Columbia corporation together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company,” is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. With the exception of Adherex Inc., all subsidiaries are inactive.

 

These consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) of America that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

 

The Company is a development stage company and during the year ended December 31, 2012, incurred a loss from operations of $3,620. At December 31, 2012, it had an accumulated deficit of$110,543, and had experienced negative cash flows from operating activities since inception in the amount of $85,037. In addition, it had a deficiency in working capital at December 31, 2012 and the Company's operating losses since inception.

 

These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance our business strategy, operations and growth through the issuance of equity, debt or collaboration. If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing.

 

These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

 

2.         Significant Accounting Policies

 

Basis of presentation

 

The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation.

 

On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “Share Consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).

 

Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.

 

The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2012, the Company had $2,303 in cash accounts (2011- $5,297). Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments. The Company has not experienced any loss or write-down of its money market investments. 

 

F-11
 

 

Financial instruments

 

Financial instruments recognized on the balance sheets at December 31, 2012 and December 31, 2011 consist of cash and cash equivalents, accounts payable and derivative warrant liability, the carrying value of which, with the exception of the derivative warrant liability, approximates fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading.

 

The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.

 

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature.

 

Common stock and warrants

 

At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company’s U.S. dollar functional currency.

 

In November 2007, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF No. 07-5, Issue Summary No.1 “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock” (“EITF 07-5”), codified as ASC 815-40.  In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock. This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company’s outstanding warrants to purchase common stock that were denominated in Canadian dollars. This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”), codified as ASC 815-10. SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133. As a result, the Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. ITF 07-05 is effective for financial statements for fiscal years beginning after December 15, 2008 and earlier adoption is not permitted. Since the warrants to purchase common stock that are denominated in Canadian dollars expired on December 19, 2008, EITF 07-5 did not have a material impact on the Company’s financial statements through 2008. However, the Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this results in warrants shown as a liability which is marked to market as at December 31, 2012 and December 31, 2011. At December 31, 2012, the derivative liabilitieswere valued at $6,640 (2011: $5,077) and the unrealized loss on the value of the underlying securities was $1,563 (2011: gain$8,071) for the year ended December 31, 2012.

 

Revenue recognition

 

Non-refundable up-front payments received in conjunction with the development and license agreement, including license fees and milestones, are deferred and recognized on a straight-line basis over the relevant periods.

 

The Company records royalty revenue in accordance with the contract terms once it can be reliably measured and the collection is reasonably assured.

 

At this time, the Company does not have any revenue.

 

Research and development costs and investment tax credits

 

Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.

 

Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.

 

F-12
 

 

Income taxes

 

The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities. The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized.

 

The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (‘‘FIN 48’’), codified as ASC 740-10-25, ‘‘Accounting for Uncertainty in Income Taxes – an Interpretation of SFAS No. 109.’’ FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, ‘‘Accounting for Income Taxes.’, codified as ASC 740-10. FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a “more-likely-than-not” threshold of being sustained by the applicable tax authority. Tax benefits related to tax positions not deemed to meet the “more-likely-than-not” threshold are not permitted to be recognized in the financial statements. Upon adoption of FIN 48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense.

 

Foreign currency translation

 

The U.S. dollar is the functional currency for the Company’s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations.

 

Earnings/(Loss) per share

 

Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the treasury method.

 

Newly adopted accounting pronouncements

 

On May 12, 2011, the FASB issued ASU 2011-04 “Fair Value Measurement Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. Specifically, this update will require (a) an entity to disclose separately the amounts of significant transfers into and out of Level 1 and 2 fair value measurements and to describe the reasons for the transfers; and (b) information about purchases, sales, issuances, and settlements to be presented separately on a gross basis in the reconciliation of Level 3 fair value measurements. Level 3 reconciliation disclosures are effective for annual and interim periods beginning after December 15, 2011. The adoption of the guidance to has not had a significant impact on the Company’s consolidated financial position and results of operations.

 

In June 2011, the FASB released ASU 2011-05, “Comprehensive Income (Topic 220) – Presentation of Comprehensive Income”. This update requires and entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income in either a single continuous statement or two separate but consecutive statements. This guidance does not change the items that must be reported in other comprehensive income. Subsequently, in December 2011, the FASB issued ASU 2011-12 which deferred some aspects of the June guidance that relate to the presentation of reclassification adjustments. ASU 2011-05 is now effective for fiscal years and interim periods within those years, beginning after December 15, 2012. The adoption of this standard to has not had a significant impact on the Company’s consolidated financial position or results of operations.

 

Recent accounting pronouncements

 

In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company is required to adopt this ASU in the first quarter for fiscal 2013.

 

 3.         Capital Assets

 

At December 31, 2012 and December 31, 2011, the Company determined the carrying values of its capital assets to be nil. 

 

F-13
 

 

4.        Stock options

 

The Compensation Committee of the Board of Directors administers the Company’s stock option plan.  The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the Stock Option Plan from a fixed number of 20,000 to the number of shares that represent twenty five percent (25%) of the total number of all issued and outstanding shares of common stock from time to time. Based upon the current shares outstanding, a maximum of 6,290 options are authorized for issuance under the plan.  The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years from the date of grant.  The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2012 is below.

 

The following options granted under the stock option plan are exercisable in Canadian dollars:

 

       Exercise Price in Canadian
Dollars		 
   Number of
Options		   Range   Weighted-
average		 
Outstanding at December 31, 2010   3,901    0.63-58.50   $1.26 
Granted   310    0.54-0.81    0.62 
Reinstated(1)   10    5.04-35.10    8.93 
Exercised   -    -    - 
Cancelled   (50)   35.10 –58.50    49.39 
Outstanding at December 31, 2011   4,171    0.54-0.81    0.78 
Granted   -    -    - 
Exercised   -    -    - 
Cancelled   -    -    - 
Outstanding at December 31, 2012   4,171    $ 0.54-0.81   $0.78 

 

(1)Includes 10 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which had either expired and or were cancelled prior to the agreed severance agreement.

 

Price in Canadian Dollars   # outstanding and
exercisable at
December 31, 2012		   Weighted average remaining life (years) 
$0.54    88    5.26 
$0.63    303    5.42 
$0.81    3,780    4.64 
TOTAL    4,171    4.70 

 

The following options granted under the stock option plan are exercisable in U.S. dollars:

 

       Exercise Price in U.S. Dollars 
   Number of
Options		   Range   Weighted-
average		 
Outstanding at December 31, 2010   721    $ 1.80 - 24.30   $9.90 
Granted   138    0.50-0.63    0.54 
Exercised   -    -    - 
Reinstated(1)   104    $ 5.04-21.60    9.15 
Outstanding at December 31, 2011   963    $ 0.50 - 24.30   $8.51 
Granted   1,137    0.15-0.56    0.32 
Exercised   -    -    - 
Cancelled   (773)   $ 5.04-24.30    9.92 
Outstanding at December 31, 2012   1,327    $ $0.15-11.34    0.67 

 

(1) Includes104 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which were cancelled in error in 2010.

 

F-14
 

 

Price in US Dollars   # Outstanding at
December 31, 2012		   # Exercisable at
December 31, 2012		   Remaining life
(years)		 
$0.15    33    33    6.62 
$0.18    61    61    6.38 
$0.20    254    254    6.25 
$0.35    689    689    6.89 
$0.50    94    94    6.10 
$0.56    100    100    6.97 
$0.63    45    45    5.64 
$1.80    4    4    2.71 
$5.04    7    7    1.92 
$5.22    2    2    2.41 
$7.20    2    2    1.70 
$10.26    23    23    1.37 
$11.34    13    13    1.33 
      1,327    1,327    6.44 

 

Pursuant to employment agreements dated May 3, 2010 between the Company and each of Robert Andrade, Rostislav Raykov and Thomas Spector (collectively Messrs. Andrade, Raykov and Spector) and conditional upon the approval of the amended Stock Option Plan, the Board approved the grant to each, Messrs. Andrade, Raykov and Spector an option to purchase up to 5.0% of Adherex’s common stock estimated by the Company to be outstanding upon completion of the proposed rights offering announced by the Company on April 20, 2010.On August 18, 2010, Messrs. Andrade, Raykov and Spector were each granted 971,885 options and on August 19, 2011 Messrs. Andrade, Raykov and Spector were each granted 51,152 options.

 

Pursuant to Independent Director Agreements dated May 3, 2010 for each of Dr. Porter and Messrs. Breen and Bussandri and conditional upon the approval of the amended Stock Option Plan, the Board approved the grant to each Dr. Porter and Messrs. Breen and Bussandri an option to purchase up to 1.33% of Adherex’s common stock estimated by the Company to be outstanding upon completion of the proposed rights offering announced by the Company on April 20, 2010. On August 18, 2010,each of Dr. Porter and Messrs. Breen and Bussandri were granted 255,759 options and on August 19, 2011,each of Dr. Porter and Messrs. Breen and Bussandri were granted 16,369 options.

 

Effective upon the Continuance, Chris A. Rallis and Steven D. Skolsky were appointed as members of the Board of Directors and Dr. Arthur T. Porter, William G. Breen and Claudio F. Bussandri resigned from the Board of Directors. In addition, each of the new directors has entered into an Independent Director Agreement with the Company, dated as of August 25, 2011, which provides for (i) cash compensation in the form of $ 1,500 per board meeting attended, and (ii) non-cash compensation in the form of a grant of options to purchase shares of the Company’s common stock having an aggregate value equal to $5,000 (with price per share and exercise price based on the value of the Company’s common stock as of the date of grant) per board meeting attended. The options immediately vested when granted and are otherwise subject to the terms and conditions of the Company’s stock option plan, as amended. The Independent Director Agreement also provides for the reimbursement of such director’s reasonable travel and related expenses incurred in the course of attending board meetings.

 

Stock compensation expense for the fiscal years ended December 31, 2012 and 2011 was $326 and $250 respectively.  These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted during the fiscal years ended December 31, 2012 and 2011 was $0.29 and $0.56, respectively. The intrinsic value (being the difference between the share price as at December 31, 2012 and exercise price) of stock options outstanding at December 31, 2012 was NIL.

 

The fair values of options granted in fiscal years ended December 31, 2012 and 2011 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions:

 

   Year Ended
December 31,
2012		   Year Ended
December 31,
2011		 
Expected dividend   0%   0%
Risk-free interest rate   1.09-1.26%   1.85-2.5%
Expected volatility   118-133%   121-132%
Expected life   7 years    7 years 

 

The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price.

 

F-15
 

 

 5.      Derivative Instruments

 

Effective January 1, 2009, the Company adopted ASC Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in shareholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' deficiency.

 

The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:

·Warrants to purchase 13,337 shares at CAD$1.44 per whole share that expire on April 30, 2015; and
·Warrants to purchase 4,698 shares exercisable at CAD$1.44 per whole share that expire on March 29, 2016.

 

These warrants have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.

 

As of December 31, 2012, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $4,698 and $1,847, respectively (December 31, 2011 – warrants expiring April 30, 2015, fair value of $3,672, March 29, 2016, fair value of $1,340), and the loss on these warrants for the twelve months ended December 31, 2012 was $1,026 and $507, respectively (December 31, 2011 - warrants expiring April 30, 2015, gain of $6,778; March 29,2016, gain of $643). There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.

 

Gain/(Loss) on Derivative Instruments  Twelve months ended December 31, 2012   Twelve months ended December 31, 2011 
Warrant expiring April 15, 2015   (1,026)   6,778 
Warrant expiring March 29, 2016   (507)   643 
Rights offering derivative   -    613 
Options to contractors   (30)   37 
Total   (1,563)   8,071 

 

In February 2011, the Company filed a final short form prospectus for a rights offering. In accordance with the terms of the rights offering, each shareholder of record on March 2, 2011 received one right for each common share held. Every right held entitled the holder thereof to purchase for CAD $0.03, or USD $0.0303 at the shareholder’s option, a unit consisting of one common share along with one warrant to purchase a common share of the Company at CAD $0.08. The rights began trading on March 2, 2011 on the TSX and on the Pink Sheets and expired on March 29, 2011.

 

On March 2, 2011, the Company recognized a derivative financial liability of $1.25 million associated with the Company’s obligation to carry out the rights offering. The deficit was adjusted by a corresponding amount. The derivative financial liability will be adjusted to fair value at each quarter end with changes being recognized in earnings until the expiry of the warrants. During the year ended December 31, 2011, the Company recognized a realized derivative gain of $613. The rights expired on March 29, 2011.

 

Under the terms of the rights offering, the monetary amount to be received by the Company upon the exercise of rights was not fixed. Each holder of rights could elect either the $0.03 CAD or USD$0.0303 subscription price. Furthermore, the CAD $0.03 subscription price was not denominated in the Company’s U.S. dollar functional currency. Therefore, the pro rata distribution of rights to the Company’s shareholders was accounted for as a derivative financial liability measured at fair value.

 

Upon the closing of the rights offering in March 2011, the Company issued a total of 84,559 units for total net proceeds of $2,566. Accordingly the Company recorded an increase in Common stock of $1,023 (4,697 shares). Expenses and fees relating to the rights offering totaled approximately $300 and were expensed since it was uncertain as to whether any shares would be issued.

 

F-16
 

 

During the fiscal year ended December 31, 2011, the Company issued 108 optionsto contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13, no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise. 

 

6.         Fair Value Measurements

 

The Company has adopted Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

Assets/Liabilities Measured at Fair Value on a Recurring Basis

 

Fair Value Measurement at December 31, 2012

 

   Quoted Pricein Active Markets   Significant Other   Significant     
   for IdenticalInstruments   Observable Inputs   Unobservable Inputs     
   Level 1   Level 2   Level 3   Total 
Assets                    
Cash equivalents  $-   $2,241   $-   $2,241 
Liabilities                    
Derivative liabilities   -    6,640    -    6,640 

  

The Company's financial instruments include cash equivalents and derivatives. Only cash equivalents and derivatives are carried at their fair value. The derivative liabilities include warrants denominated in a currency other than the Company’s functional currency and options issued to contractors in a currency other than the functional currency of the Company. The warrants are carried at fair value and calculated using the Black-Scholes option pricing model using the following assumptions; expected dividend 0%; risk-free interest rate of 1.15%-1.36%; expected volatility of 146% - 155%; and a 2.3 or 3.2 year remaining life. The options also use the Black Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 1.37%-1.41% expected volatility of 140%- 145%; and a 4.9-5.4 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument.

 

F-17
 

 

7.         Shareholders’ Equity

 

Authorized capital stock

 

The Company’s authorized capital stock consists of an unlimited number of shares of no par common stock.

 

On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “share consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the share shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our 2011 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).

 

Equity financings

 

On June 5, 2001, the Company completed an IPO issuing 74 shares of common stock at a price of CAD$135 per share. Net proceeds of this offering credited to common stock amounted to $5,727 after deducting the underwriting fee of $501 and expenses of $354. As additional compensation in connection with the offering, the Company granted the underwriters non-assignable support warrants representing ten percent of the offered shares. At that time, each support warrant entitled the holder to purchase one share of common stock on or before June 5, 2003 at CAD$7.50.

 

On December 19, 2003, the Company completed a private placement of equity securities totaling $16,095, comprised of (i) $15,050 for 11,522 units, at a price of CAD$1.75 per unit. Each unit consisted of one share of common stock and one-half of a common stock purchase warrant in Adherex with an exercise price of CAD$2.15 per share, which expired unexercised on December 19, 2008 (on a post-consolidation basis, 640 shares of common stock were issued), and (ii) $1,045 for 800 Series 1 Preferred Shares and warrants to purchase 400 Series 1 Preferred Shares of 2037357 Ontario Inc. The $5,777 estimated fair value of the warrants has been allocated to additional paid-in capital and the balance of $8,053 has been credited to common stock. At that time, the non-redeemable Series 1 Preferred Shares of 2037357 Ontario Inc. (“Preferred Shares”) were exchangeable into 800 shares of common stock of Adherex (44 shares of common stock on a post-consolidation basis). Upon such an exchange, all of the then outstanding warrants to purchase the Preferred Shares would be exchanged for an equal number of warrants to purchase Adherex common stock, which warrants expired on December 19, 2008. The $1,045 was to be spent on specific research and development projects in Ontario, Canada as designated by Adherex. Adherex could compel the exchange of the Preferred Shares into common stock and warrants for common stock of Adherex at any time after January 3, 2005. 2037357 Ontario Inc. has been accounted for in accordance with the substance of the transaction. The $1,045 has been recorded as non-redeemable Preferred Shares and the amounts expended were recorded as expenses in the relevant periods. On June 14, 2004, the preferred shares and warrants were exchanged for 44 shares of Adherex common stock on a post-consolidation basis, and warrants to purchase shares of Adherex common stock, all of which warrants expired on December 19, 2008. In June 2004, 2037357 Ontario Inc. became a wholly owned subsidiary of the Company and was amalgamated with Adherex Technologies Inc. The investment has been split between the estimated fair value of the warrants of $363, which has been included in additional paid-in capital, and the remainder of $660, which has been recorded in common stock. On May 20, 2004, the Company completed equity financings with total gross proceeds of $9,029 less $555 of issuance costs and issued4,669 units at a purchase price of CAD$2.65 per unit. Each unit consisted of one share of common stock and one-half of a common stock purchase warrant, and, at that time, each whole warrant entitled the holder to acquire one additional share of common stock at an exercise price of CAD$3.50, all of which expired unexercised on May 19, 2007. The financing resulted in the issuance of an aggregate of 259 shares of common stock on a post-consolidation basis. The $2,118 value of the warrants has been allocated to additional paid-in capital and the balance of $6,356 has been credited to common stock.

 

On July 20, 2005, the Company completed a private placement of equity securities for gross proceeds of $8,510 and issued 6,079 units at a price of $1.40 per unit, providing net proceeds of $8,134 after deducting broker fees and other expenses of $376. At the time, each unit consisted of one common share and 0.30 of a common share purchase warrant and the private placement resulted in the issuance of an aggregate of337 shares of common stock on a post –consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. At that time, each whole investor warrant entitled the holder to acquire one additional share of common stock of Adherex at an exercise price of $1.75 per share for a period of three years and each whole broker warrant entitled the holder to acquire one share of Adherex common stock at an exercise price of $1.75 for a period of two years, all of which expired unexercised on July 20, 2007 and 2008, respectively. The warrants, with a value of $1,074 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $7,060 has been credited to common stock.

 

On May 8, 2006, the Company completed a private placement of equity securities for gross proceeds of $6,512 and issued 7,753 units at a price of $0.84 per unit providing net proceeds of $6,040 after deducting broker fees and certain other expenses. Each unit consisted of one common share and 0.30 of a common share purchase warrant, and the private placement resulted in the issuance of an aggregate of 431 shares of common stock on a post-consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. At that time, each whole investor warrant entitled the holder to acquire one additional share of Adherex common stock at an exercise price of $0.97 per share for a period of four years, and each whole broker warrant entitled the holder to acquire one share of Adherex common stock at an exercise price of $0.97 per share for a period of two years, all of which expired unexercised on May 7, 2008. The warrants, with a value of $822 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $5,218 has been credited to common stock.

 

F-18
 

 

On February 21, 2007, the Company completed the sale of equity securities providing gross proceeds of $25,000 for 75,759 units at a price of $0.33 per unit providing net proceeds of $23,221 after deducting broker fees and other expenses. Each unit consisted of one common share and one-half of a common share purchase warrant. The offering resulted in the issuance of an aggregate of4,209 shares of common stock on a post-consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. At that time, each whole investor warrant entitled the holder to acquire one additional share of Adherex common stock at an exercise price of $0.40 per share for a period of three years, and each whole broker warrant entitled the holder to acquire one additional unit at an exercise price of $0.33 per unit for a period of two years, the unexercised portion of which expired on February 21, 2009. The warrants, with a value of $5,379 based on the Black-Scholes option pricing model, have been allocated to additional paid-in-capital and the remaining balance of $17,842 has been included in common stock.

 

During the second quarter of fiscal 2007, the Company received gross proceeds of $694 related to the exercise of warrants and issued 116 shares of common stock on a post-consolidation basis and additional investor warrants, which expired on February 21, 2010. The warrants, with a value of $131 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $563 has been included in common stock.

 

On April 30, 2010, the Company completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066,664 units, at a price of CAD$0.03 per unit for net proceeds of CAD$7.2 million. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). At that time, each Warrant entitled the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. As a result of the Share Consolidation on August 25, 2011, the number of sharesand warrants issued upon exercise of the units consists of 13,337,037 shares and warrants to purchase 13,337,037 shares of common stock at the exercise price of CAD $1.44 per whole share.

 

Special warrants

 

From May 2000 through November 2000, the Company issued special warrants. At that time, each special warrant was sold for CAD$25.00 and entitled the holder thereof to acquire, for no additional consideration, four shares of common stock of the Company. The special warrants also included a price protection adjustment determined by dividing CAD$32.50 by the initial public offering (“IPO”) price of CAD$7.50.

 

During the year ended June 30, 2000, 16 of 126 special warrants were issued, with the balance of110 issued in the year ended June 30, 2001. Upon completion of the IPO, on June 5, 2001, these special warrants were converted to 30 shares of common stock, which included 2 shares of common stock issued under the price protection adjustment (such shares are presented on a post-consolidation basis).

 

Special A warrants

 

During October 2000, the Company issued Series A special warrants. At that time, each Series A special warrant was sold at CAD$6.25 and entitled the holder to acquire, for no additional consideration, one share of common stock of the Company. At that time, the Series A special warrants also included a price protection adjustment determined by dividing CAD$8.125 by the IPO price.

 

Upon completion of the IPO, on June 5, 2001, these Series A special warrants were converted to 69 shares of common stock, which included 5 shares of common stock issued under the price protection adjustment (such shares are presented on a post-consolidation basis).

 

In addition, each Series A special warrant included a share purchase warrant entitling the holder to purchase an additional share of common stock at the IPO price, which was also subject to the price protection adjustment. These share purchase warrants expired unexercised on September 3, 2001.

 

2010 Private Placement Warrants

 

On April 30, 2010, the Company completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066,664 units, at a price of CAD$0.03 per unit for net proceeds of CAD$7,202. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). At that time, each Warrant entitled the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. As the exercise price is denominated in a currency other than the company’s functional currency, these warrants are treated as a derivative instrument. (Note 5) As a result of the Share Consolidation on August 25, 2011, the number of shares issuable upon the exercise of the warrants issued in connection with the April 2010 Private Placement consists of 13,337,037 shares of common stock at the exercise price of CAD $1.44 per whole share.

 

Equity rights

 

On September 28, 1999, University Medical Discoveries Inc. (“UMDI”) invested $171 for equity of the Company. The form of this equity was to be the same as the first class of securities to raise greater than $683 subsequent to the date of the investment. The date of conversion was dependent on certain milestones being met under a specific research project. On August 24, 2000, the Company and UMDI agreed to convert UMDI’s $171 investment into 3 shares of common stock of the Company.

 

F-19
 

 

The Company a rights offering to its shareholders on March 2, 2011, the record date for the rights offering (the "Rights Offering"). Pursuant to the terms of the Rights Offering, the Company distributed rights to subscribe for up to 425,000,000 Units at a price of CAD$0.03 per unit, for gross proceeds of up to CAD$12,750,000, to the shareholders on the basis of one right per each share of common stock held by such shareholder on March 2, 2011, the record date for the Rights Offering.  Purchasers of units in the Company's April 2010 Private Placement described above that owned common stock as of the record date for the Rights Offering agreed not to participate in the Rights Offering. Each right was exercisable for one unit which consisted of one common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. Adherex filed a short-form prospectus for the Rights Offering with the securities regulatory authorities in Canada to qualify the distribution of the rights in Canada on February 11, 2011 and a Form S-1 registration statement with the Securities and Exchange Commission to register the rights and underlying securities in the United States, which registration statement was declared effective on February 11, 2011. As of 5:00 pm New York City time on March 29, 2011, the expiration date for the Rights Offering, the Company had received subscriptions for an aggregate of 84,559,178 Units, representing estimated aggregate gross proceeds of approximately $2.5 million.

 

Triathlon settlement

 

During fiscal 2000, other advances totaling $175 were settled by the issuance to Triathlon Limited of 16 shares of common stock of the Company. The number of shares issued was determined with reference to the fair value at the time the advances were made.

 

Shire BioChem Inc. agreement

 

On August 17, 2000, the Company entered into a subscription agreement and a license agreement with Shire BioChem Inc. (“BioChem”). Under the subscription agreement, BioChem purchased 5 shares of common stock of the Company for $341. Pursuant to a price protection clause in the agreement, an additional eight shares of common stock were issued on completion of the Company’s IPO on June 5, 2001.

 

Acquisitions

 

On November 20, 2002, the Company issued 446 shares of commons stock to acquire all of the issued and outstanding securities of Oxiquant, a holding company which held certain intellectual property rights, including rights to sodium thiosulfate.

 

In connection with the acquisition of the intellectual property of Oxiquant in November 2002, the Company issued warrants to purchase shares of common stock with an exercise price of CAD$3.585 that expired unexercised on May 20, 2007 and introduction warrants to purchase shares of common stock with an exercise price of CAD$2.05 that expired unexercised on November 20, 2007.

 

As a prerequisite of the Oxiquant transaction, Adherex licensed all of its Cadherin-related intellectual property for non-cancer applications and transferred $158 in cash to Cadherin Biomedical Inc. or CBI, a wholly-owned subsidiary of Adherex at the time, in return for Class A Preferred Shares of CBI. These CBI Class A Preferred Shares were then distributed to all of the Adherex shareholders of record by way of special dividend, effecting a “spin out” of CBI and the non-cancer assets from Adherex.

 

In order to effect such a distribution under Section 42 of the Canada Business Corporations Act (“CBCA”), the Company was legally required to reduce its stated capital so that the aggregate amount of its liabilities and stated capital did not exceed the realizable value of Adherex’s assets. Management determined that the stated capital needed to be reduced by $9,489, in order to comply with the requirements of Section 42 of the CBCA. The Company decreased common stock and increased additional paid-in capital by $9,489.

 

In February 2004, the Company and CBI became involved in litigation. On December 3, 2004, the Company and CBI settled the litigation and the Company agreed to acquire all of the issued and outstanding shares of CBI and reacquire the non-cancer rights to the cadherin-based intellectual property. As part of the agreement, the Company issued 37 common shares valued at $1,252, net of transaction costs.

 

Convertible note warrants

 

On June 23, 2003, the Company issued senior secured convertible notes with a face value totaling $2,219. These notes were convertible into common stock and warrants to acquire common stock of the Company upon completion of an equity fund raising round. At that time, investors also received warrants to purchase shares of common stock of the Company with an exercise price of CAD$2.75 per share that expired unexercised on June 23, 2007. The notes bore interest at an annual rate of eight percent compounded semi-annually, and matured one year from issue but were renewable for one additional year at the option of the Company. In connection with this issuance, at that time, the Company issued broker warrants to purchase shares of common stock exercisable at a price of CAD$2.35 per share, which expired unexercised on June 23, 2005.

 

On December 3, 2003, the Company issued additional senior secured convertible notes with a face value totaling CAD$1,458. These notes were convertible into common stock and warrants to acquire common stock of the Company upon completion of an equity fund raising round. Also, at that time, investors received warrants to purchase shares of common stock exercisable at a price of CAD$2.15 per share which expired unexercised on December 3, 2007.The notes bore interest at an annual rate of eight percent compounded semi-annually, and matured one year from issue but were renewable for one additional year at the option of the Company. At that time, the Company also issued broker warrants to purchase shares of common stock exercisable at a price of CAD$2.15 per share which expired unexercised on December 3, 2005.

 

On December 19, 2003, the Company completed an equity financing resulting in the conversion of the June and the December notes into 156 shares of common stock on a post-consolidation basis with a carrying value of $1,785 credited to common stock. At that time, the Company issued warrants to purchase, shares of common stock with an exercise price of CAD$2.15 per share which expired unexercised on December 19, 2008.

 

F-20
 

 

Warrants to Purchase Common Stock

 

At December 31, 2012, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years: 

 

Warrant Description
(Warrants in thousands)		  Common Shares Issuable Upon
Exercise of Outstanding
Warrants at December 31, 2012		   Exercise Price in Canadian
Dollars		   Expiration Date
Investor Warrants (1)   13,337   $1.44   April 30, 2015
Investor Warrants (2)   4,698   $1.44   March 29, 2016
    18,035         

 

(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

 

(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

 

8.         Research and Development

 

Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows:

 

   Year Ended
December 31,		   Year Ended
December 31,		   Cumulative
FromSeptember 3,1996 to
December 31,		 
   2012   2011   2012 
Research and development  $2,075   $1,494   $69,168 
Investment tax credits   -    -    (1,632)
National Research Council grants   -    -    (197)
   $2,075   $1,494   $67,339 

 

9.      Capital and Operating Lease Commitments

 

We had no material commitments for capital expenses or commitments extending beyond three years as of December 31, 2012.  The following table represents our contractual obligations and commitments at December 31, 2012 (in thousands of U.S. dollars):

 

   Less than
1 year		   1-3
years		   Total 
OCT Clinical Service Agreement (1)   402    -    402 
Oregon Health & Science University (2), excluding potential royalty payments   -    -    - 
Life Sci Advisors, LLC (3)   55    -    55 
Total  $457   $-   $457 

 

(1) Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia.  The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients.  The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled.
(2) Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million.  Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included.

 

F-21
 

 

(3) Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of the agreement.  Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.  

 

10.      Commitments and Contingencies

 

Oregon Health & Science University agreement

 

On February 20, 2013, Adherex entered into a new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, a 2.5 percent royalty on net sales for licensed products which can be reduced to 1.0 percent upon a $150,000 buy down and a 5 percent royalty on any consideration received from sublicensing of the licensed technology. Milestone payment fees payable to OHSU include $100,000 upon first commercial sale for any licensed product.

 

On February 20, 2013, Adherex terminated the previous exclusive license agreement with Oregon Health & Science University and Oxiquant a wholly owned subsidiary of Adherex, dated September 26, 2002(the "Previous OHSU Agreement"). Pursuant to the Previous OHSU Agreement, OHSU granted Oxiquant an exclusive worldwide license to intellectual property directed to thiol-based compounds including STS and their use in oncology. In consideration, Oregon Health & Science University was issued 13,902 shares of common stock of Oxiquant that were subsequently converted upon the acquisition of Oxiquant into 21,250 shares of Adherex common stock, and warrants to purchase shares of Adherex common stock that subsequently expired in 2007. In addition under the Previous OHSU Agreement, the following milestone payments were included in the agreement: (i) $50,000 upon completion of Phase I clinical trials, (ii) $200,000 upon completion of Phase II clinical trials, (iii) $500,000 upon completion of Phase III clinical trials. Also, Oxiquant was to be liable for an additional milestone payment of $250,000 upon the first commercial sale for any licensed product. Further, the Previous OHSU Agreement required Adherex to pay Oregon Health & Science University a 2.5% royalty on net sales of any licensed products and a 15% royalty on any consideration received from sublicensing of the licensed technology.

 

The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Adherex, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Adherex or Oregon Health & Science University in the event of a material breach of the agreement by either party after 45 days prior written notice. Adherex has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

 

GlaxoSmithKline

 

On July 14, 2005, Adherex entered into a development and license agreement with GlaxoSmithKline, or GSK. The agreement included the in-license by the Company of GSK’s oncology product, Eniluracil, and an option for GSK to license ADH-1.  As part of the transaction, GSK invested $3.0 million in the Company's common stock. On October 11, 2006, the GSK option to license ADH-1 expired unexercised. Under the terms of the agreement relating to Eniluracil, Adherex received an exclusive license to develop Eniluracil for all indications and GSK retained options to buy-back and assume development of the compound at various points in time.

 

On March 1, 2007, the GSK agreement was amended and the Company purchased all of GSK’s remaining buy-back options for a fee of $1.0 million.  As a result of the amendment to the GSK agreement, Adherex now may be required to pay GSK development and sales milestones and royalties. Specifically, if Adherex files a New Drug Application, or NDA, with the Food and Drug Administration, or FDA, Adherex may be required to pay development milestones of $5.0 million to GSK. Additionally, depending upon whether the NDA is approved by the FDA and whether Eniluracil becomes a commercial success, the Company may be required to pay up to an additional $70.0 million in development and sales milestones for the initially approved indication, plus royalties in the low-double digit range based on annual net sales. If the Company pursues other indications, it may also be required to pay up to an additional $15 million to GSK for each FDA-approved indication. The GSK agreement continues until the earliest of (i) the licensed patents expire or (ii) is terminated by either party in the event of an uncured breach by the breaching party after 60 days prior written notice.

 

F-22
 

 

11.      Income Taxes

 

The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows:

 

   Year Ended
December 31,		   Year Ended
December 31,		 
   2012   2011 
Domestic loss   (4,397)   5,623 
Foreign loss   (766)   (938)
Loss before income taxes   (5,163)   4,685 
           
Expected statutory rate (recovery)   26.50%   28.25%
Expected provision for (recovery of) income tax   (1,368)   1,324 
Permanent differences   489    (2,209)
Change in valuation allowance   2,467    (589)
Non-refundable investment tax credits   0    157 
Effect of foreign exchange rate differences   (245)   (204)
Effect of change in future enacted tax rates   (1,378)   (77)
Effect of tax rate changes and other   36    1,599 
Provision for income taxes  $-   $- 

 

The Canadian statutory come tax rate of 28.25 percent is comprised of federal income tax at approximately 16.5 percent and provincial income tax at approximately 11.75 percent.

 

The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2012, December 31, 2011:

 

   December 31,
2012		   December 31,
2011		 
Future tax assets:          
SR&ED expenditures   2,195    2,071 
Income tax loss carryforwards   21,783    19,635 
Non-refundable investment tax credits   1,719    1,719 
Share issue costs   25    84 
Accrued expenses   -    - 
Fixed and intangible assets   970    685 
Harmonization credit   248    280 
    26,940    24,193 
Less: valuation allowance   (26,940)   (24,193)
Net future tax assets  $-   $- 

 

There are no current income taxes owed, nor are any income taxes expected to be owed in the near term.

 

F-23
 

 

At December 31, 2012 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below:

 

   Federal   Province/
State		 
SR&ED expenditures (no expiry)  $8,283   $- 
Income tax loss carryforwards (expiry date):          
2014   6,089    6,089 
2015   11,499    11,499 
2021   26    - 
2022   233    - 
2023   133    - 
2024   1,536    1,455 
2025   4,795    4,768 
2026   20,562    20,496 
2027   8,340    8,320 
2028   10,840    10,823 
2029   8,502    8,502 
2030   2,608    2,607 
2031   3,377    3,377 
2032   3,660    3,660 
Investment tax credits (expiry date):        
2018   10     
2019   8      
2020   96      
2021   55      
2022   548      
2023   399      
2024   178      
2025   199      
2026   86      
2027   90      
2028   50      

 

F-24

 

 EX-31.1 2 v337350_ex31-1.htm EXHIBIT 31.1

 

 Exhibit 31.1

ADHEREX TECHNOLOGIES INC

CERTIFICATION

I, Rostislav Raykov, certify that:

 

  1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2012 of Adherex Technologies Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  March 28, 2013

 

  By: /s/ Rostislav Raykov
    Rostislav Raykov
    Chief Executive Officer

  

 
 EX-31.2 3 v337350_ex31-2.htm EXHIBIT 31.2

  

Exhibit 31.2

ADHEREX TECHNOLOGIES INC.

CERTIFICATION

I, Robert Andrade, certify that:

     

  1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2012 of Adherex Technologies Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  March 28, 2013

 

  By: /s/ Robert Andrade
    Robert Andrade
    Chief Financial Officer

 

 
 EX-32.1 4 v337350_ex32-1.htm EXHIBIT 32.1

  

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. §1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Adherex Technologies Inc. (the “ Company ”) on Form 10-K for the period ended December 31, 2012 (the “ Report ”), each of the undersigned, Rostislav Raykov, Chief Executive Officer of the Company, and Robert Andrade, Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date:  March 28, 2013

 

  By: /s/ Rostislav Raykov
    Rostislav Raykov
    Chief Executive Officer

 

Date:  March 28, 2013

 

  By: /s/ Robert Andrade
    Robert Andrade
    Chief Financial Officer

 

 
 EX-101.INS 5 adhxf-20121231.xml XBRL INSTANCE DOCUMENT 0001211583 1996-09-02 0001211583 us-gaap:AdditionalPaidInCapitalMember 1996-09-02 0001211583 us-gaap:CommonStockMember 1996-09-02 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1996-09-02 0001211583 us-gaap:PreferredStockMember 1996-09-02 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1996-09-02 0001211583 1997-06-23 0001211583 us-gaap:AdditionalPaidInCapitalMember 1997-06-23 0001211583 us-gaap:CommonStockMember 1997-06-23 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1997-06-23 0001211583 us-gaap:PreferredStockMember 1997-06-23 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1997-06-23 0001211583 1996-09-03 1997-06-23 0001211583 us-gaap:AdditionalPaidInCapitalMember 1996-09-03 1997-06-23 0001211583 us-gaap:CommonStockMember 1996-09-03 1997-06-23 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1996-09-03 1997-06-23 0001211583 us-gaap:PreferredStockMember 1996-09-03 1997-06-23 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1996-09-03 1997-06-23 0001211583 1997-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 1997-06-30 0001211583 us-gaap:CommonStockMember 1997-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1997-06-30 0001211583 us-gaap:PreferredStockMember 1997-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1997-06-30 0001211583 1997-07-01 1998-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 1997-07-01 1998-06-30 0001211583 us-gaap:CommonStockMember 1997-07-01 1998-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1997-07-01 1998-06-30 0001211583 us-gaap:PreferredStockMember 1997-07-01 1998-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1997-07-01 1998-06-30 0001211583 1998-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 1998-06-30 0001211583 us-gaap:CommonStockMember 1998-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1998-06-30 0001211583 us-gaap:PreferredStockMember 1998-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1998-06-30 0001211583 1998-07-01 1999-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 1998-07-01 1999-06-30 0001211583 us-gaap:CommonStockMember 1998-07-01 1999-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1998-07-01 1999-06-30 0001211583 us-gaap:PreferredStockMember 1998-07-01 1999-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1998-07-01 1999-06-30 0001211583 1999-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 1999-06-30 0001211583 us-gaap:CommonStockMember 1999-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1999-06-30 0001211583 us-gaap:PreferredStockMember 1999-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1999-06-30 0001211583 1999-09-01 1999-09-28 0001211583 adhxf:UniversityMedicalDiscoveriesIncMember 1999-09-01 1999-09-28 0001211583 1999-07-01 2000-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 1999-07-01 2000-06-30 0001211583 us-gaap:CommonStockMember 1999-07-01 2000-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1999-07-01 2000-06-30 0001211583 us-gaap:PreferredStockMember 1999-07-01 2000-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1999-07-01 2000-06-30 0001211583 adhxf:OtherAdvancesMember 1999-07-01 2000-06-30 0001211583 us-gaap:WarrantMember 1999-07-01 2000-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:OtherAdvancesMember 1999-07-01 2000-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:WarrantMember 1999-07-01 2000-06-30 0001211583 us-gaap:CommonStockMember adhxf:OtherAdvancesMember 1999-07-01 2000-06-30 0001211583 us-gaap:CommonStockMember us-gaap:WarrantMember 1999-07-01 2000-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:OtherAdvancesMember 1999-07-01 2000-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:WarrantMember 1999-07-01 2000-06-30 0001211583 us-gaap:PreferredStockMember adhxf:OtherAdvancesMember 1999-07-01 2000-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:WarrantMember 1999-07-01 2000-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:OtherAdvancesMember 1999-07-01 2000-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:WarrantMember 1999-07-01 2000-06-30 0001211583 2000-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2000-06-30 0001211583 us-gaap:CommonStockMember 2000-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2000-06-30 0001211583 us-gaap:PreferredStockMember 2000-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2000-06-30 0001211583 adhxf:ShireBiochemIncAgreementMember 2000-08-01 2000-08-17 0001211583 adhxf:SpecialWarrantMember us-gaap:IPOMember 2000-10-31 0001211583 us-gaap:IPOMember us-gaap:CommonStockMember 2001-06-05 0001211583 us-gaap:IPOMember us-gaap:CommonStockMember 2001-05-10 2001-06-05 0001211583 adhxf:SpecialWarrantMember 2001-05-10 2001-06-05 0001211583 adhxf:PriceProtectionAdjustmentMember adhxf:SpecialWarrantMember 2001-05-10 2001-06-05 0001211583 2000-07-01 2001-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2000-07-01 2001-06-30 0001211583 us-gaap:CommonStockMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2000-07-01 2001-06-30 0001211583 us-gaap:PreferredStockMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2000-07-01 2001-06-30 0001211583 us-gaap:WarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:WarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:CommonStockMember us-gaap:WarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:WarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:WarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:WarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:RightsMember 2000-07-01 2001-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:RightsMember 2000-07-01 2001-06-30 0001211583 us-gaap:CommonStockMember us-gaap:RightsMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:RightsMember 2000-07-01 2001-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:RightsMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:RightsMember 2000-07-01 2001-06-30 0001211583 adhxf:SeriesWarrantMember 2000-07-01 2001-06-30 0001211583 adhxf:AllOtherMember 2000-07-01 2001-06-30 0001211583 adhxf:InitialPublicOfferingMember 2000-07-01 2001-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:SeriesWarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:AllOtherMember 2000-07-01 2001-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:InitialPublicOfferingMember 2000-07-01 2001-06-30 0001211583 us-gaap:CommonStockMember adhxf:SeriesWarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:CommonStockMember adhxf:AllOtherMember 2000-07-01 2001-06-30 0001211583 us-gaap:CommonStockMember adhxf:InitialPublicOfferingMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:SeriesWarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:AllOtherMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:InitialPublicOfferingMember 2000-07-01 2001-06-30 0001211583 us-gaap:PreferredStockMember adhxf:SeriesWarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:PreferredStockMember adhxf:AllOtherMember 2000-07-01 2001-06-30 0001211583 us-gaap:PreferredStockMember adhxf:InitialPublicOfferingMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:SeriesWarrantMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:AllOtherMember 2000-07-01 2001-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:InitialPublicOfferingMember 2000-07-01 2001-06-30 0001211583 2001-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2001-06-30 0001211583 us-gaap:CommonStockMember 2001-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2001-06-30 0001211583 us-gaap:PreferredStockMember 2001-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2001-06-30 0001211583 2001-07-01 2002-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2001-07-01 2002-06-30 0001211583 us-gaap:CommonStockMember 2001-07-01 2002-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2001-07-01 2002-06-30 0001211583 us-gaap:PreferredStockMember 2001-07-01 2002-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2001-07-01 2002-06-30 0001211583 2002-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2002-06-30 0001211583 us-gaap:CommonStockMember 2002-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2002-06-30 0001211583 us-gaap:PreferredStockMember 2002-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2002-06-30 0001211583 2002-09-01 2002-09-30 0001211583 adhxf:OxiquantMember 2002-11-01 2002-11-20 0001211583 us-gaap:IPOMember us-gaap:CommonStockMember 2003-06-05 0001211583 adhxf:SeniorSecuredConvertibleNotesMember 2003-06-23 0001211583 2002-07-01 2003-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2002-07-01 2003-06-30 0001211583 us-gaap:CommonStockMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2002-07-01 2003-06-30 0001211583 us-gaap:PreferredStockMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2002-07-01 2003-06-30 0001211583 adhxf:ConsultingFeeMember 2002-07-01 2003-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2002-07-01 2003-06-30 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2002-07-01 2003-06-30 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2002-07-01 2003-06-30 0001211583 adhxf:FinancingWarrantMember 2002-07-01 2003-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:FinancingWarrantMember 2002-07-01 2003-06-30 0001211583 us-gaap:CommonStockMember adhxf:FinancingWarrantMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:FinancingWarrantMember 2002-07-01 2003-06-30 0001211583 us-gaap:PreferredStockMember adhxf:FinancingWarrantMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:FinancingWarrantMember 2002-07-01 2003-06-30 0001211583 adhxf:BusinessAcquisitionOneMember 2002-07-01 2003-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:BusinessAcquisitionOneMember 2002-07-01 2003-06-30 0001211583 us-gaap:CommonStockMember adhxf:BusinessAcquisitionOneMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:BusinessAcquisitionOneMember 2002-07-01 2003-06-30 0001211583 us-gaap:PreferredStockMember adhxf:BusinessAcquisitionOneMember 2002-07-01 2003-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:BusinessAcquisitionOneMember 2002-07-01 2003-06-30 0001211583 2003-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2003-06-30 0001211583 us-gaap:CommonStockMember 2003-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2003-06-30 0001211583 us-gaap:PreferredStockMember 2003-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2003-06-30 0001211583 adhxf:AdditionalSeniorSecuredConvertibleNotesMember 2003-12-03 0001211583 adhxf:EquityFinancingMember 2003-12-19 0001211583 2003-12-01 2003-12-19 0001211583 adhxf:EquityFinancingMember 2003-12-01 2003-12-19 0001211583 us-gaap:PrivatePlacementMember 2003-12-01 2003-12-19 0001211583 adhxf:PostConsolidatonMember us-gaap:PrivatePlacementMember 2003-12-01 2003-12-19 0001211583 us-gaap:PrivatePlacementMember us-gaap:PreferredStockMember 2003-12-01 2003-12-19 0001211583 adhxf:CbiMember 2004-02-01 2004-02-28 0001211583 us-gaap:PrivatePlacementMember 2004-05-20 0001211583 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2004-05-20 0001211583 us-gaap:PrivatePlacementMember 2004-05-01 2004-05-31 0001211583 adhxf:PostConsolidatonMember us-gaap:PrivatePlacementMember 2004-05-01 2004-05-31 0001211583 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2003-07-01 2004-06-30 0001211583 adhxf:ConsultingFeeMember 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2003-07-01 2004-06-30 0001211583 adhxf:FinancingWarrantMember 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:FinancingWarrantMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember adhxf:FinancingWarrantMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:FinancingWarrantMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember adhxf:FinancingWarrantMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:FinancingWarrantMember 2003-07-01 2004-06-30 0001211583 us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodTwoMember 2003-07-01 2004-06-30 0001211583 us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodOneMember 2003-07-01 2004-06-30 0001211583 us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFourMember 2003-07-01 2004-06-30 0001211583 us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodThreeMember 2003-07-01 2004-06-30 0001211583 us-gaap:NonredeemablePreferredStockMember 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodTwoMember 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodOneMember 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFourMember 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodThreeMember 2003-07-01 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:NonredeemablePreferredStockMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodTwoMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodOneMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFourMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodThreeMember 2003-07-01 2004-06-30 0001211583 us-gaap:CommonStockMember us-gaap:NonredeemablePreferredStockMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodTwoMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodOneMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFourMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodThreeMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:NonredeemablePreferredStockMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodTwoMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodOneMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFourMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodThreeMember 2003-07-01 2004-06-30 0001211583 us-gaap:PreferredStockMember us-gaap:NonredeemablePreferredStockMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodTwoMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:ConvertibleNotesPayableMember adhxf:IssuanceDuringPeriodOneMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFourMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodThreeMember 2003-07-01 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:NonredeemablePreferredStockMember 2003-07-01 2004-06-30 0001211583 2004-06-30 0001211583 us-gaap:AdditionalPaidInCapitalMember 2004-06-30 0001211583 us-gaap:CommonStockMember 2004-06-30 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2004-06-30 0001211583 us-gaap:PreferredStockMember 2004-06-30 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2004-06-30 0001211583 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2004-06-30 0001211583 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2004-06-30 0001211583 2004-07-01 2004-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2004-07-01 2004-12-31 0001211583 us-gaap:CommonStockMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2004-07-01 2004-12-31 0001211583 us-gaap:PreferredStockMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2004-07-01 2004-12-31 0001211583 adhxf:ConsultingFeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2004-07-01 2004-12-31 0001211583 adhxf:EmployeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2004-07-01 2004-12-31 0001211583 adhxf:BusinessAcquisitionTwoMember 2004-07-01 2004-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:BusinessAcquisitionTwoMember 2004-07-01 2004-12-31 0001211583 us-gaap:CommonStockMember adhxf:BusinessAcquisitionTwoMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:BusinessAcquisitionTwoMember 2004-07-01 2004-12-31 0001211583 us-gaap:PreferredStockMember adhxf:BusinessAcquisitionTwoMember 2004-07-01 2004-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:BusinessAcquisitionTwoMember 2004-07-01 2004-12-31 0001211583 2004-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2004-12-31 0001211583 us-gaap:CommonStockMember 2004-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2004-12-31 0001211583 us-gaap:PreferredStockMember 2004-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2004-12-31 0001211583 adhxf:SeniorSecuredConvertibleNotesMember 2005-06-23 0001211583 2005-07-20 0001211583 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2005-07-20 0001211583 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2005-07-20 0001211583 us-gaap:PrivatePlacementMember 2005-07-01 2005-07-20 0001211583 adhxf:PostConsolidatonMember us-gaap:PrivatePlacementMember 2005-07-01 2005-07-20 0001211583 adhxf:GrossProceedsMember us-gaap:PrivatePlacementMember 2005-07-01 2005-07-20 0001211583 adhxf:NetProceedsMember us-gaap:PrivatePlacementMember 2005-07-01 2005-07-20 0001211583 adhxf:AdditionalSeniorSecuredConvertibleNotesMember 2005-12-03 0001211583 2005-01-01 2005-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2005-01-01 2005-12-31 0001211583 us-gaap:CommonStockMember 2005-01-01 2005-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2005-01-01 2005-12-31 0001211583 us-gaap:PreferredStockMember 2005-01-01 2005-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2005-01-01 2005-12-31 0001211583 adhxf:ConsultingFeeMember 2005-01-01 2005-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2005-01-01 2005-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2005-01-01 2005-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2005-01-01 2005-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2005-01-01 2005-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2005-01-01 2005-12-31 0001211583 us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFiveMember 2005-01-01 2005-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFiveMember 2005-01-01 2005-12-31 0001211583 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFiveMember 2005-01-01 2005-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFiveMember 2005-01-01 2005-12-31 0001211583 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFiveMember 2005-01-01 2005-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodFiveMember 2005-01-01 2005-12-31 0001211583 2005-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0001211583 us-gaap:CommonStockMember 2005-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2005-12-31 0001211583 us-gaap:PreferredStockMember 2005-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2005-12-31 0001211583 us-gaap:PrivatePlacementMember 2006-05-08 0001211583 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2006-05-08 0001211583 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2006-05-08 0001211583 us-gaap:PrivatePlacementMember 2006-04-15 2006-05-08 0001211583 adhxf:PostConsolidatonMember us-gaap:PrivatePlacementMember 2006-04-15 2006-05-08 0001211583 adhxf:GrossProceedsMember us-gaap:PrivatePlacementMember 2006-04-15 2006-05-08 0001211583 adhxf:NetProceedsMember us-gaap:PrivatePlacementMember 2006-04-15 2006-05-08 0001211583 adhxf:GlaxoSmithKlineMember 2006-10-01 2006-10-31 0001211583 2006-01-01 2006-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0001211583 us-gaap:CommonStockMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2006-01-01 2006-12-31 0001211583 us-gaap:PreferredStockMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2006-01-01 2006-12-31 0001211583 adhxf:ConsultingFeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2006-01-01 2006-12-31 0001211583 adhxf:EmployeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2006-01-01 2006-12-31 0001211583 us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodSixMember 2006-01-01 2006-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodSixMember 2006-01-01 2006-12-31 0001211583 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodSixMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodSixMember 2006-01-01 2006-12-31 0001211583 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodSixMember 2006-01-01 2006-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:PrivatePlacementMember adhxf:IssuanceDuringPeriodSixMember 2006-01-01 2006-12-31 0001211583 2006-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0001211583 us-gaap:CommonStockMember 2006-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2006-12-31 0001211583 us-gaap:PreferredStockMember 2006-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2006-12-31 0001211583 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2007-02-21 0001211583 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2007-02-21 0001211583 us-gaap:PrivatePlacementMember adhxf:InvestorWarrantMember 2007-02-21 0001211583 us-gaap:PrivatePlacementMember adhxf:WholeBrokerMember 2007-02-21 0001211583 us-gaap:PrivatePlacementMember 2007-02-01 2007-02-21 0001211583 adhxf:GrossProceedsMember us-gaap:PrivatePlacementMember 2007-02-01 2007-02-21 0001211583 adhxf:NetProceedsMember us-gaap:PrivatePlacementMember 2007-02-01 2007-02-21 0001211583 2007-05-20 0001211583 adhxf:OxiquantMember 2007-05-20 0001211583 2007-03-31 2007-06-30 0001211583 us-gaap:PrivatePlacementMember 2007-03-31 2007-06-30 0001211583 adhxf:PostConsolidatonMember us-gaap:PrivatePlacementMember 2007-03-31 2007-06-30 0001211583 us-gaap:PrivatePlacementMember 2007-06-30 0001211583 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2007-06-30 0001211583 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2007-06-30 0001211583 2007-01-01 2007-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0001211583 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2007-01-01 2007-12-31 0001211583 us-gaap:PreferredStockMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2007-01-01 2007-12-31 0001211583 adhxf:ConsultingFeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2007-01-01 2007-12-31 0001211583 adhxf:EmployeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2007-01-01 2007-12-31 0001211583 adhxf:IssuanceDuringPeriodSevenMember 2007-01-01 2007-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:IssuanceDuringPeriodSevenMember 2007-01-01 2007-12-31 0001211583 us-gaap:CommonStockMember adhxf:IssuanceDuringPeriodSevenMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:IssuanceDuringPeriodSevenMember 2007-01-01 2007-12-31 0001211583 us-gaap:PreferredStockMember adhxf:IssuanceDuringPeriodSevenMember 2007-01-01 2007-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:IssuanceDuringPeriodSevenMember 2007-01-01 2007-12-31 0001211583 adhxf:CadherinBiomedicalIncMember 2007-01-01 2007-12-31 0001211583 2007-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0001211583 us-gaap:CommonStockMember 2007-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2007-12-31 0001211583 us-gaap:PreferredStockMember 2007-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2007-12-31 0001211583 us-gaap:PrivatePlacementMember 2008-12-19 0001211583 us-gaap:PrivatePlacementMember us-gaap:PreferredStockMember 2008-12-19 0001211583 us-gaap:PrivatePlacementMember 2008-12-01 2008-12-19 0001211583 2008-01-01 2008-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0001211583 us-gaap:CommonStockMember 2008-01-01 2008-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2008-01-01 2008-12-31 0001211583 us-gaap:PreferredStockMember 2008-01-01 2008-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2008-01-01 2008-12-31 0001211583 adhxf:ConsultingFeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2008-01-01 2008-12-31 0001211583 adhxf:EmployeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2008-01-01 2008-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2008-01-01 2008-12-31 0001211583 2008-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0001211583 us-gaap:CommonStockMember 2008-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2008-12-31 0001211583 us-gaap:PreferredStockMember 2008-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2008-12-31 0001211583 2009-01-01 2009-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0001211583 us-gaap:CommonStockMember 2009-01-01 2009-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2009-01-01 2009-12-31 0001211583 us-gaap:PreferredStockMember 2009-01-01 2009-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2009-01-01 2009-12-31 0001211583 adhxf:ConsultingFeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2009-01-01 2009-12-31 0001211583 adhxf:EmployeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2009-01-01 2009-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2009-01-01 2009-12-31 0001211583 2009-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0001211583 us-gaap:CommonStockMember 2009-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2009-12-31 0001211583 us-gaap:PreferredStockMember 2009-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2009-12-31 0001211583 us-gaap:PrivatePlacementMember 2010-04-30 0001211583 adhxf:PrivatePlacementwarrant2010Member 2010-04-30 0001211583 adhxf:PrivatePlacementwarrant2010Member us-gaap:DerivativeMember 2010-04-30 0001211583 2010-04-01 2010-04-30 0001211583 us-gaap:PrivatePlacementMember 2010-04-01 2010-04-30 0001211583 adhxf:PrivatePlacementwarrant2010Member 2010-04-01 2010-04-30 0001211583 adhxf:PrivatePlacementwarrant2010Member us-gaap:DerivativeMember 2010-04-01 2010-04-30 0001211583 us-gaap:StockOptionMember 2010-06-24 0001211583 adhxf:PlanMaximumAmendmentMember 2010-06-24 0001211583 2010-06-01 2010-06-24 0001211583 adhxf:RaykovAndSpectorMember 2010-08-10 2010-08-18 0001211583 adhxf:BreenAndBussandriMember 2010-08-10 2010-08-18 0001211583 adhxf:RaykovAndSpectorMember 2010-08-10 2010-08-19 0001211583 adhxf:BreenAndBussandriMember 2010-08-10 2010-08-19 0001211583 2010-01-01 2010-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0001211583 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-01-01 2010-12-31 0001211583 us-gaap:PreferredStockMember 2010-01-01 2010-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2010-01-01 2010-12-31 0001211583 adhxf:ConsultingFeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2010-01-01 2010-12-31 0001211583 adhxf:EmployeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2010-01-01 2010-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:IssuanceDuringPeriodEightMember 2010-01-01 2010-12-31 0001211583 us-gaap:CommonStockMember adhxf:IssuanceDuringPeriodEightMember 2010-01-01 2010-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:IssuanceDuringPeriodEightMember 2010-01-01 2010-12-31 0001211583 us-gaap:PreferredStockMember adhxf:IssuanceDuringPeriodEightMember 2010-01-01 2010-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:IssuanceDuringPeriodEightMember 2010-01-01 2010-12-31 0001211583 2010-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0001211583 us-gaap:CommonStockMember 2010-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-12-31 0001211583 us-gaap:PreferredStockMember 2010-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2010-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInCanadianDollarsMember 2010-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInCanadianDollarsMember 2010-12-31 0001211583 adhxf:StockOptionInCanadianDollarsMember 2010-12-31 0001211583 adhxf:StockOptionInUsDollarsMember 2010-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInUsDollarsMember 2010-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInUsDollarsMember 2010-12-31 0001211583 adhxf:RightsOfferingDerivativeMember 2011-03-02 0001211583 adhxf:RightsOfferingMember 2011-03-02 0001211583 adhxf:RightsOfferingMember adhxf:SubscriptionsMember 2011-03-02 0001211583 adhxf:RightsOfferingMember 2011-02-15 2011-03-02 0001211583 adhxf:RightsOfferingMember adhxf:SubscriptionsMember 2011-02-15 2011-03-02 0001211583 adhxf:NonbrokerRightsOfferingMember 2011-03-01 2011-03-29 0001211583 2011-03-01 2011-03-31 0001211583 adhxf:WarrantTwoMember 2011-03-01 2011-03-31 0001211583 adhxf:WarrantTwoMember us-gaap:RightsMember 2011-03-01 2011-03-31 0001211583 2011-07-20 2011-08-10 0001211583 2011-08-25 0001211583 2011-08-01 2011-08-25 0001211583 us-gaap:PrivatePlacementMember 2011-08-01 2011-08-25 0001211583 adhxf:RaykovAndSpectorMember 2011-08-01 2011-08-31 0001211583 adhxf:BreenAndBussandriMember 2011-08-01 2011-08-31 0001211583 2011-01-01 2011-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001211583 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-01-01 2011-12-31 0001211583 us-gaap:PreferredStockMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-01-01 2011-12-31 0001211583 us-gaap:RightsMember 2011-01-01 2011-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember us-gaap:RightsMember 2011-01-01 2011-12-31 0001211583 us-gaap:CommonStockMember us-gaap:RightsMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:RightsMember 2011-01-01 2011-12-31 0001211583 us-gaap:PreferredStockMember us-gaap:RightsMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember us-gaap:RightsMember 2011-01-01 2011-12-31 0001211583 adhxf:ConsultingFeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2011-01-01 2011-12-31 0001211583 adhxf:EmployeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2011-01-01 2011-12-31 0001211583 us-gaap:StockOptionMember 2011-01-01 2011-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInCanadianDollarsMember 2011-01-01 2011-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInCanadianDollarsMember 2011-01-01 2011-12-31 0001211583 adhxf:StockOptionInCanadianDollarsMember 2011-01-01 2011-12-31 0001211583 adhxf:StockOptionInUsDollarsMember 2011-01-01 2011-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInUsDollarsMember 2011-01-01 2011-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInUsDollarsMember 2011-01-01 2011-12-31 0001211583 adhxf:RightsOfferingDerivativeMember 2011-01-01 2011-12-31 0001211583 adhxf:WarrantTwoMember 2011-01-01 2011-12-31 0001211583 adhxf:OptionsToContractorsMember 2011-01-01 2011-12-31 0001211583 adhxf:WarrantOneMember 2011-01-01 2011-12-31 0001211583 us-gaap:MinimumMember 2011-01-01 2011-12-31 0001211583 us-gaap:MaximumMember 2011-01-01 2011-12-31 0001211583 us-gaap:GeneralAndAdministrativeExpenseMember 2011-01-01 2011-12-31 0001211583 us-gaap:WarrantMember 2011-01-01 2011-12-31 0001211583 us-gaap:StockOptionsMember 2011-01-01 2011-12-31 0001211583 adhxf:CanadianStatutoyIncomeTaxMember 2011-01-01 2011-12-31 0001211583 adhxf:FederalIncomeTaxMember 2011-01-01 2011-12-31 0001211583 adhxf:ProvincialIncomeTaxMember 2011-01-01 2011-12-31 0001211583 2011-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001211583 us-gaap:CommonStockMember 2011-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0001211583 us-gaap:PreferredStockMember 2011-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-12-31 0001211583 adhxf:CadherinBiomedicalIncMember 2011-12-31 0001211583 us-gaap:PrivatePlacementMember 2011-12-31 0001211583 us-gaap:StockOptionMember 2011-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInCanadianDollarsMember 2011-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInCanadianDollarsMember 2011-12-31 0001211583 adhxf:StockOptionInCanadianDollarsMember 2011-12-31 0001211583 adhxf:StockOptionInUsDollarsMember 2011-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInUsDollarsMember 2011-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInUsDollarsMember 2011-12-31 0001211583 adhxf:RightsOfferingDerivativeMember 2011-12-31 0001211583 adhxf:NonbrokerRightsOfferingMember 2011-12-31 0001211583 adhxf:WarrantTwoMember 2011-12-31 0001211583 adhxf:OptionsToContractorsMember 2011-12-31 0001211583 adhxf:WarrantOneMember 2011-12-31 0001211583 adhxf:SrEdExpendituresMember 2011-12-31 0001211583 adhxf:IncomeTaxLossCarryforwardsMember 2011-12-31 0001211583 adhxf:NonRefundableInvestmentTaxCreditMember 2011-12-31 0001211583 adhxf:ShareIssueCostMember 2011-12-31 0001211583 adhxf:AccruedExpensesMember 2011-12-31 0001211583 adhxf:FixedAndIntangibleAssetsMember 2011-12-31 0001211583 adhxf:HarmonizationCreditMember 2011-12-31 0001211583 adhxf:RightsOfferingDerivativeMember adhxf:CanadianDollarMember 2011-12-31 0001211583 adhxf:IssuedInQuarterMember 2011-12-31 0001211583 adhxf:ReclassifiedMember 2011-12-31 0001211583 2012-06-30 0001211583 2012-01-01 2012-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001211583 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-01-01 2012-12-31 0001211583 adhxf:ConsultingFeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:ConsultingFeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:CommonStockMember adhxf:ConsultingFeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:ConsultingFeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:PreferredStockMember adhxf:ConsultingFeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:ConsultingFeeMember 2012-01-01 2012-12-31 0001211583 adhxf:EmployeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember adhxf:EmployeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:CommonStockMember adhxf:EmployeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember adhxf:EmployeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:PreferredStockMember adhxf:EmployeeMember 2012-01-01 2012-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember adhxf:EmployeeMember 2012-01-01 2012-12-31 0001211583 adhxf:GlaxoSmithKlineMember 2012-01-01 2012-12-31 0001211583 us-gaap:StockOptionMember 2012-01-01 2012-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInCanadianDollarsMember 2012-01-01 2012-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInCanadianDollarsMember 2012-01-01 2012-12-31 0001211583 adhxf:StockOptionInCanadianDollarsMember 2012-01-01 2012-12-31 0001211583 adhxf:StockOptionInUsDollarsMember 2012-01-01 2012-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInUsDollarsMember 2012-01-01 2012-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInUsDollarsMember 2012-01-01 2012-12-31 0001211583 adhxf:RightsOfferingDerivativeMember 2012-01-01 2012-12-31 0001211583 adhxf:WarrantTwoMember 2012-01-01 2012-12-31 0001211583 adhxf:OptionsToContractorsMember 2012-01-01 2012-12-31 0001211583 adhxf:WarrantOneMember 2012-01-01 2012-12-31 0001211583 us-gaap:MinimumMember 2012-01-01 2012-12-31 0001211583 us-gaap:MaximumMember 2012-01-01 2012-12-31 0001211583 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsOneMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsTwoMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsThreeMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsFourMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsFiveMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsSixMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsSevenMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsEightMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsNineMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsTenMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsElevenMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsTwelveMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInUsDollarsThirteenMember 2012-01-01 2012-12-31 0001211583 adhxf:IssuanceDuringPeriodEightMember 2012-01-01 2012-12-31 0001211583 us-gaap:WarrantMember us-gaap:MaximumMember 2012-01-01 2012-12-31 0001211583 us-gaap:StockOptionsMember us-gaap:MaximumMember 2012-01-01 2012-12-31 0001211583 us-gaap:WarrantMember us-gaap:MinimumMember 2012-01-01 2012-12-31 0001211583 us-gaap:StockOptionsMember us-gaap:MinimumMember 2012-01-01 2012-12-31 0001211583 adhxf:CurrencyCanadianDollarMember 2012-01-01 2012-12-31 0001211583 adhxf:CurrencyUnitedStatesDollarMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInCanadianDollarsOneMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInCanadianDollarsTwoMember 2012-01-01 2012-12-31 0001211583 adhxf:PriceInCanadianDollarsThreeMember 2012-01-01 2012-12-31 0001211583 adhxf:LicensedProductMember 2012-01-01 2012-12-31 0001211583 adhxf:SublicensedTechnologyMember 2012-01-01 2012-12-31 0001211583 adhxf:PhaseIMember 2012-01-01 2012-12-31 0001211583 adhxf:PhaseIiMember 2012-01-01 2012-12-31 0001211583 adhxf:PhaseIiiMember 2012-01-01 2012-12-31 0001211583 us-gaap:SalesMember 2012-01-01 2012-12-31 0001211583 adhxf:DevelopmentMilestoneMember 2012-01-01 2012-12-31 0001211583 adhxf:DevelopmentAndSaleMilestoneMember 2012-01-01 2012-12-31 0001211583 adhxf:FdaApprovedIndicationMember 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2021Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2022Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2023Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2024Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2025Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2026Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2027Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2028Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2018Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2019Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2020Member 2012-01-01 2012-12-31 0001211583 adhxf:FederalMember 2012-01-01 2012-12-31 0001211583 adhxf:ProvinceStateMember 2012-01-01 2012-12-31 0001211583 adhxf:CurrencyCanadianDollarMember 2012-01-01 2012-12-31 0001211583 adhxf:CurrencyUnitedStatesDollarMember 2012-01-01 2012-12-31 0001211583 2012-12-31 0001211583 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001211583 us-gaap:CommonStockMember 2012-12-31 0001211583 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0001211583 us-gaap:PreferredStockMember 2012-12-31 0001211583 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInCanadianDollarsMember 2012-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInCanadianDollarsMember 2012-12-31 0001211583 adhxf:StockOptionInCanadianDollarsMember 2012-12-31 0001211583 adhxf:StockOptionInUsDollarsMember 2012-12-31 0001211583 us-gaap:MinimumMember adhxf:StockOptionInUsDollarsMember 2012-12-31 0001211583 us-gaap:MaximumMember adhxf:StockOptionInUsDollarsMember 2012-12-31 0001211583 adhxf:WarrantTwoMember 2012-12-31 0001211583 adhxf:WarrantOneMember 2012-12-31 0001211583 adhxf:SrEdExpendituresMember 2012-12-31 0001211583 adhxf:IncomeTaxLossCarryforwardsMember 2012-12-31 0001211583 adhxf:NonRefundableInvestmentTaxCreditMember 2012-12-31 0001211583 adhxf:ShareIssueCostMember 2012-12-31 0001211583 adhxf:AccruedExpensesMember 2012-12-31 0001211583 adhxf:FixedAndIntangibleAssetsMember 2012-12-31 0001211583 adhxf:HarmonizationCreditMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsOneMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsTwoMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsThreeMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsFourMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsFiveMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsSixMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsSevenMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsEightMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsNineMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsTenMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsElevenMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsTwelveMember 2012-12-31 0001211583 adhxf:PriceInUsDollarsThirteenMember 2012-12-31 0001211583 adhxf:PriceInCanadianDollarsOneMember 2012-12-31 0001211583 adhxf:PriceInCanadianDollarsTwoMember 2012-12-31 0001211583 adhxf:PriceInCanadianDollarsThreeMember 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2021Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2022Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2023Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2024Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2025Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2026Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2027Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2028Member 2012-12-31 0001211583 adhxf:CurrencyCanadianDollarMember 2012-12-31 0001211583 adhxf:CurrencyUnitedStatesDollarMember 2012-12-31 0001211583 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001211583 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001211583 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001211583 us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001211583 adhxf:LessThanOneYearMember adhxf:OtcClinicalServiceAgreementMember 2012-12-31 0001211583 adhxf:LessThanOneYearMember adhxf:DatabaseIntegrationServiceAgreementMember 2012-12-31 0001211583 adhxf:LessThanOneYearMember adhxf:DrugPurchaseCommitmentMember 2012-12-31 0001211583 adhxf:OneToThreeYearsMember adhxf:OtcClinicalServiceAgreementMember 2012-12-31 0001211583 adhxf:OneToThreeYearsMember adhxf:DatabaseIntegrationServiceAgreementMember 2012-12-31 0001211583 adhxf:OneToThreeYearsMember adhxf:DrugPurchaseCommitmentMember 2012-12-31 0001211583 adhxf:OtcClinicalServiceAgreementMember 2012-12-31 0001211583 adhxf:DatabaseIntegrationServiceAgreementMember 2012-12-31 0001211583 adhxf:DrugPurchaseCommitmentMember 2012-12-31 0001211583 adhxf:LessThanOneYearMember 2012-12-31 0001211583 adhxf:OneToThreeYearsMember 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2014Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2015Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2029Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2030Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2031Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2014Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2015Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2021Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2022Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2023Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2024Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2025Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2026Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2027Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2028Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2029Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2030Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2031Member 2012-12-31 0001211583 adhxf:FederalMember adhxf:Year2032Member 2012-12-31 0001211583 adhxf:ProvinceStateMember adhxf:Year2032Member 2012-12-31 0001211583 1996-09-03 2012-12-31 0001211583 2013-02-01 2013-02-28 0001211583 2013-03-16 xbrli:shares iso4217:USD iso4217:USDxbrli:shares iso4217:CAD iso4217:CADxbrli:shares xbrli:pure 10-K false 2012-12-31 2012 FY ADHXF ADHEREX TECHNOLOGIES INC 0001211583 --12-31 No Yes No Smaller Reporting Company 25157618 1401073 0 5947000 5297000 2303000 35000 56000 19000 6000 5351000 2365000 342000 259000 52000 423000 5077000 6640000 5471000 7322000 5471000 7322000 65952000 65952000 38065000 38391000 105380000 110543000 1243000 1243000 0 0 0 0 0 0 -37000 0 0 0 0 -37000 -37000 0 0 0 0 -37000 -435000 0 0 0 0 -435000 242000 0 1615000 20000 0 -1393000 47000 426000 2583000 36000 0 -2998000 9792000 0 15134000 218000 0 -5560000 6071000 0 15134000 229000 0 -9292000 698000 11147000 16726000 70000 0 -27245000 20454000 21117000 33603000 -149000 0 -34117000 16654000 21760000 34362000 1243000 0 -40711000 11077000 23110000 41306000 1243000 0 -54582000 1268000 24523000 46524000 1243000 0 -71022000 14148000 32355000 64929000 1243000 0 -84379000 3053000 34860000 64929000 1243000 0 -97979000 406000 35225000 64929000 1243000 0 -100991000 -4924000 37717000 64929000 1243000 0 -108815000 -120000 38065000 65952000 1243000 0 -105380000 -4957000 37717000 65952000 1243000 0 -110543000 5351000 2365000 25158 25158 25158 25158 0 0 0 1494000 2075000 69168000 0 0 386000 0 0 497000 0 0 13094000 1944000 1545000 32094000 -3438000 -3620000 -114245000 8071000 613000 643000 37000 6778000 -1563000 0 -507000 0 1026000 3257000 0 0 -1283000 0 0 19000 9000 -5000 259000 43000 25000 2897000 8123000 -1543000 5111000 -37000 0 0 0 0 -37000 -398000 0 0 0 0 -398000 -958000 0 0 0 0 -958000 -1605000 0 0 0 0 -1605000 -2524000 0 0 0 0 -2524000 -3732000 0 0 0 -3732000 -17795000 0 0 0 0 -17795000 -6872000 0 0 0 0 -6872000 -6594000 0 0 0 0 -6594000 -13871000 0 0 0 0 -13871000 -16440000 0 0 0 0 -16440000 -13357000 0 0 0 0 -13357000 -13600000 0 0 0 0 -13600000 -3012000 0 0 0 0 -3012000 -5163000 0 0 0 0 -7824000 4685000 0 0 0 0 4685000 -5163000 38065000 0 -5163000 -109134000 0.20 -0.21 0.19 -0.21 23983 25158 24050 25158 0 0 1404000 0 0 1187000 9000 0 -36000 0 0 412000 0 0 168000 121000 152000 1048000 129000 174000 10269000 81000 -280000 -174000 -3226000 -2994000 -85037000 0 0 1440000 0 0 115000 0 0 24000 0 0 190000 0 0 209000 0 0 22148000 0 0 22791000 0 0 166000 0 0 640000 0 0 -1483000 0 0 68000 0 0 65000 0 0 8000 683000 171000 5727000 16095000 9029000 8510000 8134000 6512000 6040000 25000000 23221000 12750000000 2566000 0 86443000 0 0 465000 0 0 544000 0 0 3017000 0 0 87000 0 0 35000 0 0 51000 2566000 0 88445000 10000 0 378000 -650000 -2994000 2303000 0 89000 89000 89000 239000 264000 446000 446000 893000 1993000 2030000 2368000 2799000 7124000 7124000 7124 20461000 25158 25158 0 18000 18000 0 0 0 0 89000 0 -141000 0 -141000 0 0 0 116000 694000 131000 563000 0 0 0 -493000 0 -493000 0 0 0 0 0 0 0 255000 255000 0 0 0 0 1722000 1722000 0 0 0 0 4335000 4335000 0 0 0 0 53000 53000 0 0 0 0 54000 54000 0 0 0 0 4000 4000 0 0 0 0 148000 148000 0 0 0 0 39000 39000 0 0 0 0 604000 604000 0 0 0 0 276000 276000 0 0 0 0 100000 100000 0 0 0 0 491000 491000 0 0 0 0 59000 59000 0 0 0 0 2263000 2263000 0 0 0 0 88000 88000 0 0 0 0 2417000 2417000 0 0 0 0 10000 10000 0 0 0 0 355000 355000 0 0 0 0 53000 53000 0 0 2439000 2439000 0 0 0 0 -100991000 20000 20000 0 0 0 0 129000 129000 0 0 0 0 152000 152000 0 0 0 0 2439000 174000 0 0 0 0 5000 341000 0 341000 0 0 0 0 0 0 0 0 0 446 446000 37 37000 11620000 543000 11077000 0 0 0 1252000 1252000 0 1252000 0 0 0 1058000 1058000 0 0 0 0 1983000 1983000 0 0 0 0 89000 239000 16000 16000 5 74 74000 640 800 259 259000 640000 0 337 337000 431 431000 4209 116 4209000 13337037 13337 84559 4697 4697000 0 0 0 0 0 0 0 1615000 0 0 0 0 793000 0 0 0 175000 0 175000 0 0 0 341000 5689000 0 5727000 0 0 -38000 8474000 13830000 1045000 2118000 5777000 0 6356000 8053000 0 0 0 0 0 0 1045000 0 0 0 8134000 1074000 7060000 0 0 0 6040000 822000 5218000 0 0 0 23221000 5379000 17842000 0 0 0 240066000 0 0 0 0 0 84559000 1023000 -28000 199000 1023000 0 0 -1250000 174000 0 30000 4000 69000 60000 96000 800 0 -1977000 1977000 0 0 0 0 -171000 171000 0 0 0 0 -4335000 4335000 0 0 0 171000 1123000 -398000 -93000 569000 1216000 0 0 0 0 0 0 1000 1000 1000 0 0 0 0 4000 0 4000 0 0 0 23000 0 23000 0 0 0 25000 0 25000 0 0 0 171000 171000 0 0 0 0 -7000 0 0 0 0 0 0 -22000 363000 660000 0 -1045000 0 -158000 0 0 0 0 -158000 44000 0 9489000 -9489000 0 0 0 20000 0 0 20000 0 0 16000 0 0 16000 0 0 182000 0 0 182000 0 0 11000 0 0 11000 0 0 -159000 0 0 -159000 0 0 -219000 0 0 -219000 0 0 1392000 0 0 1392000 0 0 <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Going Concern</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Adherex Technologies Inc. (&#8220;Adherex&#8221;), a British Columbia corporation together with its wholly owned subsidiaries Oxiquant, Inc. (&#8220;Oxiquant&#8221;) and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (&#8220;CBI&#8221;), a Canadian corporation, collectively referred to herein as the &#8220;Company,&#8221; is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer.&#160;With the exception of Adherex Inc., all subsidiaries are inactive.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">These consolidated financial statements have been prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States (&#8220;U.S.&#8221;) of America that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company is a development stage company and during the year ended December 31, 2012, incurred a loss from operations of $3,620.&#160;At December 31, 2012, it had an accumulated deficit of$110,543, and had experienced negative cash flows from operating activities since inception in the amount of $85,037. In addition, it had a deficiency in working capital at December 31, 2012 and the Company's operating losses since inception.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance our business strategy, operations and growth through the issuance of equity, debt or collaboration.&#160;If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Significant Accounting Policies</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Basis of presentation</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or &#8220;Share Consolidation&#8221;, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company&#8217;s common shares, stock options and warrants outstanding at the effective date.&#160;Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they&#160;had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Use of estimates</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation.&#160;Actual results could differ from those estimates.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Cash and Cash Equivalents</b></font></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.</font></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment.&#160;At December 31, 2012, the Company had $2,303 in cash accounts (2011- $5,297).&#160;Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments.&#160;The Company has not experienced any loss or write-down of its money market investments.&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Financial instruments</b></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Financial instruments recognized on the balance sheets at December 31, 2012 and December 31, 2011 consist of cash and cash equivalents, accounts payable and derivative warrant liability, the carrying value of which, with the exception of the derivative warrant liability, approximates fair value due to their relatively short time to maturity.&#160;The Company does not hold or issue financial instruments for trading.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company&#8217;s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment.&#160;Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy.&#160;Securities must have a minimum Dun &amp; Bradstreet rating of A for bonds or R1 low for commercial paper.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments.&#160;As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Common stock and warrants</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company&#8217;s U.S. dollar functional currency.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In November 2007, the Emerging Issues Task Force (&#8220;EITF&#8221;) of the FASB issued EITF No. 07-5, Issue Summary No.1 &#8220;Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock&#8221; (&#8220;EITF 07-5&#8221;), codified as ASC 815-40.&#160;&#160;In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency.&#160;The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock.&#160;This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company&#8217;s outstanding warrants to purchase common stock that were denominated in Canadian dollars.&#160;This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, &#8220;Accounting for Derivative Instruments and Hedging Activities&#8221; (&#8220;SFAS 133&#8221;), codified as ASC 815-10.&#160;SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133.&#160;As a result, the Company&#8217;s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability.&#160;ITF 07-05 is effective for financial statements for fiscal years beginning after December 15, 2008 and earlier adoption is not permitted.&#160;Since the warrants to purchase common stock that are denominated in Canadian dollars expired on December 19, 2008, EITF 07-5 did not have a material impact on the Company&#8217;s financial statements through 2008. However, the Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this results in warrants shown as a liability which is marked to market as at December 31, 2012 and December 31, 2011.&#160;At December 31, 2012, the derivative liabilitieswere valued at $6,640 (2011: $5,077) and the unrealized loss on the value of the underlying securities was $1,563 (2011: gain$8,071) for the year ended December 31, 2012.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Revenue recognition</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Non-refundable up-front payments received in conjunction with the development and license agreement, including license fees and milestones, are deferred and recognized on a straight-line basis over the relevant periods.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company records royalty revenue in accordance with the contract terms once it can be reliably measured and the collection is reasonably assured.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At this time, the Company does not have any revenue.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">R<b>esearch and development costs and investment tax credits</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred.&#160;Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured.&#160;They are applied to reduce related capital costs and research and development expenses in the year recognized.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Income taxes</b></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities.&#160;The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (&#8216;&#8216;FIN 48&#8217;&#8217;), codified as ASC 740-10-25, &#8216;&#8216;Accounting for Uncertainty in Income Taxes &#8211; an Interpretation of SFAS No. 109.&#8217;&#8217; FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements in accordance with Statement of Financial Accounting Standards No. 109, &#8216;&#8216;Accounting for Income Taxes.&#8217;, codified as ASC 740-10.&#160;FIN&#160;48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements.&#160;FIN&#160;48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a &#8220;more-likely-than-not&#8221; threshold of being sustained by the applicable tax authority.&#160;Tax benefits related to tax positions not deemed to meet the &#8220;more-likely-than-not&#8221; threshold are not permitted to be recognized in the financial statements.&#160;Upon adoption of FIN&#160;48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Foreign currency translation</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The U.S. dollar is the functional currency for the Company&#8217;s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Earnings/(Loss) per share</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year.&#160;Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the treasury method.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Newly adopted accounting pronouncements</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On May 12, 2011, the FASB issued ASU 2011-04 &#8220;Fair Value Measurement Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. Specifically, this update will require (a) an entity to disclose separately the amounts of significant transfers into and out of Level 1 and 2 fair value measurements and to describe the reasons for the transfers; and (b) information about purchases, sales, issuances, and settlements to be presented separately on a gross basis in the reconciliation of Level 3 fair value measurements. Level 3 reconciliation disclosures are effective for annual and interim periods beginning after December 15, 2011. The adoption of the guidance to has not had a significant impact on the Company&#8217;s consolidated financial position and results of operations.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In June 2011, the FASB released ASU 2011-05, &#8220;Comprehensive Income (Topic 220) &#8211; Presentation of Comprehensive Income&#8221;. This update requires and entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income in either a single continuous statement or two separate but consecutive statements. This guidance does not change the items that must be reported in other comprehensive income. Subsequently, in December 2011, the FASB issued ASU 2011-12 which deferred some aspects of the June guidance that relate to the presentation of reclassification adjustments. ASU 2011-05 is now effective for fiscal years and interim periods within those years, beginning after December 15, 2012. The adoption of this standard to has not had a significant impact on the Company&#8217;s consolidated financial position or results of operations.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Recent accounting pronouncements</b></font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif; color: #222222;"><font style="color: black;">&#160;</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif; color: #222222;"><font style="color: black;">In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company is required to adopt this ASU in the first quarter for fiscal 2013.</font></p> <p style="text-align: justify; text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;<b>3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capital Assets</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At December 31, 2012 and December 31, 2011, the Company determined the carrying values of its capital assets to be nil.&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock options</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Compensation Committee of the Board of Directors administers the Company&#8217;s stock option plan.&#160;&#160;The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company&#8217;s annual meeting, shareholders approved an amendment to the Company&#8217;s Stock Option Plan (the &#8220;Plan Maximum Amendment&#8221;). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the Stock Option Plan from a fixed number of 20,000 to the number of shares that represent twenty five percent (25%) of the total number of all issued and outstanding shares of common stock from time to time.&#160;Based upon the current shares outstanding, a maximum of 6,290 options are authorized for issuance under the plan.&#160;&#160;The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant.&#160;All options vest within three years or less and are exercisable for a period of seven years from the date of grant.&#160;&#160;The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants.&#160;A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2012 is below.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The following options granted under the stock option plan are exercisable in Canadian dollars:</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"><font style="color: black;">Exercise&#160;Price&#160;in&#160;Canadian <br />Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Number&#160;of <br />Options</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Range</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Weighted- <br />average</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 55%; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2010</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">3,901</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black; font-size: 10pt;">0.63-58.50</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">1.26</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">310</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.54-0.81</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.62</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black; font-size: 10pt;">Reinstated<sup>(1)</sup></font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">5.04-35.10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8.93</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;"><font style="color: black;">Cancelled</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(50</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black; font-size: 10pt;">35.10 &#8211;58.50</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">49.39</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2011</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,171</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.54-0.81</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.78</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;"><font style="color: black;">Cancelled</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2012</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">4,171</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black; font-size: 10pt;">$ 0.54-0.81</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">0.78</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 1.5pt;"></td> <td style="width: 18pt;"><font style="color: black;">(1)</font></td> <td><font style="color: black;">Includes 10 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which had either expired and or were cancelled prior to the agreed severance agreement.</font></td> </tr> </table> <p style="margin: 0px;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Price&#160;in&#160;Canadian&#160;Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">#&#160;outstanding&#160;and <br />exercisable&#160;at <br />December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Weighted average remaining&#160;life&#160;(years)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 31%;"><font style="color: black;">0.54</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 31%;"><font style="color: black;">88</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 30%;"><font style="color: black;">5.26</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.63</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">303</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">5.42</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">0.81</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">3,780</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">4.64</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;" colspan="2"><font style="font: 10pt times new roman, times, serif; color: black;">TOTAL</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,171</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4.70</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The following options granted under the stock option plan are exercisable in U.S. dollars:</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"><font style="color: black;">Exercise&#160;Price&#160;in&#160;U.S.&#160;Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Number&#160;of <br />Options</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Range</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Weighted- <br />average</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 55%; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2010</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">721</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black; font-size: 10pt;">$ 1.80 - 24.30</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">9.90</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">138</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.50-0.63</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.54</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;"><font style="color: black; font-size: 10pt;">Reinstated<sup>(1)</sup></font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">104</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black; font-size: 10pt;">$ 5.04-21.60</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">9.15</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2011</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">963</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">$ 0.50 - 24.30</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">8.51</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,137</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.15-0.56</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.32</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;"><font style="color: black;">Cancelled</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(773</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black; font-size: 10pt;">$ 5.04-24.30</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">9.92</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2012</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">1,327</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black; font-size: 10pt;">$ $0.15-11.34</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">0.67</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">(1) Includes104 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which were cancelled in error in 2010.</font></p> <p style="margin: 0pt 0px 0pt 19.5pt; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px 0pt 19.5pt; font: 10pt times new roman, times, serif;"></p> <div style="border-bottom: black 1pt solid; margin-top: 12pt; margin-bottom: 6pt;"> <table style="width: 100%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr> <td style="text-align: center; width: 100%;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td> </tr> </table> </div> <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt;"> <table style="width: 100%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr> <td style="text-align: center; width: 100%;">&#160;</td> </tr> </table> </div> <p style="margin: 0pt 0px 0pt 19.5pt; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Price&#160;in&#160;US&#160;Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">#&#160;Outstanding&#160;at <br />December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">#&#160;Exercisable&#160;at <br />December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Remaining&#160;life <br />(years)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 23%;"><font style="color: black;">0.15</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 22%;"><font style="color: black;">33</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 22%;"><font style="color: black;">33</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 22%;"><font style="color: black;">6.62</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.18</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">61</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">61</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.38</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.20</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">254</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">254</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.25</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.35</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">689</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">689</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.89</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.50</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">94</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">94</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.56</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">100</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">100</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.97</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.63</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">45</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">45</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">5.64</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">1.80</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2.71</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">5.04</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">7</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">7</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1.92</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">5.22</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2.41</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">7.20</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1.70</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">10.26</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">23</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">23</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1.37</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">$</font></td> <td style="text-align: right; padding-bottom: 1pt;"><font style="color: black;">11.34</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">13</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">13</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">1.33</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,327</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,327</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.44</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Pursuant to employment agreements dated May 3, 2010 between the Company and each of Robert Andrade, Rostislav Raykov and Thomas Spector (collectively Messrs. Andrade, Raykov and Spector) and conditional upon the approval of the amended Stock Option Plan, the Board approved the grant to each, Messrs. Andrade, Raykov and Spector an option to purchase up to 5.0% of Adherex&#8217;s common stock estimated by the Company to be outstanding upon completion of the proposed rights offering announced by the Company on April 20, 2010.On August 18, 2010, Messrs. Andrade, Raykov and Spector were each granted 971,885 options and on August 19, 2011 Messrs. Andrade, Raykov and Spector were each granted 51,152 options.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Pursuant to Independent Director Agreements dated May 3, 2010 for each of Dr. Porter and Messrs. Breen and Bussandri and conditional upon the approval of the amended Stock Option Plan, the Board approved the grant to each Dr. Porter and Messrs. Breen and Bussandri an option to purchase up to 1.33% of Adherex&#8217;s common stock estimated by the Company to be outstanding upon completion of the proposed rights offering announced by the Company on April 20, 2010. On August 18, 2010,each of Dr. Porter and Messrs. Breen and Bussandri were granted 255,759 options and on August 19, 2011,each of Dr. Porter and Messrs. Breen and Bussandri were granted 16,369 options.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Effective upon the Continuance, Chris A. Rallis and Steven D. Skolsky were appointed as members of the Board of Directors and Dr. Arthur T. Porter, William G. Breen and Claudio F. Bussandri resigned from the Board of Directors. In addition, each of the new directors has entered into an Independent Director Agreement with the Company, dated as of August 25, 2011, which provides for (i) cash compensation in the form of $ 1,500 per board meeting attended, and (ii) non-cash compensation in the form of a grant of options to purchase shares of the Company&#8217;s common stock having an aggregate value equal to $5,000 (with price per share and exercise price based on the value of the Company&#8217;s common stock as of the date of grant) per board meeting attended.&#160;The options immediately vested when granted and are otherwise subject to the terms and conditions of the Company&#8217;s stock option plan, as amended. The Independent Director Agreement also provides for the reimbursement of such director&#8217;s reasonable travel and related expenses incurred in the course of attending board meetings.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Stock compensation expense for the fiscal years ended December 31, 2012 and 2011 was $326 and $250 respectively.&#160;&#160;These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted during the fiscal years ended December 31, 2012 and 2011 was $0.29 and $0.56, respectively.&#160;The intrinsic value (being the difference between the share price as at December 31, 2012 and exercise price) of stock options outstanding at December 31, 2012 was NIL.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The fair values of options granted in fiscal years ended December 31, 2012 and 2011&#160;were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions:</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Year&#160;Ended<br />December&#160;31, <br />2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Year&#160;Ended<br />December&#160;31, <br />2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 64%;"><font style="color: black;">Expected dividend</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">0</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">%</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">0</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Risk-free interest rate</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">1.09-1.26</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">1.85-2.5</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected volatility</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">118-133</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">121-132</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected life</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">7 years</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">7 years</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company&#8217;s share price.</font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;<strong>5.&#160;&#160;&#160;&#160;&#160;&#160;Derivative Instruments</strong></font></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Effective January 1, 2009, the Company adopted ASC Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in shareholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' deficiency.</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:</font></p> <table style="background-color: white; margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.25in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol; color: black;">&#183;</font></td> <td><font style="font-family: times new roman, times, serif; color: black;">Warrants to purchase 13,337 shares at CAD$1.44 per whole share that expire on April 30, 2015; and</font></td> </tr> </table> <table style="background-color: white; margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.25in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol; color: black;">&#183;</font></td> <td><font style="font-family: times new roman, times, serif; color: black;">Warrants to purchase 4,698 shares exercisable at CAD$1.44 per whole share that expire on March 29, 2016. </font></td> </tr> </table> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">These warrants have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">As of December 31, 2012, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $4,698 and $1,847, respectively (December 31, 2011 &#8211; warrants expiring April 30, 2015, fair value of $3,672, March 29, 2016, fair value of $1,340), and the loss on these warrants for the twelve months ended December 31, 2012 was $1,026 and $507, respectively (December 31, 2011 - warrants expiring April 30, 2015, gain of $6,778; March 29,2016, gain of $643). There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.25in;" cellspacing="0" cellpadding="0"> <tr style="font-size: 9pt; vertical-align: bottom;"> <td style="text-align: left; color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">Gain/(Loss)&#160;on&#160;Derivative&#160;Instruments</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black; font-size: 9pt;">Twelve&#160;months&#160;ended&#160;December&#160;31, 2012</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black; font-size: 9pt;">Twelve&#160;months&#160;ended&#160;December&#160;31,&#160;2011</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; font-size: 9pt; vertical-align: bottom;"> <td style="width: 54%; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Warrant expiring April 15, 2015</font></td> <td style="width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; width: 20%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">(1,026</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; width: 20%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">6,778</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: white; font-size: 9pt; vertical-align: bottom;"> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Warrant expiring March 29, 2016</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">(507</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">643</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; font-size: 9pt; vertical-align: bottom;"> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Rights offering derivative</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">-</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">613</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: white; font-size: 9pt; vertical-align: bottom;"> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Options to contractors</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">(30</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">37</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; font-size: 9pt; vertical-align: bottom;"> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Total</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">(1,563</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">8,071</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> </table> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In February 2011, the Company filed a final short form prospectus for a rights offering. In accordance with the terms of the rights offering, each shareholder of record on March 2, 2011 received one right for each common share held. Every right held entitled the holder thereof to purchase for CAD $0.03, or USD $0.0303 at the shareholder&#8217;s option, a unit consisting of one common share along with one warrant to purchase a common share of the Company at CAD $0.08. The rights began trading on March 2, 2011 on the TSX and on the Pink Sheets and expired on March 29, 2011.</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On March 2, 2011, the Company recognized a derivative financial liability of $1.25 million associated with the Company&#8217;s obligation to carry out the rights offering. The deficit was adjusted by a corresponding amount. The derivative financial liability will be adjusted to fair value at each quarter end with changes being recognized in earnings until the expiry of the warrants. During the year ended December 31, 2011, the Company recognized a realized derivative gain of $613. The rights expired on March 29, 2011.</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Under the terms of the rights offering, the monetary amount to be received by the Company upon the exercise of rights was not fixed. Each holder of rights could elect either the $0.03 CAD or USD$0.0303 subscription price. Furthermore, the CAD $0.03 subscription price was not denominated in the Company&#8217;s U.S. dollar functional currency. Therefore, the pro rata distribution of rights to the Company&#8217;s shareholders was accounted for as a derivative financial liability measured at fair value.</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Upon the closing of the rights offering in March 2011, the Company issued a total of 84,559 units for total net proceeds of $2,566. Accordingly the Company recorded an increase in Common stock of $1,023 (4,697 shares). Expenses and fees relating to the rights offering totaled approximately $300 and were expensed since it was uncertain as to whether any shares would be issued.</font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"></font></p> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"></font>&#160;</p> <div style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">During the fiscal year ended December 31, 2011, the Company issued 108 optionsto contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13, no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise.</font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company has adopted Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Level 1: Quoted market prices in active markets for identical assets or liabilities.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Level 3: Unobservable inputs that are not corroborated by market data.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Assets/Liabilities Measured at Fair Value on a Recurring Basis</b></font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font: 10pt times new roman, times, serif; color: black;"><b>Fair Value Measurement at December 31, 2012</b></font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Quoted Pricein Active Markets</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Significant Other</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Significant</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">for IdenticalInstruments</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Observable Inputs</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Unobservable Inputs</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Level 1</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Level 2</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Level 3</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Total</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="color: black; font-weight: bold;"><font style="color: black;">Assets</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 40%; color: black;"><font style="color: black;">Cash equivalents</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">2,241</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">2,241</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="color: black; font-weight: bold;"><font style="color: black;">Liabilities</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; color: black;"><font style="color: black;">Derivative liabilities</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">6,640</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">6,640</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company's financial instruments include cash equivalents and derivatives. Only cash equivalents and derivatives are carried at their fair value. The derivative liabilities include warrants denominated in a currency other than the Company&#8217;s functional currency and options issued to contractors in a currency other than the functional currency of the Company. The warrants are carried at fair value and calculated using the Black-Scholes option pricing model using the following assumptions; expected dividend 0%; risk-free interest rate of 1.15%-1.36%; expected volatility of 146% - 155%; and a 2.3 or 3.2 year remaining life. The options also use the Black Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 1.37%-1.41% expected volatility of 140%- 145%; and a 4.9-5.4 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shareholders&#8217; Equity</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Authorized capital stock</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company&#8217;s authorized capital stock consists of an unlimited number of shares of no par common stock.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On August <font style="font-weight: normal; text-underline-style: none;">10, </font>2011, the Board of Directors approved a 1-for-18 reverse stock split, or &#8220;share consolidation&#8221;, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company&#8217;s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has <font style="font-weight: normal; text-underline-style: none;">retroactively adjusted</font> its financial statements for all periods presented to show the share shares, stock options and warrants as if they had always been presented on this basis. <font style="font-weight: normal; text-underline-style: none;">The number of units and unit prices (including with respect to the units issued in our 2011 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).</font></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Equity financings</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On June 5, 2001, the Company completed an IPO issuing 74 shares of common stock at a price of CAD$135 per share. Net proceeds of this offering credited to common stock amounted to $5,727 after deducting the underwriting fee of $501 and expenses of $354. As additional compensation in connection with the offering, the Company granted the underwriters non-assignable support warrants representing ten percent of the offered shares. At that time, each support warrant entitled the holder to purchase one share of common stock on or before June 5, 2003 at CAD$7.50.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On December 19, 2003, the Company completed a private placement of equity securities totaling $16,095, comprised of (i) $15,050 for 11,522 units, at a price of CAD$1.75 per unit. Each unit consisted of one share of common stock and one-half of a common stock purchase warrant in Adherex with an exercise price of CAD$2.15 per share, which expired unexercised on December 19, 2008 (on a post-consolidation basis, 640 shares of common stock were issued), and (ii) $1,045 for 800 Series 1 Preferred Shares and warrants to purchase 400 Series 1 Preferred Shares of 2037357 Ontario Inc. The $5,777 estimated fair value of the warrants has been allocated to additional paid-in capital and the balance of $8,053 has been credited to common stock. At that time, the non-redeemable Series 1 Preferred Shares of 2037357 Ontario Inc. (&#8220;Preferred Shares&#8221;) were exchangeable into 800 shares of common stock of Adherex (44 shares of common stock on a post-consolidation basis). Upon such an exchange, all of the then outstanding warrants to purchase the Preferred Shares would be exchanged for an equal number of warrants to purchase Adherex common stock, which warrants expired on December 19, 2008. The $1,045 was to be spent on specific research and development projects in Ontario, Canada as designated by Adherex. Adherex could compel the exchange of the Preferred Shares into common stock and warrants for common stock of Adherex at any time after January 3, 2005. 2037357 Ontario Inc. has been accounted for in accordance with the substance of the transaction. The $1,045 has been recorded as non-redeemable Preferred Shares and the amounts expended were recorded as expenses in the relevant periods. On June 14, 2004, the preferred shares and warrants were exchanged for 44 shares of Adherex common stock on a post-consolidation basis, and warrants to purchase shares of Adherex common stock, all of which warrants expired on December 19, 2008. In June 2004, 2037357 Ontario Inc. became a wholly owned subsidiary of the Company and was amalgamated with Adherex Technologies Inc. The investment has been split between the estimated fair value of the warrants of $363, which has been included in additional paid-in capital, and the remainder of $660, which has been recorded in common stock. On May 20, 2004, the Company completed equity financings with total gross proceeds of $9,029 less $555 of issuance costs<font style="font-weight: normal; text-underline-style: none;"> and</font> issued<font style="font-weight: normal; text-underline-style: none;">4,669</font> units at a purchase price of CAD$<font style="font-weight: normal; text-underline-style: none;">2.65 </font>per unit<font style="font-weight: normal; text-underline-style: none;">. Each</font> unit <font style="font-weight: normal; text-underline-style: none;">consisted </font>of one share of common stock and one-half of a common stock purchase warrant<font style="font-weight: normal; text-underline-style: none;">, and, at that time, each</font> whole warrant entitled the holder to acquire one additional share of common stock at an exercise price of CAD$<font style="font-weight: normal; text-underline-style: none;">3.50,</font> all of which expired unexercised on May 19, 2007. The financing resulted in the issuance of an aggregate of 259 shares of common stock on a post-consolidation basis. The $2,118 value of the warrants has been allocated to additional paid-in capital and the balance of $6,356 has been credited to common stock.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On July 20, 2005, the Company completed a private placement of equity securities for gross proceeds of $8,510 <font style="font-weight: normal; text-underline-style: none;">and issued 6,079</font> units at a price of $<font style="font-weight: normal; text-underline-style: none;">1.40</font> per unit, providing net proceeds of $8,134 after deducting broker fees and other expenses of $376. At the time, each unit consisted of one common share and 0.30 of a common share purchase warrant<font style="font-weight: normal; text-underline-style: none;"> and the</font> private placement resulted in the issuance of an aggregate of<font style="font-weight: normal; text-underline-style: none;">337 </font>shares of common stock on a post &#8211;consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. <font style="font-weight: normal; text-underline-style: none;">At that time, each</font> whole investor warrant entitled the holder to acquire one additional share of common stock of Adherex at an exercise price of $<font style="font-weight: normal; text-underline-style: none;">1.75</font> per share for a period of three years and each whole broker warrant entitled the holder to acquire one share of Adherex common stock at an exercise price of $<font style="font-weight: normal; text-underline-style: none;">1.75 </font>for a period of two years, all of which expired unexercised on July 20, 2007 and 2008, respectively. The warrants, with a value of $1,074 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $7,060 has been credited to common stock.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On May 8, 2006, the Company completed a private placement of equity securities for gross proceeds of $6,512 <font style="font-weight: normal; text-underline-style: none;">and issued 7,753</font> units at a price of $<font style="font-weight: normal; text-underline-style: none;">0.84</font> per unit providing net proceeds of $6,040 after deducting broker fees and certain other expenses. Each unit consisted of one common share and 0.30 of a common share purchase warrant<font style="font-weight: normal; text-underline-style: none;">, and the</font> private placement resulted in the issuance of an aggregate of <font style="font-weight: normal; text-underline-style: none;">431</font> shares of common stock on a post-consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. <font style="font-weight: normal; text-underline-style: none;">At that time, each</font> whole investor warrant entitled the holder to acquire one additional share of Adherex common stock at an exercise price of $<font style="font-weight: normal; text-underline-style: none;">0.97 </font>per share for a period of four years<font style="font-weight: normal; text-underline-style: none;">, and each</font> whole broker warrant <font style="font-weight: normal; text-underline-style: none;">entitled</font> the holder to acquire one share of Adherex common stock at an exercise price of $<font style="font-weight: normal; text-underline-style: none;">0.97</font> per share for a period of two years, all of which expired unexercised on May 7, 2008. The warrants, with a value of $822 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $5,218 has been credited to common stock.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On February 21, 2007, the Company completed the sale of equity securities providing gross proceeds of $25,000 for <font style="font-weight: normal; text-underline-style: none;">75,759 </font>units at a price of $<font style="font-weight: normal; text-underline-style: none;">0.33</font> per unit providing net proceeds of $23,221 after deducting broker fees and other expenses. Each unit consisted of one common share and one-half of a common share purchase warrant. The offering resulted in the issuance of an aggregate of<font style="font-weight: normal; text-underline-style: none;">4,209 </font>shares of common stock on a post-consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. <font style="font-weight: normal; text-underline-style: none;">At that time, each</font> whole investor warrant entitled the holder to acquire one additional share of Adherex common stock at an exercise price of $<font style="font-weight: normal; text-underline-style: none;">0.40 </font>per share for a period of three years<font style="font-weight: normal; text-underline-style: none;">, and each</font> whole broker warrant <font style="font-weight: normal; text-underline-style: none;">entitled</font> the holder to acquire one additional unit at an exercise price of $<font style="font-weight: normal; text-underline-style: none;">0.33</font> per unit for a period of two years, the unexercised portion of which expired on February 21, 2009. The warrants, with a value of $5,379 based on the Black-Scholes option pricing model, have been allocated to additional paid-in-capital and the remaining balance of $17,842 has been included in common stock.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">During the second quarter of fiscal 2007, the Company received gross proceeds of $694 related to the exercise of warrants<font style="font-weight: normal; text-underline-style: none;"> and issued 116</font> shares of common stock on a post-consolidation basis and additional investor warrants, which <font style="font-weight: normal; text-underline-style: none;">expired </font>on February 21, 2010. The warrants, with a value of $131 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $563 has been included in common stock.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On April 30, 2010, the Company completed a first closing of a non-brokered private placement (&#8220;Private Placement&#8221;) of 240,066,664 units, at a price of CAD$0.03 per unit for net proceeds of CAD$7.2 million. Each unit <font style="font-weight: normal; text-underline-style: none;">consisted </font>of one common share and one common share purchase warrant (a &#8220;Warrant&#8221;). At that time, each Warrant entitled the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. As a result of the Share Consolidation on August 25, 2011, the number of shares<font style="font-weight: normal; text-underline-style: none;">and warrants issued</font> upon exercise of the units <font style="font-weight: normal; text-underline-style: none;">consists</font> of 13,337,037 shares and warrants to purchase 13,337,037 shares of common stock at the exercise price of CAD $1.44 per whole share.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Special warrants</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">From May 2000 through November 2000, the Company issued special warrants. <font style="font-weight: normal; text-underline-style: none;">At that time, each</font> special warrant was sold for CAD$<font style="font-weight: normal; text-underline-style: none;">25.00</font> and entitled the holder thereof to acquire, for no additional consideration, four shares of common stock of the Company. The special warrants also included a price protection adjustment determined by dividing CAD$<font style="font-weight: normal; text-underline-style: none;">32.50</font> by the initial public offering (&#8220;IPO&#8221;) price of CAD$<font style="font-weight: normal; text-underline-style: none;">7.50.</font></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">During the year ended June 30, 2000, <font style="font-weight: normal; text-underline-style: none;">16</font> of <font style="font-weight: normal; text-underline-style: none;">126 </font>special warrants were issued, with the balance of<font style="font-weight: normal; text-underline-style: none;">110</font> issued in the year ended June 30, 2001. Upon completion of the IPO, on June 5, 2001, these special warrants were converted to <font style="font-weight: normal; text-underline-style: none;">30</font> shares of common stock, which included <font style="font-weight: normal; text-underline-style: none;">2 </font>shares of common stock issued under the price protection adjustment (such shares are presented on a post-consolidation basis).</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Special A warrants</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">During October 2000, the Company issued Series A special warrants. <font style="font-weight: normal; text-underline-style: none;">At that time, each</font> Series A special warrant was sold at CAD$<font style="font-weight: normal; text-underline-style: none;">6.25</font> and entitled the holder to acquire, for no additional consideration, one share of common stock of the Company. <font style="font-weight: normal; text-underline-style: none;">At that time, the</font> Series A special warrants also included a price protection adjustment determined by dividing CAD$<font style="font-weight: normal; text-underline-style: none;">8.125 </font>by the IPO price.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Upon completion of the IPO<font style="font-weight: normal; text-underline-style: none;">, </font>on June 5, 2001, these Series A special warrants were converted to <font style="font-weight: normal; text-underline-style: none;">69 </font>shares of common stock, which included <font style="font-weight: normal; text-underline-style: none;">5</font> shares of common stock issued under the price protection adjustment (such shares are presented on a post-consolidation basis).</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In addition, each Series A special warrant included a share purchase warrant entitling the holder to purchase an additional share of common stock at the IPO price, which was also subject to the price protection adjustment. These share purchase warrants expired unexercised on September 3, 2001.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>2010 Private Placement Warrants</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On April 30, 2010, the Company completed a first closing of a non-brokered private placement (&#8220;Private Placement&#8221;) of 240,066,664 units, at a price of CAD$0.03 per unit for net proceeds of CAD$7,202. <font style="font-weight: normal; text-underline-style: none;">Each</font> unit consisted of one common share and one common share purchase warrant (a &#8220;Warrant&#8221;). At that time, each Warrant entitled the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. As the exercise price is denominated in a currency other than the company&#8217;s functional currency, these warrants are treated as a derivative instrument. (Note 5) As a result of the Share Consolidation on August 25, 2011, the number of shares issuable upon <font style="font-weight: normal; text-underline-style: none;">the </font>exercise of the <font style="font-weight: normal; text-underline-style: none;">warrants issued in connection with the April 2010 Private Placement consists of</font> 13,337,037 shares of common stock at the exercise price of CAD $1.44 per whole share.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Equity rights</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On September 28, 1999, University Medical Discoveries Inc. (&#8220;UMDI&#8221;) invested $171 for equity of the Company. The form of this equity was to be the same as the first class of securities to raise greater than $683 subsequent to the date of the investment. The date of conversion was dependent on certain milestones being met under a specific research project. On August 24, 2000, the Company and UMDI agreed to convert UMDI&#8217;s $171 investment into 3 shares of common stock of the Company.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company a rights offering to its shareholders on March 2, 2011, the record date for the rights offering (the "Rights Offering"). Pursuant to the terms of the Rights Offering, the Company distributed rights to subscribe for up to 425,000,000 Units at a price of CAD$0.03 per unit, for gross proceeds of up to CAD$12,750,000, to the shareholders on the basis of one right per each share of common stock held by such shareholder&#160;on March 2, 2011, the record date for the Rights Offering. &#160;Purchasers of units in the Company's April 2010 Private Placement described above that owned common stock as of the record date for the Rights Offering agreed not to participate in the Rights Offering.&#160;Each right was exercisable for one unit which consisted of one common share and one common share purchase warrant (a &#8220;Warrant&#8221;).&#160;Each Warrant entitles the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date.&#160;Adherex filed a short-form prospectus for the Rights Offering with the securities regulatory authorities in Canada to qualify the distribution of the rights in Canada on February 11, 2011 and a Form S-1 registration statement with the Securities and Exchange Commission to register the rights and underlying securities in the United States, which registration statement was declared effective on February 11, 2011.&#160;As of 5:00 pm New York City time on March 29, 2011, the expiration date for the Rights Offering, the Company had received subscriptions for an aggregate of 84,559,178 Units, representing estimated aggregate gross proceeds of approximately $2.5 million.</font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Triathlon settlement</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">During fiscal 2000, other advances totaling $175 were settled by the issuance to Triathlon Limited of 16 shares of common stock of the Company. The number of shares issued was determined with reference to the fair value at the time the advances were made.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Shire BioChem Inc. agreement</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On August 17, 2000, the Company entered into a subscription agreement and a license agreement with Shire BioChem Inc. (&#8220;BioChem&#8221;). Under the subscription agreement, BioChem purchased 5 shares of common stock of the Company for $341. Pursuant to a price protection clause in the agreement, an additional eight shares of common stock were issued on completion of the Company&#8217;s IPO on June 5, 2001.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Acquisitions</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On November 20, 2002, the Company issued 446 shares of commons stock to acquire all of the issued and outstanding securities of Oxiquant, a holding company which held certain intellectual property rights, including rights to sodium thiosulfate.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In connection with the acquisition of the intellectual property of Oxiquant in November 2002, the Company issued warrants <font style="font-weight: normal; text-underline-style: none;">to purchase shares of common stock </font>with an exercise price of CAD$<font style="font-weight: normal; text-underline-style: none;">3.585 </font>that expired unexercised on May 20, 2007 and introduction warrants <font style="font-weight: normal; text-underline-style: none;">to purchase shares of common stock </font>with an exercise price of CAD$<font style="font-weight: normal; text-underline-style: none;">2.05 </font>that expired unexercised on November 20, 2007.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">As a prerequisite of the Oxiquant transaction, Adherex licensed all of its Cadherin-related intellectual property for non-cancer applications and transferred $158 in cash to Cadherin Biomedical Inc. or CBI, a wholly-owned subsidiary of Adherex at the time, in return for Class A Preferred Shares of CBI. These CBI Class A Preferred Shares were then distributed to all of the Adherex shareholders of record by way of special dividend, effecting a &#8220;spin out&#8221; of CBI and the non-cancer assets from Adherex.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In order to effect such a distribution under Section 42 of the Canada Business Corporations Act (&#8220;CBCA&#8221;), the Company was legally required to reduce its stated capital so that the aggregate amount of its liabilities and stated capital did not exceed the realizable value of Adherex&#8217;s assets. Management determined that the stated capital needed to be reduced by $9,489, in order to comply with the requirements of Section 42 of the CBCA. The Company decreased common stock and increased additional paid-in capital by $9,489.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In February 2004, the Company and CBI became involved in litigation. On December 3, 2004, the Company and CBI settled the litigation and the Company agreed to acquire all of the issued and outstanding shares of CBI and reacquire the non-cancer rights to the cadherin-based intellectual property. As part of the agreement, the Company issued 37 common shares valued at $1,252, net of transaction costs.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>&#160;</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Convertible note warrants</b></font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On June 23, 2003, the Company issued senior secured convertible notes with a face value totaling $2,219. These notes were convertible into common stock and warrants to acquire common stock of the Company upon completion of an equity fund raising round. <font style="font-weight: normal; text-underline-style: none;">At that time, investors</font> also received warrants to purchase shares of common stock of the Company with an exercise price of CAD$<font style="font-weight: normal; text-underline-style: none;">2.75</font> per share that expired unexercised on June 23, 2007. The notes bore interest at an annual rate of eight percent compounded semi-annually, and matured one year from issue but were renewable for one additional year at the option of the Company. In connection with this issuance, <font style="font-weight: normal; text-underline-style: none;">at that time, </font>the Company issued broker warrants to purchase shares of common stock exercisable at a price of CAD$<font style="font-weight: normal; text-underline-style: none;">2.35 </font>per share<font style="font-weight: normal; text-underline-style: none;">,</font> which expired unexercised on June 23, 2005.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On December 3, 2003, the Company issued additional senior secured convertible notes with a face value totaling CAD$1,458. These notes were convertible into common stock and warrants to acquire common stock of the Company upon completion of an equity fund raising round. Also, <font style="font-weight: normal; text-underline-style: none;">at that time, </font>investors received warrants <font style="font-weight: normal; text-underline-style: none;">to purchase </font>shares of common stock exercisable at a price of CAD$<font style="font-weight: normal; text-underline-style: none;">2.15 </font>per share which expired unexercised on December 3, 2007.The notes bore interest at an annual rate of eight percent compounded semi-annually, and matured one year from issue but were renewable for one additional year at the option of the Company. <font style="font-weight: normal; text-underline-style: none;">At that time, the</font> Company also issued broker warrants to purchase shares of common stock exercisable at a price of CAD$<font style="font-weight: normal; text-underline-style: none;">2.15 </font>per share which expired unexercised on December 3, 2005.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On December 19, 2003, the Company completed an equity financing resulting in the conversion of the June and the December notes into <font style="font-weight: normal; text-underline-style: none;">156 </font>shares of common stock on a post-consolidation basis with a carrying value of $1,785 credited to common stock. <font style="font-weight: normal; text-underline-style: none;">At that time</font>, the Company issued warrants to purchase<font style="font-weight: normal; text-underline-style: none;">, shares of </font>common stock with an exercise price of CAD$<font style="font-weight: normal; text-underline-style: none;">2.15</font> per share which expired unexercised on December 19, 2008.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Warrants to Purchase Common Stock</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At December 31, 2012, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years:&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-style: normal; font-weight: normal;" nowrap="nowrap"><font style="color: black;"><b>Warrant&#160;Description</b><br />(Warrants&#160;in&#160;thousands)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Common&#160;Shares&#160;Issuable&#160;Upon<br />Exercise&#160;of&#160;Outstanding<br />Warrants&#160;at&#160;December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Exercise&#160;Price&#160;in&#160;Canadian<br />Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; font-weight: bold;" nowrap="nowrap"><font style="color: black;">Expiration&#160;Date</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0px; width: 55%;"><font style="color: black;">Investor Warrants (1)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">13,337</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">1.44</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="padding-left: 5.4pt; width: 14%;"><font style="color: black;">April 30, 2015</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0px;"><font style="color: black;">Investor Warrants (2)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">4,698</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">$</font></td> <td style="text-align: right; padding-bottom: 1pt;"><font style="color: black;">1.44</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; padding-left: 5.4pt;"><font style="color: black;">March 29, 2016</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">18,035</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black; font-weight: normal;">(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (&#8220;Private Placement&#8221;) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a &#8220;Warrant&#8221;). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black; font-weight: normal;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black; font-weight: normal;">(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a &#8220;Warrant&#8221;). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Research and Development</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows:</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Cumulative <br />FromSeptember&#160;3,1996&#160;to <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 52%;"><font style="color: black;">Research and development</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">2,075</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">1,494</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">69,168</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">Investment tax credits</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(1,632</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">National Research Council grants</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(197</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">2,075</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">1,494</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">67,339</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>9.&#160;&#160;&#160;&#160;&#160;&#160;Capital and Operating Lease Commitments</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">We had no material commitments for capital expenses or commitments extending beyond three years as of December 31, 2012.&#160;&#160;The following table represents our contractual obligations and commitments at December 31, 2012 (in thousands of U.S. dollars):</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="color: black;">Less&#160;than <br />1&#160;year</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="color: black;">1-3 <br />years</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="color: black;">Total</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 46%;"><font style="color: black;">OCT Clinical Service Agreement (1)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">402</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">402</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Oregon Health &amp; Science University (2), excluding potential royalty payments</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Life Sci Advisors, LLC (3)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">55</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">55</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;"><font style="color: black;">Total</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">457</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">457</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 6%;"><font style="font: 10pt times new roman, times, serif; color: black;">(1)</font></td> <td style="width: 94%;"> <p><font style="font: 10pt times new roman, times, serif; color: black;">Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia.&#160;&#160;The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients.&#160;&#160;The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled.</font></p> </td> </tr> <tr style="vertical-align: top;"> <td><font style="font: 10pt times new roman, times, serif; color: black;">(2)</font></td> <td><font style="font: 10pt times new roman, times, serif; color: black;">Under the license agreement with Oregon Health &amp; Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million.&#160;&#160;Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included.</font></td> </tr> </table> <p style="margin: 0px;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 6%;"><font style="font: 10pt times new roman, times, serif; color: black;">(3)</font></td> <td style="width: 94%;"><font style="font: 10pt times new roman, times, serif; color: black;">Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of the agreement.&#160;&#160;Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.&#160;&#160;</font></td> </tr> </table> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>10.&#160;&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Oregon Health &amp; Science University agreement</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On February 20, 2013, Adherex entered into a new exclusive license agreement with Oregon Health &amp; Science University (&#8220;OHSU&#8221;) for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement").&#160;OHSU will receive certain milestone payments, a 2.5&#160;percent royalty on net sales for licensed products which can be reduced to 1.0 percent upon a $150,000 buy down and a 5&#160;percent royalty on any consideration received from sublicensing of the licensed technology.&#160;Milestone payment fees payable to OHSU include $100,000 upon first commercial sale for any licensed product.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On February 20, 2013, Adherex terminated the previous exclusive license agreement with Oregon Health &amp; Science University and Oxiquant a wholly owned subsidiary of Adherex, dated September 26, 2002(the "Previous OHSU Agreement"). Pursuant to the Previous OHSU Agreement, OHSU granted Oxiquant an exclusive worldwide license to intellectual property directed to thiol-based compounds including STS and their use in oncology. In consideration, Oregon Health &amp; Science University was issued 13,902 shares of common stock of Oxiquant that were subsequently converted upon the acquisition of Oxiquant into 21,250 shares of Adherex common stock, and warrants to purchase shares of Adherex common stock that subsequently expired in 2007. In addition under the Previous OHSU Agreement, the following milestone payments were included in the agreement: (i) $50,000 upon completion of Phase I clinical trials, (ii) $200,000 upon completion of Phase II clinical trials, (iii) $500,000 upon completion of Phase III clinical trials. Also, Oxiquant was to be liable for an additional milestone payment of $250,000 upon the first commercial sale for any licensed product. Further, the Previous OHSU Agreement required Adherex to pay Oregon Health &amp; Science University a 2.5% royalty on net sales of any licensed products and a 15% royalty on any consideration received from sublicensing of the licensed technology.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Adherex, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Adherex or Oregon Health &amp; Science University in the event of a material breach of the agreement by either party after 45 days prior written notice. Adherex has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>GlaxoSmithKline</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On July 14, 2005, Adherex entered into a development and license agreement with GlaxoSmithKline, or GSK.&#160;The agreement included the in-license by the Company of GSK&#8217;s oncology product, Eniluracil, and an option for GSK to license ADH-1.&#160;&#160;As part of the transaction, GSK invested $3.0 million in the Company's common stock.&#160;On October 11, 2006, the GSK option to license ADH-1 expired unexercised.&#160;Under the terms of the agreement relating to Eniluracil, Adherex received an exclusive license to develop Eniluracil for all indications and GSK retained options to buy-back and assume development of the compound at various points in time.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On March 1, 2007, the GSK agreement was amended and the Company purchased all of GSK&#8217;s remaining buy-back options for a fee of $1.0 million.&#160;&#160;As a result of the amendment to the GSK agreement, Adherex now may be required to pay GSK development and sales milestones and royalties.&#160;Specifically, if Adherex files a New Drug Application, or NDA, with the Food and Drug Administration, or FDA, Adherex may be required to pay development milestones of $5.0 million to GSK.&#160;Additionally, depending upon whether the NDA is approved by the FDA and whether Eniluracil becomes a commercial success, the Company may be required to pay up to an additional $70.0 million in development and sales milestones for the initially approved indication, plus royalties in the low-double digit range based on annual net sales.&#160;If the Company pursues other indications, it may also be required to pay up to an additional $15 million to GSK&#160;for each FDA-approved indication. The GSK agreement continues until the earliest of (i) the licensed patents expire or (ii) is terminated by either party in the event of an uncured breach by the breaching party after 60 days prior written notice.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>11.&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company operates in both U.S. and Canadian tax jurisdictions.&#160;Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another.&#160;A reconciliation of the combined Canadian federal and provincial income tax rate with the Company&#8217;s effective tax rate is as follows:</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 92%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 64%;"><font style="color: black;">Domestic loss</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">(4,397</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">5,623</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Foreign loss</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(766</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(938</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">Loss before income taxes</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(5,163</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">4,685</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected statutory rate (recovery)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">26.50</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">28.25</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected provision for (recovery of) income tax</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(1,368</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,324</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Permanent differences</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">489</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(2,209</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Change in valuation allowance</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2,467</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(589</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Non-refundable investment tax credits</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">157</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Effect of foreign exchange rate differences</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(245</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(204</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Effect of change in future enacted tax rates</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(1,378</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(77</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Effect of tax rate changes and other</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">36</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">1,599</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Provision for income taxes</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Canadian statutory come tax rate of 28.25&#160;percent is comprised of federal income tax at approximately 16.5&#160;percent and provincial income tax at approximately 11.75 percent.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2012, December 31, 2011:</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">December&#160;31, <br />2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">December&#160;31, <br />2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; font-weight: bold;"><font style="color: black;">Future tax assets:</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="width: 64%;"><font style="color: black;">SR&amp;ED expenditures</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">2,195</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">2,071</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Income tax loss carryforwards</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">21,783</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">19,635</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Non-refundable investment tax credits</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,719</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,719</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black;">Share issue costs</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">25</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">84</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Accrued expenses</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Fixed and intangible assets</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">970</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">685</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Harmonization credit</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">248</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">280</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">26,940</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">24,193</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Less: valuation allowance</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(26,940</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(24,193</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Net future tax assets</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">There are no current income taxes owed, nor are any income taxes expected to be owed in the near term.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At December 31, 2012 the Company has unclaimed Scientific Research and Experimental Development ("SR&amp;ED") expenditures, income tax loss carry forwards and non-refundable investment tax credits.&#160;The unclaimed amounts and their expiry dates are as listed below:</font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Federal</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Province/ <br />State</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 64%;"><font style="color: black;">SR&amp;ED expenditures (no expiry)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">8,283</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"><font style="color: black;">Income tax loss carryforwards (expiry date):</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2014</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6,089</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6,089</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2015</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">11,499</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">11,499</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2021</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">26</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2022</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">233</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2023</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">133</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2024</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,536</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,455</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2025</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,795</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,768</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2026</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">20,562</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">20,496</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2027</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,340</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,320</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2028</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10,840</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10,823</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2029</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,502</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,502</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2030</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2,608</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2,607</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2031</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,377</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,377</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2032</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,660</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,660</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Investment tax credits (expiry date):</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: right;" colspan="2"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: right;" colspan="2"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2018</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2019</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2020</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">96</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2021</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">55</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2022</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">548</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2023</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">399</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2024</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">178</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2025</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">199</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2026</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">86</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2027</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">90</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2028</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">50</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Basis of presentation</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or &#8220;Share Consolidation&#8221;, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company&#8217;s common shares, stock options and warrants outstanding at the effective date.&#160;Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they&#160;had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Use of estimates</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation.&#160;Actual results could differ from those estimates.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Cash and Cash Equivalents</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment.&#160;At December 31, 2012, the Company had $2,303 in cash accounts (2011- $5,297).&#160;Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments.&#160;The Company has not experienced any loss or write-down of its money market investments.&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Financial instruments</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Financial instruments recognized on the balance sheets at December 31, 2012 and December 31, 2011 consist of cash and cash equivalents, accounts payable and derivative warrant liability, the carrying value of which, with the exception of the derivative warrant liability, approximates fair value due to their relatively short time to maturity.&#160;The Company does not hold or issue financial instruments for trading.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company&#8217;s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment.&#160;Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy.&#160;Securities must have a minimum Dun &amp; Bradstreet rating of A for bonds or R1 low for commercial paper.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments.&#160;As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Common stock and warrants</b></font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company&#8217;s U.S. dollar functional currency.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In November 2007, the Emerging Issues Task Force (&#8220;EITF&#8221;) of the FASB issued EITF No. 07-5, Issue Summary No.1 &#8220;Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock&#8221; (&#8220;EITF 07-5&#8221;), codified as ASC 815-40.&#160;&#160;In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency.&#160;The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock.&#160;This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company&#8217;s outstanding warrants to purchase common stock that were denominated in Canadian dollars.&#160;This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, &#8220;Accounting for Derivative Instruments and Hedging Activities&#8221; (&#8220;SFAS 133&#8221;), codified as ASC 815-10.&#160;SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133.&#160;As a result, the Company&#8217;s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability.&#160;ITF 07-05 is effective for financial statements for fiscal years beginning after December 15, 2008 and earlier adoption is not permitted.&#160;Since the warrants to purchase common stock that are denominated in Canadian dollars expired on December 19, 2008, EITF 07-5 did not have a material impact on the Company&#8217;s financial statements through 2008. However, the Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this results in warrants shown as a liability which is marked to market as at December 31, 2012 and December 31, 2011.&#160;At December 31, 2012, the derivative liabilitieswere valued at $6,640 (2011: $5,077) and the unrealized loss on the value of the underlying securities was $1,563 (2011: gain$8,071) for the year ended December 31, 2012.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Revenue recognition</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Non-refundable up-front payments received in conjunction with the development and license agreement, including license fees and milestones, are deferred and recognized on a straight-line basis over the relevant periods.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company records royalty revenue in accordance with the contract terms once it can be reliably measured and the collection is reasonably assured.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At this time, the Company does not have any revenue.</font></p> <div><font style="color: black;"><font style="color: black;"></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">R<b>esearch and development costs and investment tax credits</b></font></p> <div><font style="color: black;"><font style="color: black;"></font></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred.&#160;Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.</font></p> <div><font style="color: black;"><font style="color: black;"></font></font></div> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured.&#160;They are applied to reduce related capital costs and research and development expenses in the year recognized.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Income taxes</b></font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities.&#160;The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (&#8216;&#8216;FIN 48&#8217;&#8217;), codified as ASC 740-10-25, &#8216;&#8216;Accounting for Uncertainty in Income Taxes &#8211; an Interpretation of SFAS No. 109.&#8217;&#8217; FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements in accordance with Statement of Financial Accounting Standards No. 109, &#8216;&#8216;Accounting for Income Taxes.&#8217;, codified as ASC 740-10.&#160;FIN&#160;48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements.&#160;FIN&#160;48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a &#8220;more-likely-than-not&#8221; threshold of being sustained by the applicable tax authority.&#160;Tax benefits related to tax positions not deemed to meet the &#8220;more-likely-than-not&#8221; threshold are not permitted to be recognized in the financial statements.&#160;Upon adoption of FIN&#160;48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Foreign currency translation</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The U.S. dollar is the functional currency for the Company&#8217;s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Earnings/(Loss) per share</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year.&#160;Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the treasury method.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Recent accounting pronouncements</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif; color: #222222;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif; color: #222222;"><font style="color: black;">In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company is required to adopt this ASU in the first quarter for fiscal 2013.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The following options granted under the stock option plan are exercisable in Canadian dollars:</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"><font style="color: black;">Exercise&#160;Price&#160;in&#160;Canadian <br />Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Number&#160;of <br />Options</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Range</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Weighted- <br />average</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 55%; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2010</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">3,901</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black; font-size: 10pt;">0.63-58.50</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">1.26</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">310</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.54-0.81</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.62</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black; font-size: 10pt;">Reinstated<sup>(1)</sup></font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">5.04-35.10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8.93</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;"><font style="color: black;">Cancelled</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(50</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black; font-size: 10pt;">35.10 &#8211;58.50</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">49.39</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2011</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,171</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.54-0.81</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.78</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;"><font style="color: black;">Cancelled</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2012</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">4,171</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black; font-size: 10pt;">$ 0.54-0.81</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">0.78</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 1.5pt;"></td> <td style="width: 18pt;"><font style="color: black;">(1)</font></td> <td><font style="color: black;">Includes 10 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which had either expired and or were cancelled prior to the agreed severance agreement.</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The following options granted under the stock option plan are exercisable in U.S. dollars:</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"><font style="color: black;">Exercise&#160;Price&#160;in&#160;U.S.&#160;Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Number&#160;of <br />Options</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Range</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Weighted- <br />average</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 55%; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2010</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">721</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black; font-size: 10pt;">$ 1.80 - 24.30</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">9.90</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">138</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.50-0.63</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.54</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;"><font style="color: black; font-size: 10pt;">Reinstated<sup>(1)</sup></font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">104</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black; font-size: 10pt;">$ 5.04-21.60</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">9.15</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2011</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">963</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">$ 0.50 - 24.30</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">8.51</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Granted</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,137</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">0.15-0.56</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0.32</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;"><font style="color: black;">Exercised</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;"><font style="color: black;">Cancelled</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(773</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black; font-size: 10pt;">$ 5.04-24.30</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">9.92</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Outstanding at December 31, 2012</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">1,327</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black; font-size: 10pt;">$ $0.15-11.34</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">0.67</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">(1) Includes104 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which were cancelled in error in 2010.</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Price&#160;in&#160;Canadian&#160;Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">#&#160;outstanding&#160;and <br />exercisable&#160;at <br />December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Weighted average remaining&#160;life&#160;(years)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 31%;"><font style="color: black;">0.54</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 31%;"><font style="color: black;">88</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 30%;"><font style="color: black;">5.26</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.63</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">303</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">5.42</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">0.81</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">3,780</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">4.64</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;" colspan="2"><font style="font: 10pt times new roman, times, serif; color: black;">TOTAL</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,171</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4.70</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Price&#160;in&#160;US&#160;Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">#&#160;Outstanding&#160;at <br />December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">#&#160;Exercisable&#160;at <br />December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Remaining&#160;life <br />(years)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 23%;"><font style="color: black;">0.15</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 22%;"><font style="color: black;">33</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 22%;"><font style="color: black;">33</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 22%;"><font style="color: black;">6.62</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.18</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">61</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">61</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.38</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.20</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">254</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">254</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.25</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.35</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">689</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">689</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.89</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.50</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">94</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">94</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.56</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">100</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">100</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.97</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">0.63</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">45</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">45</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">5.64</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">1.80</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2.71</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">5.04</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">7</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">7</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1.92</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">5.22</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2.41</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">7.20</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1.70</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">$</font></td> <td style="text-align: right;"><font style="color: black;">10.26</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">23</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">23</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1.37</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">$</font></td> <td style="text-align: right; padding-bottom: 1pt;"><font style="color: black;">11.34</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">13</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">13</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">1.33</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,327</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,327</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6.44</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The fair values of options granted in fiscal years ended December 31, 2012 and 2011&#160;were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions:</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Year&#160;Ended<br />December&#160;31, <br />2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Year&#160;Ended<br />December&#160;31, <br />2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 64%;"><font style="color: black;">Expected dividend</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">0</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">%</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">0</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Risk-free interest rate</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">1.09-1.26</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">1.85-2.5</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected volatility</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">118-133</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">121-132</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected life</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">7 years</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black; font-size: 10pt;">7 years</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.25in;" cellspacing="0" cellpadding="0"> <tr style="font-size: 9pt; vertical-align: bottom;"> <td style="text-align: left; color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">Gain/(Loss)&#160;on&#160;Derivative&#160;Instruments</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black; font-size: 9pt;">Twelve&#160;months&#160;ended&#160;December&#160;31, 2012</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black; font-size: 9pt;">Twelve&#160;months&#160;ended&#160;December&#160;31,&#160;2011</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;" nowrap="nowrap"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; font-size: 9pt; vertical-align: bottom;"> <td style="width: 54%; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Warrant expiring April 15, 2015</font></td> <td style="width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; width: 20%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">(1,026</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; width: 20%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">6,778</font></td> <td style="text-align: left; width: 1%; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: white; font-size: 9pt; vertical-align: bottom;"> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Warrant expiring March 29, 2016</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">(507</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">643</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; font-size: 9pt; vertical-align: bottom;"> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Rights offering derivative</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">-</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">613</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: white; font-size: 9pt; vertical-align: bottom;"> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Options to contractors</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">(30</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">37</font></td> <td style="text-align: left; color: black; font-size: 9pt;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; font-size: 9pt; vertical-align: bottom;"> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">Total</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">(1,563</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">)</font></td> <td style="color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> <td style="text-align: right; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">8,071</font></td> <td style="text-align: left; color: black; font-size: 9pt; font-weight: bold;"><font style="color: black; font-size: 9pt;">&#160;</font></td> </tr> </table> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Assets/Liabilities Measured at Fair Value on a Recurring Basis</b></font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font: 10pt times new roman, times, serif; color: black;"><b>Fair Value Measurement at December 31, 2012</b></font></p> <p style="text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Quoted Pricein Active Markets</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Significant Other</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Significant</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">for IdenticalInstruments</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Observable Inputs</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Unobservable Inputs</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td colspan="2" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Level 1</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Level 2</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Level 3</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; color: black; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Total</font></td> <td style="color: black; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="color: black; font-weight: bold;"><font style="color: black;">Assets</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 40%; color: black;"><font style="color: black;">Cash equivalents</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">2,241</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="width: 1%; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%; color: black;"><font style="color: black;">2,241</font></td> <td style="text-align: left; width: 1%; color: black;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="color: black; font-weight: bold;"><font style="color: black;">Liabilities</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; color: black;"><font style="color: black;">Derivative liabilities</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">6,640</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">-</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; color: black;"><font style="color: black;">6,640</font></td> <td style="text-align: left; color: black;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">At December 31, 2012, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years:&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-style: normal; font-weight: normal;" nowrap="nowrap"><font style="color: black;"><b>Warrant&#160;Description</b><br />(Warrants&#160;in&#160;thousands)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Common&#160;Shares&#160;Issuable&#160;Upon<br />Exercise&#160;of&#160;Outstanding<br />Warrants&#160;at&#160;December&#160;31,&#160;2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Exercise&#160;Price&#160;in&#160;Canadian<br />Dollars</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; font-weight: bold;" nowrap="nowrap"><font style="color: black;">Expiration&#160;Date</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0px; width: 55%;"><font style="color: black;">Investor Warrants (1)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">13,337</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">1.44</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="padding-left: 5.4pt; width: 14%;"><font style="color: black;">April 30, 2015</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0px;"><font style="color: black;">Investor Warrants (2)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">4,698</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">$</font></td> <td style="text-align: right; padding-bottom: 1pt;"><font style="color: black;">1.44</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; padding-left: 5.4pt;"><font style="color: black;">March 29, 2016</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">18,035</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black; font-weight: normal;">(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (&#8220;Private Placement&#8221;) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a &#8220;Warrant&#8221;). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black; font-weight: normal;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black; font-weight: normal;">(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a &#8220;Warrant&#8221;). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows:</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Cumulative <br />FromSeptember&#160;3,1996&#160;to <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 52%;"><font style="color: black;">Research and development</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">2,075</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 12%;"><font style="color: black;">1,494</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">69,168</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">Investment tax credits</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(1,632</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">National Research Council grants</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(197</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">2,075</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">1,494</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">67,339</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <div>The following table represents our contractual obligations and commitments at December 31, 2012 (in thousands of U.S. dollars):</div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="color: black;">Less&#160;than <br />1&#160;year</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="color: black;">1-3 <br />years</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="color: black;">Total</font></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 46%;"><font style="color: black;">OCT Clinical Service Agreement (1)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">402</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">402</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Oregon Health &amp; Science University (2), excluding potential royalty payments</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Life Sci Advisors, LLC (3)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">55</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">55</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;"><font style="color: black;">Total</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">457</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">457</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 6%;"><font style="font: 10pt times new roman, times, serif; color: black;">(1)</font></td> <td style="width: 94%;"> <p><font style="font: 10pt times new roman, times, serif; color: black;">Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia.&#160;&#160;The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients.&#160;&#160;The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled.</font></p> </td> </tr> <tr style="vertical-align: top;"> <td><font style="font: 10pt times new roman, times, serif; color: black;">(2)</font></td> <td><font style="font: 10pt times new roman, times, serif; color: black;">Under the license agreement with Oregon Health &amp; Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million.&#160;&#160;Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included.</font></td> </tr> </table> <p style="margin: 0px;"><font style="color: black;">&#160;</font></p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 6%;"><font style="font: 10pt times new roman, times, serif; color: black;">(3)</font></td> <td style="width: 94%;"><font style="font: 10pt times new roman, times, serif; color: black;">Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of the agreement.&#160;&#160;Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.</font></td> </tr> </table> <div>A reconciliation of the combined Canadian federal and provincial income tax rate with the Company&#8217;s effective tax rate is as follows:</div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 92%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">Year&#160;Ended <br />December&#160;31,</font></td> <td style="font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="color: black;">2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 64%;"><font style="color: black;">Domestic loss</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">(4,397</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">5,623</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Foreign loss</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(766</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(938</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">Loss before income taxes</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(5,163</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">4,685</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected statutory rate (recovery)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">26.50</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">28.25</font></td> <td style="text-align: left;"><font style="color: black;">%</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Expected provision for (recovery of) income tax</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(1,368</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,324</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Permanent differences</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">489</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(2,209</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Change in valuation allowance</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2,467</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(589</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Non-refundable investment tax credits</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">0</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">157</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Effect of foreign exchange rate differences</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(245</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(204</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Effect of change in future enacted tax rates</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(1,378</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">(77</font></td> <td style="text-align: left;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Effect of tax rate changes and other</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">36</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">1,599</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Provision for income taxes</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"></font>&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2012, December 31, 2011:</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">December&#160;31, <br />2012</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">December&#160;31, <br />2011</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; font-weight: bold;"><font style="color: black;">Future tax assets:</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="width: 64%;"><font style="color: black;">SR&amp;ED expenditures</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">2,195</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">2,071</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Income tax loss carryforwards</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">21,783</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">19,635</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Non-refundable investment tax credits</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,719</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,719</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black;">Share issue costs</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">25</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">84</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Accrued expenses</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Fixed and intangible assets</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">970</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">685</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Harmonization credit</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">248</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">280</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">26,940</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">24,193</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">Less: valuation allowance</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(26,940</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> <td style="padding-bottom: 1pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right;"><font style="color: black;">(24,193</font></td> <td style="text-align: left; padding-bottom: 1pt;"><font style="color: black;">)</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;"><font style="color: black;">Net future tax assets</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left;"><font style="color: black;">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left; padding-bottom: 2.5pt;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"></font>&#160;</p> <div>The unclaimed amounts and their expiry dates are as listed below:</div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Federal</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="color: black;">Province/ <br />State</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 64%;"><font style="color: black;">SR&amp;ED expenditures (no expiry)</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">8,283</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> <td style="width: 1%;"><font style="color: black;">&#160;</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">$</font></td> <td style="text-align: right; width: 15%;"><font style="color: black;">-</font></td> <td style="text-align: left; width: 1%;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"><font style="color: black;">Income tax loss carryforwards (expiry date):</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2014</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6,089</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">6,089</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2015</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">11,499</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">11,499</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2021</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">26</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2022</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">233</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2023</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">133</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">-</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2024</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,536</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">1,455</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2025</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,795</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">4,768</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2026</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">20,562</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">20,496</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2027</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,340</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,320</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2028</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10,840</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10,823</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2029</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,502</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8,502</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2030</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2,608</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">2,607</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">2031</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,377</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,377</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2032</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,660</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">3,660</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;"><font style="color: black;">Investment tax credits (expiry date):</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: right;" colspan="2"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: right;" colspan="2"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2018</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">10</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2019</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">8</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2020</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">96</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2021</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">55</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2022</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">548</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2023</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">399</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2024</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">178</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2025</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">199</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2026</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">86</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2027</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">90</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font style="color: black;">2028</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">50</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> <td style="text-align: right;"><font style="color: black;">&#160;</font></td> <td style="text-align: left;"><font style="color: black;">&#160;</font></td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> 3620000 1-for-18 1-for-18 3901 721 4171 963 4171 1327 33 61 254 689 94 100 45 4 7 2 2 23 13 1327 310 138 0 1137 50 0 773 10 104 0 0 0.63 58.50 1.80 24.30 0.54 0.81 0.50 24.30 0.54 0.81 0.15 11.34 0.54 0.81 0.50 0.63 0 0 0.15 0.56 0 0 0 0 0 0 0 0 0 35.10 58.50 0 0 5.04 24.30 5.04 35.10 5.04 21.60 0 0 0 0 1.26 9.90 0.78 8.51 0.78 0.67 0.62 0.54 0 0.32 0 0 0 0 49.39 0 0 9.92 8.93 9.15 0 0 88 303 3780 4171 P6Y7M13D P6Y4M17D P6Y3M P6Y10M21D P6Y1M6D P6Y11M19D P5Y7M21D P2Y8M16D P1Y11M1D P2Y4M28D P1Y8M12D P1Y4M13D P1Y3M29D P5Y3M4D P5Y5M1D P4Y7M21D P4Y8M12D P6Y5M8D 33 61 254 689 94 100 45 4 7 2 2 23 13 1327 0.00 0.00 0.0185 0.025 0.0109 1.26 1.21 1.32 1.18 1.33 P7Y P7Y 20000 6290 0.25 0.0500 0.0133 1500000 5000000 250000 326000 0.56 0.29 0 971885 255759 51152 16369 18 18 4698 13337 18035 4698 13337 7.50 2.75 2.15 2.15 3.50 2.35 1.75 2.15 0.97 0.40 0.33 2.05 3.585 0.08 1.44 0.03 0.08 1.44 1.44 0.0303 1.44 1.44 1.44 0.03 1.44 1.44 2016-03-29 2015-04-30 2118000 363000 660000 1074000 7060000 822000 5218000 5379000 17842000 131000 563000 5777000 1340000 3672000 1847000 4697000 108 0.08 1250000 2566000 300000 49000 53000 2241000 0 0 2241000 6640000 0 0 6640000 0.00 0.00 0.0136 0.0141 0.0115 0.0137 1.55 1.45 1.46 1.40 P3Y2M12D P5Y4M24D P2Y3M18D P4Y10M24D 0.03 0.03 7200000 2547000 P5Y P5Y 135 501000 354000 376000 15050000 11522 4669 6079 7753 75759 240066664 240066 240066664 84559178 84559 1.75 2.65 1.40 0.84 0.33 0.03 0.03 0.03 0.03 1045000 2.15 400 425000000 6356000 8053000 1045000 1494000 2075000 69168000 1045000 694000 7200000 7200000 7202000 2500000 2547000 6.25 0.08 0.30 8.125 3 69 5 156 171000 1785000 158000 9489000 2219000 1458000 555000 13337037000 0 0 -55000 -548000 -399000 -178000 -199000 -86000 -90000 -50000 -10000 -8000 -96000 1632000 0 0 197000 1494000 2075000 67339000 457000 457000 402000 0 55000 0 0 0 402000 0 55000 457000 0 100000 0 0.0015 0.025 0.05 100000 50000 200000 0 250000 5000000 70000000 15000000 3000000 1000000 0.01 150000 13902 21250 5623000 -4397000 -938000 -766000 4685000 -5163000 0.2825 0.2650 1324000 -1368000 -2209000 489000 589000 -2467000 157000 0 204000 245000 -77000 -1378000 1599000 36000 0 0 24193000 2071000 19635000 1719000 84000 0 685000 280000 26940000 2195000 21783000 1719000 25000 0 970000 248000 24193000 26940000 0 0 8283000 0 26000 233000 133000 1536000 4795000 20562000 8340000 10840000 6089000 11499000 8502000 2608000 3377000 6089000 11499000 0 0 0 1455000 4768000 20496000 8320000 10823000 8502000 2607000 3377000 3660000 3660000 0.2825 0.165 0.1175 <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;"><b>Newly adopted accounting pronouncements</b></font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On May 12, 2011, the FASB issued ASU 2011-04 &#8220;Fair Value Measurement Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. Specifically, this update will require (a) an entity to disclose separately the amounts of significant transfers into and out of Level 1 and 2 fair value measurements and to describe the reasons for the transfers; and (b) information about purchases, sales, issuances, and settlements to be presented separately on a gross basis in the reconciliation of Level 3 fair value measurements. Level 3 reconciliation disclosures are effective for annual and interim periods beginning after December 15, 2011. The adoption of the guidance to has not had a significant impact on the Company&#8217;s consolidated financial position and results of operations.</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">&#160;</font></p> <div><font style="color: black;"><font style="color: black;"><b></b></font></font></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In June 2011, the FASB released ASU 2011-05, &#8220;Comprehensive Income (Topic 220) &#8211; Presentation of Comprehensive Income&#8221;. This update requires and entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income in either a single continuous statement or two separate but consecutive statements. This guidance does not change the items that must be reported in other comprehensive income. Subsequently, in December 2011, the FASB issued ASU 2011-12 which deferred some aspects of the June guidance that relate to the presentation of reclassification adjustments. ASU 2011-05 is now effective for fiscal years and interim periods within those years, beginning after December 15, 2012. The adoption of this standard to has not had a significant impact on the Company&#8217;s consolidated financial position or results of operations.</font></p> Includes 10 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which had either expired and or were cancelled prior to the agreed severance agreement Includes104 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which were cancelled in error in 2010. (2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. (1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement ("Private Placement") of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. (1) Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia. The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients. The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled. (2) Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million. Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included. (3) Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of the agreement. Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform. iso4217:USDadhxf:Warrant iso4217:CADadhxf:Warrant EX-101.SCH 6 adhxf-20121231.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Capital Assets link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Stock options link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Derivative Instruments link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Research and Development link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Capital and Operating Lease Commitments link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Stock options (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Derivative Instruments (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Research and Development (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Capital and Operating Lease Commitments (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Going Concern - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Stock options (Price In Canadian Dollars) (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stock Options (Price In US Dollars) (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stock options - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Derivative Instruments (Gain Loss on Derivative Instruments) (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Derivative Instruments - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Shareholders' Equity - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Research and Development (Investment Tax Credits Earned) (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Capital and Operating Lease Commitments (Contractual Obligations And Commitments) (Details) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Capital and Operating Lease Commitments - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Income Taxes (Reconciliation Of The Combined Canadian Federal And Provincial Income Tax Rate) (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Income Taxes (Future Income Taxes (Recovery) (Details) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 adhxf-20121231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 adhxf-20121231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 adhxf-20121231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 adhxf-20121231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
Shareholders' Equity - Additional Information (Details)
In Thousands, except Share data, unless otherwise specified
 1 Months Ended 3 Months Ended 10 Months Ended 12 Months Ended 196 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 10 Months Ended 12 Months Ended 10 Months Ended 12 Months Ended 10 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Aug. 25, 2011
Aug. 10, 2011
Mar. 31, 2011
CAD
Apr. 30, 2010
CAD
Dec. 19, 2003
USD ($)
Sep. 28, 1999
USD ($)
Jun. 30, 2007
USD ($)
Jun. 23, 1997
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2012
USD ($)
May 20, 2007
Jul. 20, 2005
Jun. 23, 2005
Senior Secured Convertible Notes [Member]
Jun. 23, 2003
Senior Secured Convertible Notes [Member]
USD ($)
Jun. 23, 2003
Senior Secured Convertible Notes [Member]
Dec. 03, 2005
Additional Senior Secured Convertible Notes [Member]
Dec. 03, 2003
Additional Senior Secured Convertible Notes [Member]
CAD
Dec. 19, 2003
Equity Financing [Member]
USD ($)
Dec. 19, 2003
Equity Financing [Member]
Nov. 20, 2002
Oxiquant [Member]
May 20, 2007
Oxiquant [Member]
Feb. 28, 2004
Cbi [Member]
USD ($)
Jun. 23, 1997
Common Stock [Member]
USD ($)
Jun. 30, 2000
Common Stock [Member]
USD ($)
Jun. 30, 1999
Common Stock [Member]
USD ($)
Jun. 23, 1997
Preferred Stock [Member]
USD ($)
Jun. 30, 2000
Preferred Stock [Member]
USD ($)
Jun. 30, 1999
Preferred Stock [Member]
USD ($)
Jun. 23, 1997
Additional Paid-In Capital [Member]
USD ($)
Jun. 30, 2000
Additional Paid-In Capital [Member]
USD ($)
Jun. 30, 1999
Additional Paid-In Capital [Member]
USD ($)
Mar. 02, 2011
Rights Offering [Member]
CAD
Mar. 02, 2011
Rights Offering [Member]
Subscriptions [Member]
USD ($)
Mar. 02, 2011
Rights Offering [Member]
Subscriptions [Member]
Jun. 05, 2001
Ipo [Member]
Common Stock [Member]
USD ($)
Jun. 05, 2003
Ipo [Member]
Common Stock [Member]
Apr. 30, 2010
Private Placementwarrant 2010 [Member]
CAD
Apr. 30, 2010
Private Placementwarrant 2010 [Member]
Derivative [Member]
Aug. 25, 2011
Private Placement [Member]
USD ($)
Dec. 19, 2008
Private Placement [Member]
Feb. 21, 2007
Private Placement [Member]
USD ($)
May 08, 2006
Private Placement [Member]
USD ($)
Jul. 20, 2005
Private Placement [Member]
USD ($)
May 31, 2004
Private Placement [Member]
USD ($)
May 31, 2004
Private Placement [Member]
CAD
Dec. 19, 2003
Private Placement [Member]
USD ($)
Jun. 30, 2007
Private Placement [Member]
CAD
Jun. 30, 2007
Private Placement [Member]
USD ($)
May 08, 2006
Private Placement [Member]
May 20, 2004
Private Placement [Member]
USD ($)
May 20, 2004
Private Placement [Member]
Jun. 30, 2007
Private Placement [Member]
Common Stock [Member]
USD ($)
Feb. 21, 2007
Private Placement [Member]
Common Stock [Member]
USD ($)
May 08, 2006
Private Placement [Member]
Common Stock [Member]
USD ($)
Jul. 20, 2005
Private Placement [Member]
Common Stock [Member]
USD ($)
Jun. 30, 2004
Private Placement [Member]
Common Stock [Member]
USD ($)
Dec. 19, 2003
Private Placement [Member]
Preferred Stock [Member]
Dec. 19, 2008
Private Placement [Member]
Preferred Stock [Member]
USD ($)
Feb. 21, 2007
Private Placement [Member]
Whole Broker [Member]
Feb. 21, 2007
Private Placement [Member]
Investor Warrant [Member]
Jun. 30, 2007
Private Placement [Member]
Additional Paid-In Capital [Member]
USD ($)
Feb. 21, 2007
Private Placement [Member]
Additional Paid-In Capital [Member]
USD ($)
May 08, 2006
Private Placement [Member]
Additional Paid-In Capital [Member]
USD ($)
Jul. 20, 2005
Private Placement [Member]
Additional Paid-In Capital [Member]
USD ($)
Jun. 30, 2004
Private Placement [Member]
Additional Paid-In Capital [Member]
USD ($)
May 20, 2004
Private Placement [Member]
Additional Paid-In Capital [Member]
USD ($)
Dec. 31, 2012
Maximum [Member]
Dec. 31, 2011
Maximum [Member]
Jun. 05, 2001
Special A Warrant [Member]
Oct. 31, 2000
Special A Warrant [Member]
Ipo [Member]
CAD
May 08, 2006
Post Consolidaton [Member]
Private Placement [Member]
Jul. 20, 2005
Post Consolidaton [Member]
Private Placement [Member]
May 31, 2004
Post Consolidaton [Member]
Private Placement [Member]
Dec. 19, 2003
Post Consolidaton [Member]
Private Placement [Member]
Jun. 30, 2007
Post Consolidaton [Member]
Private Placement [Member]
Sep. 28, 1999
University Medical Discoveries Inc [Member]
USD ($)
Aug. 17, 2000
Shire Biochem Inc Agreement [Member]
USD ($)
Jun. 05, 2001
Price Protection Adjustment [Member]
Special A Warrant [Member]
Feb. 21, 2007
Net Proceeds [Member]
Private Placement [Member]
USD ($)
May 08, 2006
Net Proceeds [Member]
Private Placement [Member]
USD ($)
Jul. 20, 2005
Net Proceeds [Member]
Private Placement [Member]
USD ($)
Dec. 31, 2007
Cadherin Biomedical Inc [Member]
USD ($)
Dec. 31, 2011
Cadherin Biomedical Inc [Member]
USD ($)
Feb. 21, 2007
Gross Proceeds [Member]
Private Placement [Member]
USD ($)
May 08, 2006
Gross Proceeds [Member]
Private Placement [Member]
USD ($)
Jul. 20, 2005
Gross Proceeds [Member]
Private Placement [Member]
USD ($)
Stockholders Equity Note [Line Items]                                                                                                                                                                              
Reverse stock split ratio 1-for-18 1-for-18                                                                                                                                                                          
Expected dividend rate                 0.00% 0.00%                                                                                                                                                          
Risk-free interest rate                                                                                                                                       126.00% 2.50%                                    
Expected volatility rate                                                                                                                                       133.00% 132.00%                                    
Expected life                 7 years 7 years                                                                                                                                                          
Issuance of stock (in shares)                                               89,000 16,000 239,000                   74     13,337,037     4,209                               800                           431 337 259 640 116   5                  
Share Price                                                                       $ 135                                                                                                      
Issuance of units, net of issue costs           $ 683     $ 0 $ 2,566 $ 86,443                                           12,750,000     $ 5,727                 $ 9,029   $ 16,095                                                           $ 171     $ 23,221 $ 6,040 $ 8,134     $ 25,000 $ 6,512 $ 8,510
Payments for Underwriting Expense                                                                       501                                                                                                      
Payments for Fees                                                                       354               376                                                                                      
Warrant exercise price 1.44                     2.05 1.75 2.35 2.75 2.75 2.15 2.15   2.15   3.585                     0.03   0.08   7.50 0.08 1.44                     0.97 3.50 3.50               0.33 0.40                                                    
Proceeds From Issue Of Units                                                                                             15,050                                                                                
Issue Of Units     84,559 240,066                                                           84,559,178       240,066,664       75,759 7,753 6,079 4,669 4,669 11,522 240,066,664                                                                              
Price Per Units     0.03 0.03                                                                   0.03       $ 0.33 $ 0.84 $ 1.40   2.65 $ 1.75 0.03                                                                              
Proceeds From Issue Of Preferred Share and Warrants                                                                                             1,045                                                                                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                                                                 425,000,000.00               2.15                                   400.00                                                        
Fair value of warrants                                                                                                         563 17,842 5,218 7,060 660   5,777     131 5,379 822 1,074 363 2,118                                        
Fair Value Adjustment To Common Stock                                                                                                     6,356               8,053                                                        
Conversion of convertible securities (in shares)                                                                                 800                                                                                            
Research and development         1,045       2,075 1,494 69,168                                                                                                                                                        
Non Redeemable Preferred Stock         1,045                                                                                                                                                                    
Financing expenses                 0 0 544                                                                                                                                                        
Proceeds from Warrant Exercises             694                                                                                                                                                                
Proceeds From Units     2,547 7,200                                                           2,500       7,202                   7,200                                                                              
Warrant Price                                                                                                 $ 0.08                                           6.25                                
Warrant Issued                                                                                       $ 0.30                                                                                      
Price Protection Adjustment                                                                                                                                             8.125                                
Conversion of Stock, Shares Converted                                     156                                                                                                     69             3   5                
Conversion of Stock, Amount Converted                                     1,785                                                                                                                   171                    
Issuance of stock               0                               0 793 1,615 0 0 0 0 0 0                                                                                           341                  
Stock Issued for Acquisitions (in shares)                                         446   37                                                                                                                                
Payments for Repurchase of Preferred Stock and Preference Stock                                                                                                                                                                     158        
Fresh-Start Adjustment, Increase (Decrease), Common Stock                                                                                                                                                                       9,489      
Stock Issued for Acquisitions                                             1,252                                                                                                                                
Senior Notes, Noncurrent                             2,219     1,458                                                                                                                                          
Debt Related Commitment Fees and Debt Issuance Costs                                                                                         555                                                                                    
Shares and Warrants Issued                                                                               $ 13,337,037                                                                                              
XML 12 R46.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 196 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Income Tax [Line Items]      
Investment tax credits $ 0 $ 0 $ (1,632)
Federal [Member]
      
Income Tax [Line Items]      
SR&ED expenditures 8,283    
Federal [Member] | Year 2014 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 6,089   6,089
Federal [Member] | Year 2015 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 11,499   11,499
Federal [Member] | Year 2021 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 26   26
Investment tax credits 55    
Federal [Member] | Year 2022 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 233   233
Investment tax credits 548    
Federal [Member] | Year 2023 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 133   133
Investment tax credits 399    
Federal [Member] | Year 2024 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 1,536   1,536
Investment tax credits 178    
Federal [Member] | Year 2025 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 4,795   4,795
Investment tax credits 199    
Federal [Member] | Year 2026 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 20,562   20,562
Investment tax credits 86    
Federal [Member] | Year 2027 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 8,340   8,340
Investment tax credits 90    
Federal [Member] | Year 2028 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 10,840   10,840
Investment tax credits 50    
Federal [Member] | Year 2029 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 8,502   8,502
Federal [Member] | Year 2030 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 2,608   2,608
Federal [Member] | Year 2031 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 3,377   3,377
Federal [Member] | Year 2018 [Member]
      
Income Tax [Line Items]      
Investment tax credits 10    
Federal [Member] | Year 2019 [Member]
      
Income Tax [Line Items]      
Investment tax credits 8    
Federal [Member] | Year 2020 [Member]
      
Income Tax [Line Items]      
Investment tax credits 96    
Federal [Member] | Year 2032 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 3,660   3,660
Province State [Member]
      
Income Tax [Line Items]      
SR&ED expenditures 0    
Province State [Member] | Year 2014 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 6,089   6,089
Province State [Member] | Year 2015 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 11,499   11,499
Province State [Member] | Year 2021 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 0   0
Province State [Member] | Year 2022 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 0   0
Province State [Member] | Year 2023 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 0   0
Province State [Member] | Year 2024 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 1,455   1,455
Province State [Member] | Year 2025 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 4,768   4,768
Province State [Member] | Year 2026 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 20,496   20,496
Province State [Member] | Year 2027 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 8,320   8,320
Province State [Member] | Year 2028 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 10,823   10,823
Province State [Member] | Year 2029 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 8,502   8,502
Province State [Member] | Year 2030 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 2,607   2,607
Province State [Member] | Year 2031 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards 3,377   3,377
Province State [Member] | Year 2032 [Member]
      
Income Tax [Line Items]      
Income tax loss carryforwards $ 3,660   $ 3,660
XML 13 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Derivative Instruments (Gain Loss on Derivative Instruments) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 196 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Derivative Instruments, Gain (Loss) [Line Items]      
Gain/(Loss) on Derivative Instruments $ (1,563) $ 8,071 $ 3,257
Warrant expiring April 15, 2015 [Member]
      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain/(Loss) on Derivative Instruments 1,026 6,778  
Warrant expiring March 29, 2016 [Member]
      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain/(Loss) on Derivative Instruments (507) 643  
Rights Offering Derivative [Member]
      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain/(Loss) on Derivative Instruments 0 613  
Options to Contractors [Member]
      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain/(Loss) on Derivative Instruments $ 0 $ 37  
ZIP 14 0001144204-13-019057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-019057-xbrl.zip M4$L#!!0````(`*QY@4(NT4:H)`L!`,$A$P`2`!P`861H>&8M,C`Q,C$R,S$N M>&UL550)``-3W%E14]Q9475X"P`!!"4.```$.0$``.S]>W/;2)(HBO^_$?L= M<+R>LW8$R2;X$NF>F1NR;/=HUK9T+/7V3MS?+SH@LBAA#`)L/"1S;L3][#>S MJO`B01(@\2@`=>+,MDP2J*Q\9U96YI__KQ\K0WDFMJ-;YE]>J;W^*X68?7K_:?N]-7_]==__[<__Z]N5_F%F,367+)0/`>^5S[^J_L_[[]]]A]7 M)KU^;]`;*O]W?_C3`/Y_7QTJZN#=2'TWF"JW7_[_RL-&^:"YVKVMS;\[2K?K MO_B]YL!+X0WT=8.>&GY'/_E@S;T5,5WE"P"VU.&W+[K[A.M_7.BN92O_S2%0 M*02SK87@BR^6N=`V'>5R;>N&TE<["H6N/WVGPO_O*Y=?^)(_'FQ#?X?_5P', MF,X[;?'T8_F75T^NNW[WTT_P+V*3'[VYM<+]#=3!4'W%?VGHYO?@AR\O+SU\ M2\^R'^&7@!'\^@$VZO\I/__/E\]W\B:RTKFXZKF;.8[#H!V#?_KWN6*.!>G'H"?8+_X$%6=MD MCKRS]YG93YH]MRV#_+34YFZ7_%@;FJD!=3>?X-_^B^:69[KV)HXVA\Q[C];S M3_Q+2IEN7^V&M)E[M@U\O>\Y_FW"@PNB)S\#7R3\G/R8/R7_'K])>$`WGXGC M)C_"ODMXR-3TN9/\#/T*'U'CCSCZ//D!^"+IY^[:WO-[^";A`<_I/FK:.GAF MJ3D/E++\BX1=_#`.\,__?(XPM>?:!]@&OGV%HHMB\,ZA#/Z-+!4J%N\X3QT6 MGI_6MK4FMJL3)RJF]`7N9@U/._IJ;02?/=D$5`+5#%U?"_1^.(M7/_D:[
[(W$7%%-,N<_ZE#L+`?_C[I?/[S?+W_J![1]9=@&SR*OP]:#[=W83_ MUA?X">A!6Z';C>_.)]35]7^]^FN_C^"IX^GPSS]M/XPO_"EY!4"&;BTB*U+Y M=^$#!*W;GW7[@_#I\%O_D_#YGV);SHB#W^]<4!FH^3_^X0&`5]9J;9GP3^?R MA^[\?KD`[0_8U8Q;35]^EQW M&2S*0H?OF8GE\O#NX-9>_=7_V<$]_OFGQ.4B>(]`5FM2PS]7EGGG6O/OC2+O MSK[:0]++.3AUGH$^P8T+7A5^;9,G1.0SN08?=$4:1>K4^VT/"]R"'27@>BV: M)]A)6VL/82.\_H$L<:L?/!M"Q@_DF1C6&I^#%SPV5L!3;+KNS#`8=O_NF<@, M%^*ZJA?=_J0[&):``^FJ5NRJ"D-JZ:HVCJ325:W*516&!:2KVE#"2E>U>E>U M,&:X\AS76@GKJ\(F;?<#4"'JL4?0$/T^`'H1/K"#M_#;O/$F_=OR_=OFL(?T MB24;2#^Z7#^Z.6PC?6_)#-)?K]9?%Y:!6+PW[(OIX>^&.<-^43%O!`?26Q*&$E9ZMX)DHXM@AD__^!AAA:E0CNJ6?P\X M@/^OIO?OI]M(R\N_WT*:]&PKST/7E3>D*RQY0/K.U66@Z\HSTMF6G""]UH5=_ MI5VUWZ7:5PGQGCC,$,D6#(`4@DM0AB`9=U-"B@67D>%AY04-&4]*'I`! M:'4'.'7E&1FQ2DZ0(:XX!S@UX)Z[.3$U>"/E&JIX+Q?/.'W+J1EK1#?B!W8) M^Y%4WZ'Z;YIM:Z9;:WK[7\?V(FE]6O390.U03)PJM50].+>>&DY,GI6:]LQ< M3NNT:Y:LC]2HXG)H$[5HF;PI-6=!&=#6:=0\OADW!0R-4)6;5:]:5&D4@MBU`;1U)94UK)I4:16$"6B#:4L++BL^)+ MC44R`[^4/R9'^@9%<&@C_8'RF5/Z`#GS9?/M?OE,*FU]%2?'S?4!1#A` MEKY!^1S=2)]!'&:6OD1)?-Q\'T,1IDYJO&2PK"`;'O<4,+* M+L;5CY=>Q:&U-+A;AQ)I?]< M5>Y9&!:0[G!#"2N]V^ISSX4Q`Y_`#MQP1];B^:I;+CZ@89;5Q9\5XN)SO`WZ MW:_6,Y.B;X2RRRU`M+FW-=/1Z,QVY_TF^@T5J9L?^A]>;=^60P4;[/T`=]3?01^BWNZ/BS+B@V'(9A_(@WL-;[<]!)B7RINZ9=^1N0>^ M"SSY3&Q7?S#(5\LE->E)O+NKL#S]Z.;*(>]@F#]YX_G'H>`V.5O:;5A.TG8H M$TZ5'PG7E3?J9W`%,H`-X0&9TJKN2+BN/"-S8)(39-),G"/A&G!/[+8<_-KQ M#!=0]HG4C362+J,E[$=2_;2(I($<(W(;:/6\IN?2@XM))IK'>>* MTU)/2YD^23XN+A%O'P8*U#Y&\G29._Z2;FCD')-6S#5D2X9.W M)&F?:[1><[X1.6"7_%M0S-YHGBT_;)=\6G+DWFC^%2=XEWQ=7/S>:!:N)(27 MW%I%%-]H/A8LD)</Q;&F/YT"56JFRH<:$K7C&9GW!VJ_UZ4 M%Q)E!!G=M3NZ$X::6*5/!LY;UY`19!B5"L_T:<$]C>DJ*T[JQ!E27S?8+BUTDYPH0+[6. M6]O2;+^N'"J;[8M_3A.GU[QKI%#- M&6M`>]EL7_R`7?)O03%[HWFV1^-9N%V-=NO*[?* M9OLU"^0EAZ<_2Q:=D3*8\R8U*X/,HLB:"2*';P)3,C@LM@\[(A4@AE!J1(*6Q+ MUJ,*.9*9CDI[_\@,2'WN(]8J$I.9D5K+;],R)E)^929%./F5&9::2:[809_, MO-149IN7D9%"*S,U(DEM6S(X(LF=S.R4U0-7)G&$[,A3JWA/YFOJ(I5-2\U( MJ919F)*D4B9J=ZY@-(6^6:Z8-(VGJ^LR&D#J/>M2&L4"#W:VR'!HQ"9O-V6P( MR7/SL.O'#-Z#HR]TS=[<:0:Y65*>/Y0=:;)?MP\79>0>I%-9*&/6SPNM`3,V MR`6>?/GX^U#M?B!S\4+XK> M!=*0#>$!F54H,:O0$)Z1:0C)"3)O46'>HG[3H?&+-UC%O MR;=/)9\6'0FWCH.%J::5O)T^3O^X6AO6IG:-;SHV+X%[%Q)I"\YM[JXOP4\+5@60')[_.:UH%=?MR[_ M;N$@Y]OG\B:K0(T&!"&UO)C:.)+*>Z;5=:\2A`7DM=&&$E;>`A6A>U6AS#`8 M^DV"QK]_(`_N-;S=]A!@R@%WQ-0M^X[,/9"!JZUI#?4@^^ZN_*@EQ>8*)^\8 M6_`,AH61%WM`&92\XD8B8PS?!H7UP8K@0#9HJUE/K&KCIOHR9OT"K1HP8_E1 M7F$,>.4YKK4ZBP/;R%%Y)2S'61.6.XR05\(R@1$^DT?-^$@WQ,AO.2[>J[(, M?:&YENDKH(;PRX+H[[:V[#N(R3O/1>-(YLR'.7^Q+<>YM:TY(0NG/9R9L&W) ME@*QY5?BMH\I=S8M6;(LEF0!17_H9_82DSEA,-7HM$ZF;9;@PJN#;K^`!`\= M$1:D5 M9^1AN>0$>;I>X>EZ_;BG,:W$Q.G850.JRQ[+A<4NDG,%B)=:QZUMZ;%<5PZ5 M/9;%OQ`J.?K<6+-US-NB'LMUY5/98[E.ESTE;Z>)T_>4;3)*7\.;;.*XUX[C M@4VU\;_:@T'>;^XW:T*?IQ^9<\)(?4LA_03FMF:<'6>@XDLYT^+79^;#:)9\ MG6LF0LJ$P$D-*9N-D5]_7KF!FZ$^[7[0-,L.D,5?OA;P2'R/J MI(LQRU1$HC;:6:]!\ZQJ(X7Z,F;]0HL:,&/Y<4UA#,B;T4A[5TT+&*#KJ*N. MTZ?H=A@AYZY$44:0G=S:W;/ M_6)H/ZR[E>X^_9>AFW7)5^WG`ZX2DW95"A.H_4S'K?2!XHLE)D(=MNY*3K8S MZDDY%2:31B=\!,VY-(0WZI=S$2CMT1`>D.>_U?5VJRO/R`-CR0GRA+G"$^;Z M<4]C6AB(TRF@!E27O=T*BUTDYPH0+[6.6]O2VZVN'"I[NXE\A59R=#ZQ9NN8 MMT6]W>K*I[*W6SVN7TK>3A^G?URM#6M3.TY,(GA\*Y+6N4;G->43D0-SR:\Y MQ^2-Y-'RPW')ER5%XHWD5W&"<,G'^-WI/VK&TW5LE15@67)UKED%*1'B)BFD9#9%,JOLH=XT:90MU*4$EI\I MDI)9C\23E-BF2&S%_=.;)IRR?;J4P^JR?U)":Y1,E+(KKNQN=R<5ZSK_5I>R MDCJTRMOYU7=$%(34\K)]XT@J[\Y7U3M=&!:05^$;2EAYL[WZWND%,\-`[7XB M#\@,%[+-=LTZ&U?K5%YT^X/NH(Z,63\OM`;,6+X+7%\&O#:?B>-:]F^:;6NB MMPZM`Q/R-%026B4;[F7#WYXL@[RWK>_$EBR8#PONH+2^[,>;TY[#?VWDI[QR MVI2N67+:.XR0=>*[:4_=PE2Y;)DMQCZ_L3!B[$/?V[P)[V M@WYA7FN(@]^_$9I,NP6B;.[!,7>T.68MG/>;Z#=4"&]^Z']XM8F(TF_,E\WX M_LKP#8LA\O#+Q]^'_>[?/5,\-M_5#L-8_C2%=IATA_W\M<,6TAICBVIB(P3E M`CFWJ]USN\3A3'XZ*#54.7RP;:GC1,WYR/<,HLI3OI:?\M64,>4I7P',6,DI M7S$,&"^S%SV&R5;??%'.W82+1ML&0=5S0WBC?NI9(`W9$!Z0M;0%<[?JRI=R[I;00;CDX_SC[T:R;#OF;M65.^7>:7 M9Y#R4&DN0K)^*?D*R>6"YC0D_U><]Y"2D9]D;'=BN0*4P8O-]SJ8[(4^UPRP MWF+SZX'N*@=VTRJJ;\]`$.OB]];5]Y+F0,A[W-6WV1"$U/):=N-(*F]95S6A M21@6D)>F&TI8>0>Z^@E-!3.#.O.982H;\I76D&^*1%5G(A*UB;J^!JW/*C$T MA;$A[YXOE4LU75\I7;/D0W88H9@LV%2H;,@.TC(FD:;EI`ZG,GU2>1N\NO*& MS+=('I`)FNK:X-659VKIY8OE:#>$$V0*2(0V>#7@GL9T>Q"GJ4(-J"[;X!46 MNTC.%2!>:AVWMJ4-7ETY5+;!$Z(R7G)TH;%FZYBW16WPZLJGL@V>8-7IDK?/ MCM-KVA]"B#8,-:"U;(,G;F`N^37GF+R1/-J"-GAUY4O9!D_H(%SR49Z6Q+3I#>>87>>?VXIS%EA^)4]]6`ZO(^5F&QB^1< M`>*EUG%K6^YCU95#Y7TL\4O!)$>?&VNVCGE;=!^KKGPJ[V/5J3Q,\G::.+VF MA8I"U`/6@-;R/I:X@;GDUYQC\D;R:`ON8]65+^5]+*&#<,G'^DAR(E=D.MM(WF^K(IG\(9X5.A$B'Q_!%# M0X;\T2[>\LH?[>)-6N7B$XB",X"TY.5:\I8PA[3^[;/^PK(V\VL'H^[?/9-Q M=EKNI-2]66-VO1[LF9DQ=G98AE\XZ0Y&184OIY`9A-7\HOW05][J$K:VJ(_3 MDYK>7#GMW6A]R>H],7KX1FIJ\!8@V]V"U M'&V.BL%YOXE^0T7FF[;Y;CT#N]VMR=RU['J(2_H-^A*3O,]RS.>TJ_8S,0H\ M,!6-4=[;A)B`O_>>XVCFPM:;RBE[-MI*5IE)G=(@G3(3C5&D3FD1J\0*.85W M[C+5"L(#952_1A.]LDJNFMZ.M>4-658G>4#6X576V[&V/",+]R0GR$J_"BO] MZL<]C6EA(DRGD#I07?9V+"QVD9PK0+S4.FYM26_'VG*H[(37JDYX=>#3)ERC M%^&V>AUH+;N%B>OJ27[-VR6U@+NH75ECME MMS#9+:QA''TP_F*/7,.+;>*XUX[C@26U\;_:@T'>;_`"`GT-_DLL%C4\E_U<5?L,IGAFV8^LM#JBVYB5R8>D5UY(`'F?',Y M=_5G@/P]X,XS77NSW94,_1I36^B:^<$R#,UVZL$8P;Y#)H@AX)R@BI?:'L*@ M'T<=1V1#F8VU`&LQLT41()FM`&9K*E-)@I]/\%^=1I-Z:WM-(G(._DI-B"^R MI](.!CO51VD`@U7MG32,P?J#[A>-]C17?[\R-,>Y6?[&NG+?V-_PV(1U'\2_ MX*LE8;%GO?J2[]U7T'3PX/8*)[':[0^[_4$9)#Z<88GCH1[$/9)'22*P)"M8 MC0\\E?B-/!/3(Y\/7!!= MRU\`D)GP%A]7D//LN+&8:-L.?J?=0<2_S'O"EJ!(V.6=:5:9B^,M;S<[Q%N& MD9KU4/L'QF%6/GA7.$8`?R%@!#D629RQ2*5E5XU:M^ MW!,[D:W3F<">`]CJBC-RL`94EV.' MA0VY)><6%W7,X5(127'%UH/-Y(&YI)?^E$/BA0[" M)1_G'W\WDF7;,22^KMPIA\37)."6'!UP]!?MGY:-75.F@M&RCLR M!Q*Y.G&V&R[7@S-3;BSDT9T=MIHOY)P:<;J_ES9)HH[<>6K3^,9P9]6MXR5W M;G-G4[E0%N2(W/ULQK`D55[6)(C(Y933O,I M:YI/`WA"-N%N)]V9YG3N+7S4UK"W9$WLSU$.V+\UR0N'=,"-V11+L+VA5M-] M3\PD.I'/"'Q:1=.HZUU'FJ8,'9I/TSL@R\+#AN'^X>L=L9_U.;E[TFSR7G/( M`@^/`:<:VK=+P[#F]*^;Y3F0E>K.?:H1U$/ECK@3O@_B>VG MU32_?-'L13B.+TS"U"1ZB,&?6-H@8P7U=U;;>:_]N/3<)\O6>3-]_Y@*2X<\ MU]H$/ZL'[9-W%=PQ.KPYR0^[_/")+-!$-HH-DOM;-N=XP!MB[ MK5;Q`)OQ)>HPC:T97ULXR'?>NIR-4>EL##%)+4==-(ZD?+6\<;%7$E)?H2KU$5Q69Y9TX<:JT2[M3(@"SR2MN M;;GB5A6S-96I),'/)WA-+G`(?+E"`!,B[Y,U^?:.``PFKX=)!BO`3,G;7F7= M]A(K$?;5,A]LZSNQXXBH!W4/]IXZN+,F$5;>RFLX&>4EN\:25MZ9JQ$9]Q0P MWMD?%_0VQT)W/9O41#0/5R\F[ZD%Q`P^_FPYSA4P\V9IV5CLWPBR'MM="P@, M;N$WLO3,A?9@D&OSF3@N;@A^=V63A;_C>I,YW1Y;0&QZF^_:<3R"M_2:0-JD M';6`D)?SN>V1!;\TV0A=G+BE%I#RD_Z#+"[-Q;4)ZS[JH*$N'8?493;UD5L_ M!_?6`N+^3;-7EJG_B]Z5;HY!W;NM)I'TU!QP<`H1W.>-G^K6@P&*RQ0?!2%^ M'A'>*HY?*(TBLTEL%V+R_>:KAM$F"\30QP%%^G\\S79)39@H>2]!])6TI1:0 M\AN9HW`A?A=-H./N?FI/Q'[W[YZ)1!R(>T%ST.U/NL-^_CB(7U06"P-;-WL' M66_V#LJYW3V0=UK+O]/:$-Z0EV`E#\B;=97-@P09<2]Y.$Z?7=-2Z$!/-:T#KW*+SFO*)R(&YY-><8_)&\FCY MX;CDRY(B\4;RJSA!N.3C_./O1K)L):&WY,XRH^Y&\JU@`;?DZ)"CO0='7^B: MO;G3<)(952R4$7\QM!_6W4IWG_[+T.MRM7CO=GS2)^ZJU1P@VZ&6V@ZU-GPA M^Z>*TY6LM`Z'=>1.V7"U+0U7:\.=3>5"R2$5<$A-FBX*W!"Q-EPA>\"*X&U) MCLS5SVH`1U;M84F.C%A.V66VK"ZS#>`)V;VTG727[4XE+\C^J&V@^YZ8270B MGQ'XM(JF4=>[CC1-&3HTGZ9W0):%AX>R_O'[';&?]3FAW2C?:PY98/D`X)0V M2+LT#&M._[I9?B-SZ]'4_T46MQ04[%KIO-]\(VO+=C_K)F.57XA);,VX-!>7 MBQ6(D@/&$?UCWARQ'BQ4-)9"SDR%KE9S[*VAF5^U%>&E9T"$2"3>[XWKP5'1 M7?@.Q/9FI">1@M[JM#D$E^%C"H(/^@TB^),MZ]V.DWS8(*7^R?(*;`_9%(J/ M&R3DGV0V.`W%)\VA^)W^0Q+\&,$GPP81G#P369UZA.1J;]H@K?X1T[^2Y(=) M/N[U1\TA^5=Y-2$%Q0>#YE#\7FKU8P2_:%1`_M&0ECR%)>_W!@URU^]?B"%# MM*-$5WO#!AGS^R?==HF4=2`[NW]W#5_:Q''9*),;&_^+0P;?A\-_Z$?FG+!K MPNP\*^('B\X6:?<9'>IR8+NMYIFC=3V\(KFF-0,'BGW\G\3V>8`74J\IZQ0. M\-LECK(-%%&D#-NI-Z/%]I5XZ?EX%:'DL(HT6ITJVT31:+*:[@2-5B=&JURC M20[;NLT:#N_D']1IB.>1"9H'=B1IGT3[7TW=Q4YEL*C3'/KOVU6K>2`IG;-U MY[_?&]<_I[.U)UDVF9KX#3B#W]J3+*%,3?RIVCCBRW)*1G[;6GAS"/+X+07* M!I_A#],A"_YE36B?L!.?!Q(W).F^3?<[[\'@F+HG\R?3,JS'3?VI?V!;K>:! MH,7J+\1ZM+7UDS[7#&8'GC2'7->#\GMW$1B`R&8DO0_06V\4P75)\>,4;QC) M)-`]N(9(K#_;2:YCBY17=Q=Q]_S`UOH9N/ MGRWST27V*OR*8:;[7OMQZ;E/E@V;8HQ! M%MBO@A]9?_RQUNT-KD^__`?1[$%_4),\8_(.`[Z(;O2.WF>2W<^QI3?K/",-O/L(DOQWAMW9P5&MI?6M;S[HY M9_5(3:!XPH9:3??8-9@Z7GX]=`5&7GW-0O6Z77M-0WEYZ16H?^G\?K.,TK\< MBJ9$FVX"8BBBDW`0?ILS#L(:<=;S"H?36";\TZ%"<;E8Z%C6I!FWFK[`:W1K MW:V+TW-P:V$5\<$]%B$A8I(:B]PLDS;?:!1Y=_;5'I)>SN?>RC/@)XL;]XG8 M^+5-GA"1SX0YB(TB=>K]MH<%;FVR).`$+)HGV$E;:P]A([S^@2QQJZSY9*2. M'5[PV%@!3['I)C'#GA9?OQ^<1?][;`C]5@N$>C#&&6V[CJX1CY$2,1C<(3^* MR(8R6[3I8RN9+6772\ELIS);4YE*$OQ\@@<]V)M)ZJWM-8G(.?@K-2&^R)Y* M.QCL5!^E`0Q6M7?28`8[VN4[:"`H.N,<:.C-2+J]H5:1\4;TA@99R5AH5].J MR+BG,./._KCX^&--S(7N>G:]FMOLJ\U(WE,+B!E\_-ERG"M@YLW2LK%'?"/( M>FQW+2#P5\O\1I:>N<`I2M?F,W%H4PWXW95-%OZ.ZTWF='ML`;'OGC2;T-%9 M5Y;3"-(F[:@%A+R&\M(.[?-'MEF?J_:!^JYAC4O=MJ$DD/SE/M]VK25R'---5&1J='R%>7 M>Y7I1B`W,$ETA'YUN3>6;IIQH9,O!*7@L$$:])/E%5B^+R@!QPT2P4]ZD3/D M125@37KUI"'@G?ZC=?1KP`"PD'[DF138J5=("JJ]:8-4Z$<\^VH9!<>]?DWZ M.::AX%>]=8'@N%>7AL.I`HG6J="+1@6"'XTV6D$(YAODB-Z_$*-UL82J]H8- M,H3W3[KMDK9(HIPJW6!:-B!&+'-(M-"TE#.?:T)-.6ZG$>-V:L@^-0EFQ6&? M`J?GU)!]:N(LB,,^!0[#J2'[U"1N$(=]1I)](NQ3DX(`<=BGP%$U-62?FB01 MQ6&?`B?/U)!]Y"`9<0;)U)!]:E)/*@[[%#BG0X@LGFQ9W2`BR@[4]23F)TVW M_ULS//)^$_SY-\"J9L^?-I^Q12%3\/YWU^;:J0(HD_>N/,K0S?UN6;<$?M9 MGY/+1YO0[^O!)UNH\..21(SDH9Q2(-6'X2AN)4LFL>0'S=4>-`>,BTL>;=H6 M0+)FSJR9&L>211-9U/8>;SWPC@"%.']&=R57YL&5!]#:9$8$G-];M'P14>]( M\_TN$2/2?->!)9MNOD5@36F^SV/1YIEO(;BR)>:[%899&LK3B=\8$RA-4@[, M4&-C(Y7_:4D$T>F:4PZ@]L1+])IJ2KRL'F#MB'=Z/:4J[Y)DJZ?T$2;9AV)# MWB7)R#[R+DFTFGLFV2=;-?=,LD_(/L.:]*02AGU\A$GVH=B032`RLD][FD#< MVM:S;LX)+=MOO@.=L%WI1I?.2HUPILMGI?:XU*E9J1G]C4IGI19U.4K/2HWH M=50^*[6GXU%Z5FI$WZ/R6:D]W8_2LY)TNT]B)>EV-[0?4OFL)-WNAO9&*I^5 MVM,A*3TK-:)/4OFLU)YN2>E9J1$]D\IGI09V3CJ;E1IQ8%L^*[7GV#8U*S7C M\+9T5FK1$6YZ5I+9;GF<>W8U0"/RW&56`\@,=T.9J'Q-5'M6NO(:D< M%DB)!-BD[2+NX2-U-IMT^[-N?QA!:^3[`.@%_R`);^&WN>!M,.U^(@^(MZ&P M>$/@NOU!MZ^FQQM]8##-'V],=:F3[A?-%@]M,9D#'`R[ZN14F?M?W:Z"+525 M.S+'JW.*TNWZG__[OUW_O^K_[]-_W_Z-_"`?QI.+Z3^^D3_TO_[/K]?_+W[\ MCQ?]>3X:C>;C\7A^__\\_77RY[]]_//HEU_43W_[\SMU^FDR5C]]^MO/ZKN_ M_&W\EU_^//EE-KGF[V>`>+@R(MYYTFP":HM_OF+=M/[*V8!^Z0/O?^?_&]^1 M\,9?[S[LO$YWK-%`O7@'WV5_V^^`QM_O$)3@O0O]&0CXU\B/OWHK*K] M[G_]^:?M9W$A_.P2/EC@AY\,[3'="Y>:X1#VQMC3_BO]96ZI+OK(]'2Z5X<& M,@YQ[%7;ZWS2G;EFH/_S"3YQTJ\47V/K-:/WS[^CW+_ M\>IO7V\^W_QR_?%.N?YZQ19+>F]\S2N"=P>-:W-!?OP7V:1;-&HR][[*7X?U M!(\0+1.?=:-,MN]5\2W]1@SCOTSKQ;P#L;5,LKAV'`\<@53K?;6B6]KSJBT4 M,JB^D;5ENTA:""'2,MT_4+,=>U5\N?^V#,\$'VSS23>(G7*=^+:V7A%_/_WL M"K#Z:-DI^>%NI1GPD!+`K5Q9J[5F;J*+QMZ[A4%KM;+,.]>:?ZJ"']W_\T^9ULP3R)"3^H>! M',]&%Z!YA`!5/0+J8"8,J`>8$4$=#/O#\T"]MX3H[H4&.'PWB:R>NE!,LQQ`QGF6'Q?;( MXK.N/>B&CJUB`\:F8PY0T#7*06\$ M%@/?@YCSDW?_P]'?F;KQEU"024Q%[;ND,^D"6>)X)=\E:>`8'WXH.'`S"VG\C%-^V/ M`=U;"OY+.^U M'[F0;C#:<62RP%`T^,=(DB/X5+B>+&-!;`=C7SS1)[QJ0VC0(SJO#N"F8+TZ;./6)DL"[N>BCHCG6C=9U5:W ME\&0)H=A+Q>'E^\.XP%<,3#4366D!UT(E9$!TR*KC/3;$$5EG(3XLU5&@3++ M#Y4JU1L1&.JF-]*#+H3>R(!ID?5&^FV(HC=.0GP]],;T"`RCK6.V8H"HK^(X M!KI@BN,HINNA.(YM0SS%D0'QYRN.4H1V=N2`<.NPLA@8ZJLXCH&>47&H$[4, MFI>C/@;]ZKM$.$()0G`H9#2;5PY]1CPS& MTS+H7HX>&0J`?\'T2#;DGZ]'!N#Z%$^$(X=8LXM9TKSGHU!VZJXKV8PP"N44].=P#-R_ M4(M+6`1[&A^]%7%1@EH;%ZA0AA2-5>\@HT(9J<-^<0%/>KS72:$ZZ10:E,Q?PKZSUC3FI35'\*^G,HJH?U9L5G9(^U2NT"9QV0J!*%"A['2#JV0'617*3E^] M:O!>)X52FT+[4]"?AT+9:=57R*:.E-J#BS(NP<`76&M?DHN2<\E]21JEI)+[ MFHMB'):=IO''%LT=P*R-YK,`&!'ZK]:M M9I_<2C@R^"MEU^*,ZPW.78_-9J&#=Q:9=[AW&,PTL5-Q=*V\P!F4`$ZZ>3DY MHFAK5$YN@)V-K#V`?0.]9GI[VGG'YQD=T2L1@?5?>N)"1_3#.0LEC&8];RV' M:/85ZM=9T&Y^_`F%_S%F:-^8$[OY^)YH#KOO#FU._,ASAI%LH1H..$ M*AR@K$0;\5%C:0$[+)B!`.9L*0^NE2]866Q=H6!EI:0Z[*+/& ML>3LSL<#>.6.F&9\Z$XE@5D5Z+RAR(K@;JJ.MJ^[7L$%%2U^!FJ M6W^6U;4)=*3C@W'`Q*U-W#U3+C+1:KK=EB3MTD6!^_N5H<&;EK]I-HX5OK&_ MZ8]/+LTLT;_@*S!`-)_D+Y4J-ZD.Z[)-_M']BY7N7+@V&[M98SKFP\$8K7!@7IBGKL,)N:Z([[0DG1H9V= MJB?JL;ML.D+M;S6>*7UGV?W1<7Z<]HW0@Z1[Z[/NZH\:\L4=<5V#QIRYQI&I M5BP"Q/0Q98D@9O=Q!]-DVY`:V&M8V2:.FUM4&0%FZ]WG+9N>8&*[R^0#R3&.'!<)2E;2;$^\3@'.M?D,Q&-)&?PN M^NOS";45-1Q:+$>@CF*I'*`R4V\ZNS@)LET*YZ;=INK6-?"]:^4%T/'P8%0X M1%DI-U:WFIBD@XFXZ7)`)X_>BZUP[M*E]'PM$^*,=6=5X37W<3=E0G]685E% M:,Y]*M89^Z"Z,?4DK.%6V];\%A9=^+.!6XGD9\2H2&*?#?2J9/YD!.<@\$4) MWI%KM]W9N*B%ZR7Q.5^LK02CXDI\H7=FJT!P#M?N"Q&\X_.FNNJD/RYHY1J) M?/Y3I2K!J*`B7_3,J"H0G,,MD<(D[UBERV"[K5U^*]=+YG.^G%H)1L65^4+O MG5:!X!PF*!0F>4?KRBZ&@X)6KI?,YWQ]M`H0Q1"<4J]4%L>^1T87==6+BUE! M=KK`B455@"N`Y)0TBZ@*T,40^E+G#14H>D=&@G0GTXN"]$V!8T"J`%<`H2]I MP$<5H(LA]*6.\,A3\B9?(J4`QV5^/,O-.=]:6729SP9N)3*?$:,BR7PVT*N2 M^9,1G(/,YRAYL?*?8Y-ZNNIPNG65*+^E11?Z;.!69^C+'KQ3!>B5&OIJ1NL4 M*'I'QNETU0F]NEO(TO62^IPGYE2"47&EOM!A.%4@.(]3K\)$[U@UJSHWC+7L23-5 M@"Z&U)=:QEJ@Z!TK9!WVU7SS]V5,C:D"7`&$OGZ5K.5,?ZD"P3F4=G MO(S5K4X?^:U<*YG/>XA+)1@55N:+G<]2!8)SF&H[S;FL+?6%\,DTWP*!,B:O M5`&N`")?OTK6/@KX/ M@F*!SPGO:8#_0,`AG.NT'1OVB5Y9MJO_B_XSU\9K!];)#YST#=D*`B=SH[91 M/V[94L+E=PV;:\Y3$6WR$MY__O+IJ9/3\IFIH4[C!VI'X/ADV2!XYI4'88HY MW]S;FNEH[BC7I:U"X0Y/4TK`SBSPSF[=&.NU?'$?5X1?@5V(`#E:2-U)V M0%+OB/VLS\';L:\,35_E0`5U$"^HS+1\D7`?G58R$`7NS+S0'TWS@=T/@\D" MTR-@OW-R;-5!W!HGKY,+),=P=3$J#I+LA!M,LB+FVIS;.$$*5K#9)*E@)`I/ M!IY/KNF6"!]=,G<`C_D<@ZUIV:6`F#T5M\5LV:#\2MPK<*1O;>M97Y#%^\VO M#@[C"QZY!*?JF8ZF/9_BW>%@JUU^^M4+@_DH$\QVK^R4#W-FKIB.^[O=-$^` M^U;;4-_JWN*3&N%Y>,+=W!J@ZD'I8Z)[G7N___3+%@9L>I^L$F"S9S6VRM%/ MA!H'T)&%\\FV5G>:`=:_)(9(OVYQX&9@B6K`S9Y^:,C]-\++8O(?]/=IX6MO<`+\9EOQ'%M?>Z" M9PFF)L<\RL%U\@,G;,;J9N?2]Y^@F`=OL@(OF3Y:Z-B^72]W0-3>/X/T0 MHQY=OG#@SU`)50"?/1$_.:PJSML$/*"9C_J#48BC?FRUO$$[@Q?R!RTKI2?' MHO1#(.Y)\3`MDG,R[WAF*6'9PH!-3_-*@,V>U!U-=XH[3P`[:EI\3OIDV32H M^Z2;FCDOCBLRKETLV*- MMV^1G`!)3^;<`9?UAX>V/("[KQH@@^&@T%E3L<`&-U.@77R`^H`ZOP-^84Z*$I9!U#G;\K+@#I? M8]YG0!<)\5DC&_;IC]%$+1C19[6=3],LM`"0\[7D*4'F?=H6__3XM;5[:T\W M<9K99>_8']H6:"R#2],9@8T2)O6C:79X)"45MS:I5RX,W.)ZR-=MJZ-N!!^=WE.(#AUWTSM!O4F``D%@27OF)+U\[\WRYL7D]@.V\NQ M_1>2W>`9F9.!CAER?/S),A;!MZFL8(%A3-1K.@1-N/`GE(H6_JEWW`V0V5%`>D)59VD M-1')4!_=\G]KAD=.W_&1&PC\4/!4"(J&OL!`8ZC6>>=9+_WQ<5$UW6U^YJ"F M"#C)@-1TKSF;G'.PD"7$B:QPO'1_\B6*D2/IG^YHZVCG''#*W%8I3G9#D)'5 M76\J3U22=*H!8@I/3=4`!Q4FL`YA)_U1`CS-S1OB'-PT_FVI@]^`D*M)N'HLQV63P49=%CL5=D MTSVI=$GB38MQ9D\E!F:)>\SNITK\G&U_SK?.0J$CM0O;;C0E.;3MQD@V][;9 MN%+/WYYZ,1B(K5B/N:\%&Y[Z(ZAEEN?5>LD\=1Z M6Y5;793$5]MM5;Y55`(A+<.5;=ID\NR@"G[M>`9.V/M$4A6512]39(6SK!WF M9I[:@YVT1BDS1NJ)CG-M44O0E,$$M00CN5B>AN!J7W"4>7O^)'FQ]UB=U:DQ M?EIF=XJ.@5J"IO;9G5(BGMKB:N\=F_.V-YR)HU9SO'Q]7:\/:I-O9I"]0`JEXB],2U*2U-EG044],G&MHFH^A##:F M^2D137_2T+*(YRBTRHDF#IO9%-!D8I_41S3ZKD\EK'ZD7==6IA4R*:HDU-\S'4JHBF%`-3?S3-\C*=JK!%53,1(IKZHJ=E$-%LQ=5B7K(K18Q7;1%Z&E7/',4':USU/>JB&PI8Y':,16O']J"F]:XG\>Y MI.WN9YZ:L_G(D.YG#KJ7/7(-+[:)P_O4W]CX7^W!(.\W]YLUH:^A'YESPG!\ M2P"!BX_ZXU.JKOE=%:()86^EJ?O&96;V/@:BIMS5(L9DM@@]+?/@BQZ,V1(T MM2_0*6489O-P=;)+H@Z$C7N*L#@M04U[0L*B#4WS,=2JD+`4\U)_-`UR*R$: M#T35H0,1`IH:XZ=E$-)LXE.U3C$3+*TUR:1AT MR9W=.Q2__U@R/G+#M=-M(*L<=J6EV$<)5X"9R,Y59$"#R MWL_FVUH2_$RSUQ3B9S!N3=ER+B:L2&0P>W?HIQ]_S)\T\Y'<+&]>3&([;)_' M<*/.9K.4QC;[XD4#?HX";^JF=S1W4S>:6ELW%0%):KJI>\VFGPO%0BJO^W(. MOW>H]G$2MW\%<8NU^GW0[WZUGM%"#7[_1NC^;C7;W=S;FNEH<_K\^TWT&XJ. MFQ_Z'YYF[A:V[88+_5=_'8TF*8.%*-CY[35NBHJXW1Y.(6_DW*PZH27,68%M_@MYA9IGXZ>\6A8)^3DK`\3^:5_D4HF1$') MN8'ZZ:BJ#XXR!/%M0$3-'[)L09XXVE,5>0%6E7;+2XEWS9494_DMP0Q^27^6X*PDPX* M6H*;G`\6&H*UT1%5/)L.FZ2*SPJE)*JDUG9CB_%VQO M>[(AU"I<+IZQ@Y%3`RQPZ50ONI?>(T/$9_*H&1]-5^=G!W=/NDW>Z];\B:S` MQ%T^VH3N.UWEPKC:C?7'D>)1[\'1%[IF;^XT@]PLZ=M9SZG;FVVJYL#AL/N+ MD1#A^#5L5@=3XCT8^OQF"98=@$K)Y?Q*6:5&*K=+]J&N6L5 M\<1@/!-"2^1UYK:'><[J`/C)\M)>JP)TBN)5B(S1^R<[X9Y>,DHGHU25:'5" MZ5?+!$T%G@RB*K/F2G=\5:CB&B!*#$3)N"K%-4Q=EEH(3P3GG&.!Q>R3_IQ6 MRH99:EJ+\I>GOCF<5,55HZ$J!%=-!.:J._U'VAKY8:K[FL6J*M4O6KO(GUL& M_:J\I^&7J&&ZJ$I>5#7MQ9!BY25S7N],$2#/Q$PK!,`DE4L!L,KEVN:=M%/S MP(MFVYKIXE,<:U^T?UHVHL:Y66+R]M)<,$3>D3E`YNJ$X?L#H:]*9W^0CX9H M@,0PZ2<,,RB@P?A^-`D0L]JL3^&5H3G`"+\Q-KFQO^%.Z#[Y1^FNU&`H/AI7 M%HB>M;'TI*?O2).61<,RF8DA"GDE[U)OGFI,V'TQ&I/6]&4],LJED+!P*`N] MR5Z''9Y>-R#RKO(_]!=YMV>=V(N\L8*.VTO<[K-G+_N5S0K0EF\JQ$ M/;-O;:$TW]=U.5UM95(GI$FZ^O=2MY:;N3L9+75`2+YUMTF\<3%(WQ.J6MXX MT_XUFD\RV,%&XR$7>W@RAKK#J1BRM*\M4FF%MPG(F8[2%?@W"SO)1;1)<&]Y5*;\2OP5+=!L0W`(9 MSY"ED.(L-"H;);D9<-F>$#B/1)H4XIHBN5'BG0N6ZVN=DRY!5W.I.2E44X?5 M)H537Q$7)7.5%K-JO^)T>WTOWR?5;/8GU2;GT_.I@'%>6BS7`;]5QS`-0J6P M[D^=D#PI$2])3262TMG]=-V`2D6.T$8])6*G@_0#9RK%JVB=3Y(.]@85GYFF M9U(!+7I*)-2@VI+8NL$[O;LX&// M"(X,V>E;%(,A1&AALS[="C68;AIU6386>$XC3W82[IYR'F@0QJWW/6IZFL M[^G>B*C;SBTTSX"RKCK+T+Z@5I@[U[U+S&0T%5GGAO\ME](,^8*68RJ7!$-[ M<%ALJDG475>0I.ZJ%^FKW6J%MP*RVDU%E7!)\%IAK\JD>:T057*2O>8HS)`M M:][F<[.$F1'7'0V'Z5M1U`I_^:1F$W#67)2=:QFEW&8SD!)?>=G)5F!R7T/> MDH])FA0K5(#2I"./))2J&8J*1,5I;HY-]2S>'<[2U_E)>A0N']T,X_-J10X! M3F53BL0X786")$&!5F*@IK\&52L:G!N+5"\>DBHB2DP3J9(AY)1BT5P"M%@" M_O%EC9.9\_$'LN>Z010IZ#+,ZMT=++U/E=@X`7?B6 M,_OSM=WRZ=U4:[]EO+3J@8TUYYO+N:L_PY[?PZX]T[7YU-?PO9C$,+6%KID? M+,/0[#3W%/II9+PV^__5:=#.!RVG?*;]"T9Y:A5/MF5'3F)3ISZJ@?Z3^-+1JP)#W]`X0]ZY;G&!NF>2(LRS*J18C!GN-3RG:7BV<$,&W/INY% M1,@S;NT$G%!EG`TE&;9XB*C90"QG:[D5ZK8`+?D(02-0<6YY7@M0E*%4JP78 MR*4XIWP\'7+HOQ#[D=CG)["[?,I>VA7SAJXX_WTX&8J\LXR^_80WZ!-T-WD[ M_\)M,'M@T%7[HW%-:)9?[)!NEW[*XH/^K"^(N7"N-.?I_$J)KCJ.WUZ+O?^L MA4O)U)8&;O;$0OD8S3TK6AKH9V4SJT#PV>)_7/`.:@<63I=B6O=T;AX=5]11 M(*,[0@1R<;]<_--S7(3K?%T6`2=QA5Q`*$ZKS4;360RGE6TBHZ[KB@-Y_DY5 M95LY(Z\J!@'R])#V[L?7GONH_=ERG$^63?1'TR^5O;:_].(80=3:;'3EIC3<)+P9,,1!1BK_78@2>[H&V&&DY&00IQKEX MZBW&6T$5#$W%:(I2B4DK1++8B@V)0&E9JRU>D6(L+:M0!3TMP*AZ1"2G@[;( MY%F]EB4KG=!L62(MQW;+4H[/Z+TL.3'O'LP2H_W^X%CWWK:(Y$":UF(1*$WK M*5R7DVF58BPM:UZ,*"UK*HP>KV2;M44HRZFM:S$"I6VMKOA&"K*TKH*5(;4` MHTPG4YY86E($OKFA\KUL.ZLDLZOU@`(^QX3FSS@^[,#ZD'7@#OMM653)E=< MZY&@L"@ONONDZ*ZCO#Q9AK%1K!>3+!3'>W#TA:[A8&GEYH?^AZ>9;F=W:?^K MZ-J*9BX4#A-[I*,\6+#*!V)H+YI-HH``1O#G5QK^7C>5]SJ(ZT*?:\;N8E?O MK[?WZ,^[B+ZR`_\P#(+#(@ALR-?0L&4%88)%-$>!O2O15X/.T,Q-)_)^17=@ M@46HD(!,H)&4!]U:/VGV2IL3SZ6`SMG##)6:`G"X2\O0+<5:*FO;6GAS5YG# M+O4%Z#L'=-D"\!Y]\=*R%<\A"H"&<+DVT=A=17C!'+O$V!'9_0U7P9^1'W-" M6S?BSWQ.8>C6#"-.0L2Z;FH4)STIEF<"=/]$'-J`R`$R(U$7RA*P:\YUX`;' M-WR.\J0]`[\08@(;D+6&3(C<-P=F72!9&<<\$I/8&LH>?`,4A5_A3SS31:6Z M!JF8ZVL#H([*PB^7E[.\\RL82G@!M;[Q)W[MW?5B3R#7K&#;U%S* M(]IZ;<`'#P9!<=&41XLW)$3%#BI"G_,>`ZNU05>@3^+"5X$0&`;]B6YZE*.M M->$Z!]D`YNDD<1S)^#HP?$'J/>O25(245 M]>DH439$LQ4"^%N`&9A3KTX9JAT%7:(.4&[N41VM*>!2.NHEO%%#[2R MHO&0/P210X7.*#[Z8MG?J;"Q7("B)>R/`AV1MO]T(I`AYG:ADDR?D[;7;>`G MX''L\Z;8F@Z?H8F%#UQ4^PO+>W"I9V$Q+J!J:8-L$%6/\.V*$)?J+NL!\,TY MG+DD&Q0?`G)#-6*'FPH@KK'IT-=X3*,EVX?#RGNE;4`UNE3#KL$M@0=!-GK* M_;;R-@ESEJP'5]-#QH4]+L%UP5=R1N>Z&W6\C2X-/,/,(,#HV8':!$1HX=D!/`K&53MTY[X%Y>1!-<+Y47 M@$;3#;IO&V*Y1VIE@$!+)F)N(%8@IQIE`["W#YJC`S?`PX@<0(R-2W)?$322 MBZ^,;24B_8A_`Y\%#RW$%;P`]NJ[`^:C%+]\Q"_1OUI8E*/!PT=WG_+/VG() M%4@@[PI^:.,C6A#2!T["'-AD@[S\C"W(J(6)^!@1KX+)';AOX-439BU,A_"P M!;]ZT`S*L,X3RO7<@-?HP'20S'/D3\[WJ)%9W`Q2;[I4BB2BMX%$8WH(P/X8QOA-- M,J#J0X4)SD*8.>HF9([PA_17H#3LKA\:N&'JE?V$J]!HP$P,?06@(8C>VC(C M0*?W:=M'WAM3N?0>@>7AG31B4)GY>F]I-B79!_!NYJYE.\RB/-.02^V"K]15 MIV#E<'PWF#(\S%`<\";=#CI>D2P";7>'F=Z0&I&D0H>G"![(7`,_EBR7+`V' M7A<';#!F@#''\]#2BD8?)XR%XGZTOZ9Z\3..$L##0(7U\.OP5UCKD+]>J$^( M/.RYZ+!3)Y;G+4(8%]2X!B3%/8(W!P+A.]^^E_P$SKI-7-O2_!PCJ.XC35M&NCX^HVYFLZ3]4)72+$%6)MY#9L05!I.&B_:Q@FR3?SEF.E] M`HU*/5V&PAW3:!Y&Z M_N`>7\*C!E*UK]S:^C,ZP+?`E'3K@9_$!D$DE\\@J(A)T\'4W-$GOE^+SHK]G9@H51D29O.6=2`%@&J94X%'/"O#C]QV2Z![,MVG<2$HUY)$&` MQ?/7.NAUK@R"0(]E\0X$AD$RF@583-QIA$"UWIYG'-_NH+7QA?RX1^8KO"3P MT'2:+&/DAZ?1S"M[A*:*J.WI)0KQ2+)(0BU3`=8<:]2=P@\!C M-'3X&AVH9^)GIJ@^LVP=8`,Q`!;W;*XTXAIC[=ES<$&Y]K`)4<#'<)\<]-2- MC,=(^38I=3-&M">".;U-1&OK)N@8UV/F)<&-I.YS M\`9EC=FD#6A3!S04CBLAVWP_4][^5(V:K+W*L!.J MDK6VH;$M=8H/>(:=A-,7&KUBWJ@3!MJQXB9J_0Z^E&:S?G`'=JGI-G\SGJ2R MQ`5\9!-#XPD;YPE\8HIY%B-06[O9HT86%F%ZY,D"90]Z@V8_ME2^3P-:Y&)K M"WGVEZ]UCF7\=NVG[C!"8N@7MU@6,.F3#H:IXY_]L=-JU/@K#(U00#I;-LIZ M^"?+"H:'$?9S$/H$1KG#_3@_Y+$),)*I6&:RM;X.X<),*<%#^06LC2D>_`L! MI`$M\%!0V?B@F=\!:W/N#79H4@E'-0.8:VW-=K+S%+`.L!(]_61I=_HH>"7^ MJ>8>AX6*.?P!W`S>I$4K*X/'\"OE@V>R/#7^3WD/ M$@C;QQ-97AV#QQ=4.!\L7*%'D890#%J9Y)]LTOF:ZXP;0%ATMIR MR-;!`2H*E&8-8BANK((*MMTL_QPS#B;5(<_65KB&B2&JZ5&A*)@C]XPHS)*' M\DM/1-/HT=,0F8/-[ZK!CFO8O]B-)!./63!D]7,2L1,/5O:"1QR`7,L_SP79 MI-C:5+Y:SXQI0H;Y"+;T$8E!IZ4YRKWF?%<^63;$(=&" M](_7]Y^V"]+Q\4^7=^_]`T;\#2S14_H7W7&'O5"Y\U8KK)Z"S]7HV?0'@L=S MX`_`TK\]L>LMP%77@7>NO+'H)Q\!X`7Z*9\(5=5OT2I<@P;XP1(P^!,3?"*L MK[UY,15ZN2]Z-61[&Q2\^-V4N;70ESH[U+N\NU*FZK@[ZB=6*P$6_^Z9!#$X M[8#S&#T7F!N>0UTHFX`;B]40]-S07[0_!C'`4T-J-,%MXR<:L`-6/=DU=/-[ M[%0A#%9X11HO"J4!'[R;REN`"AJ+^;C`1`D_RV0`HH?YG;"38\3AEIAK@00I M%J4&P&8&99[$AEO'HQJTD"]9E?OVPI]&T,A7^]GZSD\ MR`0H4H5$-7QP.XK?)W%8UL&G)4-(,HJQ>,*-\@G5-<%55:IIU.&P$]4JDXCKX9(/@;65"U=QD4">_3&7>P+BYT7&6H497A/T:]3?RI+^WTY-%F M9YA!I2E%Q`NR$:TX9TD4P(ONA[%:-*G""."OT/$5,.S83W''#Q.Y:+'S4X=9 M]#?:V[U20C'TYN%M4"'+6(5^AWD58CO_R<6$YMA=)SS_C!\(@U?/ML#%>E=_ MQ3:6J/F0DCQ`8)[\>FW0A)2/@'A0X5=E=+))SA&Q",M[([`#WA[VZQH6@K-] MTS(2#,#Q`2H5C'6.[-WAF0H\E<`'7)X=BV3-J$4)LFO1!$8@GD#RL'(*L;FW MZFD)ZA`^924&"9 M>_DE$5W^10AO5"R7GDW5W!;DL8V%_K')*[2&K"BP3Y'\A8;` M@QG/][(3>Q8=T_-WO)+DOP$+U,PMMN!.NNZPXY(%R[_1@Q,M2Z8YU6E6A*E,1GUVJO4.3[7Z%Q=O@U($S^07"A?\_,>,5RBPW\!"3!%$ M\ESH8;U6.^/)T'_W(QB:UU-XO_HVN-5XZ(:;#"".A?C?>!$+/\+(K>R[?2C] M:IE=L`O`RC11YJV[2QL?6&N;X)2(Z,],\X'A^2=W%,.SE^BE3E;`-*=%1=JC M30A+E(4UHOZ72\)+HE:Z04#=FC1A3'4MOW_OFYWPA$JC5\.P+A0]8\*J5!4( M*&WN;!CD&0]Z>-'L.1FU]O%!]`2+67L@O;71#'<3E(SMJ7(-O4E6[DHOE-(> M!NR2'*I@O%]%-*Q\6P0JUN^[P"PVJ%L'X@_\)5;Z0NAAG03N)R#T#?`INR)\U/#QN8KHJ<([K8UPAX5)=9Y3R)X=.`XCQJ M-["#A+4A)%8-VE'X!5_+WE"+0C]0'`]O-OLGD+'C&Q?+05EM*]8%!YF$0(71 MP%6W%V#_;';RB4:)U\G2>,EO/A!Q1#]L$ MC&+P.L_V.2GBT=`3?9:_"W\5'NYS*TD+43`0T0X9RF@*=!.V9O%OKRR\.0GR M6/[5]E"O'8;?"7NET*`EW((P1L57X5O,=5PI5U+OQIK,(;<=OA:2H#LC(,KO4(=KEVIREAO&$1NV"!'JG[9"U8GB>X#\)"B2"L9'<7_)Y@H"#X M50VLGH[I08>@F1=[MP6?]#=C5PSK*'V`X)K!:H=W9=@7WQ0-P7PC5" M0KHG+(+S[W)0!0&O?_`O02=?(ME3I<:+;U"GA?QUS9A-^OI@<=H&IY-J).? M(W]^NOX*WT;REI$_$\XK+D;]KMKOX@W?Y/=M':7\&M\DUZ+W=)/!4^K/[`PW M!C;(!DW4T_.:_JR7#*+"X`^.DISMHZ1CF([8=HR4Z7DB@J$[Y'@R-R&VOHL> M:!RA&M]:2E1&<1?%QCXB170(("G\!V`KT"./GLY@QP7P0#5`%=4:_C&,XY]' M/$2=H4Z0'>A$KB-'KLR%91U)V#L`7TROD]B5M#A8KO:=F/0XUU?A[&R%?>[W M@0FZQ+$+B%2FX#6LDI.>)>P>&].;P+&UV&T(M$?1HT-4HUVF1KNH1KN@+*-' M@GA[QV%%Q4N`C*:=01D"ADEPXA9MZH2ZV@,+MUVKC#:#F&2IT^Q><+@9!Q$5 M]0+S=XN@"94;;X*9'ER-GUL%!S($\` M,]8%BY4:4A/E-Q^DQ..GC1MVBY'"!=2$^(#R(CC#FD'-?01MVUY`3"7$5(3O M3@OC-HMFWP(/F3=?#LL6W+#ALLSSG^P[1.O6='[/:K?N(_!EDYMG1.X>A_W9 M>EBPY=^XQ:-^ECH!AP_/OKA/RAH.TKNY283URV9X#0R]%<;.%D'0(TL)@E#A M*!Q(ST?-QC-SYZ MRTPQA.XZS?XE/<5-]0O!HRRT3<_`VX\I6H)$JT:VFJ5&LY&Z0<&(+KT'4NQ3 MR-[A8`,>%@]W^&VJ@T"F@)!+,M49\+"KHU.R(.!Z\'S8_K8U':P87.`^\`B? M%JEPIRH*,Q:Q@,_HQ_%2,1Q3#%_)"^T^9.UVC;9,"_WUHUF\D7; M*%AN$G;-BA8B7][]2K_I]D=1E_D3%DW]-RTA^<+B'1K>7<+_703WSR[9_3.% M7V/8\PPMC@G;B7QC84X02X:-3O"'UY^^W8&-OF-U@/1&=H<=(7IKVB>`YF9X MJ$3K\L)J6`QI>`P&2*)-5PB_DA/I*N)$>H-0F[XD-@)"RZ-I13W^ZC/FEA56 M/32(EI"MPIWQQ!8&4L[5C1!S24_79!>7)8[$KRZ/Z97L+B%=L,)-%(*(\\%.J*(*-":R\#)<$EATFG17LG M4^<@\F(6"O,[W<&$'_R=2?LGL&_#\I#H+UB==M+[4!J)SJYO8#OS1X/X0;WE MQH$FT73TGGX+2^HIA=,'R+M MEH*Z\B1X00][#Y%>@7JD:O2(-5$'_%@R2,@[B`"-MMP+&LU1_@DEG)UN&-'+ MLEOD!V44ZT,<[8#16LNRQ9<<9U\YEE)N29M[Y*;Q_D`2X`]]LQ%EZ\*8N&2W@."?(VW*MVAMW^@-XL6-$6L%L7.Q+4A^.[>]&9&H?T M(0HZ+A:>2<8<8E^$=\R;XSVXU,!%KP)>WEUUV+DC3^_R?@1,2S/`V6$`56+; MSFNJS22:(*#5)B$H5!DS-8SD M"G+V-B#V#V`DU.,1@X"\L[_]?+:N\M$^]+I5\9NRE MJ)5"^2S9-:7:<9AX(32?O_A06>62GM;GDBJ4!6;XBZ1K*LEW6[9J><.S036>+`\JQ+(VTR1H!T-`%.ZXJQ&U28]21O\;?V-/N?&S"R-VM:^CQ.?QQ?;/TTYX]@]ZI\-R M_OSR;60@@!FZ:U%O;?MMC/UO[TRAOM@H*Z(=?M!^T05.0$XU>>F;>2?+O M>(S+CO$Q3/>/"5;\E^D[KH=8VP6:XE@#%P?OVX:O'/0[_7[?W__.4CP(#W(D M+P0+B);H)(+FI<'1F\'X3T%3"Y9`"5]#IV(PKYRG4X-CECV;V>&%"/-2=!-X!LT?MGKR!(= M)3J>[=`E5TI``MN05QCRL(!AC:?/P;Y5".5FAZEV.#CA=ON[II.G3,BC`+@4 MXQR(%WWA/N&[^G_Z&80-6TYVZ0##M4/>*?Y?6994YL0PG+6&8P7_\JK/_KW& M\8SLWQ%`;!\*>DP/H;N/#I!ZUUK]'/TM=C!XL;7U7UZQ_^9`%'<1>S]_!P>U MRV"`/:]=V%31B\/#@#/S+Z\&Q:]5Z48/+$Z9K,LJ/Y`'C$5Y\'#6]\&A[T*@ M%)JLYW+)N7-.ZZN3P0WH.#D1](_<)PFW<(O.2?A/W8SF3KC.I.&CK2@_X2L^ M,`5:+U+\Y-IUU`R-XME3=<]7&B^$&P#7+L:0-Y'<0PWQ+!H\PM#]&QY*UQ6+ MHL$C#%5_XZ67W;@0\T+,>J%WCU79/0W]C_E\N9S/?U92&9RX\SP>_REQ:^FV M=MB9]56AMRG) ME[PL$RQ'_Q=AX2=[I-^;#+OC:6^<6CPD4?]'33*LF3GYB`41R( MLIUB'.\3V?0;P;["&E>RCD>3X6_4MQ10_D_)5_LMMM2^0FK?<:\_Z@['/4F? MJNE#?S'MS8:B;*DV<(55 M5H9Q7*/FL%:QQQ;%LF`62#*QZ)MSLHQG$..M)'CI!$_VM*F3';W)?&;JN52" M2>[(5QV,9KWA3&C:%^']^R^A\E'`.>?1%&*+?:111[V0*58A3@U M+J:B;*>B#+@\4DRUE#!AIZ2"&'N15*A^+S)K+=E$"JND@J2"S%K+--69::K3 M652F)R7=)=T%@*1!="\R);T-_J`WWG/9*-V>CF2J4]=8)L-5+F?1-96%Y3T8 MI'(VWP],B>GP'6XOF"R2"W+G@N14_&OE_&2\9(Y3F2/U):(B-<-9^?]R:!\S MA#_17BSAOROO#2-<`_Q8LQH&5->UUA2P\#88[5Z3&D*.M(#.5(/DT;8&`$OV M4'PXXPQUY-+@-#WS^7<9SD[67/NS<]2PWYH=W)[`EFX?>G=SP)ORQ;-M;]]@I#T<[3]GI/N\?CQW3><]\\F--^_O2OG*V\D)L[#7* MDP;8D0W;YK.V=O2UBZ1U$GIX91>VD-=_%,F]-6JU=$*L4FA+@A0M<,)/:MG^ M1EQXA&&"_X@TF`DCM/!#5"3XEJ!C1:3!7.17[E:S)![=A;^`,"_\QSGQ7M64 M$PT>83CIM^WA=G# M+OVBF9&D?:0_(=G=\?W-_>5G41M0&$KT+H1IO93A7%GTP2CUFEL3 MF464=F9-$S'>A&//1@]>.?O4I"X;%>H,IL#3KU(FS*!VJ_G1NIPL4SVORLDR MM8!'&+K+R3)-I*J<+'-*;B>H_Y7C9FHPKX3^XF(@A\W4D7C[+I:HO6E?Z2J# M46\H!\X(4?>501AGO9F(1"OK:,`W'RG!EZVCCBVE#H7I,=96.NSMQ=?ORO*F MZLGC4^/TL]G:.^L9.Y(*8NQ%4J'ZO93MO9Y8K%/*W0"6<#M3>1!9ZMXPF>NU''0I.^@F.`HE+_<@+# M`3Z4286JZ7"@Z=/YN?G&TZCX>X73WEB8JF296Z^??#/OOZ,.+\393SLIL2^[ MKHZ[H&Q/O\DMR9-G=GW8DDNK,KO>CHRBI((8>Y%4J'XO- M7%R/1H. M3L\>R=[_M>>"?=;Q-4U>J6IOF&-Q@60/48#)VO]0=!V1M6U]OJ,?:M$C)`XD M0E0XB&_4MXH_'T'MCPJ9C[`U!4$W%6+;EHU_X.6\A'$'*=IYT/^JL]#Y$:C5 MR)FP19=8Z,]IO>SH(!%U@$MOC029^$+--<+>AB;I0<[2M>28+O)OZ49!H2_X M1%-8_ZO;53[IQ%B\4^[('QX!=OI9N=^LP2I>VMJ##K[U5VT%_[K5'LE72^EV MJ?NHGH$UYX_)\3E58TZ^?6NYIU8Q(5'&/)'AIS<)`XYD>-+)(^$ ML'^4(VZ$@D<8'OF6/-$FSAARJDV*B+^*[@:#88:I-N=4R,N6%`7T&AFD[TTQ M/./D5M).TD[2[C3:37J3,TY+:]\31JR;`V#"9$>50B4DK50(9DZ2#*+MI,1TFO<'I:1<9->1S`TX8"K1; M%*8S<78CZ2#&;MI,AYXXA&AOW#"6<8,(PC"3[JHD@R1#8!K2#]@0QC0T+&J0 M#4R$$`6U+XPD2#J(LIL6TV'2FPG3^*J]48-L\RB$,(QD9D^209*!+S7N380) MW]H9->#\-U$HT&I1$$8.)!7$V$N+J3#H70A3*-;6B`';;HE"@U8+@S"QLZ2" M&'MI,174\S""(,XNQ% M4D&$O;28"FKO0ABEU,YX0>WW!K(L2019&,@"`$D&28;`,H@SC:_LOD]GC$0X MIP/4&$EX2?AJ"-\[IP&92`-_2@SE2O2=1'0( MZPOY^:[L6;.!)"4D)9I'B4EO)$SU4FDS;TX'=^\<&HZ68.Y>K;C:?`+ MUU+(:FU8&SI4)A@OXR@+.H_FB[91AG3`3%]Y(.X+(:;B/A'EREJM-7.C:.9" M(=K\2;&6RC?K`0RPQG5[D%>&#_(FW]!]SRUSH.#Q',Q1O;3&8M/7:MI[A M$X"%_ALVLH`]W+D6>$PW=-B.7AN$KLKW"IM86PZ\@(JO`Q\O@1UPRJ!I@J-3[;V-R@`_>>\Y#OS7UDN3S6PP[9=0#('J)*)*@HR> M0"8J5+X\#<;CSL5X=D18SUY&G72&DYD4VR,`?02NH.8PE)TK>$`W/9SIUE&N MGFS=42Y[H"L-0V?4NG/),R#_0T^Y^VX9SO<-PSR(CZ53W(/!7=$!'H[/C$S` MD)Q<';`W(7$O;??)LY5[G\P=Y3<=EM)6RB]1,E\9FK?0+>53+T)QFSC@R,"* M2T#!GH5ZH(X43!X@(W0"+8,_1MPM`H!`3A4ZX8+.L0,Y`TD^K,F4%]U]BHI0 MAZLVC6ZV,^WTZF^^!;G!%0-;I4%^7*K8.Q=$;'=YF6F;WZ!LUKM_@3U\.H]K*>=(` MM3Z:^.;V*ZLG[9DI%G#H`#>/@`,%E*\'EO0/#Y0PO/KUN-.'';RA&%OCR"@V M:1`78EX=&PQ#^)0_/^2C15RNR MT.$EX"L^@T8&B%Z>@!]]'8-P(_P6+&:_(/".]_!/8!+<,0(`S+1RXE;J(%;9 M!KCY6%/S!+OAQJNG(&Q'.%(S'"O.8;B63?35`QAH/LIQ"7`"(_JL'P/!)IH# MMA1GH[FV!FXR!=\F!F5L\@-9"MZLFW//9I)"5YA;^'K*6A2GB-T8KLM2P7$% M6XE.94Y&3/PXW@*"+'5G#H)!Q]DHS#79&(Z#=N_F392!L]/==Y`6D]\I:$*.C>$[`Y99A6"_XKQV9T1S'6['E MWIV1R:$?UF(6"YHNF"DU'J65(??Z!;ANZ>CE&)N4B+T/8- M!%/'Z<+?,1/Q\GGJ2F_2O$FQ)! M'"56N$0Z%J^%'.[U)$JL6?J[9GJ:O5'H`5]_UHG7"B^L-3H;EW=7RKVUUN?* M5!UW1_V.\BJD%:O.X+S]2GF#/V8_>XO5;T'5"3#VW/`<>AIH8PT1O!BV3FPE M?((>Y;I/FHN5,.0/#S1$U]#-[UB?I)N:.==!>^@!;R@OEF,2&5RX]<\YK)_W?LC/]<+_[MSLW-*":S@LFM?DVA$`2,N2!+?:Y3X:Y8MQ^OSJK.K,2E,*I'(HS`D1RR:[1L M4IUV^L,QKY[L)$@6\Q)9&2B2++7"/L8"#E=O1VI'8@401S#==:TUQ79X_-#' M6HG4:/??XY^'TH`ICR()`"PY+\'A[/<&Z#*%)2`'#ZNV?QUE$AKO+;65;FS> M*='!NT)G73?A MQ\Q;LDEW131,%]!7'GP9O:3A>`\.N-3H-S]H!GVW\T3`F\?R3+S%MU&`_=IG3UJKD/7(];RY>TVGBGCIAY=CM4"VE&B8N$B)M3=H$MIN=HRF!! M\)Z(;@:!Q6NF4&EMN]J9CB[BQ>W*FVV05"5(':H_'X6CLP7[ZV%G<@&[BH.V M\RNU,QSUWW:"T`^EA9=!1QG6ORT`DFB`+ED!AI_VEV332GZUT_PJ]'P[<\'$59,RUV'6L)SK2B@],]CR8Q%I&\ M$1/U&-UC4MY3KG>$.?:#>+:*:AG03@0C#GY_;&W]EU?LO]F.L6;^*=8OU`)^1@L84L,RD_+;X6?;B>X4QU\'(2EN M>]D/"+,#&BE0S@?H>ZI"0]"9+@W_395JE$))]%R?B_&N4/;$ M@XL+7"$Z?=P_O?-DM6IWZZ^MM6;[8PP2C% MK$9BUJT[GL2`0E3LE*6LSQF-4`MEG8,379FJO@G[Y/EEJ%;Z6Q_B,7+U;%.^ M-ST\XPZ^=*;;SCYGC!:KAWK.Q9M$P>L9M85&J@@0HHKTVE4_DP:9W M$5FK[VAIUU(WL%*4WEPR%.?)LFE-V0I+O&BAF\=O#V^WZF>MR^=8L4K+7X-V MXZRO-"\[W'J(MSB/7$W#'[*ZUTBA-2^EXQ5G^`U_DQ+,8O"[:M-R[2=B+'K* M1_`$-OQW^`F[G&CP*X!\.;RZ0A"X2(DXOO3J\@/VZNT/.U@!^^L=_U=_Z->L M16".785FY:T=0)!GZOR.FT/+>[$9K$GBD&J&A3?G$%?X'2^^BT&CQ9^(=^3F M5>L4N"FKT.4H?B"/>!_'UNA=L1U<\I:P]W?_XP\UP'_>ZN9WY0X+EQW>,1@K M?Q<[->]JU7>S&B2/-UNDBN^M>2;A6%!-RU\[0W&R@J'$@#--,>Q MYCJMQM[N_A_GV0=0EYH_!V0.3+C!FX9)$LMXC%W2W_\Q!X/VB]^!U`$FT[IX7VO\!>@OG:Q"3[XF5DR*_XX(1=.DF/&%C MYX)H_2OEZ,UV%71/^1"V]\8.&7MJ@`\1)ZC/CVPTK-Q5AS'IE()5/*2_FES! M'S%!^"'H5^*B160<&]RBR*!EYN7^@^LJ_Z(3!LQ M;>Q'30 M8B7\/(`JX1IODD+XM7?7X_>?]UZ[CUR)1N<`"[I!0V%+?OW!\X?[\/T>:QW" M;_\R?<+NYF,C`O0SG.-Z+_FJCI2D_"3)YW?LH<)=F0110H[BVFQ'5=(N#J@F M7$K^(0;\!.0RO$Z#J'$!`/>DIE]2UA%6,S8X.9I>DZ,`( M'`E"+UE=1<>LL"LA_<%0>8/75?S;IF]!/OW!$>CN+`EQV/B02+^;[4U2,`F? MP/6#7G8"D%X/^WUVG8QVZ6=OA=!*1U^86TH<9,6:2FA4)%Z>"!5]W`:_D,AZ M13SPKA<+\7FX5O#MO=&_T)^KA_5#XH21=)X(%R^U/_7G0,2/?IBOI&WWQHC9 M@VB'EAY.UN(W&HU-?"W3>J'SIZ(7C+:$Q@G'43`).*L#S*]W!VS15D#44WY[ MT@W"XCJ%#@'#.TP,(_-]R1T2)!R>?<%U%J2[HG&A^RUE9[$,IFZP6A+*TM15YL>SO5&&PY1&0R&KZ;L+LE\O+VXZ?>H'_ M..A1^ZC1'C`HC[Q@%0$LAB9"AZ(Y?!*6M@B43<1_#CH]46PB%AWV@&ZN/?C0 MQS9EQQ[@8]P?7I")]%R"B'CQW$]>"=!PL04GO5@V?Y$7_Z.!<3W$O<'<3]\I_QZ"+.LZ5WCL%M%6U3?!;RD*N*G MSQ$U_R62#HI8<6KKOQ&,&U"%OT=3G]6;J[P!K``@IGXZJ1N43[9D[RIQZ&1S M:)34$H(U#A-ZIE_FB\[YU76?>>.Z,$#F9]Q[I[_@[M`M^D&8>6!>T!?F!340 M8<(`3[LE47$E#"!G$RV2++BFX6H#D20,(&=3*Y9>J!N]I%V3=JW0V5C^ M1.X2!)$GMFN'+F$`J91NYS09E'2KCFZI+U8)@RYA`*F(;N=>?2P36<5.'3ZZ MN72;80<>QS!:!A>)-_-2V$W5%W))#J$@E^00"O(&DJ/46=Q^9\W13N//E+NZ MPOD'6`7VK!E94HW[.GJ61[:]3453@O#Z=-X,EAZ"*=\_+V:>D8HJ%)YW)**_6OI*24AXE%1LK MC^D:7I9YO4FT>Y>19@/_Z41N@.MA]3%V!3*\!6&SDB-G!>RN=]C$I*?(YU\L1XA`1=T[ADIYL$KL7GPD1^'E^XUV,V*[>QGVF%ICJ]=Z,]X M87RAX!&2K3O?NTN\FZ]CA0MQ7#9G&G:@]M3QG[IJ;SCY4^3I9PO[UOB-"-31 MY$]*5U''.*<9P=>406^(%Z:'O0'KQF.3E:9C4T$@ZY+3VD>W9C@6-B\(-ZGX MFV2["IHP)F[JW2F;&E[@ID;JG_;OJ?\GV-(HW-*H-^N.>Z/]^\$%%;H@70=; M5[$+Y$"F]YI)VVG11D*:\MZ"5U(VH\VZ''VE8Y\>[-O`>FMM0X0O@QW0MEGT M_C.C])/N`&_22_]Q\%\(^8Y"B?T8>`=4WCR`=:%=@YQ9"Y17>-3OV!7;4]AA MPE<)^^Y9AZUU#K;$B?;.N[FJ^62A(8[0O?1N2BPC\Y=I+]? M1'DI#%L4^0\!&8X:E,3FSO$;OSV@$6 MS(KK]J'P?H^=U?9@U._N3'4?&%#/-$`!HF(S/7J''54B:^P'?YF6LM;LH)LS MOJ"N'1_*:(I\Z3V"@"O;OXV=TYC8,\C@&L##?J^&;I(N_2E^:Q+V.K7?46([ M"SOHO;R%Q;$84LEX1=^K:"K0[&O`!.,3DO:2=)^LE M;-R>!B.P)YUB%O>'F'[1-MAGFIB1-]/&J+KC=P[+!0E(_5"!L`:I"!EM*,^] MGS^4-0*N[P3O#'>1R&1^9&^0C`?3^OI(_R\D&J@!#/\=\\D"C5,_:V>LR`\:X.X MK/7R]>T-%2`4ZXO1/A'#/EB\`2S&D)IK]D!/^;K5_9GJUJ#U\MPF M"]WU,QK1]ZYXRW#XXO6X42FU?"@CP=`MN%'S`1!_4#AMXD-%<2JI]X4WD?48\H]WSL M2``"MCL'E=_%SH./)NL,Y*VQ+V6H*6S"#0W=`-H=8N/='5_YT.6P!E09J$*;I'&QAQGN\6#`?(-.DBSV+I@PXB_XZ(+H$!OVUOTQ\=$";>T/WI[:#`6XW7G<4*/3UE$FH_X^A?7"NDBC&_66N35O=(K53G\TIDB= M]OO*'<$FH`IZ5P0D$H&Z8^^+.911.1L=?`S`&/2'%\/QA7)CNAJXL\JU.6=Q M`>JWBXM($BV20$:6VUO1%%Y49#VM]Q^U!,ZACA;IP M"@PT#%^U3PEOJQ_J_8""@Y\3LJ(*+ON&WT3BJ^V'(L'56[_M/IL&PYLO`H!( MG3VDA7_[W/=FM-=B'62=MSV%CD:@C<)9HW&Z?B<:EL'_S)C7F\@/=/K2-E:" M:0#^B_E,#)/G.Q.U%-^0+3_!`9!+-CN1PAF/,_L*&%@`T$&F@1C+Q MCSEV5T*?F-#!#^RLA#8,IFH+;/D_P4C20P=.V(Z?.Z8MY*GQXZE@#F\O`CCN MGQI>?WH/PX./VQV,4:+O**5@LZQW>S(3H#X$-8S,RYV'OVLFG9(VI-@8]Y)9 M-)2QV."2/0$*SF9Q?=&B[`&0.1KU(V+H#EX;#KAPMN4I4=W@2YD_Y#"?!I^E MXA%]4^#M\"DP-C'(,RIE'CSC81BS\NJ(;G_D3WKQEW02-%Q,"AD>8J*5Q)&' M1:RS7X4>?FT@@YGX_9IOFFTXD=X\@:/!BRW#V"C6BXG8`+KJ"UVSMX_+./R` M*(C]'[55.(W+A_J>S)],43<&:EXWGT'%4R$*6('E?AZ(^X+_H@*1Q@I0 MAW8R]$4_>!T_C&0'CWMM0AC-LW,5WDS\]632WWECP&'4/X[:!CKE#`<.1IEI MU_4AV]$$#&)@ M*P=%78)<7C[J3":S^-MYRH]";C>%;4]_UR>3US('5G@[+J,8BLSAB4)>08T&:-J?M[ND.(_*Z9[/N?G\ZEYT- M(=SKQ'<1T[A[W'/4`ES?7C!-%P@[3ZV%H\D"46;'*]KCHTT>^='W8#P[R6?C M1G;04=5ID5[SI#,<3U)XS8+$IR(&S'_WC,!BC,\.EM$92;`@T\Y8[>>CDS2_ M%F*A0#A^<4"I^\*8CR2JO:T"MB"([^!>GW4:=NP,5IMVU.%H)T_V8%O?X0,Z M"HTJ3%H?%$^.74QXL$>BJ:;D5$%\W"V6M/2&_;CV954=16A?7S*WL+/#,!D4 M3SZZ$@8>8Y`K>')UF`!4[7J"?MVY-M6[+7I\[I M?&LW39ED#+>WD8M5W([W$@QD7C)Y,=Z52094K'*)&A^LM<)R+#YU&:6)(2%. MM30H"/:=&&L5O^DX7^]L]<5B&^VD/UB!U_TEU@ MVC&>OAB%%6SI*A`[['#R)#<@K#^+.@07G?ZD+QV"\^9D;Y0I989)4>[`!-R! M0>[NP$7G8CPLRQWH]Z:C9'?@D#<`'LNH?]0;\(>NQ;V"@V<%E3H`G0(\@'RX M8S2,W[\_*9B1=G^_W:_`_O5[LXO=C$JRT5]B20XUA3DR^CZ<;KD1N:SHDR6^ MGIB."1(FM3>6S45!FW01/2XYX(E,!X/J_9!Q9Z!.<_-#VET](Q!*P#WZ1!YL M>F`U4)G'O,])H@=1FD&2/:/024CPCP;C3K_/R@ERDB[ M=-/Y+NI%9SH:))]@2^PC,L._Y>Z@UASUNY8T6O>?W&\]/1I"36'K_VR$O$#T\-.!; MI?! MZQ^66T42Z%AY&S4@X;VW/+DHWL(,UU&'G>'PHM,?7B360$9)NOO3A#*=F"&, MDA6T=V\THG1EOC"[)".(6L)?U.:6V!U6*H.=BCH98D$JFM7YA(J"E6SV^QCS M6=[CD_+5>F8EL_AIW`YQ;\O9PG1)$?C6LK3B%E07JT'.KV1RW.MOE=K0V/6P MAN>A9(<90RM^J0R4#/RM$33A=$8D':-(C=*:"%\LPG[?/^"N=7D&R%:GF=MJJ#R5;. M].N%UC3"*R0<,=4L@PAOZ!Y"K\FM&W-/G61U\`(2DP^IDMB[I.@FZ M@>X0%`[VAF4!73YBOK6E9/7EA\>!;LI''Z=*1',DLQO][!++?JWXAE[F\AT[ MVFXJTNOAT%TP082UEG[9I?3,LFKCF[EK'?3$^&W+RZI"S23 MWF"KX'*O9Y;%(SMP'W[+'RL`ISMU2WM)*I3C-^VI@ZTZ4.[X89<("IDPRE(T MX=YOZ',Z:]M.*2>Y#OO9K"`?8I+J1+D8'V)+:T@?0D2QN`YOJ/+LZE[K$E&" M>]*YS"CX$4U"$Q3-3'6_+J;1PHOU7!D[WL,_(QVY#O`+C>7#]J9;X#K[*L_N MR-IER9@A#Q,$(5:M/%`\4$GHBO:;=$=;?3S5&?0'.?ET>ZY!IRH*DP=3":H:VZ?-T;=-]SR?6UMRUB1:T_8LT=(]TDE;>8+]G9?PV[S.TL!LA/>?*A1%Q MG1@C;I^>Y;+*UJ'=OE9I3&?LT;Z1OKIQR9$':H+`R-LNTKD;TDBF,9*ANS:8 M=A1U-IMUE%]-'7O[(B:_D`5M?X^]XZUGYMSNM,#Z]SYUT6@1?K]@7H$'Y[\*N3JPH'#O;,*7K&VO-8:W]HVWG%%M#V7JD"I)K MV]>3Z9"VP6$M@GV_=\$O3;FQGC9\2`;_C@64#M4/M"L4[5K$>DSY-\Y6NH$% M5R;!,B):JP1FFX5C6D(C*MYXBC:>\17NJ).0+$-#BVA5--B-?PV"QK=*%-O4 M<%`D1QKST&Y3PY0'=H)P8DK16.C/I8%T'R4'5RGAH2"@&&LZG,@<`7;O!LD\ MB-I0UGV(<16*`OULZVUO\,-76[V.7X&?=.O96#@?\&VLD_#6[^,L/ M'HHA7\ZEX9\SAX\9*-X:/QNQVQ/T!L6O"9<<=OS3SIYKJNQUM&?CH',QIF_L M^)!O8XJ=8SFTD2KUY2B0=`W6(C0QOGTB!DT/AJD,]LJ0?](380M]/25\R2UW M&VVV+]:V.C;QYC^=P[["@C`\@Y_V`(J3>;NL*5?<,0BHF0)$7QO0-LZT;[^K MS_4U/L&AV]Y3N"5:S<9P3*>=,$^$^G*X&E*`!@`L7U!.&+`%W58$X`@;`81P M^YZ$9L\DCCB:R[(T_X(&/:/(;%`(& ML,VBOF3)ZT#.(WE9+N_A,]$B7945Z:I\[LXGA/6NJ^+"^"H6$`3]ZT,8[T(8 M\: M8G``,#2/S2O8V6&43E3,QN]`Q:U7RE>P#/^P[._*%3H;M+=BJ#9F4;U!DUP, MA$."N3UW8!&6G'.-RUOY\T:9L8O;TU%G/)YUU(LI4[^=>(?EL)E>^-2N[J73 M(7[0'QH;Y?6@-PX*67HLF@>JQ MA3K=^0AO=X!3P?(IVN(9ZV!B+:%!/O,!^-@_>PD M2XE;8F*$++AV"@XR^1`,[(?.UZ8Q3&0:7=BOBOX1[(CN8:4M9![@I`*.)[PD M]UZWKI[(B@6LU'62HEG40"3U(BF,)70TX(*%I%K,%H8$X8Z(`>Z9B<=

=4 M>A)(&5?@_/0Y!4[P?M\[W"AC-.)/[7@KXY MBQ-9.WZ.1_.8*1J]*XDG\$G3E?#P;^L(72J14R;683F.0^DD..$HZQBJ1.K(7N82BH6XYG+&D<*`;J MA>.%Z^3#%2T4J##WFD2&"#E1?T:O=R3S5'"ZD\^)5&([]YABCB'Z\)B07$`: M]L;3K>(UFE$ZT/XGUJ`0\&Q;M$4(S68W'%N#7C\#LK;5UH6\IW\VE/3<>6V# M^\)$/LC-!7(=F3#1"7J+=$`1;H>'Q+Q6AU/Z0DP#E7'E#5?`MW"%3_QHIXFWM)Z?]T)QBITD\8J M1%JW^K$<6A"(^US/-ME5+WI>=9DX8086\$NMX,_]/Z6^H(MC6Z*I?;28H:7T M08DGVY=^;OD!3]8HS'YYFC_2N^.GTC#)'!L?NJ9S&J-Y6PYT.$XQ@G4'PFZ> M,_7GIHC,IO40IFN<<<:K`1F9^&R?>/*7'3O><:L[&@0Q`A^*CC/-<23%E66O M+9N+QN4\7LYT]?[J,AI,QVAJCV2[S#P`;&M!$Y9A^WH@?&M4=E[/.J/IC,IV0`\:DFU"'X=C MA8U^!:@2R`$89DFDX*B.S&%#SL[1$+7;_E<'VEP$H$F'=+\$A4U*=@:](*)1 MH?$9.KKY;!G/K$8(N?)18V.0;B*S>89)`V/\]_BI1_PN?$&@+X.?!T?[&6*> MJ-F@WP)[\*>W='$8N="*,]^*LK8KB3:45K;AH:(/1"1ID>!T#R_B@YR9*-+[ M,Z_5SF`,KCH6,>*[0EO/YM\(PZAURD=B?5]\G):AN0$&Z`U3)IQ MZ?<((*8.OAI-*U!='$>WX[S/[;/P8N MH@@.)2"]W;LX;/0>'5'EH4K0=%K*;(.1711R!,`A./H^,1SNT MQU)BQ/VC$`Y%BU$^XJ."&+D?<`*M3A/>CM^,3S--5+`V/^DE?HG+G)63KM9( M(!/L4]'-Y1 M:_LH*S%1HSO!:5E.]^?CBFDO+D&+%R_X@0E),!BY MYR5C*U>I0]1].B3E]&C?[M3;[!3@D>Q<2@^B+'H%76S+D@]7I+4$PBE]L<;< MFSOC7OD%*OQ+]^]O!5<#.&]3D^Q'^,%B3$2I'L^%5=3Q=L.@4YK&JY"VYL,X>/]B+"FH_#%1'Y&!CQ"HPR(A%U;R223OZ#2=&" MR)MP"B#(H?P6X2:_R)]6,./-=21XUEQ*HL-*/]3I92'85&^LF]+5_AX(?VBV M6)WVUI$^5D_3*DG+,*P76B8?C`R/9$*CMCL^,!D%=!$4O^L@O`MX%=;R<\7' M!!1U/2AQ[3'I6B:[DLD*TW9^'K:3-O0E&_O;F[#K`N_$8_UT`+G4P^%O>=$7 M[A,"T?_3S^A@@NH"0P(X7#N@N?R_LL"JS(EA.&L-S>E?7O79O]?H-;)_1P"Q M?2AH'#37#)])'RS7M58_1W^[\'_+@60_X?M75("+&C\&::AYF5Y.4M:OX(\7 M6UO_Y17[[XGZ)43Z!Q+4'\95RX.M*#_A/]X$31V"AW0S_-M]LCP'&-%YNTL_ M=Y&$"X[6`!F`AJW-/EC&XN2M'N"G9'A2T68+-%@7N,7\RZO!B6`RG1X"RP[1 MPW]?\XOLX2?8XRA&F(]<*T3NEBW#OV]"711[:I>:6HP=F.X+/P$E&/X#M6%= MR2P:/)6PW2[/W*))219MWS[%^.<#LU5UQ;IH\)S"!2=2WK\I%I%VS26'`?W) MM9-,WP.\]I&FX[I\I?^8SY?+^?QG)8M5C+IX!EEB9,')@_]ZQQP.;NS'XS^E M/TWG4T8";_J-FMHZ^;Y%ZM6RTWQWVR4O2H_>PU4'J9=EC42$WF<]Z/>Z7+)! ML-!VHL4UR[@W6D>V-DJ]<*QIU_CPXJF5Y\N3[I*\5&?,LNWJT]-UZ.`L#[\R M"[J#*2$@8;*<$I119S*;GB[`I9*CU,5RW>LY.OF,9<]3SLVE;0I]QK1X2@AB M[1,FAZ$HUNW=WMF@-SYS;^=CE\%0KFJD:RH+RWLP2.5Z>C\PF52U.NWTAT?\ M@BSR7#!=2EZN\OVF4-U-1X$0RY6A[&)*_"=Z@!#^6[@#CE(`2CY3P,?>J&^5 M(SV)-=,$TS?W+Z;H+CT**[]3<7*78M8"#MN5IFI3W,\\:3Z'IL*IFMWR=L/L M4(^8RAMU^C:,PDSKQ>\_5F#[L:2&KYF;D`G,[361R0&5R:2^7^EE,B:`VWT= M@^Y>F62*%HKN2-;K06<\NI!B58U8_?DGS^D^:MKZ'2T3X7=K6;]A;+:-#7)! M+WLVN0<'Y+T!O_GKO__;G[7%TX_ENV^\_^NEN?A`GHEAK5'])CR")$4'YAM9 M_N75%?O[]T__^/C[4.U^(/,NG@^^^FO)]M7@9]O32#^]O/_R,42Y-H(C2H!6 ME..4<`_!B29A&2!JO2B`GO\/QAPX_8 M(=JDWSTRL8^,;,?[^+'+PH??Z^`['5X$Y+QK*/7K6G53TN%MA>?&45::TS9F M!54,_`.$(-('U_0G2(4%`8DE(^)C4!)/$D]HXEUY*^RTC.Y@C&8X8SP8BQ`A M7$>=S2:1PCRKSJ3>DX%/H_W+RF3M*QTJ-6V]YW@Q)6.F`[6(JC])I/R)I-8% M256O+R6IHI//W<./6/33[?<&-/[9*EOAG_J5@.D+G[[MB>'2TD`6DR7P<*=_ M<<8!9S.JR6I'-;4SFK6^!E`0JJ6O9)[,.NKDC,JOPG!:;FEC!B-Q5K+Q&*)+ MX\L2ZQ]2+M459R^2"B+LI<54>*-V)L/4?ORI&SI2;5W5S9Q8.)*_8OZJ\38M M@>M^A0?+9JQ\!-K1?T"T\\X\,&Y67XFCD.2"DN%KA*=G54E>L5'6N!YTLV: M8$,-\U&A&&&#IFE.,7/'^]H5!I9'N-\(+6DW+6S]"@\"\N!\B'M:\O%R\4X\L3:P-,;9:UMPD2!K+*0M2Z2"I(*-:"" M"%5':=,-./L`=+-RN7C6')SC\:PL)JD1X641 M43OI+KC`"UM+=%;23A83G%5,,!KG6/>=#_`D][-*"PRXZ MH!`/Q'X!_VA-XVEZ4LGF&5YZCY[C)G2.U7&(-IT$3ANLK;3O^'*<5F@$F5`% MF[/QX;6>[=">B5A0R-]A*SK:>L?YGR7[6`2395KC46G-U5@3$Y_'&IY]CTTEMO8G^@Z:3 M\.X%86\+R:7[#7VQ.0A=+221REIY/H6SL6G#WL@$>1UG`^./D.!`-I\=(FC9 M0YR>\LFS<1M;S4KW`4F'$],**!\FU]9,AT&%8^0!$6M4_AI.EEUHH$MP7?@& MJ,K;.N#X[`V"VE.NS6`?:0"`-6[FKH656+S)ZB`1-\#PL.*@']*/`<"(2Q:' M.]Z>TMUH1R'EKGV.SW0I3KT8P$RFLZM>,ARSW/SM[M>WE%AW]W>T/^I"^40> M;$\#.1RP+M;#3D3F68-J:[7",7C(Y)I!-0T^_H(:8@,4A>]I^\]P)3!A,Y9'G2X8O+;`D=E`+?(VUZ>L,^QO\\0IXXWGQ/'`76ZJ\<"!;&C MONDFKFY^P5K-N^N;VX^?>\K]`:8XM%WE10-9)/9*-^DO8/D=)N@IW[:.WCI\ M>#7VX,6J3=!I7!L@4V`O9/C"M-P`EPGRG=U%"]VQU*.8I(-UEHI+G^_?=K!* M]:KPN&+GM"(?-RIF[A(5E']6$C\JX9`ZO@1TE`?/#<3"T%>Z2R'IX`!ZW1\8 MMB*$%L6#$_1H:RM6^6P35BFO*=\)Z"#0%SBH&KPJ%W3.*KDD_Q1I"]M@'[VE M$+W2$"G=OS075[XV`(OCG'6_8:$_IY3Q5+]X"%`1_A7#4.P??/'2R\-]0-7^ M>5B=6@.MA'.(>)BA*'#.-`G#_Z)(WHP?`@7>[%L8P$N5;@L MGSX"@`%TX#T2=DT*'`4([N'E"_!LYLREP$C),GC`CV$%'L`$WV>5U]A]S1R",JU7[V-V"3Z%4T.P;H$89X#'!J\)T@" M1:(%#3.[X<,`,E;I!Q5]@$"F0MO#GFH6B\,0=GZ8'P*0-T MKVJOK_BOHV&5IKQ6Q_U.O]\'CPOP8KV8=*^:38B^"HB_;B%"6!/8'_Z#1AA\B<@<1P.XSL.DVDJ-M M&F0"H-OX.9P^::.D2R5XHA*,Y`)BN90\-2&]`?Q#_\/#*44:G>AC@!"^8)88 MY`QD4$?@0,HX5)V]^0NFK&Y]*'D/4G,>'0(_QWL&F:^'H! MQ%-J0-@,"#*H>L2L!+PJ2&!I.,BELU6O""+L)<%W-@=Y5U#QG`2Y`=U,YX> M>*>\T=\JK\<1-1[/ZO&,WE8^#^3WC8X/#OK'GDQ^E"UZ]-F=AWO*I>%8G9!J M-!=(\_*&K@5)33-ZLK&#%#:^++KG_8K?N:QASYA`B?0519"D4GSH"/R MIV3'`X]P$H!SN/N@QI_+S5^0YDE:[K2U;7BZ!_;9YZ=='YVK0$?AR9("ATL9NBH34-G`50' M'MWJ28JQ1TV<[BASS[:9JH;?NLQ`/F!.TWVR6-<&M'X^!#OG+X$E-B)B2J6- M8H'^GN\.0/CHH3%FQF#`CG#I>44(`^]LP<$%-4%]#!>6=]B)2@*"]>"X!!4D M`$]TU%R!3L(SW_3ZB"]-GKDFU<).'0\V';JXG8..++G6T-/0EO"`,AH#K3=( M`SPN>[%U%W"(N69`4R\`[@D5_!./)JEKXA-P'S_A1$;`/'(KT^Z3_OZ%*(XC M=D&#\)#&/`LOC'=".[R[7.VTHV![U!&-7\=[LX_1J9FH5O=$W5LLW4'[\\O=?T724/=;%4-!<0.: MQJ[_6K`J44L+RAO>XF0'!C`.5C`$KPS/H]%\.KLFVB8& M.[*%%T>1Y),ZB!1BV85(3H$3/_(PBYT,+)M;0`@7-L;";=@$,Z]8O;%F7V`0 MYVVZ>!N#4<9QO!6)\10'VL]'H*%_UFP:=JTM'=TOQ#!P>#-LLE2$@N$K&,[. MA/(B%,J(AL/)Q;SNT*_W]#64GR5:4*E(T%(5-'BARSGH)-H M(>O=FLSU):9RC$U'T<,$V1*?!7#1M?Y@>X_*)G@B-<6B<\.$2PRY6&\PB1@H\?$QSA_RG$67)ZO,0$=$4%"NVB]<%[=D3 M*]J+I[Y>7_3C]N0C7>4=9@`$(R^Y;-L%ZZ[':&LM`? M=;`JFOD(AIKR/$U`F9AQ#O)7$+[=%Q?&0(A1-$0,"K.-2#&B&8Z5&@SK> MHFFX,#W%Q*@5:---V"N+JN-"SNH'$3X/_C!8/$SS"PZ5-\RIQI)G?GJ`1_JP M)$V?ZK$ZQNTH>2?0QH3PW,.]\D";?08RK*?*5B(5+:ZZ M-I&1[[4?=6L5JR;[>FG_8OM68..IZY7J&QR5FT`,7'S:@I?IFP=0#:QA*JT6 MTTQMH8.$X'BO?WJV[H#\4H41U3'40Z14`LESO(=_DCDUA^!%;NBM#OIR-)CP M%AK!6([#"B(Q`[=@AUPDM@`>\&-])*@BCZ<>K>72(:Z_E(L,$1RAZZ@%J5:+ MFA5TKRT<>Z-KT7)J>/Z!.LG!]I9D0>L_:=8*Y[\'N=-L9EYTA.$QK/#D2J@ZZR\2S^I.F3T^78>TD\43!XQB#[*MOB M)M)6W$ZYQ;!B$>.Z)5&K)ZI:+R16U"-YLN\>U.Y./F"F`E:D_G%:Y,JVK`>6 M?3/J#,^9P)9YG[*+=1YD&W_7@Q MF9S.P\7-?I04+XSBL^%41(J+T&XVR=]+M[G/H,.4![*T6,%UD/N37%X1EX\[ MZN0,ZRPUFQ"09&OMUIE,V]>%-&\RE>;HE^C=EQ>]Y+Y2?2%O(#E*]E%20O_Q MQYI=37!_G3Y(`^PDP[0U. MM]KY$$#$$42!5-.C?L:296^RWTY9+8>/-.C@P[$.Q-9^+LIL5T>#/H#/J%DR*OW&&) M]OOJB=8_ZZ;RK!D>*^W3L,9.`\F6#+7?'^R,)JFFIW,/1X4G=V3D?0C__<(#[UK:\%"\YX&COO1< MS\8A'QIKA<=OR$CY/IQ;NY"YM2HI<%&X&1#R&Q-^=G.=WLQ+ MBTM9O)%O\<:PFC+$?"Y;"('NFA)>[8QGIZ<9A*K:*:@RD4V9/+TV\39V@)A' M=:*<02J'STK"-X_P&4;/RH8520#1AA5^OX:P'"O>H`'\3U;TLC/?0:=MX=:V M3GOF+(..#Y$6#]C@%!O5_-"Q\RIVYILDC:K8WR-B]P5J[V+L#Z4XW#U-N/X/ MY5(6"+/"1O\N6:TM&_^*)`'YR(]'G+>(!,1F(#RA$&L&$E;E(2G\"^[*4&7C M2#L['ZFU[,E!]0.\A5[O?>6_E%]ZFPHUJK",JNI#T M[*&(*_B2CI70,?=;]_6.Z$[>T"=F0*C==ASB)O5GDIE0@3=57\@;2(XB$]79 M&VGX9!1YV=<1NPA&U*\ATD7_\BM1- M4D^SK\/X'KMI*'/-MC=+RW[1[(4\OC[`96KG8GKZ-7'I+N18CC;K3(:%UPJ) MX"K(LM.J;B%=J/+2B*1$*18]90R`(T/9P%-E;CE2?`_9:F&,0ZO),*W?16:;^+W9CFT75:9$H:X/SK0T>C*II52JK MPBNG_/1T"U+?FG!I^O++%DPZLY'T0H0@Q:BCSH0Y9*F-(_*9.,Z[4YK'2)M4 M4$_I,W6*;"HM!B19&QB)9M/AY#6[#;;0GTL#Z3+A[E9LBOV3AA/BYX8&+U\H=W,="*0O];GR MC3B`W_D3/57`+L^VCD4\F@$O?":&M:8E/6]>Q>J#7[V-50AWHC?ZPHH_Q2_Y MH^\VT]0+1291XQ6W$&)M!2Z$R]X$^])M-L!^HRSHH&S*4XYBZ`X=7P]POR3< M30"*",POB=.CA;^:5G[DW]K+3I_8_=NZX*GJ]2NCTRV[Z4Q^BE]$NW-!58F- M//'GO>Z_IJ*\`=>#&86&311-[9GG!YE7)V^G'8B*5&IM4\OR4=+#EO,/ZK:&9W1[5**U0IQ4+0H7Y2 M7*XEEDFN`S+<&9\Q`T1*<9Z4&(WK=V^T;'LLTUS[EQIU+L[HO2AE.5=*3`H? MSU9SJWS4ZK28?P;]SGB2NBN[%.5B23&:">,A"6N7CTY#;#$+33M#>2=:%$H, MA*&$H';YJ-_28OY1^YVI%&5A2'$\.RN<+)=MEX\>M;>8A::=<5\ZV9(2M;#+ MPZ-FI\7\,^A,^L+D6UI/B:.QH'"27+)5'LKRKOU+#3O#"V$X2%)"E/U4>U;\T_12+RO"#O':9"(#:TF)&OCBUXD=/02\+J"6DT&\395?X,O;R`?6$J<.OU6DT&\337"XLLT]0')/V,TEA1]*?I" MFWQYU_G`J8@X36M:30?Q-M4(FR^O2!_(SE](FR\"'<3;5`-LOKQ/?4#PIP#YPI"4.8`&OSC&UG^Y=45 M^_OW3__X^/M0[7X@\R[.U'SUUUQW=YP8\(L'_(-N0;&6RMHF#L[G='7+I#AY M"*@3(U729-0H2_S3U:>BC,0L=8`MTI^.!M1PANA2-S5SKFL& M/`,?X+4&!\><&MZ"T,FJ&N,F2I3+!;(VG93QXT`X"`WS]IST1Y(,14 MB*&O`#0$T5M;9@1H>*IF$W++`^C&5"Z]1V!Y>">=CJMV*!'?6YI-2?9!M\G< MM6S`^WIM6\\XC6+;"]CD=#/H_WSWA M#-JK*#6";]6?.QCWS)^`A'-M112R7,)J.M#4"@`;C!E@/05Y\=#2BD8?)XR% M`/C(H%]_3?7B9P=X8[6"!1P$#3%&7V&M0_YZT6Q@.>1ASP4V-]&)4C27OC"$ M$04B,I@7]TC^\$`@C$UG9\BP35S;TNB#QD;1%JAG<)8S+)(H4DN<"`W;P,'# MUL+Q]1N;!.T\62]TA11;@+5UBHI-".J3ACAZT38.$Y[PY1;.E@:-^H!ZE:'< M].CX9,"G9^I\U##^!4_I*(-OF/0CBEYT]PEVZN#,:H33I;.*\2'=<3PVNMKR M;.42'C60JGWEUM:?8=/*+3`EW;H_RECYAGZ`H]P`OFUX^5LF[*;E,I@#%,(Z M-ED:=$EX+('A.L$[P[TDDOCD%1`)5//9"U1,#!'X6YS/[?B\Z*_9V8*%41'_ M\CF3DA-Q1F>(^8$!;#?'M&:Z_1A)P#YY+=W4<`V_W:'IJ,D`#.V1:7/0G2OM.PD9F?EXH-I6W%JY3V!9=;"47+T"%);M1F;; MH^?H.(2;'D/7'G2P]KZ[N`AB'*9`J4ZB=F3/,XYOR=%^^VKSN(_KFY`D\-`9 M,3U"?T-G+X/P+CRT6I%'\%_,FD>@0A&"ZPL@;O@A983H>5Q:Q'7_5&K<*4Y3Y?F`O_S$=@&P$0TGQQ[ME%H M`T`1B93@](\(.FMN-:2!$(;7*&>1D+.HQM0=ZG<^@:<.08VAP]?HX_O]#AQF M("Q;!]A`KX`.`*7(M'!PY1$E?'-B$*N,'NDX/!I$&\CX?@:0TV'AMYS7W'.M]D;K&Z4D9\(6,*'3<0UT$VP:J['?)B$Z(]&O6'K MCS4U;&"R';#X+*9Z"08<'`/=^?ZS\F2]8/*E@PO9`!7L;D,TVZ'PA`ABKXWFZ)XM`SP.@W`' M`QTBYD^"GV-BBN11LVDJ%>$Q(FQ0)'79M4#DS4X_FDZ?9_HS=VL_SD8^D:N,CV5N&30F?;/\6X MG\,ML^VY`92(7Y0Q"Z*$?_GI.>+GOQ7GB=`0)T$[4*VV_:D:M=I[=5\GU!QK M;4,S4#30.A!M,%TTAX\W*+]!S$&SNYTP'49^S,G:#U^H`W#PI33G_(,'14L0 M'_[F!?R/I1?A(YL8&D^K.D\09U',L[B3NAN;/5IC81&F-IXLT.V@)FB.?E=(.S3U2VP*YEI;LYWL M/`6L`ZQDXX_8X1A]%)P0@[]ECW]"Q1S^`&X&A]K2S.CC^&4("4W]6#8!QJ5` MXM&#]:PO"$LG6`_`TAI_*VSPT=-0:@FA(D0U@((Y)/.1'QD!5M')YZZBWH#&/PULI'SR3G2;A_Y3W((&P?5!Z?`UZR$B%\\$R%]38?U-A M@R_TLVV42LG-)4W(1!-]0<8"0&%86`?]2QEDC=*'IS[HRSAN-,/&I`W/6%`U M!\DW<#2M%VIGDEVQ2^9:KC`5!I'BVG+(UO$>*@J49@W"2&ZLP"!8:WS3[EG< M'+-8)M4AS]96Q(K)1JKI4:$H>)+E&5&8CZ>\4KEYZ!=JBZ/4K/,#>`=@/`_L5N`)AXJ(F1II]>B9TOTL0[/5`$ MY%I^]03(V(/EI_593I$;GX5E&!#F^6?V+(AC3\0!>:9GP8FP)"Z)O]!Y^4B2 M7T!!8:LK2\^DA2!H`3W;AF!O(ZL[]@!T;2I?K6?&-"'#?`2;^(C$N$9_UU'N M->>[\LFR(9YX$RG<^'A]_RE2J?'6U[B?+N_>^\?Y^!M8HJ?T+[KC#GNAM M8&<;_%R-5H)\('@8#G8=EO[MB>"A-O"7$JI&Y8U%/_D(`"_0W_A$J,I]B]K] M&C3`#Y8WP9^8X-ML_M-1;B"FI[HS`NK.-BAXT;V@M[70ESH[0K^\NU*FZK@[ MZD?#_XA[I_S=,PEB<-H!)S!Z9C0W/(>Z0C8!=Q1KC^@IO;]H?PQB@&?TU/B! M^\5/NV`'&&^YFZZAF]]C)TYAT*&\T.,75H[``C=X-Y6W`!4TIO)Q@?D-7CG` M`$1/\3MA=1J(PRTQUP()4BQ*#8"-B3(EKPVO3)2V6#2E,R9ZL"WO\2DH^J`( M0!<,3^<\!W'$XC0&-I:O(`XHY!BUT7,FSA\$?6@*CW_\%0W$X)W$YX\EXP_F MA42P@AF>`!DQ>!$)(43\F&V1@AA8M(9JBP6QZ%0Z>2/V9\7QT'MQ]NK!J"8- MU&MV];ZMT+PX-,@"(U?U3#PR,LA*,A\Q,X92SZX+1D"$E&,98J MN5$^H;KFSC^#I9I&'0X[4:T2UJ'0!3^$^83KZ)L!@K^1!55[EQ@!THACG\ZX M@W5QH>,J0XVJ#/\QZC7B3WUII]Z;SD(U6&,^P9`C@1??#42V: M'&$$\%?H^`H8=NQGIN,'S5RTV-FZPRSZ&^WM7BFA&'KS\!8)"\)!]ZGS[S`_ M0FSG/[F8T-0X/!N+!<`[9UO@8KVKOV(;2]1\2$GNZ#./?+TV:&+)1T`\ M./!KH#K9).>(6##90?`CL`/>'O;K&A9*LWW3HBT,I/$!*A6,=8[LW>$9!SQ, MP`=0/*P3A&QN;?&<`GJ$#YE"?P'`A)"#;2V!&4< MNIPJ+<+L3UF%@V8;.AKO!2LXQ-4036M4WRYL,U;?@'G*:/';$86E'==7"NV< MSK*A(82S#K?0@<4'5<_8S\\IP`MIZH07FUCF7GY)1)?[1(T<7::G_,T_!8F' MH50LEYY-U=P6Y+&-A?ZQR>LAAZP$MT^1_(6&LH,9S]NR:@X6Y=+:#,!+\`8L M!S6WV(([Z;K#3CD6+(]&SSNT+!GC5(=0$9Z.E-I0^:$L2_GX]:0S&?798=0[ M/(SJ7UR\#M;("/Z,S-"(+#_ MY#Y[>)P5R3+R.L,YK?W3'FU"6.XQ+([WOUP27KFXT@T"EL^D.7AJ]I;$I@X2 M]P#"0S\-8SD-"^(Q2"&L/%^!V-[F?I]!GO'LC-\6J&>YC)0-<60C>E#*G%$0 M!VNC&>XFJ';=<^4A#';8W0?\$L*Z.1YZ458%#\'80-2C8='N(O````B\8L$= M2O`&'`B/\9=8+&RC5RF))/DW?;ZM;P%E[3O'H62*SFWKB0*UJ'$-Y&Z;^K.=S M'.6PJ,=&5FO#VA`2NR[140SMP;(UU[(WU)>C'RB.MUX;03E%["S:Q?L2[/(' M7IP)TJF!H:39.]U>@.=ILS(.=`?Y11*:-`*8,$LL2#;MQ4^/E>*$1F&"EAHDE8\@1$_QR9Y]F^W$0B)UJ,Q8YLPE^%=5G<\Z0UA)A[T@XY MG]%3KPU]AT8EGE\/7GAS$AQ=S+6U[M(:+2=(Z!Z"WZ%WOL(\5;B%-$[)43\C MZI8$O4'J5&'"@$;F27T1MAZA934!75#>B\E1/8);;ICHD1[>GHQ=GL20S7VR M%BQ/']SU9/F'P"-F]Q)Y(@.EG5_#Q(L\D5N8?EH6V9^V;%AZM"*,Z@>_D<*< MG?ZX!`LZL:2`745D7SP0]X5P\4Y(UX?%R/X]32KM\/H'OV5,\@71/=7"O`@2 M%51X!Y,5KM$3CD`'Z/1D:1C0-SY;5R<^1/S]=?X5O(^=.D3\3SILO1OVNVN]B M/Y3D]VT=A?\:WR37H?=TD\%3ZL^L!B<&-L@&/6BEY^W]62\91(7!'Y0".-NE M`,4OD.GQ8EI>$O0/P MQ?0ZB5TWCX/E:M]!H6$YCJ_"V=DX^YPO#EBT6;$N:RY`90I>PRKJZ5GP;MD/ M[9L26XM=0D-[%"W]0#7:96JTBVJT"\HR6M*!%TD==KEC"9#18T-0AH!A$E1, M4!]NSKJLH*[VP,)MWQE!FT%,LM3ID4!0G!('$17U`I/^[*35+^DX"5R-UQT$ M!^H`=#>0WQD)2M_<$*75Y.;DP50#^0U]NF@]N,ZO'>_6 M4P8Q1G(+N$B_%PL4+1/]'A9"^UU.L(2.9>/`$<>:$AXK6`[&Z[0?2A*S^^6H MO+:47I)F-3N@@"-+'=5J)VNLJ-K[J-E8T.7<$INV!I/*[13EYF/QIS>?@?IO MT3*SKFU2LTG-EA-JL+'>'%[BTFPHXS8CSFT*KK3V7>;``J4[S_4E/<0_W MA6#9"+ITSZ!Z'E/T'8P6RT:Z6&%F,GK^H!L4C.C2>R#U'/\=#G;Y9&FD#K\, M?A#(%!!R14M5.NVACK[\@H#'SG/"^WMC=O"BQ`+W@96+M#:7QR)1F+%V%T(M M/_UU7&\?4;E1[?R5O$0:*=J6:6$4&+DG*-7U:76#M"M)-(*)X;:^6GOOX)#3 MD:OXDP@&]/\U7Y.+@\-K4_E$'FP/<]L@NL/.S@V[R[M?Z3?=_H#>-EC1)LQ; MESUH!T+_XL:<.Z&@(VF2>S[W5AZ+OMG=&U3+-GF"R!JU'@NW6:=?7"S,N!EW=7'9;+YBD#WFN`7?%G@$>:*5-;%&F$ MF&HS2=OPJ\9Y"V)6CVYB3IZL:'+!I.U^V([1TV<8\4\(@@L(F'SAB;!([B5V M,X:=&V*,8!.\:&-%WMV)7&Y;:1ME;F-%NTWXV86/SZ!J$Y8CD3Z6C!BQF^TA M*#2;PVJ;D%Q!'L@&Q/X!C(37-B+W.I!WCENLK&8H:L+N\(*89Y";)35V[[&_ MY%6D7H)^ZERRQ-J_R.)7/&*BM?0WU"3?&A#'O-]\Y)?J;O%.W3?-?"29C-[O M092T69/+'[H3?.#?P?A`X\4OM/*_[(-,I&=XJ."[(H^T<<8B\V@]3"T MM4/>*?Y?6994YL0PG+4V!Y[XRZL^^S>?V(/_C@`2S`]*-23(M%YL;?V75^R_ M.1`E>9"*/UR(P0![7KNPJ:(7AX3<.:<'>LG@!G2=MB9]56AMRG)E[PL$RQ'_Q=AX2=[I-^; M#+OC:>^,<:62J/ZBKTL51;4W.'VJ?'%$*V*B>3H(?V'YLF,X*8V!2E0%:;5W M>BLHIQ(70X=]:G@\ZO9[T]--JR1/?F("1G$@RG:*<;Q/9--O!!N1:5S).AY- MAK]1WU)`^3\E7^VWV%+["JE]Q[W^J#L<]R1]JJ8/_<6T-QN*LIWJO%G__$+Z ML_N7ZHJS%TD%$?8BJ5#]7HI-%2<>MJ?;P!5>IS2,XQHUA[6*/;8HE@6S0)*) M1=^Y%9:\DF4E@E%2059-9:IJG.3%.=SJ(R/2GI+NDN`"0-HGN1*>EM M\`>]\9[+1NGV="13G;K&,AFN:U!!RI`5TIAHDC[8U`%BRA^+#&6>H(Y<&I^F9S[_+<':R MYMKO.JGV@WY.=G![`AMU?>C=S0%ORA?/MK4-ZXR)`\-IS_]@0"QV+&.COJ=\ MTC<;BO2D+12BT^YD_K1S[%QIV6PJ_=Q/&BAK6\>.Q:RC&'WM(FF=A!Y@*80M M[!!6?)>O.O44^]4$WWM!YTTXC>DK%NFJG;:GF"C*+T^`9`>P\S(3L@-8"8LW MJO]**1W`4+M%FE?+SE^25V7G+TEWV?FK1O`(0U79^2OMD4-B?D:V`ZM!/RGZ MBXN!;`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`0KO%P"&=Z7I9HR;#'T9X9HW&P(JY:PT99,; M"U1W>W>8?K6SKI')*]=%W*7/0+WI&>U2)>V*H%T_];+CWN#T6I_ZWYL7J[I2 M7FL6I$9@V)=T$($.X]ZH)05P11U>GM=1/8\SRWQ;Z`1AD>^)1\FQQE#'B@+>J`\&&8X4#ZGI9`\E"S@4'*0OIGW M\(RK;I)VDG:2=J?1;M*;G'&]3!8#I"-,>A,F6]"+D$JX/2TBXP:N(0HKUQPUC((PTRZJY(,D@R!:4@_D5P8T]"PJ$%V?!=" M%-2^,)(@Z2#*;EI,ATEO)LRDD/9&#?)6NA#",)*9/4D&20:^U/B<"Z8R:LC# M2>J=<;M;BD*.&DF-)`L`)!DD&0++,!0FI5=VWZHXWHI] MEGWL`QOBD!N>C[+%_1-1EIIN*\\`/KS.6BH6@UUY!'SC7&3=5):Z`PZ!0MM4 M*\1`?]`]_(?HS M?[4'Q+'_T_<(:!>H8!D(&_U]=VWK.'U"65D+8G04S\%_X*^7EF%8+_BOE^V9 MSEI(DW>[_+].X/"HG/W3@STL-]Q)S'EBREF26S7D40"2)H_,A!\\4F:8E=2D M781X)V4'_'2@_@.41`CN1U06^-#A*0CQ?OA%3$*0=!:2SJDK8:K!C/.JCW15J$MJ\ON3I./\VAQ"W^25*L6103,>'V37>^=Y#. M@PT`IURQP0^707G24LRN./J_"/--_41O?]952R@0.:H0)%6B5)F.NX->X3?D M\Y+Y4@MI`^?@V3(T5S=T=R-Y*P-OJ=.N>L;ICI3W`F@R4($FA1>LUM#$!\*. M`^8D2Z5GJ0N6V!1GBY(XPA(GPV3M,E*PA\]1Z9MP2>VG9L*/Y*4?1>B>5D@/0E+<]K*KL>R`SL\8&)L(]/T+,:+H7L%OGISPW_0T+DJAI*QK MEH1Z@XE3&T"%Y*+P'UGR]H)3*7O$ MJNI%F&218E8?,>O6'4]B0"$J=LI2UN?<(ZV%LL[!B:Y,5?/#$L6UZ(&%KD>@@X M*<96>^\CE[S34ZY,%PEBZJ>5`V2+T(63"WD>*;9S&;\Y-$JJ]U/[PE\KSUS% MDE_2[LQRFL(`.:>HB?[B_W@6EK??VOJ#@">;W\E9M8>B(DP80,ZF MW!W(B;X$F8$?W;A/Q&X@DH0!)$]JU0<]1;__;*R*LI<]F2!IU*H1-@A2E&OT MNQ#Y^=32BXHK80`YFV@W#^`^/E//]-I<>Y):0E/K5].J+[VD79-VK=#KF7Y3 MJ!($\3-Y)H9RSM414754&^AVS@TR2;?JZ);ZU$P8=`D#2$5T._=VP5A-U5?R"4YA()G/VM&EE3CONN:Y9%M[XW1E""<,Q#.7WIPXMIGW`\I'?&2TN=0 M>M`9G#'A75*[7M26WFM0C/06\0!F2G'ARE\WZ79/\>YY.?N45$RQ\*0S&>5U;UM24LJC MI&)CY5&$`;9YWBW<,X\6>[<_0<1-;.?C'Y[N;KY:+N%M_YP;FS65.ON"8M[W M/8]2^3+A,EN'3G?%6<":N5&>M,7VM%>^:\4*)_QBBY:U9\^?-(?`YE-1W!)[^N&8D"PO`)XI&? M6,OP[\BT\=A3N]348NQPK/%Z[H-QRR*S:/!4PG:[/$-OLR:+MF^?8OSS@=FJ MNF)=-'A.X8(3*;_6;3IA)R+M1R=PECU_V"TX&LA'W6@WXY'2.G)1L$"VTG6ERS MC'NC=61KZ<>=L^DEPWZ:Z27EYO\3+=NN/CU=AP[.\O`KLZ#E'5UE@233T=:H M,YF=,>:B5'*4NEBN>SU')Y^Q['G*N;FT3:'/F!9/"4&6"23%NKW;.QOTQF?N M[7SL,AC*58UT365A>0\&J5Q/[P>W]!1KU._T)Q/%,W47-@TP:)$3L7ZO/U2N+C\H M:V+3GRC8VL@D+OS&FA.RP!$W^(/7%YU!O]]3/FK@#]`?SBW3T1W<`_S",L,# M.TS*TU.VG0^#LSU^^*>\T93(7F+G+&P'/>72`8!MXGB&BPLA;FG:'S!LTA"! MIN,94WZO1M&(69UHN"S9I<@]`7L"-8_-,F^,[(J>,.S'S-@)X4 M?_ZO`T0BANCI(N+Q!=Y/^..(3@T_U2V*J"66C=%3164)[$C?K3N.1Q38".F) MS.TUD99(I%]L#[$C6ZT%G/+J08E6- M6"45?V2LT8@6>GPC#D&VNS07'[")A[5&A7R)3SY2W8PU'#A^YM[BC:X_63;M MK'E6S4?AQIBEM:CI<;4?RAR$`O@>6,,V45KBG/2'!W[:T]=K0458M>.'"FY,C[W7PG0ZO M-''>I=-5B74S\?[*O;%NR@[+->FP7.'A9%+[F4*.I?\!0A""]Q&'P2OX5'CJ MG%B7(#X&)?$D\80FWI6W\@QV`R1<^@2^_(VMTF7$>=S2:1ZB^KSJ0^HV5C MJ5GO!,24FAO=LJ=M^A:>HNL&/;,Z) MGH2()VM:YWQ&;X;*2U.%P+:DNZ1[C>C^1IV=<9GL#&KD9?9."#R$*+\LEU7R MJ?-.'1076=Y]9EY*$K_.Q#\SO26)7V?B3RXZP^%,<.JG*WDOHACL8#^J/*H) MH]6)_L\]S;AY`"33<.Z3[H`)QF*4+YKKV;J[\2LAX_VLTI"G[&2R/Z9JDOI@\N;J7KDR=!/7 M5.Z(_8QW-RX?;<(OJ\DN0KD<.(_ZIY]KR"*!BHF7R[@A23HI=Y54>:0U!#9Y MM$SE;T0SW"=V`1'_I]S-=6*"3?C5U`$,!V),;(O44'1MK]KR\5[A&`_ M;&L#3V\@\-^LTDPY+(U?Q3OKEA4'D@J2"H)1083:C[3I!FQS#KI9N5P\ZXYE M.QWE\^/=,\Z MTAV-8$,OVWK& MHI\E^UD'D&1;X5)KS=59Y8^YX#NFK?ET@(SUC;.U]2;ZR[U[#/K+P;L7A+TM M))?N]^[$%@UTM9!$*NO:A[\'(?'7]O\&Z!WP>1WZ(R0XD,UGAPA:]A"GIWSR M;-S&5E_"?4#^W3,)*WOR87)MS7085+"R!HA8H_*'U1;8\4[#O_`;H"J_7`]? M/&P0U)YR;0;[2`,`K'$S=RTLO^+]%`>)N`&&AQ4'_9!^#`!&7+(XW-SRE!XS M.PHI=^US?'Q#<>K%`&8RG5WUDN&8Y>9O=[^^I<2ZN[^CK1`7RB?R8'L:R.&` M-:P==B(RSWK16JL53KQ")M<,JFGP\1?4$!N@*'Q/F_"ML54E6BW>C9'I$Z0Z MKANRQ.M^3T6]80"C)$KJK:W3#ID`@\Z0M6_O\%[&LFN;/.N6YQSZ)=]PT)%) M&4QPQ_U!ARLFOP-H5`9PB[SYX`G['/O[#''J>/,Y<1Q0I[MZ+%`0.^J;;N+J MYA<%:7=]<_OQZ2;]!2R_PP0]Y=O6T5L'PWILT&$3 M6JH).HUK`V0*;'L*7YB6&^`R0;ZSNVBA.Y9ZZHITL,Y2<>GS_=L.5JE>%1Y7 M[)Q6Y.-&Q7@([RX+F!6!CZ2G+2 M0V_;>K2U%2MWMHE&/]24[P1T$.@+G$D+7I6+A=VG25982GY6Z7?R*../RR69 M8P>\:Q/5Y+WVXQOHEF^@,_%*L$Y7.+.$_!*H&7V=3RI8[T%'9S,8!;PD"TID M1"7ZED`/[GVB!LO&SHQ!_0^'O]=U&LC4L*1^(I.%D M3UC95E02KQW$.Z-1J!QLFUO[P]-`ES.KFTG4W!N1-O+VPR3]:-,/X&$ZL*)B M6$[J2SZRX/I0?XM19WA.AXO,^Y3W4_(@V[@S&0P%W&;U\X13;NB398-F-3,I M$EF0E7-OG8O)D2&GU?36D10OC.*S835#HNO01##!WTNWN<^@PY0'L@25%LG" M$:G7JN+R<4>=G&&=I683`I)L15N=R;1]]<5YDZDT1[]$[[Z\Z"7WE>H+>0/) M4;*/DA+ZCS_69(X'KXZKN1ZM.*.G>6_P-!$`V)Q4TE,'>N3`9(-);]PO>C]_ MD@383X!I;W"ZU8`D"`P>DM45MAQ&^)O=),+/Y:Z#AW'2M;93.0`\'>]/0NJ]))SU&Y M#CJ#?N&DJ+`3^ZD@7SUAVUJ\S/"L&1ZKY].PL$X#R98,M=\?[(PFIQ^&2M'. M4;3'Q>M8L0X%4@+]U3*[-EG"\K3\5)<#W+(Q5N'QMA3O-$[Y&7><:Y`7/SO^ MIN7Q6(*_Y'4*Y,>CKW<%1XQXXZDO/ M]6R\OJO1Q)M_+4;*]^'!6556[114FFW@;.T#,HSI1 M=A>3;>4DX9M'^`Q-Y3AP__0<5U]NML:OE]9I+K:;^":WA@N>T\@AUA#"6\&V M-C=+.G@0'K[2;'L#BO5%LQ?A',+TO1_*ZZE`6Z#9.H(/Y%JM+1O_BN2Q>/^; M1VP&9.NLGQ:/B:-6(U)8ECBJL+/SD?INE^_6"9PE5EL)RN+P%GI#]97_4GYO M:RI4'YTR"H,/.<"G.R="W"Y.!VIB,X)XOX(B;I%+.E9"Q]POCM<[*#EY0Y^8 M`<&,B^8XQ'42;(%,Y@F\J?I"WD!R%)EKS=X+XNY;T(WSXP>%_%@3_2.U%B-@@HM0#V>NP=R$VA%#FT;A:VJC]7*9V M+J:GWW26[D*.%56SSF18>+F+"*Z"K)RLZB+-A2KO/4A*E&+14\8`3]C_67<< M#QL5.U)\#]EJ88Q#J\DPK=]=Q!)M].5\;GMDP<)Y1U8_%G*>*\6Y@500,[#^ MI/\`:<8"1]UT-?.1#G9AJ7C)5'N7FEW(6THBT.&JH,V$.66KCB'PFCO/NE/XGTB85U!;Y3)TB^R*+`4G6._AG::\&-WT_]VK5 M5^+Z%?)A@>.I?"XOUS3Z&O),^>&!EM>*-H*K(++[NL#;+J-QU0Z7F/"1AUT%+&&(](=;.#Q0,#=K.T8 M6^$O&)4?O[7VRLHG-N^Y+GBJ>OW*Z'3+9G&3G^+7B>Y@]T9^N(8X\_ M`%\JO5-_\!J"\B;B;;Z5%QGKM:GZ0MY`7Y*.%8RWF'U7MC,YHNR=%N:FD$-4N#X[>I&XQ"PU.;YXJ);G-%Q%* M-)*ZM[84Y6)),9H)XR$):Y>/CF5K,0M-.T-YLU442@R$H82@=OFHW])B M_E'[G:D496%(<3P[*YPLEVV7CQZUMYB%IIUQ7SK9DA*UL,O#HV:GQ?PSZ$SZ MPN1;6D^)PD=TU]TJ#V5YU_ZEAIUA\4/>I2S7C1)57K+J]P9TQ&O\GA7_-+W4 MRXJP0[PVF(<%P%O2W*R9[_87YV<2+14[\868OQ4F58^E,L4 M9S.-)D,;K%@QXBOSR`>RE^+LI<54$&]33;#;QX_+ZTJ='%A.G+J@5I-!O$W5 MW^#+&\@'EA*G3K_59!!O4XVP^#)-?4#RSQAP)$5?BK[0)E_>=3YP*B).TYI6 MTT&\337"YLLKT@>R\Q?2YHM`!_$VU0";+^]3'Q!\:?.%H(-XFVJ$S9<7L`\< MZ2+P(9Q-M4.0,M MX\#LFU!Y9-QD=$3E!]U96XYF_`+::7UMS@T/-0=\BB,I==,CBYLUL>FDUW+[U'W(+Z MZJ]J%[#85:<19!]_>X[`#,:Y`O.DV>2]YI#%E;5:$].AZ+RT;^":9+>;30+&81%M97AX>-YXF)0F"0O32`()4$1SV3,(OP25 MP-/A<6,'&A<_!>AG"/<5OY$F'S5V\"Q^K4)84?R`#/4C!V_JF.YG,$A@;GPCOI=:<.)873T3YMF"#D-`Q.&2:= MWWXZ99@`MC,Y=SMXTGX+`$.94SV!DP)J'5'X@C%!UD-HABC&[.CB!A_Q%\/@ MUITBW_8LCM1-\Q%3&0@T0=/\]0>YRI$JXR@Q:SY`>IRRUFA4%,@"M5MSH-UX M_C.RPR7F8.Q:'TB'-?J&;FD[5:``,CGN&KR]6M['C6[5Q+`NT"+D0M:T7G\\ MUQ[J'MEN0`PZJTM:8&!;__SIQO-"UPO1!?A&ZCFPY#;%%7?OB!_)D=(!HAX"PZNB?#4*0FMFO/E_,(FF8E$F)L MAZ0HI%D(N@BR^:-%D%5CJ`H3XCZAO*\H5U$0&%^2/SE%>/<5XHKP0F4HGPJ^ MX(":6!5F6O4)Y%8UL30TP"F"W)(BEDYGGQ,BPV=%7))$.BOB=D$^*^(.2W)E M10S44X2W)45,<_W]P9=FA9#%QC8;63P&%9S'?+>@[:WB[3ZT/;1[NP]J2TI6 M9&BRDZ`>R,05&5'O/J[M*=?3PK6'AFSW06U-LZI:/T!=O[8OMJM('9#/>]>P M[:=^[3"V9PP[L?8/5:/0#U3;V*A.`M4C\`'Z@>UYG^J>W)ZUP:&=@3ZABE?B M##E.;WP![&C)ZE!-8WLMM"_-[9"]M"28%DN0*1SD+=I/F0AEP4;;'W!O!W5G#U,=A;P%L'& MH@W!4#L%T3X":[DOZ/;37NX+NGV+JO4%U[[%U4IP;:`ITF^(7!*"K/$;\LT7 MM,\)-8&:X&I\_6V!IXE2OW/J#VJ-](4J@^`H4"^6Y"\/Q7B/AJ-FNIGV$6^A M>?HR*9>&NL!F5*>$^GY2;@S59MJ*]Q%OH1TQSE+>!.K[2;DTU)KIJ2@,[Z!2 MI[/*F#=8=54NYUJ5;K+B0#@2[/>5]DHW()P"ZNUH]HHMX\[`"Q)W^0B4S/K- M_=+Q@B6^$@C'`_\>["[9DB6%!*Q'PMHD5,/E6.9C MKX61K;!1R%(1=U;]:&9"Z/[!V-S/T!_`]>@WZ(G4!=V0Z"#FDX-J7PR6D642 M@^8K'#&,!CJ+Y3'72Q1Y;Q25I2;ZFA\-C`;@A%%OI+5V[W!<:](TD)R7M@*] MB5Z711BF;/4G]E!/E;.Z]VANVB[^.P'/-V?ATG0>D3^'7)L2ZV[E&-3W4^VK M/@'R=<;[:)>C(P`4&`E$E0G0SXC61'1S<2Q!5)Z=G7 M0Y2<3]P@"NBR/R-:$U$($S*J3*!Q1K06HGK2&@5DU<,SHO7T*#;PM02DRMD) MK0TIN2\A`:D\@6?[:2](BZ/*Q(J2)\H95B&PIHQ3];SO"X)U$W9^/U7.-G]U M7$O#T`33\_Z_-Z9?7!N__X$D(8,,KAI6`5TS5&LD$41FEG(B]ZR4DL"[[MD) MD.[!M(G',W#2!)Y#[2-.&[^&@1.L=+CK"(&2.1>>9@BL2^XC4"JG1(U.7*`V MP6X&3D`26+3;1Z!XBU$4]91Q2@2F63B=,DR):#,#)H%']_L(TR:$S#(,3ADF MG=]^.F68DL%>%DXG[;\P2U!2*&C!$6."\K'0:MV3[RQ+<9(H;/&78"KNQLL5-$A%I.0K< M.,5-7#_/@Z.VUJ3_\1S\&L<.5PVJMP@W$9%B?E8ZCEP5B:O4*.D8D=M'QU'D M@(A^C4>#7"69$^$>U4!NG[QEV7`D/0FX+/_W4_VK@"0JDYC.L`P/Q_(^0A5Y MC'?/]--@O`Q?/=_^$UDE;C%4+OZU=*,.U!/SOY[_N%J@X.[Y&CV%Y(#:'TLL MA@]HMO3MT,;OS)P[YHR\2)(0OZ>(OSZ!1V(/L;H9X[$M,CYG^@\*Z=]=!F)T MQG&*_!G^MOF"[IX?O=!T4H_<8@E&%F8O4021B]'5,@B]>1(DEG,,-^T7JI/0 M%/E8&8R7+[&1@AQRPGUJ^N'J$0,=F#.ZDB]7R4_H--^;J]^]-SS,`UGDWFXL M*=_Q4"7I:""XQ`:[BT>Y7`8!'L2W>9TO61:!P949O":7QJ,W#D.\X"X]O`@F M"(5%7!?'N[X\7"?)O<`^-E"E2+GQ#[HE\;/G[CXP7?JS5[QHH_59G\*(P`V% M'&,FU>G8<;P9F==\?4/V,#?@,_$?9J_(6CIX*C_,%XZW0N@!^6_V#!6HLFAD M_-/=\SV:>2\NT5)1;XDK+PBIR"T\/_QDNY$5]Q&YR#<=+!!C:XYMX2`DS8G> M4$QD7F.,+%A036]5?.PW`ACL!6`RU&H"5C=B7MK>EGYXC>G9&&!45XX98'7_FTE>&-[Y]V3#8CF" MNUL'K9,@0S]@!\W$(ZV+3M[PWZ>..4/\@8UD*)I%7FNL8#_IR?=^1]%;\3#/ M&$_WI1<+D M)MU<5?X&#BY)',SQ2E*:.84P)UJV4LTR-Q\&\:?Y>U?$L:3&T59)_O:P?`IL MRS;]U8-)H@C4C*<_SCV7/E?8Y3@F+N-D MZ4-58@#"8+)!D*"\!8GX/;=N$/I+NI%2=P>YMN=3'XALPB[VY4*;%.3A^2[N M]IR/`QSJK#5].!PD.5X>^3B,+:NA!`J9 M&@Q&=[&0I8OQPH_BA/S+X7LT`'FJLD:56#YT[\'@3DI=(_HJ^VW7:V?9*HK2 M610EB)>7GPE,YBI,1ER2*4G=U9GU,,""@7_%!MP]>D/N$B4BYT2J(EL>R^?, MMZ.`^3$M0JAN2K6.8ST(R#D<"??%\*Q#=5B]=V,'.\8.GG4U\_@\"P\[>`HVE2U\!)Y&DZ)$5` MTI430JJB&.E2]^2H3C*H.3DR(#PAH"J*D0J[MZDUF!NJ(4:JK(]."*F*<@1T M0^G<,MMN^ET2)""#$P*JJC[JGNFXK>0R1(,S]>,,`S\^NJYW#:#:H<3<1:)T MSKRI'3;,=97T[JG-NB&OO/DTE`[+[9[!K!P^%6U4E\_X_'\>05&?@MHB&I_O M>?3(P^1J$<_?S5WFGRP@&4LF@0PN,D=;^Y#4VF1KA;&5E.@M39]L\XGT:[(+ M^C7LIK7%\)T28P7/<[9]02Z)B38AOC=#R`IN?&].9,!T"<^)O?\S"N^>XS/[ MI2?F\)QR\%9-^4!5TQ*-*ZH1NV4RVL+3L))V".+9B(FJX=II4\XXB7A+AY^V48]U%3=WQW%NZ^>SN+LCMXY>KSV:(E5M4TTAY MN77_;VGZ87Z%WHY.C?PN!EF-4WZ/9F0"[6<;67P.(R_9F_0&WA3&KD7^1^;G M#9N86&/LOZEMGKQ<;7[\U<;:R9^]KCZA-^10QC:?W;J+91C0#^+&^LE73)!) MQB;&[(V/_EB2!&#Z^<0W@GM28Y6;-,];H%!)^T3<2'04/M`J?$<$G'P&KB>K M;:O0-E\D9999,V%U;+I*TY0BTZ@9R.LJV/8[ M3]??],4-^]R_()0GVN]C6\V\;<^TZU.TQLS>S>8Y)VB/=LWK?I):.;>L[O)" MN65-W?YL*J!#;.XQJ=5N:$B>KCPXMU4FM1J;R;82HMBLT3*]N;5*JP95QJ2R M.Z0+YK>!U1J51W:-T>;6:\0O0P5W>F(K,=A[[;V?JE^5"50.27S=]?1^"K_*$V#T90(RQ"M?@;3_#,1Q]#C(/T4^ M;7A7$@U>A^V31U#K'1;+;QR;//%01J0(9N`HYQ1DK?-.XGC*S\5DP6U^JG;* M*Z&4]C[Y"!7+FKB)RTV*93+R_!S&2=!MPFR=W"Q4"#D'NZM,%='#F]QK_K"U MZ*IY()"3O#70="G0M#!7^S70_I8O%MET^6ZE3`,^C5 M-1:]^?E[/#*YY.!QA=<&.\QBG/U>*U1]]Q M+K9GB&B$S;7688<#N4.2HI9[0X4$,_N6;.YLW/3ONS(=!UF7JPJ'!NH5:#1:,0;CIUPM.0XH,#_`"L)>,>!8C4+F*=>DV*%+T% MI8L=B4UL!YS:G6O(>K15NSU7&2F'(0R6$P8EO37$MI8''VW:"&A&->(V5__> M(PNA.3F-E!9QL6+&'*XHX19KO?4A/"YKG`664I@NRXZ6;["UY1:D*%<3NB.A5`EOSJ;LB0ZR_(8"9F&,."RG/AMXN$]#+ MVNFX]+5!].<06?E7.*^GRKAX0(L+,!J-OGU"+Z;SP0WM^*(%O.KHB\/5!%GV MS'3(.3`/_PD[%[?NC,]_239V91$JC*M4VIU_&IEIOM&AF>[,3=X7U-+'++FUO'LT<[W2I1E&M2Q6B M4X6Z6&Y?\8+WPZT:P-3X"+\),T#_SQ<.29;#">-XI!CI]GD5Z4T5T-';U3YY M[@LIK:-WJG'=QB?@CL[?M3W]S-FKLAE(Q0,O@@U,2W,Y%YLND, MDDHM&CQX"M(3K"0&X(E M.>DK%="7G*QM'^]'\\<5EA`[WPZN%'1+()OS_OK#,\)7C0__#>LCK.;P,^-E M^.KY:R5X@RSDKYL]?J,-T5>D&3K]\"LR?2A!P#.7%QGY[!X;D(\-Q>@X'S(7 M'_)HU'$^%"X^L`75<3Y4/CXZ/Q\:%Q^&UG$V="XV1E+'V3#XM%7'V0!\;("N MLS'B6QO=Y@+NI@ERET8C*[QJ0@]H,JQ"1YP_(#'VC\4U0_O:A#MOKSLTOSTH M8.C*V&<:O^:2$-GK^5G6STB`2;[)@S-&$D,,;^Z[(6(JY[MU61[Q$I0(/M$> MN4O3N7MR[!=Z]1%?](31UE+5LU&NW8'$4,+`I4U*OGU&W]>/4S7["07!XZOI MWKF(:-Q8%Y/[GFV4:%&,ATJD.>F3=^'LRK%=$H1Z0/Z;/4/C%Q_Q.M+IR\;4 M;X`4G\$^XH!W+//)#&CGEI?H:J[:>&@$CQY"X2]?IG'X=!OAJ6N2^?2F76U;]AQ-BN5O3 M*$P\Y<.JZ]P-J\,V5ZY"X6^57$1JW%H^[L5SLR2MT]=?7F.5V*9 MP:J2^M!4+_O2`440!HWX>!E@%*Y6ING>6YE.N)HB?U94FE3LUEQ-C9E$CFQ'82EPT7QK!9VSN#WF7=$.V^,^A1LZX(^(@]O+HM7LI%&&4FB MBF_Y&J@3-J.Z.UHKI<-8[M#'S6VO@PX^9 ML[1L]X44(H3(GV\_BFR(;>1F,QI/O?/F7%7W^!B[%IF-2NSH4L?XN;',\6+A M>V_DMA=2*40DCK@Y-C)S M(JU7TW8M\5.YT[CD:EM4EBC,&P<8"TI7PC6M:`?E%^K*(RG;HJH""2F[WT[7 MQ+'J("M2"LEU:0G+OWBT=/U<5-M)LI)!@,+@;D%7!]&H07!E^O[JV?-)Y]3@ M&N_:06C/1*0=5`VFKUC=@XXVV&#D+"X4.9-P:X^/&\]']HN0)-#%2#;VY2(F MHP4F6'.A:]IAF!"2A].,;)4H]_A-DLT"707:W@LYU5;X^9D<'WE#FR()TD@< M[]">.[,=._(0PKA4@O@.R]#S5ZDO5\Q;Y\8MH`$39TP$$-4^C\S8#-1423B/ MZ8`3M@S>;')4@AXEH*=(5G?/FX<$5!C(,%EAP#EN$X2R%@B0X]/M>U**C8JY M24[B7MO/\:F+^O!=0"@E:Q!R!JE+`2O;;W",7ZA32"^*2#(=Q_MN%E%4U2C) M'`[A&+8)*ED2!16-87-4I'-;GR5D*P,J@[S$>$+IXJ_,VIND+ZZ/3,?^$YO6 M2Y_(Z8KL:J5G9[AQ@Y)2CEO1X,U1S"JM4A@V2QG%L3ZDVP_VJ5Y)3N[6C5(5 M'UR37J00[2\""@(O].11%:Y!Q=/(WBITHSZ5\2?14V/7N@M?D2]@QU5'HQSB M(Z_3=2),9FK<5+FA+I.>E M:Y&62#E5WIQGQAE65SNR1$)J-+Y'CEURM4AC[-:MD#V>S?PELN+>6%5K*`Y# M\XW]`UE8+]^Z(=;0)#89O9JK,1\K2M(*![^:_MQS[3^IC9;I% MG<1:HT:H#@>C%J6@D/1Z.AP"W6AQ$RWDHG\ZO%B6*NMPV`4YZK`.+SZS5D.' MTXS)P3G85XE38BPMU^IL"V'NC6V==-E MC7?K@.DD)U]V[9!<<37O@++<,[:X>GF`WK'%U=H#J'+?I)"KU8>B9QR+[O/% MU?H#2JH&>\885S,00\Z8#=WGBZNM!I",OC$&N#2')F5RK-WGBTMS`*",>L88 MY.J,8JA2SS2'S-4K!9M11L_XXC(/95G7.\17CHU^1.J#G[M>*A%N]O@\EQ[R MQ>6[])`O+N>EAWSQ>2^*VB4KGY\[3A]&Z]+&QL\=IR>CC+KD>O*SQ^G/P"Z9 M_?S<\7HUL$OQ$'[V^F@JF!DB-Y8F?0MHC`VBM$1@+AEV% M1HHB`#J+R,_HN[,:6]XB1-9X1D_08@G!([KXQZCE?3#U''NV>L047SJ\YS'? M_]4)WUGVVU]?PG?DQV?\O4$0KASTSY]FGN/YOPR>''/V^[N?^+_QM/[A']N? MR%/YO\2#_\]?R&^+]9OGIO]BN[\,I$6(__WQ;D">^64`R.^A/4?!P$7?![XW M-]V?HS_\/`B0;S]7)I0B.S`C:`?F!MO!(@5N&3^++0,G":4Y7[S[7Z!)9VBR MA-ZY@XFY&@#X\X!H#OR25S2X&3]<#NSHXHOQPQ?ZR86D#"(<#0BE=^2NV@&] MK'8P06:`E08]"S[&_[6BLR2A-QC/7FWTA@;1J>A!P3.F:PW(H7O'(W\:W*,_ MEG;T43"PW<&7X<-P\'$\GM(OWM[JD-H7OAJ3 M%I*.!<_()X3@IPD!WC(DW_I$6G@,`/T3'#P3SMXH9_,M9P']E(R*R/V,3X@. M16Z[\=P`SZ1/?]^,\8Y^_6]/?\>#X0_G4=0[D5,X3A-.+B[=T:7JP/@,^XF6*EV7*:^1AK$)R!5]YLJDK=LCF M5-`,@PA`L8GY0VV;'KO!F4(>-#*BY/-*)/32%V@- M"+$L+^$_\.361(IE$<4EJH_7X+Z;4?9HS=D?OZ4[+@7A"6TH83.]AQ5(6N1* MZ'D`D4&G*M56DA=F>0OE_>24GW3[M8)>9.R/*N.[7"MYBGM@;;(M&/T&W:+% M2K[@F4)/TK=@[.`F+T3,X/QAW=;WW[)K[?FU*S]U<=VW_Q;]:LV?ACHU=ZV) MT[")9JR\!,^`CN.MC@5UK+6*ZYUML5W&R_HL4>)>B]R\J;3?'S(4%W0:73J; MI_H66&157BE`VBQPQ9!.5WE-=FQ:4468XG%%]%.W5$;AFCF2G&O>B.EE)A)/ M0%M@TD54LF6E2B14R8L/$7F@J8S2^!)\D>S M.>CU(C*OMR=_^5,./"+!0]*O1T?,+F+*)GH/3W9TA,]/JPWWC>GBZAPT[==<@ MQ%:/*2X%ETO;X4+BX]=O]0JK_IUO3Z71E*=P032]VSK=VQ/[5&Z/$V1X[,$?P./V^XWM]VU69;ZP$6TLY`SYV"OE"``(W`$%;``@< M``1-`/#O`K<%!.T`P&T!01,`!FX`!O\%``9-7,!I`4%;+,#M`@TL('!;0-`6 M"W`#T,`"_+O0[0)A.P!PNT#8Q`*<``1M`!05NB@-L"&D2!T`U`V!8`W!;0`("AVP6&;7&!H0.` M81,7&+D!&+4%@)$#@%$3`,9N`,9M`6#L`&#$`MPLTX("1&X!1 M6P!PNT`#`,9N`,9M`<#M`HVB@/-A:-B6AR&W"S1X&!JY`1BU!0"W"S0`8.P& M8-P6`-PN\)206Q)*KO)*QOPEO[6N9?N\3`&=;/Z^P[.CV\D.8!M/K"<7&>ZG MP!7S^TS_`*Z8Y"*C%`7]]GWN3>*\+-F?E931(_[4SA1_X))^\X_JI==SS-[+ M>,%>ZQ2IR1_@+^8F9\+U$N4Z=2W9BN/;X-A+FL+10@I,F^B\`76;/#7.N]X6 M9BT`,5B#Z/?#'P+B#E28AI(2T((/T*KOM0^40>?D(#AD5U:?X,UF48=)DV`* MGG(5B=*=A"QSC_Z<^?08Z<* MY-/)'IM"HR5L`!";(P+;Z3*.0G#4EO.,'?BO#YGIQ63%,!>:ZNS@(D^!A_"C MY-AGOI9B3SXS9@T_P65;U[@!8J]\+PP)MA7TS\WE5#5A%73(J'C=;:H5J,UQ24GQ] MWT(="\LQ%,:QZS7X?EUP%R6)L`/9SR"J$KB^,#;"J2SS>J(W,'@&=H]]J"3* MO,-ISPEI2X""[2)`+176&8+6X#)'4ZH)2LSVL*:N+]&;A\&)Z2.*ZK&+K-;C M:P2`,:[B,J>"%'V'$#R)#9@RC!CTUY.E!=`SR9,6.NM(WP&MG=5L";GGK&"K MH.0G'J7PC2I'V"06M.C^;084)176/1U:`# MV:"[X5`Z1@%_.QZ?<\N=#W:/^@:%[>A M>=/`4)]%!(S^34H-K5)K`%45QUPI(*9]1JB];X_U2(FSJX_XA#.YN+K^_5*S MQ;>H"W$8#)W+IY2S#@X"SM-'H3*L=H+(M[W"6U;1.712.B76R-9L93%LDNE?A;@ M5"R%?O[#6D-H@VMM@ETL.;];9/V>]/7H\'SWF6D_GN=ZNKV(Q8%"].+\>%0)```E=P`` M%@`<`&%D:'AF+3(P,3(Q,C,Q7V-A;"YX;6Q55`D``U/<65%3W%E1=7@+``$$ M)0X```0Y`0``Y5WOF?X/]]*OQ1B[[1M[XG0(V!UFG,+83MMO&7&W M@":'1"5A('_]NQ('YL>=3F<[A\[O)#.)L7:U^SRZU6HE'>]_7TSBX!&$I)Q= MU9HGI[4`6,@CRD97M<\/-_5WM=\__/C#^__4Z_]\O+L-.CR<38"IX!.V&5*( M@CE5X^#Z6_TZHHJ+X*^5K@!5G9R=7`2#9=`ABCP($GZ5`?[B$V<16?X54;*S6];#3F\_G) M8B#B$RY&C;/3T_/&NF%MU?)R(>E.Z_GYNFVS\<^GV_MP#!-2ITPJPL(G*:TF M3:YY<7'1,+_%II)>2B-_RT.B#&BY=@69+?1/]76SNOZHWCRKGS=/%C*J:0P$ MC^$.AH'I_E(MIW!5DW0RC;79YK.Q@.%5C43CQ1`5-,^:9ROQG^X54:"IZ@UO M*$-/*8G[7%)M=#LF4AKZ:H'NXO-==^,'J@(!BY.03QKZ=PU'10UM;TCB".=#16.&O2N>N M+V!*:'2]F`*3T)X)@:9;N$IO[S$W&0XF7)SYQ$5/81A:>9-/1$ICCUE(`,.0SC"U]LB2#V.%YS1!`JX\U4%(@WA\M M65ZZ!="2^1`SB+9\.TU-@KY'[X\8?5GU>J2*^>F5:,P9.9A+E8 M'?I0_/M5GP_[*KLF-06!';/14Z"Q%:526I==PKG#*8_-K/6;39.C5LPLT.X_ M3$\^^5A#O@,)Z+PN@6_E&TG%]7H1QC.]H]<*,0H(P(RU+W@(4K:YM"W%7Z*U M.KR^`+G\:%HO?RR8&F]W,B54:%?:8R)&UF`(N04B,26,9J&9/])P=Q+S'7TWW]WR8!]BY>;)+AP/GR1]Y\P9 M@82V7[V*:W\`0P]C-+H532BC4@F3CR6QVL);GF15>,M%(.'M-Z]X^Y,SONMC M/F/9,N6NFG5\TXSH&+>N[7<9XFX.0>D%?U^`LA9$G%4<<8692]'!2'3&Q;\2 M]MKV.S`%G0=^BTOKD8'I'I2*S=SE0*A=OHILYB#B7TF[JZNO(%5^0-EO625Z M#KSTL(#<98]HX2J-T"YM.VFEQ2)6+8YL_OM7#C9E[$,O\TX[I4A4B:5,K_,3 MWK()PBG4J=ZWV^Z89*09?$!`6K+K>?G=R3'+4'Q9R?V5"N[Z8.Q-S.<2E^=4 M0*B*%=P/Q;]?P?VPK[(7+*"T#;@:?J3HP,?E9ZDK?YNQVPHQWD+ MLF>&EB,NDHM3*?C,_ M6L_89$M5G$\K(#Z>4E]GDJ&^<)*[^DQK77'&4@'PL=Q_PP7VS5;'<,/E@R!, MDE#;M0XBGYD`$M-O3[E*"H6%U%2;E9\"8V05_.9,[>J&6CX%6V1K?C M>&_X`(SH^LAF?_`.0L").^VQ*R9?498*@I20]E^O'K1[>$0_60CZ1(3M`=MK M6%'*LMQ.N'GGT\S7E7*F3>P-S4E`S*O^)@*-5A(#_#V(1QJ"[(EV3.C$QEPQ M/14GMB!H">\7/O%^CU$>/A+T7)]3QLPL;V&1(5!Q)K-@V"S]?>+LC1Y*>3F+ MKF=5FEZ5-:\^E6YR?!]M?WWPMIP MFI)R-YWZ9&ERS@>>''A%$Y$8M>S'.`/B(ZBO$4QSSD<44'+<79V"1!Z\UJ(` M6/GEYM)W[$T`A4C>(#3W),:$YUED%]!2;;:+P.7?29E#\TT!#S_&A::NGN>^ MV'? M(9O#-">70F?12O+H#HQC4?FHR=']F`OU`&+R=/C+&D"=Y"O-JR-$CL?4CSL_ M%F7734&UZ74$*;]0??1G]^-,4@8XF>LKU>L#MEW6&@YI3(FR+M^>H:S:M#\# MO/QZ^/'C-UI.V(@.8H?D-U?V;3%\"$U^H;MT0C/\3EX7^[):3)J2X\U(:WYN MN##KD6(N%M7DWU"V^&N;HYQ@\^^"TAU,$\-[PUO.1GI^[<#`?E,_0Z327&8# MX7BJ[]BL)<5LVAR7 M+$+I94=.OF.3JC9W-CC\JZMLS^(FQ2Z0ISZUKS1C&1#X6`#9&EN)I5/]C2JN M:\==F4J39H'"[43?T6K3>B[N&9/D]0)$2*7UVD*^[)OA,0,:Q^-^Q_^VGCX( MRJ/]K3$+MX74')'FY[B;B5W[>0TD/I=Z!7+XU$&U9[3)M8KB\8FN]M&W(Q)R*R#?HB6LJ_Y>UL M6P?)P,`=OHZG&VU'/2;^#((/KX4_`T$?7^U0P)'D\NWKC(2ULO^C@;#!S_G[ M!5/B_OO-E[?B#_\#4$L#!!0````(`*QY@4*Y;R1DVD,``!2B!``6`!P`861H M>&8M,C`Q,C$R,S%?9&5F+GAM;%54"0`#4]Q945/<65%U>`L``00E#@``!#D! M``#M?5MSV[B6[ONI.O\A)_,ZZ41RG$O7])F2;]FN22P=V^F>>4+1)"1S-T5Z M@Z1C]:\_`"E1I(0K"1!@FE6[=MPV`*X++@O?NN`__O-E';UZAB@-D_BWUY-? MWKU^!6,_"<)X]=OK[_=7;SZ]_L__^[__UW_\GS=O_OOL]NNKB\3/US#.7GW# M;98A#%[]"+/'5Y=_O;D,PBQ!KWXOQWJ%A_IE^LOG5P^;5Q=>YMTCS_\S?87_ M\"V)`V_S[Z]F3RB,7KV;_/NKZ;O)R:MWGWZ=X/^]>S7[]NK-&_+)*(S_?/!2 M^`J3&*>_O7[,LJ=?W[[]\>/'+R\/*/HE0:NWTW?O3M[N&KXN6_[ZDH:-UC]. M=FTG;__[V]<[_Q&NO3=AG&9>[.][D6%H_2:?/W]^6_P5-TW#7].B_]?$][)" M:$*Z7C%;D/]ZLVOVAOSJS63ZYF3RRTL:5'3A-D%6?:8^P.G;\H^OB;@\Y*,D M@K=P^6K[X_?;Z^-N89R]#<+UVVV;MUX4X2\1&G[--D_PM]=IN'Z*X.YWCP@N MF2SNOD\H/R4T_QL9[6T':O#/,";SYTT`EUX>91II.QY;$Z7)V@MC,X260W>B MLQCBS1JN'R#2261CW"X4/F)BD)\_P#<5XQKII(W>A=HXR69:E\QVP(*F'4&B MP;W@\66)AYA,)]-RM_BWW<:\^]>+@\LX"[/-=;Q,T+K8JUZ_.F03#P01?/G% M3]9O"_:DANE*ZUWF99",/E]>A3'>A$,O6B1I2`8_C[PT+4X6"6HE!^I*[WD2 MITD4!OACP9D7D5/C[A'"+%UX"'_\$6:A[T42]$H.I%&^U_@P7\-9E$$48^4] M0S6I'G?72-NYESY>1N\]1#"5HO:H4V&:9^E*0Y@E\2;/#BU>GC>3X+@F(#\2+%K5-A-'V4WX6K&.]ROA=G M,]]/`>]?,''>YB2 M"7$=GWNQ%X1>?)%$D8?2"YAYHO,GS#AE&7*=SR M6SJYINX0K7CBC:3Q',!WFJ])FL[QT"A\+DR>:SS]46$,R\PK^;'T44T=O_O> MKS"L/EYF:8KMX:^A]Q!&^$,P_08]\OM@EEUY(?K=BW(XCV^AGR.$)RZ>V*&: M6EI]0!]_U3>VG]6D*X5A]?'RAX?(]I+.\XQ@:00TO$\6.?(?\7:#C=EU$A=+ M6(D3Z4'[YT/UNM?U"_IM;LXNVLX2YP[8E?Y;F$(/RPA;&A?8FHB2)S*MK^-G MF&;DIWOOY1POW#!++ST4PT">D;8C=T82O*`RC(N9 M]!5_MD$0?,D@O@L'.Y+(0!UAY,+)E_B-ST3$K98@*I9>X.@I]']9)<]O`QB^ M):(@/Q0R>?-NLO6<_1O^%=A]N?9!S!.\SN`ZW8T>>0\P*KX)1%W`NU)"QN@M MQ(.7<@%M,0ALM`&30YW-4),V?,#M!MIZ+Y3<@4N4K*6%L_MPPJ;V58*PW?#; M:]PX3S$IR5.Y9>&^A4OD5Q]O:7B:74:%]8K7`%R1'_9_Q[84#'Y[C:\BT+`V MOL*5%Y4S=O82LB;,02LP-:$1CGNLJ:$C>1^KY)A@IE)ZF.V;BX;GE#;9MTW` MT?ZD0[(L%VY3K!29,>;ZGMBA2!5SRLX"@A M3M`:?!R< M_(\YV&G@O54-E/-"7@>U]N#30+70Y&&GA].>]7"//(*%WFW6#TG$D'VC#?@\ M&'D?TKV3\0-`63=X,1.8O^G>@_6A'].20`:W0= M!_#EO^"&*_N#MF!BY)9O4/@4!G;2_]2S],]SA!JG#M_*834'$R/W>B,ZX/&P M4\-G*XO@#QA%_Q4G/^([Z*5)#(/K-,WWC%,7`Z,/F)B!`\PM"@XC^SN6G;VI MG#"W\"E!Q)]`XA295A"O"Y@,YYHKXJ/22=\7WY*PWY,HCS,/;:["""*^,@[: M@LEP;L),!BKQ]WTG+BDJ"#G'F^8J0?S#NM$23(9S(6:07PF^[POQ=D'NXR"* M0(-ZM`1_1^)T!)/AW)/EN*FTU/>EN21OD3]$H7\5)5[&54JM'9@,YY9,);X2 M.>-^_+;I.-7J2I7,<6FE^:67/A2BS=,W*\][*M4/HRS=_>9P'FQ_#2JJOG*< MJNS&K=VI&BAF>5CI#7MTLW+%=3!5F<2.7E9S7E:VT(_WD='5.KI:1U>K_FV\ M#-^>/:1%S")G&V\VM.*$;;.A'Y&MVPG;5?3;:[.T!@[:6W'5LH7+4\(QYY0 ME*XGC?!HL>(,;G>6U/R_]B=Z+?D-[YD%TM1,ZA&?[;)#V/$>MS&\5#AR9Z74 MJ)8WS-B=[/B;6ZE`J$4*:\Z<_MM:"NG"VQ`(07SKJ2IGC=[#BQ.RE+Q([+1Y72$67'M6WT M:&HXNUW2CYQB['B\S6BD[OZVOU0XJ;X\4(?=RXX77*.J!+SICN3OXF9L<9OB MB<0FJJ!!<7S6=,?_=UMRVZ@+(7AZT!1,;.(0`@&SE],A"^[8WU4U@X47!J3$ M6E'2H5%0AFV("SN#J5U(HH6ZY)ARQY2HU52YR[P5O(PSB)Y0F,(++',_)+4$ M\W4>D:IR%SDILW38@VO`=QT<3&VB'*UF@!ZFW;%P:N2R2I^2VFDW,)LO[[T7 M_LU;920PM0F9M%O]ZARZ;`\IV4%@:A,^::4N.A/N6#HBHZX#Z@^FCN`G&FZ$ M3`8%N9(F8T$EZX>/L:"R%(^QH&,LZ!@+.L:"]BO5,194.V9SD^`C4`&XV;^F5$<#7L\V?@N?89QS@QIV309CIM<(=L_1;$E^?+%CW)BK<[\?^7DU:WK>($2'Z;I M>9+RM-=A5*O6/5=GK!77A55G-L,B4>1Z_>2%B-!_CN\K*^[62.]@-2>LA?:8 M7.C8/2E/)A2_`N1Q+O(PUQ(B/">*%T*NXR#WRX>3*$*7Z68U`TQ!])*\N+Y% M5BM9>1NL>EK-(-.VU=79<7,V[^86E)7IY>[B-C=[*:J=5M1?*[E*9CUAV2[LT[(X\]X;J0+B(KP$?(8 MO,_1`+6][7PS>4TPR7=G+1R2>!%&><8-,6/TL)T#UEXK-09T/RG47B]_P'#U MB*F:/>/]=`5OA,ENZ7RS2KMGM+%2)*%0CI&'8^3A&'DX1AXZ*M4Q\E#; MG9H)SUD-DM0Y20P)QYT] MH$\_O-5Z_(84R7?R2HC$F6WG`C[A2VY8>*)),-:://SY5_&?'.5S>MDM^=^K MOOE2<&>U[]RF/GD)1.C4HK2V^ZA`KSJE<^].%,!5@F"XBLMJN?[F'GEQBAG" MQ.QVG^\Q@EX4_L7U`*@,8S>VM%_UJ\K%G;`#7:D25B-5^U4V6P(ZW*W,/(OZ M.3%?WL/8(]$1598!9AMBPX&V>I7ZVPUB[4>3R@)QQVM[!XEG)/8AR;GB0OR- MAG;#6OM=G\>1%W(= M.$KCV(U_[5?YRH)QQSV\"Q2!`2E+BDU(T76*WL%N'&W/2YTI`8%7N$>UFLNX MLQJ0VZ^B)42QT_AGZQK'$D`D!_0"EO_6>-Z6&^<&](HZVPWK[7D[EY+&'C.Q MKGMY/%F+%\QRQ+!>#XL"S^X@*PRZRPAV3>Y/SF"#"DYNP9L[BEYXF^VNMZU_ M@3G!DS/;+")L7N*#B=2U?A+DJ\D/8C?6N:6RZ)I78]H9'T=A6\`@O<+2N?,B M?*5HI7'Y4>P&4NM5N1K7[C@]C@DOH'W\ZR`G`H#"!Y4E1[`;<6U8V4R.=6SG M3(3TCS![#)#WPXL*4O"=(4.AG\'B+7LF+LKM93=R6HN6)+ETQR5Q;/,+-2G; MU>ZK&EH7G0RK[J1_'9D`=X\)RNXA6N]3/;F;JDQ_,'4PW$R3R<3BUQW/Q/$I MH*ICJ0'`U,%P,5WG)HMA=QP81Q/S+$_QW2]-BV=^=I40KN/9@2EV+>'7?%$?V89"]>A0^1A(TLZ@NF#N):FO1,X]4==X4\[UIP M+#"UB5]I5;0:T^ZX*QAT7X6Q%_N:$$S.8.!D*$G][7ASYV)5MS=VN])5@HK+ M.H4)25--8B1PXB"P)5*;V&:3Y-P90/,6/FTIGB^_)O&*&)H7\(%?^YK>!9PX MB%ZUTRB/17=P21J56P]H46]X_A!M"\/Q(PJD1P$G#B)?^C3,X=HAEU-ML]D' M-LF]WB[L"TX'0' M'6RX+,CQ/"\H22]?(/+#E)L\*.P+WCL8\M1=G4Q>AP@!:H'^P/N?!@]28]JA M0.7+Y1+ZV7QY^>(_>O$*WGH9G,>$EUE^'4F12E2MW M[B1T&A<0A4EP&#+"4:O*,.#]4*I+JG+ESG6%3OD,[ST(;?`V4[Q@KZS/@_[@ M_5!J:4FS([BK]%0TPB3$I*Z,TVF/C"RB-I:_A/I%@<*?I2O,PP%@Z5 MI7@L'#H6#AT+AXZ%0_N5ZE@X5/,V7AZ)Y"A,XN(P6!VVO64G6W/$'5/;4G0]C#X6)[.6J MWMY0=4^SMZI#!MS90G>4?8_3)^B'RQ#/*Y'5SNQCJEZG^KWJ2.`,!?$X<<9" MU*TCUZY7&I3EWN5J6^I1>%8UVMDMC5*5O773FMDM*]GF3#RD7D?H#G.&[RHU%`G]:2&>>659,UC0$=+/%'$5OBJWB].;6WX77EG0 M;"[/<)!E,%]Z&P"$2KB1./\N/O[?8[87L.!1:G\0(!A"N"8&*?B=A M7\L/N[?0G!1+#H7)+XH7^>`B\LIG821\A;0.=@L/ME$4FX]*.T8NPY?KIRC9 M"`_V9C.[E?_4CYICZBNA&KGF4NRU^Q^)NL%:=;);A4^+P=K@I1*_?8];:YQP0(G#BR0QBJIF?$KZ/"DSON53[5A&;)>"WQ$*9* MYDD[@I0TU$;)35Z=\3KTJV-''$G]*ENGJXD-PV\KC93._3(K3`SK<'O9K6ZH MM)JHR+R(M[[5(39:N+WLEAHTHHX&;V:]5+2OXSYM%DBMG]W:@&9TTN3.J`.+ M]OVK)!S6MC.BE0/NW"FO550:2.=YEF9>'&!Z.9?.H[9V2]@IY2%0<-(*>;2KEC6?#G_$?-VOM9CV:T;)[\( M6[+F3KFIXWV=OZ5*]1M.^3=G25]&BY_E/'`>]"7J0-,Y0X-1U**8+9Y7B'(%G M6!M$+1A="*K)C`%.!P7AR+)4J=,!]RIG/G;3YM$0X-1UN*<-1Y4N[:=2RMA@ M!Z^?_1%FC^6O2)#T%?2R'/'JS^OZ!#AU'4$RP7$U5^Q#2]S]Z@;^*/[4>@^O M!@"G0X&+Y/G9!P.XJL5BH^J@Q&9_<.HZ1J3,3J5"^Y@0=][M=Q'R^&^UR=Q! M'S<5/%[6;6!P.A2TJ#N?U6QPH)`B9P8;F`QRXX)3US$H;6Q64\%Q2$KUI4KU MP<"'GP*R8O)6:=IM"$N3HMEC@0\_`\3%9*U2LQ'(JT1HRDI=NSI_3%"+UAA\ M&`9LQ:*]$J^9NEC$(1M%7E9LV@L$G\,D3Z--.0EJ[S$(G*.*XX`/KJ-.K=FJ M]&4DGDB:(-;CCFV&`1]Q_*WWL`9+M%4.\+/KB.G"BQ4NG"2#9^ M06ZP153WJ"M'_M3VX(/KP(60_$K.]O$(UKLO7Y,TO4H0#%?Q>8X0C/W-/?+B MU/,+@<=!\5_E8;=G[@9F\^6]]\+9M\Q\$'P8"H)ACO]J5MF'-C!9>ZXXDZ'1 M#GP<"B!Q1'8E>@;68/;1[OW-N"A(EH[/<8_/<5M]CIM]?]SM;.R"@/2&`WAW MFTFXR8I3]<\Q2[:QFMIZ;9LM*9%$=3Z\;4JFEJO==1=N+Y7K=A\^]V(O"+WX M(HDB3U0"BM?)S"O:`N.!-T-YXF8PT(?`OV/AD.K5>#-+E83.ZFCHD6PS@N

%?,/B.C454,P,7$;XI MG&UV;I(%"GUX2^).[_%9?X8)_Y-G\1C_N-4GH97LJ3Y$X="THS(Y(VDXJT)D M9YM]DX6W(;^:_?!0L+U\_`Y3O+;P3?7RY0GZ^,?[A/RJ5O*F^%LAC**04?%_ M,E/2*F%67\U6KC!D4TPN/5=ZO'+K'-?OS,054$HJ3?-U[1[==K=L_R&KSW]W MW1D[L2THZ&,4/R$<-&HSC"C*B*(X@*+4.4ZA_\LJ><;K("SU@W\X5`O^%?@* M5UYT&6=X%C/P%4JK`8`K=*HUU].7%7))`Q,:.&QB"V9AR.Q8L`?$#D6JEH&6 MEN+M%5U1QUF-H"A]X*R&'SSN!@J:@4C:`JWOI;'`4X>!UE,W@58%X0X4:+4! MW_!FJ#+0^F&@0*L-(**MX#E,.(1X[:^Q1P7ZR".=N^IABE"&'=TQDM>[RH\\5`W6EHY(Y7=7/V.4?JXUU]O*N/=_4^+!9\B#TE MJ1=]04G^=!W[44[\,N1HPQM;&).'0O!2+E-0RA_BE50D9K>!+09?2)X9VOAT MQWJ]@1E)HEB@A*14!&>;[_CHNMZ3/?.S\%F4-RX_B,4X#T4=*_'DCM/R`C[# M*'DB]@@VQU?PDCP`](3"%.)M*/3#;.;[^3J/2%I!F<5QV(.WOCL/;O'>K[K& M=?!JT2.YOZGU%@S1(U-=VY.WY(8;KYYZ$^87>5QD,[P?0&A M#6::5;="LJ?%.Y(V98I9=.?*)*B14-88&+Y*MGRX\^HA(6@6!^0?LMZ?O8B4 M3Y5?1E+]+?H[M6I.AE$=3R#J0B$0)C,+G^'7T'L(HP(G*;VZO)..U\V*9U.S M(@7\N?,.XA18GC&Y@M$,RX)1IDAP`V:BYHUJL"KX(7 M%/O*\=_^\X7XV.DY1[4<#5+!NAX!DUY@9L)HC&T?8]N=07;:*ZE(IF.@/$=M M!A#E3J/9F9MP010SA(W2RA:T0Y4B1]`5M4,6M66\IZW,W0-\OF'!K?.U4/J- M=E9`',8D9MSJ#\AU1][>BYR\Z^VLX"QJ\CX@MY?DA*UC>W.V.2>6,&)Y0"1Z MF8%-#":"L+CH1?"2V0M;F-L,KJ&8#<*4%T_(%0-]!-`K"M6I=)!.TNTE+Z1V M9SRZ)`H2%<1=+2(^QU.5)G(I%GH3__>TA>`/.ED$8UJ(_)AX=[Q#7>MHU`IF MW.0"JT;[M\!D*$4TC;#^\\RB`M]+K^.R4K/!*=3\$)@,YK40[7R[X]>T_330 MQ/5'2[KQYHXCM>LDODK0$H;D^O/K/0J"AT^7K8] MV9QC&:5&QGC-S3'T*3(;QPHL9SG7XCHW-BYJ5U:AC:&QVL#X()@-Y<,8@ M_P(/M-V9LG5(]S-+:!\#$]<+BYKE?3<[C+S\U97HRO[J9W[0/P7"L(]G;!]3ZFB/TSX&)ZW4X3'._FR-=WD+KP4[M9Y(PO@;Z`Y*:-3"8/4-$4D<%DZQG"L#T;XCNB@123<0!@+ZI$BAI:C+J MHP),?QJX6*]0JDGI`)C\KOD\N0O"A;K)SB]98Y M^@-WK*[WF/8$W2>S%8(PN"-IV>0OQ7\2>8SY0&,^T$^3#T22WVZ\M2@EJ-YL M0%E!!V0[$\&_HXL9KTMO:#L]Z%"R.I`JUDW\OL='%>7\4%SR/ MV3E94OVL9@D=3V2:227FH'^YW_](6LF]ZF]VHWY6L] MK;[VV4GX#1YTQ(;V^$:'33^WG-`%Y.L(T>PC**KY)"8SWK^7[SK_@D1?4G`L M"^!!S.N#LAOL%A*UE'5Q,^3Y6>Y%]Q"MIQQ+T`(U5M*26@.9O]3RM+P MSW&/X0`_5-K[@'SV'Y8'>VA]A@/S,*@W"O`?1@^PUA5 MT/L^=NN#M)1UDWRC69"'W[XD4(ZBN&M][);3:"?N`_*-IA4>?OLF5+:I]UWL MEJUH)^PF]4;3\X[L'^5]Y'Z_#&W&I[8T]^K$&\UQ.UI048L]N][);GV$EKO( M`?U:TL44+HTP4C;\ZIWLEAMH>W=LTJ\E,4KA`AFB#*KO*8UN=G/XV]XC#SG0 MDOPCC!;XCN4#@P(F3I4B!E@=[:;'JX4-\'CXB;);+-<2=#V@P"CKCD41=*\' MP8U0,?8M]U/EC;+N4%'!OWTLRK"RY_L7CL4WKRDO')$TIFVMHV+%S>.SR//_ MO/,?<8=M(V*+86:^)0&,QE2F,6;EIXE9&9\VZEO8X]-&CHK:D<"4\6DC5Y_: M&9\V&OS31I;OR5=>B(JG>&=IFJ]WM[DGZ&/;\R)\#@-LR=[B`\[$O5GVVU8C M;'JY1BM(XB>=<[=A^N<5@O`:6Z8(IEF?(X?N]4*2A=E7TF/8AAH5]--:P>YET?6L8D<@SCYU[1X\ M6K-%A)#=45NK,*G2$F.=M,<,&^FA1E5L^3 ME-2TOH5/"2K,0('58_K3`WCLOD=1N#/E]+"X9U!X9)OYH"$45=J$ZV/.T&>K M,7DZ8S3\-%/4$1/TYYNK[AFZ7V`,D1=A0V46K+&:TXS4W'^&!!>,4W%TAE1_ MJQ"^N7V'/G=D)>+,%+B%$:D>O_!0MKE''I:(7V"P9+GL_R**/Y,>Q`S.;B9` M384I=UR"=>*$9\AQ8U-IX?(1;4IB%ZMNSY:3:ZZ=BAPYHXWIJIYL_D M&6_5=\0+EHB2YNC-[>;U,R8Z#5Q@DV]2QF<(PAA_]"Q/4R\.4"@0,J.]W81^ M!2ESZ'?G-MTZ5J%,9IHOB[^FLSQ[3!`QE4S$B+"^9;?B0"\A(3S6S98"PU84 M)L);X5O7?9)Y48.2ZS3-RX>%]DE%;(Q6>2B[M0WDJU:WX\QH5;$2KK]/%CGR M'_%LPO-MG<0%DL]4$*>/W9('\IH0L&"TO-BYES[6E_5],LM(O,M9@A?P-P@S MWN*0Z6RW`(*\$F1Y,5J"[":)C^G838MR&V4J0Z*OW7H(\KJ09$5'F3(]EL@6 M>8$!_:S*$G#?4R[^>($E4L4OFC`VVU'R]REH MT$(P.JK%N5'NH%;-X3K.4!BGH5^P:2146?C1OT_Q`KX,=)3("[_1=9QF*"=< M]/X&"Y6('8U?)<+AY0:P$"+/)>QL\P\8K/"EI4#]R)QY#)_.-M:L)S'^(?#Z8M_ M!;["E1==QEG(],E26CF0!-"O0IN3BBX1S=Y`6066-#"]?H=-;`7],V1V+-@# M8HP^+7S@X+"AU<(O M@KE.@M;?HJ M::B-DIN\.F,8]ZMC1VSF?I7M'JY0'N3BYZ%JS>S6"%!:6G2%'3)CT@S?O9[, M.>[H#0VEW^L]U-BDF\T)KGV0N2>QFII*?Q>>+QQAB:2ZI[RON=I&K):W=!WR M[07R./=B+PB]6.X)>4IC.W4#N-.2*F$&Z18II<.+A:NFC%$;M?EWIZ.3!* M*_W6)U`2 M+IUXQQVI_#I8LEWMYO,K!3C)L.*XSK8U!>`"A3ZL_IAN_ZHA?R$\3-,LU+;Y<^'>BY_"ZZ+?TC4W(Z\RY>G$)6/QM$?L)3L":8V M$24I[2EPXHX/9D?C39+=P2R+8%GA@Y2NJDK([(-O.4M2;2`PM5DY4FDQJC/F MSBVISS#XJ(4$9K6Z;Z`(E M/H1!>H6Y*?RJ,5G?M9J_^`R=+[<5,MG[I=HP8.H&A"+<&M79VE_475USA9G; M8`LTOQ4.C024EK&-#1C*LE[2,RUQ>H`3IR'0<0,5+*VAG34$-6D M_/)LG>0Q31^"'N!D*,@&CX-*(PQ(HY_DX%F:PBRMV3/?H$=^'\RRZJX^CV_) M&[!D.IUY::A0RY&Y.*NQR^_/XH!"PN%WOW*2A'4,JY1-K)\YW'?&&^_CI]R?*,C+$^$*2B<7E93P957H4"K5/:ZF#J2; M&]3=GCT'3]D:G2>ME'?B0-JZ0>7MV7,G!;=V;-08OD+P7SG)QY`WAUF]+3X9 MWXLMS.';02W3J&UE$!WTMO[NO*1&Y&T?"H/N'9<&U>F>66M*KPZ;LO4SJ-J@ MY(]63G>[#]_++CB%JPJ%/V?T20(_\;E#_B$NRF^[EW)2Z/@Z@V4B%C_"$,)?9;U;H*[^[86GL"CUS+-9?R#:3Y_97' M,%5VP`VU2S`O2(OH)X:`>B!U+##.=*]CH>3KLEK7]Q0&]\D%S"!:8[GN5TGY MYZ_"<($68^F)$9#_,#\P0'&-+;30R>CL'YW]H[._ M#T.L>#A:HB!DHYUUUWWG+87%ECO7(N$KX"GK&?`]3W&PB+Q8JF2(B<_9=O(? M*9<^!PRQ[LP2_REFDB-(J]4IY=[I421Q;'=:(>)ZW-AJ\("I9<^8$33FG=&C MWB=.C(05V+`.>"RZ@Z7I?U7#3&B!A@=0CBHKR7'C]CKKIBI'#D;=.G/OK-O2 M*3SF&NV'@$TLKA^0[(_];W"EP5)`E+EZ^;V7] M<8&F(#G"=M`YWD;:CIP,ZF)W;^__AD6WSM="!33:V2W6?SB3Z8(_(M@=D7LO MB[^Q M#<-N:_HV3/^\0A#N'OAHH6G:$#8KYAO7-(MA=]`!WOS\/8F\K(@.ZK"JFX,8 M*LCOAK;9++MCE_/HOL?2:*EETM5487^G=+MC5%!LM)^8J:JRW[[^]'VRR)'_ MZ*6P5OA*/F+*(([UE1-))==1*6S*(">L<"IQIQYCIZ1%J@*_C5%1YO$A.04T ME3:&0(TA4&,(U!"\^LQRAQ!6[NM?,H:`C`ZIR!,_6 MK;->GK':?3IF.Q'H#:V&Z+1XHIU"?P]RO?^1R,FU:FBU]D9[N=;I=_QST]8.1>ET5;)8D9_YK>L#-77,*-'!::+.O65'V/.U<0(_*A/4^YM M>(NBI@U<1)Y?L"@,_J1WL)M6R%L:=!TQN3")7-XD\0-*_H2H^1*4`,;D]K** M:2K(78X5ATZ:7IZ.&R+0*..S$$#C@S=)MG\TE3D3!/WT5."D?X1?;9/3I_?*FF(A4: M3))-BO5['#[CW0H3]PT&)/*#!(XD^%@DXCM7FIXGZ"DI8SO3F2_:)B3Z MVH&-Y>4NQ8``[NBF@"\H25/)+8/2U@ZD*RM@!L$[@7ZTCM;J"6$R@[>:NI`+ M>7''&ZDW1,80"-LQB&ER=/.4XL29H!C=.G(ZCJF=LGH!#L[@,B$>:A@'$B8^ MM;6=HF=RTYUVO#"9,"GG.T*<%VU](NS'Z3FM[90<:R]G)A-FT8+&5Y7DO*/0 MS4`[.3'O>3"*$/RX));<2OP)D[,+FNO,2I55BJ MRVIA,^3.W;)"E$M+B;SJF,3D'4=9GQ.M'Y@:P;AZ\SVQ>'(GH>.`0J'=0&T/ MIF9`,G7?$U/@=$4QN7'&(-"E'U=,.U75P>+`J!OK#WPVPK,BDU]4@_6P)3BQB;7) M2I=#O%'/55F9,$%R#D)J:W!B,R%63`LO#*[C<^\IS+Q(N+-P M^X$3F]FLJEN,D!6C0;-*M5*H=45.;`(F:@N"1;^.>%E=#I9_)N@>?P53>0$? MLED03]'6+I0=/>3'`&4U%1:R7O M>77&-NY;RX[D35(XQ'0DL?6A1N*/*=`^U!M+\D")&#`1V'YM*PHM/JX+3BQ"?M)KQ':K9'! MC3/KZ2J,O=C'%UK!D=9H!]X;`0I-GUY'/+B3&%B1)MS!#EJ"]V8@1>GCYUBH M`N'OZ79O$;20OB-'17LU]'(`W*/0RQZC)+Z#61;)5.%@]@#O;0*TM&E,V_>Y MY#LS\6]AY&4P6'@HV]3B7]*S3?TOHMP0Z4'`>R-PK_'D$24&=\K]Y)1VA3O; M<6/PWDPXG7RNB9K9@0C M8V;33J-CLDW*\OPA%)5RV;4`[VVBF`H2;%#L3B@NP5ZOXS1#.;$PA+#D86/P M?J`P)(V1G58^.Z85$EXL`4S1NX#WUN%%JJQE%-/DPIDC5Z]V'#E^=:FI'S@0 MQF&""E<1#,Z3^!FB+,0KGBQ](3PH[@O>VX4+.6N`"A'*<612(?LPHBZJ41H% MG-H,-E16DC)O1H,\RY.RPB($>J&V!J`W%M(Q(5_C_?T#'E^EGL1>8%$4?4M/@!.;>2MZM=_2];= M"2@O7GLY\U)RKJ^?L.GME;JH'+YGFWV3A;ZOP5.;8!174\'$U(P&O.^P)L:)@)/ZOERFV]5D,!_,DVZ+SBU M`8AUV@LDN3):5[KU/)J7D1F_PS2KWLMDWSUU?@63.W%#A>1*9A:1%U^^$"'0 M'F/C=P"G-A`S'3=+*BONN.!;[YA77HB*=YMG:9JO=[/U"?IXBEZ$SV$`X^#6 MR[BJ-OUM\,$&A&?+XE21BCNN**WLWH;IGU<(PNLX@]C`R_J<@+1O@P\V,$R7 M)B!+*GLX[>>?@=^PZM^`#T-U->B40#6+'/$BE!1> MY*CRT)64W\`?Q9_X-:-E!@`?ANIED&*M4J@C;H;:GN85C(KYCB;*#HUD=P,I'29HCWM5);2#P:8"(A3J+ ME:*[H!K,;7L/=@?_S-.LJ&B9\'$*N8[@TX!`"GF6]HEJUI<=%Y4LD]))W0@" MLE0)ZON]I2V2*QP8?!H@PM&=Y6IBV$=`;F$*L=@>L35Q`9]AE#P5C[L)D2MN M/_!I@.B(D*-*:T:RCV^2^!8&$*[))M]\"8RYKW+Z@$\#@C*DN*G$;S^N:0>D MS9=5@8GS).5:KJPNX-.`X`T99BHUV8_PJ5^AMK;4#A?CJHK3#7P:$%XBRU"E M,D,(RO[K\A!@B41\&B"20N&A$K`1-&6K4I;[]K@1^#0X-.20_$JB7=`.D41+ M&T\DTK(5^#0@:(%!?R74+C"!`$E%F+*BT.O^WB1`52D]P.8E>*D$;S\8 MH7Y_*2LNU:XU&0QX087"ON#S@.[Y2ESM2XBXI\'9.LGCK)T&#_N"SP.\L$MQ M56G02$6Q>?8(T2QX)I$LS/VNW@A\'M`5FDY^)5'[L04,R*8`\#K$*S;[@\\# MNG(K:(0!DNU&!)^'>,]OSVLU!^SGPUSA*?IXEWDHVQO)U[&/ M(&;F`I;_R@7'*HX$/@\(;>C`8Z5K!])1.*=/MXW\:`CP>4"@1QOF*K7:#P`I M2UY_3>(5R8$J"EWS-'C<&GP>$)HBX*/2B_W@"U)%>_N&"=D3PF*W(*'`A<_K M(=O%VHN<&4KC`%)39G#*5&>QTK.1V(NMZ;:/^1*`DXSVF-(!03!B5O9%0NE" M?[MG$W_GSR;CY#<-SN%+!N-@+]4&[Y@8;#2]_.(GZ[<%SW2'\77\#+?Q(-[+ M.;:ZPBR]]%",=W"8>6&4ON[]C,63F-!3"9I[FAXV!N\L6`5;(HIG?62HW;W_ M8V!F>U%T/)^YXF*>Y0?$,A_H>$6(";)?_23.\)2\+)^#_.UU"E=;O'S[]RA) M8?#;ZPSE\"<)'+'Y5*>*,D5> MX2^LT'9F6V`#6VRW,HXIUU&QGVD9T9?B#63[%9D]@,WG&66$+*9?4,O>I#UT M[CV%F1=AJN9/$'DDZ_/K#GXH[>>T5AQY_A"%JZ(F`C'M:FU&,VDTDWX>,^D& M_MA->L%KFPES!<8C]H8,E^DW\.D"(>V MIS%R/VMJ*=4>=>#21LD@V^KYV M#.^3>]RH^*3H)4EJ:RO6G+10622[<'#>#T1US.2GU!V;\I=)'JZ126FFTXM"99ZA[4JDCIWT?NNW%.IAG_CEN M%_KD)6#T'/IPML*;/E=EDCV!#8^V\OJA'GX2K)E4RH67>:26)ZGOOD(%"J&H M'.D1@,VWQ3LI285%H\_Q7J!\M=B&,^V!(I&".)W`Q.9;XMV4(F#+';B;BO5Q MSB=J>S"Q^>JX"F[%)%^P-"PCLOMWZJ_C98+6!=DC!#M"L#\/!%NQ\P4F^!Q[ M>B1FA^#VRNPS(%B6QX,SMYJ[KL092N+P\K,JR9$KIEYM M]7*9W)_6=V$&!18PK;'=,`+>7*<9NPP.G%D7>DQ*<8KQ4]^ MI5B@),C];(YV@)C`%T9I/J"+!(-\9X[A+7UD(]I2R(YO$/:Q?8=@"9NK&BH; M/ZM^'+D^:%-4/T$J^(LQ>6FJI$,4I$)K;?7NP)WH-..)Q8))(=_EV"XN/WL/ M_<KK5Y.]05Q`U\+3IAZ(ZLA(]RY33M2#B@W+\E02I2A`Y$=+649 M]A.QL?V8I#A#%Z(RV@HT=#'VXCKVDS7<`S3D2T2W_+8 M$G?CK?&/]\B+4\^7VNK$G<'$#+8E?S7GJH&]EL1LN;/$C*O0D2/+F"Y[N<-_ MB;R7Y&X=9H__A9N+@GJHK<'$:D"#W+*@W:&8W)@4^#YTX?+%C_*`1$4G\2J# M:+W_$^,H4AP!3(P@D%H/IA8L"8J,Z%+/+K!D&U:'OC<]"1Z MXC7%QV(+#=![@JF]&JH:%,%FRB@,?15XLZ<(R.?H6^C#$ZVP>URY`@09PNH`IL-(]>#1 MOZ]Q;N1\4]?8(:):M#$.6_D!P%3&Z^LM#F'U'C: M:5DZ$$E8^FIZ!>\Q?4Q$Y=6IKX'78Z6\7VP?E,%.S-(59NB\O MDZ3IN8?09IF@'QX*"#R!KW.A3YDX'4:S\DY$AWG3C55WHO,5Z+]*$`Q7O/NO M^F!6GJ+H5^U[3MT!/!3(UZ-NB^60^]*SIEEOI>1&9TM/GCFC(`V^NJZ]&)M_%^%R^W(O4Q^4MH;2X`S+GLZ(#IC% MT*E(H-%R14=1\L.C*TFAMY5<+1.G()4U';B+(47N'Q)3LF=JW:RDAIE079,G M`61C4V??8P2]*/P+W\5S1#:+#3&YN.\.2X]A)S'-A#IY'.Z4:^3YVI+X^?+\ MD90YOH[+DE:7L4=.URU#G&I>,KWME`KN;F+(\K9'`4PJ:/O%DAI2.#A[Y`3+ M<'N9RD3K22%,GBI%F$F=K9F:/+O[H)V=[*3N1MXQ%Y5X+52U.W8,3#1X!FJC MEJM[=X4@7M\H2?%OQ"X"E4%T^PK*#]8HV'U;UB?`'Z!W[%]1E@(G@)"Y88/] M%6.S/'M,4)AMI-+(#SM8K'>GKC"Z.<5DS)F4KV,*)=.2C[O8KH/'%K:L:0]"L@F('A:D-[=:"8\WT:D'%8L%DV*NB#QR M?`@$+NIHM2:>JN@EF#$:-'Y#HFZ7>1R0O"(A?B7**,JPXG:S6E5-5>Q"5HRZ!?_A MH742AW\5OA6I'9W9PV[M-56Q<]EPV$/X!6$[0,4C472P"6QW0TK$?#DO5!;(+CAI3*Y=7A:+8;J*12W-PFV&Y(>5NN!$99O]C[5"?VKH"P M:\;1JW'Y:'FSF3U,7(A\'Q'J`KZ=0O^75?*,)VA8;@7XA\,=`/\*?(4K+[J, M,S:,36EE';L^%GE3,72:->.>LB(N:6`BFX=-;`'-#)D="_:`V*%(U3(^W%*\ M[A4*U>7_LE>B4FX/$9+OCJVNTX]BN0XE6]J*[A.'"D]J58_;;JX6>NK%S;5- M*1`A@[R-*)>I9M MA=K+Z?0_T$/XU^\%FVFSFQ'@J)\;3'5'VO`F*8JQ1;/0$ M*C\WG4C)<=?,)H"O)LV'[N1$Z.)SNJ M["7-*\JQ1K'1^(3MY^2.F6FU:=O+-5>48XUBHW$&V\_)G3/3:M>VE_&M*,<: MQ4:KN&T_]T%.CA]V5-G+WE:48XUBHU75MI_[*"?'CSNJ[*53*\JQ1K&.C%N1 M'#_)R?&3_9+PBG*L46PTN77[N<]R:&L65(`W>:D[DT(I=,SOU MQ%OMD36**T$:N=8<))@Q)7G0SDXA<-5@-PK1[L1!M*K#R*E):*70M[Q&Y#AP M)]*8DE_$X:FVGUK>Z0ABD.Q5,?**WD,<^VOK-+`C"DJ_K&$_$M;>E7[Z@ MA_1@N@M[U&B0+>5QV,5F\0X5N=%W=QY;+H0UVP];M!WZS%<1:S\:"W5T/2/& M0AUCH0Z;A3IV3RILJR+OBR(+[FN"?H,JW2'FI8<84EG!TYL/JEX'DP6CX2>4 MIT+DHDR/>[@9P\N0-H\+HW$JHL+UE%862VCKM'1+,:\H-[2T9]<%+(?Z/ M_P]02P,$%`````@`K'F!0L[:K_*\>@``&9L'`!8`'`!A9&AX9BTR,#$R,3(S M,5]L86(N>&UL550)``-3W%E14]Q9475X"P`!!"4.```$.0$``.V]>W,<-Y(O M^O^-N-\!9V[$'3N"M"QI[;%G'RJFI* MG$]_`=2[\*Y')II[(S;6&C82E0GD+P$D$IG_\C^_/.S((\V+)$O_]0\OO_GV M#X2FFRQ.TKM__<,O-^]/?_C#__RW__O_^I?_<7KZ?]Y??OMZQ=-PS]4+?_\I4@&K3^_;MJ^ M?/%_?O[P:7-/'Z+3)"W**-UT5+P;%=W+'W_\\87XE34MDC\7@OY#MHE*,6A6 MOHBV!?]?ITVS4_ZGTY>O3E^__.9+$?^!CT&>[>@UW1+Q^3^73WOZKW\HDH?] MCK,M_G:?TZV:AUV>O^#T+U)Z%Y4TYOW_<,H^4?7__]1__@/AC7ZYOFA[$3T< MBA>'XO0NBO95)[OHENZ:KO[PXM_("MS]R*5_^7V?NP_\LS*+XZ'\<=!71<1X MA.#PBN9)%K]+I[$ZH@;E^5,9Y>4,KGOT0'S?9&6TF\1QCQ*(UX]TVMBV=%!C MR@PVG3:F'>6"O)8RG]X#V8T@7T?XOS^P[P\XHU]*FL;<_%5_Y90&6U[90+X& MB*4IVPPZV_'%(,N'O:I,K_O379@UM_ANES`"42?ETD6ZS M_$$L*V>W1HU!-15#KJ+;*5SQ MA9=UP7<:-#W]Y=,?_JW=7?3H2=4!Z?5`?FOZ^*]_J1A:3KZR!X>5A3SM=E/P M?RAH4<_RH5F)\DW#+_NG1=:ZQ8M-QC:U^_)T`-1MGCU, MMAX-3]GD\7KA;#3[6]"";KZYRQY?Q#1YPPIZ??OFPVL>Q/?Q7?36AQ M$]UV:TW/8,IM`.RABK&QTC2_D]]$"V!C%@2'%C.T!(\0J-*J80,:G0ZNA8D/ M;(NVJP!Y]B4I-*@8MP+"A$Y%B\9X_L8;(8`C##8=$+((HU`PT6AF'RAJ MM5QU^7AZFSU$B;0]Z$.[:0*Y>'1L*:T>F\NJ`=;2@<>?Z\(QF4/096.D?M*J M,=2]M9#0[.5Z6SAV;J87)7W0K2!&$B"D6-C6;M4'FW).000)`I:"E\`!;6O+ M`(5'%Q#T\>F`@+7Q>L.ZM>!3-`'&8\V6=N;Y[WA80^'.`T=3^(/&2%_Q5)CH M:=U:&#ACWXGYM][OHCL-"(9M@%`P9FP\D>WOA#>`QP$R?PY(F,UH+CV MP-N2?$-C3J/6*M2I=1H&=Q7BW9'7;X^"O2'#-GVH#7$0^`N(O>(%W3NX3'.Z3EQ^C!&(1QO3+?]`G(Z[&;4&!)3.JF?FZ M(1$M"6N*A:V`.':&UW(\PR),H\8RQ-0ZO!;&S@]Y/CC)F7V&VN9`2#.P.U:# MNNG@@(WG/0R5<0?,:T\P)3@4%:4A(18.WKDP3XG<7(6`7&HL:R0N.68=6WMQ5 M@+NF^RPO^7&MC$JM0\](`KO5T[&MVXO4=K$E(!4%XC9J)0F`-U5&]5'LK4RZ MLZZF_YKM#FD9Y4_ODQW;+!A5?-P65+=E1C4JT38D54L\95Z,95CMU:B$K+9J M?5A77\6GSMG>YR[+S8?N84M071TSJ9EVT8PT[;!.VV$PZPRJ1=B%!9129V4X MJ11VY6U.]O"0I9_*;//[I_N(3=OEH>39)[B'VKS9,1'";GG,(NBV#8**"#)2 MT9$>(9KC:[8P)Q#2N._F0.0!WMLY8$:QP[,#9EVH7QUN=\GF_2Z+5&_WU>U` M@3QD4*,:52,B6N&I]6Q68356,?6R@LKS[JN/VZBX%5PV^7F$4M)=V6;L&6MG M_>>_\N,.Y>$"E]OW21JEFR3:765%8DDXX44.H,N>XHSUIB4CEUO2$I*&$BVY MQ&)B9=!B60"-)A@$_*=@J[$*$X"%8"QT:14T#3$,@"XU0*QKP`>O-;(@,^R)L/LLH4).T6`NW ML0K#0>ZL*&A9..QH1PT!H2:Q*#UN$PW0-Z..?&*A:2)[D,A1*^,8-4I-A$9, M?3WF#)QQ>W#\R`QK8-1<7X8!)SO;#;]1`.CRY?;/^&C3*+(:=&HMAL/>>53< MGZ4Q_\^[OQ^2QVC'N"G.RO,HSY^2].[7:'W%!R"EY0^^2-.4SE&W)7CQ%6ER\O92X M^IF*V.43!Q60!VMJ18.TXUY&<6S7?2PBG)V_RND^2N)W7_8T+6B]ZACLNKH] MH!W7,3Q6J+H=J1LVFRT<$^W+-*T:8AGBB>RBGFB,BCS&HDF+X;!W6=[3?+#= M,P!/T1@0=4I6Q^H@&I'AX08';Q[L;H(XU"S&,"3D]/H[QIM6>:&="5;O`;R[ M(%#WE8(M4:YD+:"4O2HJR[(&?](W'^W!5?]#$MTF.Y'EFVU`11C2?;:+F2'E M&]'RR<&UYMP%('P\Q)(R3W>DXM#1)R85-;I7;D'QBKYX5%!C&9>5)NV/]:QA M8M\79F/KX(DQ%/OA[HPW$.'8"+O'N*]@H?CFO01HF-YU1`'@?!+?J/YZN\(; ML(OMN3_;;+)#6A97T1,/+;&?+#4$D!MA'8S*Y)%ZH=1(!@A4"_M24LFV>0O7)_+5QZRDY/77 M.&B=+D$`F)W//.I9U47YQ]!UT'S,,ZG7613W#&H^>YZLMHA./KMI/:X;^>06 MUL'-_<"&J<)NNHNDM&9M#4!)M=JYYCKA=%\QDTDDZ#A@!CX>,7MX2,H'$3*3 MQN=9RC/ET'1C!H^)"C+VT,B\Y`WK6E>!A_WV2"&&LP38]-O7F\Z7WXJ?7KY< M?O/I&FTX6::O"DJ)D.)[B7O0<#0[)J0@-"L@(-^@3;B(#./JT>O>2G5/A7ZO M,$."KV*Z339)^75]E1C$(^[%I,%]S^9[9QC0+6$OR8GU<<"X*?!:/&)39>O; M_$"8@?W.K!95MIPT(_LH)X^\\3^30[I+F+&G,2FJ+#K1H;S/\N0?-/YG\NJ[ MDY??_=#\DO#DFK%8D;,N-0WYBDWUR].J*>HZO=8H<`%?D=-Z-$X(E[?]G^;! M05_Y55A3+?<*H`'>@\2Q2!@1[:ZB)+Y(SZ-]P@X]/;Y,%R)V8LB;$1=1)'=] M2T0X%;E(24TW2'2%=%TR4R(>0GV:I&13T:%=GZPK!NAUBC--3V5T1]^E3"OW>5+0M]66ZVRS.3P<=A$SSF\/.;.I8PKC-:07 MZ29[H!^RHOA(R\OM3?3%'#3CU1-L*(VGD(I@CU:GJ\<_@SY(U0GAO1#6#4\= MR#I"B[U94-JL>NHTD#81G2`&Z:#(!QS-,P66BAB?"9C$=#Q[.9QQ'(U9[[UD,W+"U*[GVQM)T\[1"5)++E>UD"6R.Y-GL>Z29^470/2*JS12 MM(CTM.^/:UD>WUB7)44*Z7[.%4J^+_LP[^H^9E=1[G%AUVN/J,3HRW3BO-7QP)QP`.+V8_V1B'@F?*F4W(%2AZ8@8-5?,2`"#M651[+-$.\0A*JC`,2RGNFQ[M27 M!+WL__%HCT]AO,N)*:8R@4+8PVZ!I16V:+F47M:@YY"I54"8MS_/=B[&IV7KW M9;,[\!WNV>;OAR2G\45ZE6<;6A3G66&"\9Q>0=?".<++:T'5F[@2Z(-.':K\.=$!H!"1_;'>L$)R&5*&A(B:$B/"%JUYPC"%#QN!-D)09(5 M!8FSS8'W'/$7/\M+`C$E;B\'P*8$PN+XX+RQ.QX@QS[EM-L6[Y-,1XE^6ND+ MX7PBZ8X=(9TX3**T)Z8D/=W7)Z;\*$X:X4GE]P8*5BK\,[#^K1F,&XV2D#C9A="6C(K"J%00YK&X8)CV^9) M$O5HLA3+DBTGPR/JW8@C-,8(=\,%PDU*]Q3)Y0ZEUQKC]F3`K-Z#7]\Z?\4; MHJ5L<6-:>`:XEI&L:I^E2&D:E^,7Y9Y$UF/M#8FDQ'"P^YBEV9"-V@`X7&3: M:0$AZ2+(6'?Z-`U&FXL,[!O.*?)4KY&3VMC4UX9?H]UVKB@")**=(3+&MRL^ M`+?149)R,\/=%DW:\(N4,2,<5_SM[U5.2^/3?N MOFJQFC_1.8+?F5.Z-*=^B_M\3F$?%BC55'Y0H-)10.\?/_;)YR63!U!#`>D% MU#*M/M4JW`U(T=.>C%?'\1?M<1S-@SF);RQ#L?0H@WHQS7B4/)E&,$(NRH_, MB%57E9R!/DO&%=I`!KI<&]F7UYFF>>.\[!-@/2/T%*%>*G'3",[CFGRU$\X5 MD8N>(P%WP;=#0%[]K?H?P(W$E)N((&X@_&X>@O/6*]BO4D1E2E_]"4GI"LX! MEQO#J2*TO+\((-VG5?^=KQG@H4M+I]O[83M(B(X8E&!)VZ64MT"Z^7-@LEYQ M<%=-=T9?K,3H/BL24?IV`4YK.[9;9=Z=K)?O<(H-1UE5?!WD+%Y6!K]3SVSM M!;6U*H,EV5>%M8*SJ>^BG&>#+:YH+I*RO(F*9&.PK>KV@#96Q["4.+9N1UC# M*I'1"1%ML'@;;([E,9,?#H*1"QT3+N@H6X="A[TS->KD@LBXJJ3(\#$2,%L MJ!AJ%QPN_D*3NWOVX3,VJ]$=_7AXN*7YY59*X&5;-_SZ`<20KX!CY6SH2=T! MJ7K@93GD]'DKK4!.^_ZE!#V-:D'32M`>!J44=?42A65B5A2YD75H@!2RDZ^2 M9F10[<\D((^MTA04H]NJVG3Z)._T[0G?7AF$]+!8=2_!)/Y<3MB)$.[O)S0@ M1C9F<\;"8+=C]>8P`(ME@[.CS;)@&;(P49UF\7)['A7W[W?99Y8K(8&908SL685A8$MN:.'1MR]1TK,$"O+#@3 M5WGVF,0T?O/T2\%S/;5/L\XV9?)8U0AQ>!#EWQGLY8>_J"KWK=#"IAORYHGP MCGB^A>[!8]<7NN%81.Q.LJAMCO>N*K2)!';93P2LPJ\_#:V`:=_BOQVJP(SB M)KNF?(B2'1U<2-QDR]FO53X'F7)NG>&2J]2WG^&O(]H/D='U,?_QN&PEP@!N MLYRD67JZX0.5L(T!GEU%D+[,2-ZJ3\K4AWO2^5_YO\60'`J19(9D+BL0:(J^ M%6V3E.!O/<,$9\S?TCV;ZT0\7.%I-QZRO$S^H#`/ZI"K?.]LA456N$)RI#9K7/ M4\2*@YI9RHWAC\V&P>$AY_+OQ:8]6EE.HA`>ABBT7_W0#"VU.\L=+5Y*2A)[T.2/<2 MO.L#"T,SY>Q^Y,<-(3+]LKEG37!C)5<4JTHA\4(E':2YF(*_L1V9`+Y9.;_[ MNXO+[0U-(_XNIDWLRXX?-'E4F@L_>K`LX.X"24?5'B6_#ZIH^[FG24.-DQ=\ M(=&R;7B)PH]LUGQ2AR\W:_Q<S'X#WX)1?T#/I>044 MT_.>44/(N^XQBW*6E+J!*$6$],#'RF5[&"A:=I$/,1-81KV65JJJ=!&MTE/` MQ^I%<>!?O]R*DKMG:?R7.L47V_%\HOECLJ'%97Z^BY('$]S\^H%\SNXIH/3, MNJ87H;HB](N;^Z8/PCHA32_D,B=5/TC/WF>*6HF7[47ZVKH4/+\&8/I>'';E MLLGL/-_&+R':Z6W$[S'X,S5FQJKE^W0=Z3RS^Z(F@-RFZ%B6M$L\HA$M2;\ITK[%F6T-*.C#?I<]T15*N[EN M8[PD4!NM%83P,UGK30/H%LT(6VFK9L(L9'ZA3!?-Y53O/M$^S M$X/F&G(014Y\4S4F#=4PDJ4FQ,OB,T&D<^$O+48A%J(`HMAN[I+H-MF)R`&\ MC(/SY&K#:SYG^>];!HY,@@X953H$FQM04 M]!9Z5+!&+FMP5OC1P<%(YIH>Y6CD\DZ9`BQ9F`';.HOO;1G1+7^54&^AYR.F MSO!7`K.H7J\.VJY""HE>1.Q.LG"?CZP@40!FQ@&)CN;&#D,XLW,5/=7!T'4= M4L8LLX;ETQ6;I/(LC=^QO^XM-2L\.@$T,UZBC;6R(>8O+VIRTM`3T8$XT[5= M8$%PGI",J7M^]N8/XZL33WU@Q=K``(D#:4[\$38V(][P`C0?O(HOC8OW3.Q/ MT8Y>;B?9#X]>(`V(EW"2-M;4A),33L]O'T%MB-.V9)Z4;Y-BGQ4\_^UZ)L33 M(@+)`VI#_&$F&1%OC&%:$1'QS?X<'_@6B9Z)&?"R(.H>4*V'3B@WRU$]K>C( MR=DZ,)MH-+R%$Y5V"RXZ=`K<#YM\M/-M7@)M[VCWJ3M+M+OLLWKZ7S=^K=QO,"&7\H2,3[C/[ M@OA_C>X):S62_AN\(&I-O54;E/?[:5FWR+;Z# M<5C)(LR]IY_+.>Z-O!G1GE!`=(Y^NL_R\H;F#UV=(^.IQ(D>TR6J$)@_*"NDO5\A@4G.2VY1,D:$LUTA:XF$:HWU`0IJR/4@"=,[X6OF7#K M`-5WX:I\2M<%D*F8Z+EP%.V:QO1AWSP77-M6S'5@!"F4IP&$%`K7.>-E!'VL M!>)>ZK;=)CM^+/7:.-D[P]Q%N8CJLJ7J^A$70VUQ M4':DZOH*9HI>H=DDU6:H"6;+!26"`VC>7ZCG/_Q_.B6TM M@5"-A0X_5MN@`4^((;8&F^#129`AM0H=]`ZE#3_>5"/E(+P]402>!O4@846Y MPHRGU9D2;\RAVY3W21JEFX7"]DV=X=L8LZA>MJ;MZ@C"]OW$[B0+-VQ_!8D" M,#,.2'0T-W88XOBIJPYQE;#_.B=GONLO2N\GK&]+84R1K8+KQ\"L%%#2D?EF/7`Y4F#Z\[ M).&,SS7=UUQ=;C^P:>"NY[=L$@Q61DL":$X,;,LW"$U3?GW%&U>W5[PY%H`\ MV/\PQ$;>4&(Y1A9@'?4$8U/X,8`MVHZ+U#JUQ0<>87-YNZLSP9NV"#Z](.-9 M+YPKQ.L>B.B"]/H("??N8C;B5#&O>CAAFH+EI<$V#A:,N=@+,\!P3AI=^KYS M44Y8I`5S/%NH:9%.$SI!S.>'?A;1BJY*)HI_8'"5IY5@5`D[A$/!%!D.:5(6 M)R+JG?TOD9>.R:5(QXQU"C`BQK3O-\$%_O*TSM?9,&5+VVTD0[@RU;"OO2UM MLP2WNK9.CF_/BU)',:[I7<+=4NN4+)IV);H@ZQB7GR;]U]U[&I0?`\"MX\`= MO",2%.!*;)M`VWGS`L&KE?N.XUK;T8,7%F$:!Z-J%=?C4ZG?.#OKRK=9\N`( MBR?-1(6TFY:9-^^C>^W7\:AY[Y\])!!/)S<]"=*L1"NFL:8,6%MF#11,FV4U M#G#<;,)+[^$-[]HCN<[Z#)N=9-6562@^RW".Y>.2%-SD MS1IK-\[J6G.QSXK$^2'6D`9I91TS;EY7&WQ6S?%751OWG^CFD',EC^LVO((] M2@G`=;G'6DF5:F]:1U4ZC_2.DA^=+ZMZ$^^^T'R3%,:RNG9:K->3&D$L#R>% M]ZDF(RT=/J2]Q1%;35JW%,_Q^J5$0L#YRB*A/2PT(7V75WD_)H=X2Y3SNU9*E+-\%R8C]'.DKC!JQM`"^,IWEA#*W)^ MXF\Z(+P'_31;_Z'6#LS591E"VA+?5[G,NZ*:N>)2E%5*YP.(?=$6! M'>WJ2B+[B`IIAJ8@=6R()L`4SA2IV;BB>9+%XX18!E/DU0V@*?(43P[XTM@; M4G5!I/QS6+B<*>A7S6]?OVA%2B#-C]/&9Z:0'[OLE#ZR0=J;*7`]LW5\PGVVB]E2^TX\GG!XH^A&#UD"UU$@N:9I3=>&^]24I")%?W@X M7[!L*-@?`21S+9^+(!MH35H?E$DE:CT@AF`X*CYX]=PLY8;M[$MB.B29Z3`, MA48`::M<*537CND6:XEM#4+CWA?Q"_./@FH3!+1H-N@_H.=CR,3;["%*3"7N MU>TA?1D:AFWZ0GZKFB+!-3RV7?T+2S,.ZBTP:;?D%C"H-N#YOPOO_YD^W-+< M`$:Y+>1)7L&H_$2[>Q5#?JN:(0%P,79!3Y\Z99".F!I-@+RMIUN:YS1V4UUE M<]`[>26[\B5OW2P('79D^F.6GK)&E#Y$/)AS+`,_*1UNBR1.HOPI"#4WZ8Y\ M-:U5'#AE/XOCA%^(1[NK*(DOTOIQIE7KS72`ZF\30$I+V+8GG.#T(FT?1N-" M8JX@B5T02"0X*=88$BY:!8B-S>;P<-CQ(%@1/\8W5#F]IVF1/-*+=),]4#M. MG/N`Q(R'8'):SY:V#LL<4).*'!M+>`*"8LQ7026\>6HG"O;>TFVR2\T\;FD9YDKEZS`?M,3SE(X;UMS%-PS!#6V##@\K9^L5>!:&+M*D3*+=U>%VEVPNMUM>].K. M@B43#1BFS(S+U;U$:U(U)TU[5)`%+H$;VM85`@Z'#C@8XM$.@EFX/-OM!.(M M4!PU`T.?Q)[DOMOM:@G$8:=&.HEGK%`,PY)2H# M6L_&@V:0&::&[$F)I<3/R`?C>3R"YE]23+:4=DF>Z5F6LBGE*JHW%B+@X#+5 MWR0Z$('93@OKXXENFI->>\((4,VIIPR77Y*_'U9=`MRV(&L//=QJX*+_PV7! M0?EG(?(\2XO#CA<\?$]M0%2U!<.?FE%%/:>Z%6'-4,'FQ;!QMP($LT5'&`Y3 M!@T>0DFOOK,0U.8><3L`:)J#X4C+KCXC/>QWV9/U3#]J!G8,D=B3WH+7#5!/'YX\GW*%"K9K#PX12 M+Y?V/=]\SOQ]SQT1IN^YS[J3`Y01A.9[-LEPSJAXU`)YDV0/-$XVT8Z___H& M&V=K3P6J+UK"@]47/08#=-*9BY2I'BU*7A&/QI>YJ(S'=HUOGFX8`Y8W,F<1)+DSVEH245,;G,24/.\WKS#E!?U"PHX9JR>*6V65L:^'PW[L!2I\!Q M1E4H%H.SY9BYRJ&+8"S&0*P)%J-2R@#27BTI8-8)>+*RA(N8D75E#,>XR!CT M,RX2`.=%G]=5=JMWOU6J77NTBID*+@+=PKRV`GK]M+M.A8T=L>(KQO\Z,(;9 M%_Z)R+<)V,'HR\S(RR*$>T$G;(QBTAV`L3A>[2=\,Q4J7DT'2XUV8)_R?<5X M2S?BIR/"[(19>97&@6+6 MC@"Q4^;BG\K[0`$K`\..5PD5R\,U>9RRTO;(<.':9]\5KCR38'!P-0GROPX[ M@=?O`L?KA,GX+ER\2LAPP.L8%HOC]5/R90)<.RI4M/:9=]0/1A(<5DUBU"OK M]V$C=<)$?!\L4"5(V'$ZQL/R,*6/-)T"U!X=+E0'`KB"E1.%!U>C*._I;7[@ M*>S9=_[4JW4=(FJGS,F?PL6MC!$'Y$H`61R[[_B3YPG8[=.A8G"*+@ ML&L6Y6R?)SL&W)??A@W<21/R0[#`50#$#EP9'8#96N\C-N&7A[(HHS1F+!D" M/.2VD-E9%8Q*N4Y$&])KA);*U(';-_0N25.NUF^BG=#RKY*4%(+RZ\49WU=K M1!GEY;$R_RZ-EV#]G?C!A6_0M+$Z($KI8C4HG)>T+/[;H2BY"2]N,DVY$Y$8 MJOJZ=O'W[08DW86XSM,Y/6,>7>) M/+D^G!_LYB74Y$^]J^#>@?='6*UW7S;W;`+HY?;R<]J6L-=NUZ;T!9>0^62KXV+3%;G_5(]$:QV+V2; MY>W?;^CF/LUVV1U/%-IOA+_;"4X'`).C3L?Y*'GJ9)!#5NQB/-YGN[AEP7S: M=*,#K>!E%D"IDG7[6M40SXU3I>A<#U'-/#5]]7RU^;#*GO_M"\TU2T'C:OEK35QC[:JV@ M_GNJJD6;;K[M#"57_B(R-[\-3K/H#M`CE6V!`X"SYP*CD5K#SOX:[0YT&3-K MZ@K;RIK%]#"RHJ-CL+%^$JO,4%!F-4!Q9EE2/WDJK2N$UCT_&^I@@YQ,J-T` MA76MU!.CB4\ZYP>#F3=-VFX#NWPRB#_]/FI@NMLXMG/5>2NDFQR/L>!_[]_E M?'IWSO[G75*4N;!$H5_IV+1^RBV/1>57C]&I[4W%P0*Q.JK^@HK940L\';9- M=8$:N&$'\;@)WQJ?H$ZM1RS?8(6UY1KP M.7.?->PKL,W56-"E3'.XH3XVB57V*N0MX1+RA+;W4\)ORH9/A;WU(['W_(]: MVS&QHZ#V=2,19\0%BHY0C,9BTE9GR4PT:GS7X>[:0A!FP5AJ=T6T!5.;-#&L M+9G*P$R(II:M"W#T@>YVPRD0P4P,'9-@$\7_?A8Q8GJ21%5X5"@A1HMS#QYU MX00.90"&"S+0D2Z<\!.!WJ/%Q_E`$.\;PO!0;I0'/X)J"88#P+*L_HY0EG1_ MM=O^91XKF+H*XK9_B3#U"LMP+Q5F7O>#/E,(+SS@N,6?'TZ`H/%AQ`XL\"S# M;L[0=U;59J]7Z,KZ0L.I#_R=EE(P=YUMKEM.^@7-,%]R+"&A,$&]]L$?P-82 M+H`]G1YX7LK0;8HP>_-,BMP%OD51B>5C4`1]P/;$6[XQX@(S(8O+$X#5 MT$++YT"(:C-'U+N MT.[_?:S%E+``#U.!OO6J-H4?Z6?QT^2S7-M' MY%1O-4(_M"TF30#[+0V>O(YH8S"A&PFQ"9QA(T;T^"9"$FC"L2Q0`V$534)4 M8#9AO@`!F`$U8GS.7,$9@P MA8[]XIM"YP'POO4].C,X>2ABEAJIAN8VZ6 M&9WA&S6SJ,J"(Z=O(O8K,U,/>YH6(FJ&G/%707=5D;LW3Z3?[BIZ$G\^^QSE MXAV=]%#BY=7W[[^T^OO_D0N&5(9M7@B&=[3T+#$F?_44RM/I5.MCR*I]&Y_ MR/DIK^2Y6@CWUYP#\P#G''V;/"8Q3>/B/"KN#8[/83M` MI^:8P;$*M;\3W@#+9V?GLBCSY/8@@,O46IQFZA(UF"XYY?2/W6VJN5^OBLZT M)79`B[W&C@3QS[H4W"IKD%2T\5Z%#3:.I[RO7_ITKX$,=DW='M"6Z1B6[9?(YM\\[NO:XA@L3[8W M-=LYC0\;50D"*(,4'-^N!F=Q/8&T&D94CBV%"9)P>W219XM'#K$M(TV+Y)&R M=2=[H!^RHGB?Y32Y2\\/>4[3S=--'J5%)-3C+(W%_ZI<)QW['VEYN;V)OA@V M^RM]$/#4L-J0J3,V#KY$JD\1_BU2?XPT7R.]SY$HC4GO@SV$$/9)[IYE'\6) MK``;P//#PX$W9^-6]H8B6F]1<3S2A3L"D`?$=6W/^*2YJN&9M9W[*6,[Q7,^ M9GEZ=LNK%VWT>SEE8["-G(;5L=J)9J1N1WYK6OX7SG9H8:;A=A0FQ1AN)PQ: ML9AJODV*S2XK#CF]H5_*-ZRCWYVT5$6'HK!J`D.B!"YAY:;/)#FG)72G9+MDDM#"LD`Y$D-F1 M3*Q+YUFV_4BVR88[P3I"TE`BKJ'`XH`FZK$JEY1ZQZ99@$\/NB&6N3*MT)X= M0#XR M=+WG.R"'==1."V@<7`09*UM#V`'ARA_NMR^I7GR*"Z>+U)FAPZN MZ[5C!Y!.*5>1),"V[4F/((!3)YQ$H-X;+]63O#<^>@>XEBJY2>-_I_%=DMZ= M;=A/(E.7W^%T5K>0J^@\\1WUEY]AZQY)UV485[^@(X&V+\`0#G1WL`",I:W! M?`S#V;'W49*+IV@=,RZ[`2,9H!VRL#]60-Z\?M/:(PA@Y9\NQ\\TXJU#6O!= M=&H,&@>%P@6%R^IMID.&A\^M_[A6.72?](X+ MS)1.#O",CCYP4F9R],`2G*6XI@5EHW'/=NMOZ2/=9:X!&19"0)M@%6&L7@V! M.&WW2`+8%4/(`HD<-_4:P\5)MV8])E!_P>=9@7L/8`\,?(1RUJ-`XBC6DQ`O M*MY;"8?Q\;X:"+>H?&`[>2>GRJ@AX*(AL3A6EZI!`$N"E=,F-HCK]>6>YI&( M8A5D(DU>4JY^VU-FC`$P073Q(Y`+FUK%QPN94K^A<7BY_4"+@GH>_^RTX&@U M"Z(!\.665%1A'?.F2.2(#UQ#-6F2,M])@H>Z`XK4Z+=#",X@]+2$[1K.,_$P M@*:;P=6,P[KMUP^@H?`54*[+!;)>.B)J26FXT1CT$,@)<9)*CI$V11\#0YW+ MFNS946BX,ZYM1E4-Y!`*(VWP:+0N?)/T%`Z/5;*5F^B+UYIGH@)$FIEYJ9!, ME:.)-1]@"'UEFRI%,,N6@PZ-46%7(%0(N"Q`1C)<$)C,K08%`:PDDP7!729< MU,=!_?&6@#=1D;"3V>AU]%/U_UV0X-@!(":<11HKE2#D?I+Q&_BGYC_X[I*9 MPF5;LF>\-.*/P2T$OM^^*,GF(2F.U^E%#0)!+ M+(XUA37@4&Z;X,#5B4U>VW`U-AT1.9M12-"I]7,,+J5R`CH[HH+?2/+_\$B7 MQVC'CX'N"ZL;/:1KPU$@V5M?5'?-XA\]TG!6U=FB;?@_:$>*YI!96Q!0'XP/ M@B37BP=\$,+++[?ODS1*-TFTZST5J=@S&`4W>HQPM M?:C_&\`Q=;*XK8!)&*^?O!11&^/MH(7SJGMVY?X8EO\2Y7GDM(;Z4,/5\G04 M1N4C;RL\D6/4Z)\K1N%L5&M3@^`049R/]+T0*_I)KM+$S[?[IMN.RUH/+==$#FX4]"0'E&( MZ^@BVU'-Y*!N-QW#?OOP[@M/;4*M>U(7:O17$&-AG,.^:\(P031; MTK@GZ88GKA%_3=)'6M>E*:,O9)/3.,'=KGIHJ-L;"I5Z(MPZNJ],6A*,VT:[ ML>XNZ$)$CK\@93`WC8ZKC$5?`%T>VCH^Q;"0CX=O='J?D*Z1&8)+_@-#6;%B M7%>L"!!Q:PS&IAF,7ADM5)_*7$V7_"PSU1P.Y.^B/&7GW>**YN+MM3N4;92` M@+4+,=;$AH*7CCHV!I&;@LUR4WZD MGW=/9W&V+VGUV'TGX:`C/$_@##4>^@6GZS#I"&N-XM M(/,UW7#O1U`@G:NYXX5QHMK.N]!KMK*,]NQ+HHHMTS2$NZ:3690K^#:G,-:& M_,9;H52?#(55MSO"0)AUO`E&'O-7D@,>C"1%J9!K@ ML`A&?TD3=O[^5/+H=R^<:@G!L6H008O7BH941"&!=H(P)^27;SY]$QAHY\J! MCU4;,M1XM<`",*GQYI[&AQV]W'9EAOJ%B,1?B[-#>9_ER3]H_$L:TUQ$Z56% MYWBUP>+-T[LO--\D!;W*DPV]9M/FE@UY_8]#IE&&&$HIJV_]41[YWJ\+UO]P M73&L(-VWB?@XZ9<0%`4_BQ/RYHDT+!#!`Q%,D-]NHEOVG0!\2!NT:M11O:,B+#/$UKUSL<,-3WPFXC9U=V._:]] MGO"G%IDP\H(F)@5EX\!;H-IT[#%6V_L0;!#NQKDO56\E*_C[MFHTBN+P4/W- MW;8O^R'D#?&L(7+=_([LZZ!0]@EI/T5ZWPK)A*X];.*]["-_%K]M[7`LAR M`3%PW:@P6QU61=-`Q<)D!,IG@7K:0ZAOBV-?[2E,S,2:7*6D_ M1*IT<3?U>3L<^[O.B%6=O5`.2U3V!S&3!@G?*(<_)CB6>D'SH[?2R]D>E-.\ MLJI@DX_B,K_FQR*G,K[3^\0YHWL+;CR.Z^J"M@EG+G-2=1F4-9T_"IV`/8=M MF9$KQOE]4U6FR<&#;RJ1!49R'4P#N<%+,`GAV%DY>LY97D^`)TV_R>H=\_LL MO^3.<2=3MTCWZ'D]O(?#.?%'K^<3TO3-KW;JW@GKGE3]!^2(!!ZE\'*"3,.' M8^'5*>"`+*]3\72(=I>WN^1..#C?)\4FVOTGD^;GJ#SDS,HU%M#YB#JO7]#B M._,&0$Y/U_9'N@Y/2-4EX7V2IE/2[J0`C(%;4EN0T6CJ]J!7W8,2]\PL+FR1 MH@4`+]MTE*>9:T)C,4R5GG89R2IJ-`?U": M#`%`,W!X>(CRI\NMV(,Q#L_9,>Z)[Q!TAP.PLEX;BBY#`6M`*[ M`^J04#M9S*L\$6*6]&&?Y?Q?<<)TE4?KTX)L#R5/R-O!%!>B?AHJH=%+/1&` MQUD2>2*G(\_6!0;T[&(9L"=0)ZC#!Y^_H+^DFUV4//"+E`>>1:(Z"3#U3.KH M3`9'[$HQONJIA9V;;LYZM]CVM6>O3X1'@XC*?CJ0^19#;*2_`LY3<[<5D MB*+#O;:<8<^&#S"G&[-9]KC_,;%>:ZVMW!+,EJJ8E(+2!CI3[3U0C&`XS#I9 MKG#8=3,WB_$+9R.T&!M:`!W`%L/WAR2E%^P8J4](IFZ-@O,^LY;YY4V):(L. M^$"X]D9^('S[FX!E&,>Q!1(>]?9@#$8XWP?;E^RS(MK]E&>'_04[#1]X&`W? MK60\I^*!QI=[FHL)J_^1WE4N5![[;/"(S.P8T$\R>P@4FUW1(1$]GI"V3]+O ME+2]GI"VW^:>HLI9C>50.9X1@?3#+`.5L7=F$9PLY+/YE-RER3;91&DY*N>= MT&*N$V=&YPA>G5E#83C]]OH=)"2N>P[=\;/6L)Q:!^8(?$/_O0;'UWUT5*.# MX6&:;WUU+J?9IG?6^M+>/QC9,'NG?/H`6RW\!#/)RL_A0PT9_>4DC*28/:H_UN]G M3TA-62>T$K1HL5Z3Q&H$J%*F%KP5$3XUU+@N=W630KJ<=0T./3]G*7WZ.)1O0(Z-$A`U=B'&JB4H2$5"!`TYJT,EN1T79#AOIZ;* M\E#)TA501WL.M9X$D#AW!,88XVZH`'R9&17W!A"+GR'?25;L2"_>V)^1GBH" M,N3ZG-"=)=`G?SU-DE[N=6H$F*6`OXC6E/*3VT#F"^@Q)NUIJNSX"(7[T+ES MS2,PD3_0!`!CU9->\8_T#A@5VG([JE;0R-#6;*EG%Z7T71`<^B!D(H_@*%'7 MM]'K(>#1)TF3A\.#%2O#=I#'FA&#TK:Y^AVIQ-127()NZE53+FWA%?,-J)71 M%S>M'+2#U,H1@])\5[]C:^5,+D&U4C7EDE8JYGN18GUG_(%]4CZ]>3KG/MW\ MR:DZMIH*O$R?CGEMC;Z&@!=9J4F"J$V]HB#P5>Z,*J4N<6?2IT74W+$^-%9M M:'L5X#!J+$_G$UX-78H4+U>@N%?DX2(=5E@M+.5/'4CAKOQ=Q%!>0#65`2_2 M<;'<(H!JN>[3,[K^=)V;Y93GEV*"VHR)@^.I M.-A+R?OQ8#E_+/^M(ZH+J!JH-4O]];YW0JHO'FO)/I>AZ[597,P]S9.,UU+. MR\!$K2>69WN[5%?.6DCX=VD;T8>.:*V1AFC-A:;Z&-^759]CJPVM*HME^98F/*W=\E;)K>C"VL/X M4U70\%C755?Y[*O,,9E:M?U8VLXJC=JN"N4GU,AG"[MJ_?42FV&4@ MU[3.O>\W9;\;#CJ3?9SF>FM66ENFZW,K7$KDW?C MF#1J\PVBXW\UVS2Z+EC+,*%:YIX?ZMT7FF^2@E[E2:?GB]MG[0>/QDH;AFP] M6]WWN#9?)>*SQVFQG_L@.MQ5@`]D7WP1O0M_2?$,9899Y]N* MM^RJ;UGN4-?^VJT,L^XK/W8T:[YFJ-:#7N/R?PYKO>/@-2(?LYG&UY-C-\\F MH[2L:398)%2SW#`$9)@UGSL:TZP=KO5`UW[R69AGYP'LQ#YF$XV@+U36EV,W MTV8CM:RA-EHH5%/=7F;!F&K-YX[&5&N':SWH==>-S\%4.P]@)_8QFVH$?=G( M^G+LIMILI)8UU48+%<@5-(RMUGWO:(RU?L!`;J2?@[EV'\+1W?0Q&VT,O7DV MMMIBI=:ZD9YJK<,(DNWYV/]"D[M[)M`9PW=T1VVF'IJ#(PJ8=1]4L-=S#1^D M9@1YC<`?Z3?T+DE3?COW)MKQG=7+G.0S]:\J&])1$%?&S>(BWYH`<4Y2M MIZ5?\=&>@YD/:`$MO%[)K+6(+LA%2`OIHH,[93$MIC\1A%Y2EWF0LNJ(A_Z8 M$$+X(ULUEC=OWBO'XK;MB%:/AGWT!<2/D6-:0WR'>-5EI&7F^:\D<\>]O;H\ MVN5DL1%X9FO*)*.W^+(RQ>(%M++,?=N(Y.Z;QU=(Z\[*$X#^HOY8UR7@>7GN MS_$]AZ.+GCBN-0O"G(*_7U]H10-\V^ZY*J&P<81A"'/6G-7>RX=V*17(H(_B M&=:_E<%Z:^\Y+JVVU.-0!2R0J"2?[Y/-/2GNQ7:&*6+OE3W[$\T?V3^V64Z2 MHCCPY8DP#:ZJ:V:U>D:<4?J\GN+[K$B(=A3N2'7%U.EC]&`KGC9H!GC@&+$W M5G_^,^&_(Q'C/9ABMN$U4ENE0=,002NU%1!Z$XY<(&P!5C&T M4UVOP3CSLS;MPOA*2?TO4WWY/#;LJU@M[??,XFZ7U'AZSW?0'<=851K:KWTK"NJO?? MOPY6[Z6!<-'[L7*MH?>,:IK%[U'^]26Z]@_$\-!_3K[1."3M`PB3D*FZ\VJ_CE1;!FM, MQR-!.YHC]2WZC\'-/25IFT2YX)T7)$G+K'8F;@^[W1/)5\EZOJV>%+!^*2U)')64/XXEM^P_H@!?R;IC]I3I!^_QD,:, M#4Y7]4KVC/J(79&.9G*U9&$&&PD9:6>;0I#]'N MAN8/KVQ1&\#<0,=J@`\VWN.MEBO28XMPOE##$-!GH!N77;*EY*LGRC:17Z/' M'>"8`66T`8H-6.+XVA:9='94*BB@#ZM*IK6'NEY-T,7=DOKA6^90.F3_VV]> M?A?.:50ON_(,JM6;1=78V>^HH$!38R=?8T\/%O9^A:1A7TNA7WX:HT;+X%IU>UC,X[OX]FSU/ MI>Z1H.GT@&T7=>`$*VFT/(0K*?3K$+<:LO1F?9:T9UEU3AY];72/!$^=^VP[ MJ3,C6$N=I2%<29V_"]$^R]);U'FL/8NJ\Z?DBZK,^2]JSK-O. M>^-Q@[_MN/'<=-RLMN60AF\E37[U*D!-EH2WN.I6W6SL)NRA!T1XVXV=]RZZ M(EEKPZ$8RE74^D]A^J!5\ENV'+(>+7Q'2'?>CKL!$>)-X8!UM\M"3K+:?:$\ ME.MLI[_]YE6(?@_5`-BN#25%6OCF,,E+ZK\/&9`AO$#0"^!VB5@1K7:/J!K4 M=33]Y3>O0]QH2PKBINW#@3NV=%\NCQ'6^]81I>5R?G2P4"!G[WLG:[TS`,F; M%=K+`J#\6"YBO].+>4PYKJR1^FL;D",PM^^C)/\UVAWH65$<'AIQ]G13TOAM M\IC$-(VOHW*5#(K.WSX&<^PQD"N89_YU(CY/>M_GUKKB@#0L$,[#D1GL&4/; MRA\W\N=KR+^V[5YR!([2HON:J<4LO*>-.E*+?YT4O[_/*3L_,"33HH2T^,IO M'ZO%UPPDH,7G'!#.`FEX>"XFWW%L>;/3+1^`I!F`9V/SEQV"H[7\)G.UJN4W MV*HCM?S-6O9KMF/=[)+R"6.W/_KZL5I_[6!B[/@[)I[+`N`\O.T8/'9C\&S6 M@#FC\&Q6`+/9`MG]*VW6$>1C,,G$'SF_M!G_=3YZ#-D57(8.P]2ODBC!W;Y# M#64K+T^&<'2)(1:7^"C2/CA;F\6R.[B:&CA3_7/TMRR_85\I+K=OZ6W)\_G\ M_<`6CD]T<\B3,J&%)86W:P^`1M1=J+%2"THB2,GEEG#B*H&9("<=/7)B\&4D MS"9("(EL3^4%.FR_<`WG(J<^7DM*"O@"RIGLKZ@0$ M>N=:7^B(PC,+5E?DVI@X?5O(`X&"46D?+](D5HU0@\2LHROMI#1#.R_XD0W. MS]&7Y.'P<,:V7C'??MD"'_4D<"&/)K:5Y17JUJ1M'D*$H'7P1[&!MI$'M`F; M>QH?=O1R^^YAO\N>*/U$\\=D0S4^FIW@A?WKDXH!\$`_V4'?^F*.;:4?WUCRZF6%T;UU&%W3Q`C(#TEH(8P/@[.DR M8G1"6`]%*WT0T':N-F22]VYQ*SD`,?(1#7L89YA#EV&$M(;K@GAL`U=%,)SE M^XFF-(]V[+A[%C\D:5*4O%CP(^6^WK30OS+THP>T2ZX"C?%1TPD?QY"2U*1! MG%>]YFNLLSZ3!:>"UW3'BX->17GY=)-'##H;<=W`=P7=+Y9CB42O<&,@>6L;#IJLVU!%8R1T:/?L\>V;KSB=\@9[8DNIKF8/Y-+;O23(N&8L]0-PW`KVD>[*%/ MTSC2LZ;\34YIRCI^MLV@&FW#/APWLVC M?011V-4+T=Y+VBGX4P98TEZY?W%(4X29F)VIRE&"BY M9FC1#56O&"AB^<[I!F`4!3$5_;/,5[6&W&173)?NF=UDEO4A2\7ZHK53)AHP M@V1F7,J44RG834::]J0BJ)92'/,2M@ANQL)/!MDJ;"H1*C,0/4;)3FQSMKP4 M<"-F5[!7LA:(N'=`SA#@=MC,0O)Y5-SW]T4WV5E94G82S=@.Z&=*2]/6PXD8 M#-N.HHRUBY,-SU<,+!4E$:2DIL6!^]%)Y68!)HK%3<&&B[;IB[:/GEK\1Z(; MGMOL5HCY4/6%"'D?B`VQ[X&O64;@8Y;*GVH,3G7\T=H`%UHP$^`FR%BI&!51 MXJ5=,BM2'`-P9#*YP7^:4!S]*1-#M@!)RL'_P/<&=^Q@7_)_U`L^.QFT>X+Z M.%#M(/91^H1H%CQ`-[0*[HB#1P-9UHD*Y%/V4<^PN]-/$(KF;J=)X_<;-87*15M-NH-KSX M\2T3NGUGO,;%S41.CN%:9_(@KYG5N.*&)P2O^#DA#4>D9JEJ0CA3O80,1W_.(#LNGO"/EYGN<[? M)L5FEQ6'G/X4)>D'UNME^I9]XE&\Y+E(BS(7[M#B[)8_[]F46D>Z?T]@;O4I M0HZ1T/5!>">$]T(N4]+U0WH=D=^:KI9_6V`,5%Q%X-.>R!F&R$X7#<]-:+>; MB,"DAKM_F&RYAK<14\T6W+Y2R4W#[)NG?Z?Q79+>B9#-]OC(`6ZSX=;$\UW$%NKM7R)^?BHO\VON(K>\Z=?3`*XX M)L:E&#C>EH?+UZW)94Y$^[5>[SM9<7\)LDZ";&4)'(WBFC)`VA@K#,8FP88! M9`1;,PR8J+!1K'W`;\#Q6OD'IB/9(H42!\A9%-:6`QW1YAP+=DS,\A`V_:;Z M[$V:AF#^/06+XUEOH9?J$R]!>.8<6+U('VG!>($[^-H]1'PGP\KNU!7#SG7E(\!+/T:4#X-"/I4'?$M"_^9RY M0;]K"`W]/HNZ*61M0H"^B54#]']F.G-/7OTHD/-]&-!W&75P`;R@[R+!*W3H M2P!40G^,OGDIEO@F@NTJMI1/7G?XMZ5:,I/!I5RRL2]79^4$I*'H^Y8P;<91 MR.&&N`5%04R&Y02+45(L%TPL\)R]N,G.LU3<465Y80&J@03X,;N&;?5#\((_ M`>LU1P7G)/Y+(/Y]'K+/$@'[+;I)[55/T0TZ'\B=[H@*TJWA*WA&L*&,R-G`0ZK]NT,>(6BLE3!Z+$ M<<(-6;2[2/FCX2J0T#T\;T*G")%ZDT0W!#9IK$S7(^EU&4SXWM*C<*H;AU.$ MD?",ZGO68^$;[!?R8&#$`$ZWE+IPP,EF$F,7Z1Z^AQACYQ`E%$A\&B*GWANV MZ;SB[+T<0Y9\XXH,&<+2*$ZB]&VVVT6V5/'*QH`9P)2LRKFQJF:D:H?J`PF- M9=?L75.XQDS!I=?A<4?HP=[C49E$#VZ:VF^=?V=,.C`9-M0F/;5;W<%.YZ7L6F7/>J:Q3`].J'=G3=JQM7C)7) M[RH)^=[(\9XAI.N@$%CV7D<78!IG$?6XHYER(;/BPP9S(11G4NPG#N;J%_IW M#FN6]YC^U,$B39VC?UR*:,_^2*NL0R*7?Z\>1QNV&=1+"#@QT1]*&,J->&(, MV5[4::WH59YL:/MC4?_J_>FV*MM'R`)UNA?QE M'PG(#D'G9V]K'V58IL=?MBYLO)9QSTD7%VJ?%8G8)H!*59QT M1E5A2UTI`#NB8(&V7X0 M@-LM-6Q\S,I/M"QWM,K\R0M*M/F0NQ@.PS[)LR/`'9*WB+K5AK`>2->%V"BP M3DYZR;I)UQ'.EFBVL$*61R$+.Z5@'\"`Q('<)TQ#W'B',`EN\^(^5'N2RO&N M#_\PT,!%@1@9=W>Z5"0H02%>$M3OO#+^0(K&H@@:C3;W;9'$RC-Q3W?+R^)6 MP>Y8I'&,?9F@7HIL&2<:_0(,BK$#?!0;8T7W\@9G5+S!WZ^S7-^X!LQ[(-P- MG527)#P/T)H#TXH?U>(/?2>8VZ+G*O8,2[L0#I06V0:$K`>$3`<$9`,^S6`Z M&/I)UA+GSCZZ379)F2BKEIK;(]W;]QDVW"CW&N)?W#ORO$W2*-TDT8[L:I*G M$&[PE^,>ZRI?4G+39?Y8PV=MU*[R;$-I7+QG_/'M'QLA9@%ZA".N&_ZWI"&-#-5O45CBV-![2 MA-_0I%14W^4WX92=V@JL7=.1RN:V-0I$1^'V.M-LSG!;,\G@S+*4[_Y^8"O& M,('-.5,;K4W4$H!9/P/+TNV,:$K&>89X:PQCYL%YW\G$6IU4<3L<`(@&*V#^ MW8S2.JH#9V-L:!U:$PM45[^7[[UWR*HGU6EIG#84A14?7<=R*0IF]R5O8OM2]3TGZ`B"\$D]!EO>$Y MK0?HA7*`HL$`9:`#Y)GGY;_C$/FF?SG",<+("K.$;=;EAUG`,,]:@=J/5(R< MI;&"ES$#NCPQL[L$6VEFB:V,MJETN5Y=HC16KS"J-04C6$(1@)N"9AO'(=F?[9EA+M(;%E]\]3^\]\3FO/T^T\?Z".;!G,R M%L<.`*\:G44RV/\PO;"$ M8"-JTR5R&\H,6G/:^/6#83$``OK:V!PQ44Q M03YHU5HB#Z@B&*2+=']@IVIN&5]J$]BX4&$8&R7S!M-2M:^W("^1\CA.D^)_ M'S(>:%C%%28I.=N(>*.?H_QW?EC@8>\7,5.Q9"/2!G?YA&W"H@!+KW5:&&E5 M#A;)W46DI<;Q#QF$,3N'>H2DI0S%+^0A%:@<_DZAE21!\@C9 MH&-P!UEP@^L+:CF:Y`$:4R/[?61AW+P]?:4+SL/C(]0)M%0S7#EKRH7ML]&@ MRL53HX84LL.XO>URWU.;R+'=P[(XKE[A[OHSD-WV5+'&+M&6-C0HZ73/R>NI M5CSX8)P/AN3,BW0;=E#.!T,:XIF!.1^P,D2O/AS3PC'6'(_UPG2.=416C-=! M&I+``W\8C_P]_H_,8[097=4[9[=S[@$S]ZR&87(JK MN!?J+/[1(P\IF=UL`6E'A9;'=T490-/;^J)(RFGK"2&,5"%=H/E6SI;P9+`/ MSEV@)!2QBF7(>-$S!Y=;HD@^LGSZ#L_4(W.DVW4+%WX6DI4$P4E(X@8E?8X2 M)QQAV`CIG4KO?])7`#RT*OCY4.+J>ZYY*S:5:G""^-)XEN>/FH\^YV79)>G\&\ M*%YZ&$ZU`W&*,!2>;X>?]V#XOA(.>C0PW@-/MY:Z5\"33>4L^\^6F,/#GO=: M_%+0^"9[2YG->$C2WC:T^MG\X->W'S`K[R_@6&U[/1#>!;G)2-O)X)18-T)\ MS;NLM``#76$9]-QT/N;$8A#[5*[1P?7%6J"0>@3[P>QIN(8?L\ M>^")*ZN]$D_&?5=MIMX\=6VNHB?^-\%RQW<:7[$Y^!@]4&NXXBJ?`X3S2L,E M!>+S+HCH@_0_1/I?XE'3_8;UUT@%@1X0^+4=_R3AWT2.I00:P+X90(ZR#$=B M2-.WIET96]`5C0J@(>8)A.N]E#6>4]$8T@BJ6)5,F,C_W.Z&4>,RG1BVL0J* M'JTR2+JOTP0@_\8':PSEE+X"]'-\,$1^^?LZ/N`&2"XOMMN9>$VQ%_9\'(_@ M2[M`P"0/T1C-C% M,D>SMPK<4).&G%R#%^5>0+I6C+@1(TS=)4+\\@2Q#;&9787[KCON!VXZ'-;%#"5X>=DQ.%6/0HDP"IYQR\]V''Q# MED,="(QHY:EV41>K/-$H`KY\WT5%<;FM^;S,17%*702S`Q'DVW83Z]([:=Z8 M/T^MFY/+O"HEBA.$/$.&K),A6UL&UP?LJTH!^H3="@?IS;H-"\A8EFZW7/$\ MOLW"P[3I=M*`ZS4O8*>#VRZ,$AIK"C,'Y4U,6FH< M&S!?,J[!).E!ZI`FRPOC:`F`Q(&T!WYP&EL&+RS-VJ/WO'>-ET]SSVEN#[8O MUS,L'=SZ#MK6G0M_C^G+=_/S"2G7X-7I@B$8;MT.!S.5XD2I%7#G`@L(AR<" M,P(7NED5W=]GNY@I=K5-F9L:RK='A'M5?Z$--TC]SDA]D@@\(=2B\I\.1N"/ MS1`<02JHYSH,OC>J@8X#QH7J1'.HNT^=9@MGF7;YDQ^SDIJ3/)EHP,RSF7'E MX]V1U>7M,9,T!2Z!DW4,7`8WT[:N$'!VR0'+0\MC!_(LVW*5%>5YEA;9+HD9 M66JYX-$T![,H6G8E[P)K2/HM49_8NXSU<-J-`SUKQG])$V8V"J9(/].85^KF M:UO&_I30XB+=6!3`C1I,'UR%&:M'1T=J0M*C9+N930#ZXC530_7QF:9Y>Y/[ M)*=ODFQS3Q]8QV=W.17^+8L:6,]M@2922[C@$@634@`#+4E[OX$_W]IQ'<4K:`9UWB4%^P\/ M>V`6YJ%:BNR;#!,-W&6%D7&Y"E+5FG3-`]E%.$S`R$EM'?V9"I%&H;@TV MQSIFQ[-[I)HEU]X_S2=C17 MMH8[D6N8E0[B5;LVLO]E`(;3.-"C4[=AE!><;*^YQIUJYYF>9(-&LN.&4(G<8V8U-.@ MPZ.LG7H%!DSP?;@MDCB)\J=/T8Y>;JNGWN:R)7H:R'3?!L8E:]NV/2&\-0_V M;I[V8Y8-F25#9I8!-#&X38FD_.`6#0+4_^[[/,W^Y?:&+6E%)#S8]KHA=F)( M1+B((JE5'PXG52T.]C][I/BE*B;+E0WERMSD`D6.L_I)$'+5/3@L75Q=6FM$ M=&T`D=%G3'IYML^"**X@#=YXPLM;"VY#Z M*3S^G&O'=3C'ND&=-:<7Z2,M6',W=Y"Z-=C_"&(G`]OJ5@XDD=JW;E)30$W<`HVI>:*\^W.H=:&@R.I(2AP;. MNWT^W!:;/+%4%-6WA;M[5C*J\LJWK0+8?AJ&=W2%JQU;P'H,21JE&[;YM>PR MANT@*RV,&)3**C2_(^\1YO()::24DRY5&E#,.()>6M?M<4L,W=0N6KU91UYU ME^`514?-:Z9Z]FM MXSYJA',ZEDQ)3TYNDP`F2QJVT=N1T9A!'NYORXNT*',1KF9UB4F-00_N"E;E MT^QM2;I6Z`ZNQ5B&/6SKE$(^6FLT`DN#>;R(@TM*0X*FS0.V+0I21_Q@;WQ7 M$P!/TV7E,>N[I#GSW$\L;J3G*@A7,O.0DB MN9L$%:G)2(].9"\*P@/E/D,CCY3S],Q[8]`F8YNC2WZ]P+U*\!1.BJ+O\O4= M@:I-FLI1#/Z$>9RE?E6&KM9S8%$S=6LP==(QJZFET'/BH.N&<9R'.F`:Y!72 M,GXP5+MRHT-.S_C!4$])GU?O`U:IJ^,294;"QO"$F9.Y<7%I`+=`;KAW2>,X M!OT\OY2J*%BO[.=?*/\#C<^8$D9W])KR73O[.UL-1:K:0[3CRR?_VBL\T'2/T%TGZ"]+XA4M@7*)4-UAN@5O2H%CUO1><5TOESG3J, M?7G)W>HD/$_9':LNK(T,5='%7O\GLZ`!Z+5>V*B.G-[+6M1Y;X8H4S2F-G?T M`EK?J%H[4K@PLMW+LA)T&DET,M%3?J3:D10=C76PPC/4V@FG=16(D? MZP]IS&O@B3?%ER(PB+^22D](5/`R;/P+HCQ;19:M*+*3=7YN0KN9Y=FZFWGH M+N"S-W?;,GKXYFQ89F8Q9IV^B0KN&GK8T[2H:CAT49)OGKHF5]&3N.EA*WA< MZ53Q*RU*Q@KC-LEB_<%_T:\`YDA>=G"4F"6"FO2_,(C"??-$^NWJSQ#QG1K9 M!:F_1*I/H?@A5AZK1M+'6M+].I*ZN2F>AZR.7HS007#2H.#$`@-`1\D:5G6< MO'QYDPJ8G82S=FOG_E;#_;LO;'E,"K[3<3PIO#2$!&!P`YD_!66PE3B_=8/Y MK6&IZW'CG;(;?1TG^:[0[T+.B.#Q4)NLZ*7Y_GU-ZD3*5 M9KODZZBD/S-+]7!0%1@'9P%ZXP@SK,N[1C@/1#!!>EP0S@;A?)"&$<(Y(34K MB)M$G('FK4^W?#R29CQR1G!"=MEGFJ/N#H]A0,"WA8!63KD7A#-QSVGYB+Z@ M+Q\U"\]J^6B'%7_YJ%AYKLN'=J"UUO*PWS_GY6.A`7E>R\?0RL$O'P,3=Z3+ M!S]";4H:_YKM6#>[I'Q".'^8F3C6)<0VM&"+2,,(Z3AY;H<0W[%NA^2Q&Y+> MMEO\^UFL)A`#<[2KBI/Q6W5=<;%\SVME@3V:F)EX9BL+_/%$O[(\F_.)[UCK M#:C8D3_[E671@7EN*PO@B<7%\AW!RE)%H5XPN6A\D6KC/M?YSC&L#YH!6GX) MJ,.J$;1I:UA3VR7Q*RJL)O`'CH#!]"K5MS^W<+I7@Z%XG^6_\&=` MG_.$Q_K:`YLLA(`Z:A5!>@E4$Q!&0?HDJP4\.6KS=$FVCI)`ZKV;:HVQX*17 M*/AX3ZDIZ>&X)0X":B:-*L_;!*#B-E:W&E:1=+@__0:E[!+[D\OM+VE2ZA-/:`D`:Q%J699+$%9-"6];G4OXBV+1'.DI;:#,.SZ)=>?^ MYIZ2Z"$[L,-A3J-=PD^+7/&K]\`,%?QY[($3D\_WR>:>'R2*I!!/@#?5J]DJ M`#5*X^I-<).FX1O,DI%FM(PK11JA,J^8H`M65]\W+DF^KG(<)ND[1R[X0,.#O(E@:6.!^Q$[IM%>RW@BS# M.V!.47*7&5;6`'>)PV72=2DS<\GQ5?#*YGO!+@,)C=@J)9"$N@(IU%,J4"SI MYM)[Q*N\+F(E?`IG:5RGS?':-^H[P=Q+FD1SW**U7=2^FYR3 M=Z@^@G+4[QMAI>WJOI57LU+B6@9_E%KWJS:(PGE(E.FY/HH-T.56Y!).RH06 MY]%N1^,W3PV?=4.31V5NSX`>F/F#X)PZ\814_?+?NIY)U36_!FPZ;RG0G#UK MC8HB;5X[*IEJ5&Y[HY+I1@72K[00:,9^J&40,VM/TL4SQ'\[%"5?&&ZR.BL5 MM\W:?8B5$&SOX2""5+NM%V/5$I&;K,TSQNEP=AA'(XW;/F*".,+CU^?._$6O*`E<%OD_$2XN4\*0NLZ MHCEEA^%"7*"6]U$IG,TIDS'O9!R?EGMNZ2>&"D+3F,:(JYP#=H8+G!TX@`$# MO;-ZO;^N$QN9HP=,9)"A!&;VS?ZGYE#64J!%&4R48NLD!6@`@H,Z2=$(=EU: MS.WL'I.`&(S@=I$?2/`!)K/^KES]+8UA31HZU#IYA`2"L5< M`@U5=+X-#G4K:#RTS.G4K6J`B@@L'KTPH662@R(IQ,UFH)`8*J@2$P/M7"`, M)L]*NA%O7%J7GF$3IJ,`#H]1,ZV)0FD;]US0F&$SX3'O$T[CQGTO-%1DXMZN@5CXG(K7!/5V[.ZS"Z-35GG[;20=]T. M@DCWMBV-N+;F5"?-J]26$.V:>IY`F;-`H#?,KNHFW2$[ZAHBI?:8Y)04MR]WP"0*R MGTVER,.]FT*+41Y^7M/&*=./NQ0`3^/J#Y2QJ+OB%?-?U\?8(:_AB@R)`H MGJC.8_1.TV7`Y#DT3;+\0Y;>\8I0'[/2&&:A:@V93D?)K)2W1K0BXN<3]I]T M#1:@:<+K^EM^4UW46ER&/UD`BP\802(DSQ5MPB M\,WP>588'\[X]0.H_[X"CG6,MR%U!Z3K0:0)J6-K;ZOK+/$R3'2#A9H09(7$ MVB3E':-PBN;.+VI>]-[/66Z;=>UA"XTK&5:F/RL&;S]1;Z.#Y-RCL+43ZU;_ M3-')UKQ-5:2'""(.UX(-19%I+3#@UM"+E)="%V]"/:H2W$8?#\8\5S2N_XX@;),^0FP("^\5*O MAQ[D0[1'FAXHC^'\29*#?T+):>'#[D>QY$8[TCXJ M.\\.Z2;9D;N%>?>#WAJ\P[Z'T^BT_`9.K="S]M/JAW4?J3X\34\!MJW\ ME),UQ]E7!\N]V][:AWV16XWRC;7Z'6I3(YOMK[=L/S-ZQ9VHEDO11=K@N>UX M,\`SXB;<"JCA-MR&)KBU]2/]?%ZGH#_[DIA6UG%+P'559E(R]?0S:9J0WWBC M_\):51=A%G(ITJC`>"%2S_^L9>@_&0B*M]E#E$B&IT56OPW84C-D;#Q_XE?R M6_4[N)[-YQ#.+"HF>&@(Y=F=I5`?:%'$-"6M)>%/R6]482?>\&"\YXR\K5YF.;3B%-"K(4#5-VC$O-C"E-]D- M:R3Z+2Q*JFX-%RVH858*RF.J>9,1T9+4Y@=525T99SLBH9QZ?@&#[4R:,8JZ M,Z@%9/A=SC.5\3Q%U<[@$.UZ]7PL.TH7:M"P.A=AY`@R057EW6KI!D6_C M\\0J?<6"#8%S5C\YW,U5]X)!DW:A\*,/!U%:F^R"*:3=]U*BF7"%N&V?I(J> MV%IP)U5NSEF[9!/M/M'\,=G0LSNV(AK!XDH)^![#+H3\!&)#&B)24Y&6+(2= MC.O,C-\2N$W++*UY&Y71;530B[2D=[GP*7IJCWL/8%KD(Y04PU33DAZQAU;- MELQXIWW\XKDYV->7$,\:>"-N:!5\X3;/.N2'NZOZ^4,7W&8S""8B.!M@9EW2 M&M:<-.W[L8OXRX?+)(QTQ#X#H$^AFWW/Y>TNN5,B?_B65=$>]LFSDF'%J^!V MR]HU1'S7[,3U#7]CN?RJQ7M=E47@Y]1ZE54\H=;J*^";$K:B"N/_$\W8LK"_ MY]M&B\M)3P/YOL3`^%@Q^DV0'4D+LPWZPL2F*M([$XN>0+Z!+"OJRP*)+^Q,FO/K.WU61PG513/IZ2DEFVU MLC'8=EK#ZGCFNV:$MPM@]VP:X^&NV3#`LV:9I^C?E#1^?R@/.6VV"\T3<^U\ M6\C`9M[*_E@'&@)24731/0T-SAWH$/Z([9X2&5K MN'A(#;-26&'=CM0-`]AQ&\=Y%%9H&.1Y;^0/M[NZ[QNZN4^S77;W9)EQ$PW< M6WDCX])!NVM-NN8!Z(##^(_>8EL'?UX*.DX_;I"VC^7";0 M?P:7RF&QR1YH>U/P@7^))Z\W'X9-5*`Y+4S,RRD,>&O2-B=->^3C\;I2P*9D ML"J3G)K!IDGH6+">G4AK!6;NYGW;1E^S30U+>_P=K;KNJ5+<&V]OI MF)7B,G@[(AH2T3*`K9YQH(<[/M,HSYKL+F3PW9?-[A`GZ1U/,EK2_*'[2;.S M\^T!3"E\A)(C_=IPT):8--2#8%&4#2"Z@'#P\%;-(61\]7(A&)VE,;^F3.YH MNDD,ERAN=`B0T0E@T"-^&=&G04X1`2,+!A",RJ53?Y-FS7LQT&7P^3EA6Y`R ML^X6#"1PKP5,;,MICKOL36WK`/8.]K$?/1.P#?Q2FL"O\]A^=()":"@Q]$(K MA$D]Q)4LHPI53\PSHU47X[3,TIKW<72VW^?9(XTOTCBISJH6?3'1@&F*F7&I M/$<_1G>B,-5#:U?S6H1]]!3=,HO+J_]N[I-'VN12 MW.L"K.Q85B0QK5YV7],-92,<7Z8W>906T<;R=M:O'V#/NH^`*M][KYCPH`_2 M=$(N4]+K!NVEU!*R9C99,Z.LT+<1WLJKNJ_PU5S(U[6,KZX29/Q6E#UA2W.2 MQ;]&NX.JK+$[+>AK6[L@DCZ*BI\](E)1D8KLA`A"O(>X4!+!OM%U5#CYK:Z; MMLUS[20%3S9>7J:.IS,M`9PC1\^RY+^IF_+E)(C36Z"\.Z;RF:&14SSWII\G!X.!.[]IOL#7V3'>[N MV;]^HB7[[N"SAC.@1R>`9T,OT>0#F"`G%3U/J_B&DJH+_C]8)Z3NI0"949B%M*;BLQ>27S.UJ6?'%O'$1Q#3O4XZD_.L?'5F]HSK(G MHC3>Y9;MS9GFE@D[W?;1I+S4KNJ MKVIMCID*,I>&D7E%Y@;>7HLIM$P:84OAG$=CDAB;GAB;2HR"DR!"V@D44A8- M*R+F/<'=W-/XL!,6XN&6'\_.HS2*DRA]3[EW;W>6\G>_CTFZ2:)=%:5^$WVY MCDKV'\:.%LNS.X9[S#M_""375=UEM>94G9*F5U)W*\).NHY)_:J!5^+E?9/? M1.](D7C_W0;%L5SW\J,B_BY..[NLX'E_1#U!(709?:$%R2DW+LDNJ:X6V,^\ MCO>F^C[9-..W[8W?OAN_KBN2,RXPBWXO9&E&+]*7,3,+V=!WVRW=E,EC\XD/ MC*&+DC[H+_!=:!$LH4D0$ZY;NAYB.2T1Q.BV[%C$\K5&/G*]'9@:VDH6E(FP M`DEG!6PH@KN-?$NW-&=[-\;(65'0LKC@.\L9PFK!R36_4B4%;U=TC0T2H^^SG"9WIK">"9V%B=!.U`4`6G=V!/C4BUW_HD3G=$%^ MK`1)Z1U;IV)T00(U,R/P(N`%ISS0#]\7UP"]T5M;^#IY"Y,`8>1HT-AB6)7H'-#C+ M#(9T:]`>@\<.QV'/)^2L;%V5;>]C(BPKM=+8-(G)BU9>[B<@7W'/)./LZ6M, M["\(CK%-6`X9BU0F$&[,@GV3;62NZZ&_W+:?,]VJ.M&#URJP"Z15Q9:4GR]( M0\Q==1T4<0L8S!!NWPK'`Z-:F)%L^W5OR46N:^`OW_!]$G M#T;5\O?$[TF/>XWK@T=U600W,,[+[4GSARAE$_HV888LYS$>6ANA:@N7Y5/) MJ)3JLVE%NF8X$/?E-VZ;8;T@=./8!M"]0B)R2'/*1JT0UY@)@ZRH]X$(3X/: MCW*Q:G4>T3?`7W]4&XO=+OL3!]H4?R9 M/+9"1*L),=5_X23&^3W[7P+5JXHRTQ&ZO"BHO@N]!;#Z++3P1S1H%^DC+4I= M$34G,DP3-F3?R7;U2(*!NUF,CUEZRG3@D,;U*MXT%IN`#>LHP2D_YJ-55G3( M*H4(BU_8MBG:)?^@\?DAYWN/)^YG5&;Z\.\#$S`&P9S0T]&3I@-2]1`,F#Q$ MK%Q(?#N]K:_>Z)=-M10)']HJ1X.9ZRF,>*CFPX8^JRVQ0&^>OT\,ZN6VVK)< MI%4%Q7=IQ/T&M5_14)#4B1K.U^*API4\7:5,8LR9NO>U8E4KG2<8P MLVGWI-6AF=!:LB84#ZUVZ431K!X^#]$Q'7P^`!RY]SS0MXB1J/NLOG>6QI?E MO2$'HYD*W"CHF-<;@_9:KK8*/-I=4.':`$]!:G"();)"0E46,EM%$C_,NXIB MPWJ'\%;45L0`L&W$C1K3)M#,<]3W[@),%WGC=G`.>HE!1773WGTC@?RGA!<0(SW*VZ*J7O$XJ25T)72^-GW4-YG M>5(^.14,E`C`:Z,I6-:4$A,>J*9I$!4"E^4=OOZ93EW4A<\TNH*IXXZ%`!4D MJ'IN*YHWTI8@*O\MSS^NOKN4^M/JS;RM4?XNYB%&:9SP)41?P\_8'&[;HV-7 MV@/DY%U,^DVU11B`]C/.G%__O]'#_I_?O17Q;4USQ#V*44-&.Q*3>LQ+5-9@ M0(JNMVBLE1`N"9E=!(,)DY^V("OT='&X?X<_*",;TTL=P,Q9CKHURI/EIEBS MM/XCSY3=7+-WU]'LH^?BCMVB^X[D8`AP%D<1;T`ZRE[`A(!&18P,ASFRA1E+ M,44%AQ#QTK]YVYC[B)U_>>:Z\ZRPP4+9&&X+HV95V@;P9J1*1,@;8F]??+A. M!-<;UA!SWV)0B=&N1:\/LY3R;+/)#[3:$!76K;6Z-9A:ZI@=SW#=CC0-D?72 MEVU:-\332Z-6#!73I!+SRO$E7VA\EL87:`DRW34R/=6'0-HQM\'3VJYTNG@Y;M66HOC956<;;08OJ:J>YS^ERL7VP M9@KTZ@3>"^(FFMXCPK8>]>5>>Y_7RU2'GT0P`$$17"@>"JMQI[AK*V(T_D]Y M5GB%WE<$F''V#S-Y@A@$YYN M#M&%:#T^4B\[P9MC6H2*72?LLZ8\J`SBL?E4Y*NEX8QOQZME(-GD9G",BN&> MFEO1VNGX,N="<[CJJ!G\V4X7F=F[ST8-+EV`482SE2$45#GC\US$598RFT=X MT`K.`3QB3CH8U`GW=+XP0,^H:AA'CE#%&,Y_'L)XXQGFJ&4"56UAGXE(C"I? M8/#,0:)9`'-J&%_%4P;EX,ZOE?;TEO6I":M6-H.MAM9G3UEQZXF\%;.)$CF] M&*/`M<"D25<4_QK/^$*JIHUNUC1$4#=M)/!@'I$"F!=E%D/MU#'*QMF?I7K_ M2:.<_?F?+`O8J!F8VDGLC>>1-R"\10`KEGHLAW.H',@E9O`[MQG\#FD&O[/. MX'?AS.!W#C/XW=(S^.JETPRVS8!GL,>>9@9?O0QF!L=CJ9K!T4`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`9LS MMF9L[H4,,7VDNVPO1&R2<)SP_G>'F'>9I*?[/-O0HM#319N_'Q+^)H.-XS[* M17[KB-P>"F8(>#JQ[.$V2>NRVX>4B3FH$K&+/F,6B=`8&&,"/?"W/(8B]K)! M="`"?-=C9'T,Z;:Q(J\>UE,>+P&"2Z7GKD'CQS)6]5DH]WOOA;EKMG>)!"&_ MNX)M4\+S0=Z`0#*XKR`"H-VV*I`N*[M&>V:I\WF41G$2I9^JU?NI_8;E&&RC M`U-LNP!2)=::@C0DI']T03\[.\[(4$GA:S M$P4[&/%/LNW5@S@E>?C=?#K#R"7E(ZHQU5(OM=(IZ;HBO;Y"\O`%)#F"IW"" MBFNS3OGJ]S(@Y07B[.@3K>!A53-G\!SS%L@(0&+2S;EHXY*[%D?N-^[XV_". M>;7*_7Z7;!K76MTP/N2-4Z_R$2(ZM91ZK(%8I\05NPQ0O_\;^S?[SVU44/;# M_P=02P,$%`````@`K'F!0@]0:J.Y2P``/6(%`!8`'`!A9&AX9BTR,#$R,3(S M,5]P&UL550)``-3W%E14]Q9475X"P`!!"4.```$.0$``.U]6W/C.)+N M^XDX_Z%.[^NIKK9G"7!K7R:]?WCRLWISYN7^?^L&?V1ORAV])'/JK__MF M^ISBZ,UO1__WS>2WH^,WOWW^VQ'YWV]OIM_>O'U+/QGA^,\'/T-O"(EQ]O=? MGO+\^6_OWOWX\>/7UXRY=]>,]QJ_>.X:GOT[K^_ M7=T%3VCAO\5QEOMQL.E%AV'U._KRYEZPVU! M_^MMU>PM_=7;H\G;XZ-?7[/P%\J#-(G0+9J_*3[_MWSUC/[^2X87SQ$EN_C= M4XKF?__%#Y]>YV2`H\G1I.S^;Y6DJG_].#R/D^3.$LB')*/A2=^1-7H[@FA/+OQ4_+Q)Y3CP(\4Z%4UND+93/WNZB)(?V64M2$9%\3 MLNH3C0R(;,]P%D1)MDS1/7K-3Z(D^%,!5/>QAT-UAQ]C,NL#/\ZG09`LR>(5 M/]Z021=@TL,(.,5/]%YU_&><^]$TR\@"H;*XM-KWGPL$P^R9KJ0J'V\U'TZZ M9RC%+\5"=$GV\[38HC(R??Z!PD'QZ.'Q<^3G_WHR7: M?-:0DHM'[JU=.VN@BH[M=NI+QRW*D)\&3T229^@%1CJ3E/-H1G ME/IT8;E"Y+!(=H8%S@O!:*P$HE'ZGXGJLX8RHD$_#[1_&`"O,K[Y MO41=#WE=A]E7E.D2=M_#'J-,J/I8!E=U9>IV^_2E8J/&S1O.-`P+DX,?:1I; M-$8S1[EP@^@/I@]3]?4_)]%'Z/R=1N_/DF\N/S5Y0&.*,*<1F?^K$? M8C\^2Z+(3\EBG?M8Q9)C_),F>7"+"FLG(>8^.9.\(5\,B!"^9RWVZQY: M>*,,H,F47VO5.B$K:SB+3R(_^/,N(/L66C>BY)!9]BT)4=1'A3M^RR1JY@K1 M"9-H)(/[@(_CJR3+9C'SH*>W"TC&,D^W7&-81]W!;H^:SU`_RI1_-'B+\Z)?;'[6K MU6W4@1K^X![P]U31OE\8T)+:%UG'D0W>U=6)970R3\=1)T*.!J!DTHF2R0"4 M''>BY%B/$E9,3)2FY>@Q>J2W11H1\X5&Q!Q]+$A=__K*?T",O7,[O.9+:ZRR MT[O_>+,/"F_(L3<)S^-NI&[UWBO-=[F?YCVH;O3?$]WW"5FK.U'=IO"FZ9MZLB)O!J*_-B2W&[XY;K%N^?BRO0V>,)1+?1YFBQZL*XB*N%C M>9.DY!+T]U](XV5&R$R>R_/7P&R_(A,U*DF?OE+#!Y/Q6ZV\"0CKF6S;Y>PN ML4"\+6DX2Q8^CD4:O6[B'8-QE<$RCL9N:`5B:C7C&A.-+-GH,D<+GO:*NGCO M;59E">65"(Z`9'!/AI7PG#;Q/H#Q6,9`/LO7A`-I^920$%(R+B+_DY;$?>I3)\[=:O&01!SN MM]IX1[\YQ/(=TBL^?P`YE-^B1TQO9W%^[2^$U\VMIMX1S+6S&]=Y""KF?P1A M_BFB_J'H,@[1ZW^AE9#[6VV]([BK9U?V,R!4_/^T9_Z?+M.TM?^(SSR\YMX1 MW%557PHB%)4@/H-,A#]0%/U7G/R([Y"?)3$*+[-LB5+AA.#T\8[@+K)=)X8` M2B67+S`+5*DQM^@Y2:E/E`:LD4M77QF2S34-1"J_)]&2L#!=7>`( MI6)Q;+7UCERZ'G,AU`+8]T6YI*@@Y)2LG(])*MZU6RV](Y=NR1P`->OW?4M> M3\I-1%<1,M6,^Q*O2X*.WI%+EV@D_[F?/12L769O'WW_N50"%.59 M]9MM;5C_VA-1)?#-ZG3O[)4U@(KGJ&4W!/+6:C)S2^&Y4+A>@3<$WQR1`U09 MK2.@OR`^6@; M[I(K'\@H;'GMAD!N8[$DV%+;(=S4!I$W`^@@I+:V!B@+;ZL]D%N:+Q>1_'9I M'X$8:1HT&MU/_J$/;%[\"-%X__S43],5N305;[P$8E7J#^0'EXJ/+6U52".0 M_DV*GGT41@:V^]3Y2HX`A%.7'6<"Z4<0@V71(R=Q@CEBV[#U2@15_Q\M&,8;G>9);1DK*H&U3L M1B]!RP"-X?BL)6$6&V!M4H-LQ:WHD+ZR?4'I0V*!=-7$"A5>,HP\F[$F_2H.G'=7>X_HO.8$/. MM?H.[DV@@Y(Z:(\9V/U/A.ST5WNWPU10>?6L:'K;:Y3/YO?^J]@ZHS.2-X$U MR75;=_0QCO,$J75R]";0<5X=1,V&8>QL:+$WK8<7S9M88Y\S<._G0N2_D^ZI M!4,'Y2L6LSP$Y1^"\@]!^;L2.P3E]V+P(2A_OPO/U2$HWZV@_(;]XCHA6[*& MX6[3WJ$0?1[](XAOV'D36^11"-6$V>P!'*W?49Q;",9@B=-\[JW2#3A$OY=L MVS`&BV'8XS/ETGXSC0@)<1&NL>][4$E`39'"U8?3XW#;49P!?/X=+CB'"\[A M@G.XX!PN."8E=XM>4+P4AAM531RZQC1('L'-I:ZHM7ZMI_)(G-O'H=N+",,8 M[B_L:GAKL.>O0;0,B]KV_UK2NK^7\4V:!"C+3I-,)/D>HP+??H3RYDWT/F!' ML#84SPHO%\\^3BGR4W(3?!2NYNP.P(^7.TB>BP-V9>#6(J)EB6E)XC4!M#;B M91PN@[)D+$-@*MV`GRIKB$T1S3A">'AE3M>KC_;B7?>$?NQL;(5N(1I#0,Y7 M%!/6T/JGTW"!XR*3.+58K1DE$+FD)_3SYPXB5T!D+FK'@F/Y)LQ,Y4"^:0W] MW+F#:#DH!@N_V:,XKY,X::-;LT7AMB7M"_W<6>?:I01F#$\DZ6F$:C`]D50/ M0B]C@K'(]DIC1F]2E`M#;%6'@'X/K293SG*N@7$4[SLJP+7N%\79_] M#N5Y5$PD!:40]H=^.&U"(Z0`QV"EN:1O$5"6RT]R6RVAGU#WD3`#RCBN9L4C M@5W.B`YN[![0#ZK[2%<`:0QWLW),-)[=Q/8Z*1V0U* MBV"U$S_#@4!ZS/;P#Z/5I<@%,(Y\,^5N\NT`<'8R@HJ MU3\0?GPBB*:$"O\172\7#RB=S7?"2V6S5VL<^&?'ZAJ@#8Q?0G0$>K'6?YW8 M:\V1X-\I]]8-$31^@5-W8K1I?OB+*/F171)8*0IRP+>J-2UZ;U1WNAVBM?7? MIK*8R)DIAY!MRP)<#R';AY#M0\BV*R';URBGB^U-FKQ@LF.?K+YG-+2Q=LU/ M@QR_E.DR%#S7VH,Y%`;>"=P(@D*[VT(6]]JHM8CZ,89VIHA@"6J%0ZNUE MM(:.IM^O0G`8,(9`SHLD1?@Q+JL\!*O[U(\SP@L"HUHSO\H?0%!RB;I:>1CX5&=JUQH)\/ M[%=QM%DSF&=]GTO*.FX,A32I/3FORZZ^[`[0SQ#VO,1P>5"IQ&>'56+`A^6P MIMG]*HD",RIM^>*PMA#>I33%PADJ_VUP:UV>1_@:0M89^DW$GK<@)7YL[&I. MGV;5/25&7,O@#R[,^AXU4(^AB"4';R+'E:K3X(]&.1CJ)FZXT>[%%X_XJS&`JS"\+9 M.S\B5[].^J(^"O1+%+,*HX=[#.[`7[/,4!6;V$OZ&EA^\!T]Y2D^3U*%YML",*M0*6_-[$R9-;0 M$9.'>!S^NMU]3U=#E`;P)E:&O)HZ*_`@C\&MMS,A3I89N>%G65&&M$J0=!E/ MYW,<8:+)6NN)=#!O`IQQ9M#%10E^?R>>%2O--G8"UX\?\4.D<".1]?4F5EI. M#6D)"VU_-YX-2J'.-R.V4N\8UD9J5$WT8)MSY%EG85^7`S9C81<,YAU;\LJ\ MNX5=@FX,0=#-TUFUDEXD:6'.8J0_0P_B,C/L+MZQE=;1;MH@`MG?9F[#082%GG'5EH_^V\##)QC,)8W#T+%74GC]E"W]XZM-&;V/QJV M$([$JMW0Z36\YR3#RBZS5A_OO97FR?ZS?0?E&!ZAM-R`]#@S*S!DYZ\H#7`F M?&(O[>N]MS)LL[\J<-&.X:6).M>,&*:]]R.R..K!-O#`!-Z?<3Z?HR"?S<]? M@R<_?D2W9!^;Q90+T[@(1*+!J2]^)`G!T!G&>^].EG%=7&.P(+#1W:`4)^%V MV)I`)72&\=Y;DL-4025T<9FKZ0.W2K`Q3\EJF:8KLC#^[D=+?5W8ZN^]=R>= MJ3(@8]4HG@L%(S2F^:AU`-;4.(`.?#1G52AUX#QN7C3W6%^@>-#_E$0$3$81 MYRL"O[A7T0?^Y$\HSHI$B$49/[C:`\7YODVG5A$"?O]#-0+]:@1";G*FUJ$L M@65)W`]E"7[BL@3EK*5K?!(76QQ;JY7ZN5:L@(/!\;H%6ZBX4TG8WI;J`SP1 M<6[T'"@V[#`]#N>;0(9OB%:[$AW$M]L"EQO@2H1S[&:0/X*XOYN*4#4ALIH# MY_37E",'P1C>OT_#$)=$W_@XO(S7<6A2H0K[`2?8UY2N#,H8PKRG0;!<+"/J M^>7=@N4B5QT#.&.^KO@U8(W!9M[`>X;F.,#YV3+%\6,CIQTYKSQJZ8/"0-!I M\[MKA2(X<\9SP.2AU4'U+D"QG^)$]?[4;`^=Y%[[XK1-O+$%'^:`7<'Y'F?/ M*,!S3%18=FOB]H%.0\\7$D>H(B!N7YS6R8NEZW*K'73Z>+$\V#+<`0!Z9^*F M$"I."]/PA<9D9URI<-M")W'7D8P0!.PUB"N>RYBI*X$R^,P#TKM,JU2CF\@OR_XI^)=9':"S,7<1 M,A])+5G+C"SGB^UFT-F1];?67?IK@5AF/F&*%II:="Y[<4MW9IT#-H0T-F(5?UY.GB, M&=L@@R)Y4"E0Q3A)^1#0&86UI-I%,=I0H5R$?#?&.NM/&7Y0OMV3FXF$O:#3 M_VK)@^G9D*&STV'((EN^.0M[0:?H'424+72V>A=9=),^729FHQ]TTMQAY-G& M9ZGCD47Y1;*4.2+%W:"SW`XBSS8\2_V63,+Q2Y?YN>D&G:9V&'&VX,'Z.;7$ M>8=?.TBS[@6=4W808;;06>KX9-*-7E#<19J;?M!)8(>19QN?I0Y1%N7GU`O? M0:*-?M#97`>1Z!8^6!^JX;#QJRH5A2C4>#=O!7#:5NV`\1;EQC9,H&AQFBDC MFRWS+/?CD&BI2'3;;:$3KG(DPA$?BWI3E@+PG#>[N2N$:HQ_3NB,W;Z M>D'I0P)W@-[>T,1[@5(_"Y.7ZFSI6TA@;1F#BEE?P!8F(=46;3/A:&]S1L?9 MVVW=+OZX#K(5YB_O/):%^44[K=M\=):&CG/0%/DQS8A=,)2%&44UI2X!-X8X M=)53:8,[JD6M^@SKO;?$?F;J5"\":BRZW?26H0)L/2M*:`9N^HSQO/<.F.1Z M(QQ%I+LV_I[K1VLL[[U#!K].Z&R-F5>R:Q24;2#OP[B,@5O0@$/R#5X1 M><=II=NBL+/WP2$#H!J<483SB\[3':6^Z>M]<,`*J(6FEKEE44HBXLU8>P5# M>1\N"R_5/1=.@GRKL#.%] M<,"BV`54K0@N!U"I''>W:@#_@?.G\E<9:7N!_'R9BFJNF/J$]\$!(^40H&M% M<]EZ*5QCK]&/XD^=MYYZ`.^#0Q9)=4BU"KB<6D.TN/;0@'9_[X,#5DAM1)MX MH_')OU3WS()LX`FJ0VKO?1 M`2NG,:2U'HW6Z*E;+%Y_,._C6(RB7'BUFHS52&I(2_AC>1]'8D3EHJMUQ#*C M:FD`+).Z5FFLN6935F/OHS.&41[YM6QZFSY-ASV];M-P&9?[Z,#-CHM-)M'8':=8`NDX=K?L/%)"(3';.]]=,!$ M)D50"\EERQ>O4N15DF4728KP8WRZ)$#B8'6?^G'F!X6LXK#XK_)XL&'+-9\<,GWM4%[+S6FK5J\$ M')],8*K$PG'+?D6,3GN/`C_-I$"3+F%9YNDDB' M0U_'#07$[9`BF!;R3EK3P]!VH,97P1:A-`#0W%)B.6_S4`7FZF2KKKU9AO)L MWS/G)DW([IFO;B+*WSBDVW-1KEYA`DG[`LPC+DUJ&U2788#GE(H4.%-+$Z6I M";9K^!QZBC6=V/N>81M>TKB:F,L$G38)5IFO/D8%G<&]! M!91%Q9OM_:"[>GKF3_0+'Z>%TWT#&.Z&RB)&8?Z*N@',6C%+]6#8,N\D+.;, M-ADB5Z=3<1YHFZ7!#>,J^QRW$X0M9X<8NDCI;63*8T#O6B+&*[L#^-AW M9"3"R2>R`9^A%Q0EQ;UZWW.)387"?!)W-.,^8']#QY&@/`+P))%RD^E>T$'G M[D6MLG[&X>P9I3XU[EXAU((2-GP7&'.:(T#,*64 MZ%.97WH#`4\V7:EPYJ(V9G?WK3*T[-Y_W?]4K#^M-?$$O0"F&8,:E4DEZ@8\ MA<3\Y4P8"1YWIT??")+J%X=($ET$)WZ&R7%HBZ95^?\J2>*[VXW]&#C@[M(=0<`;`EX0Z=0/Z/W?OH/M9"]^!%= M.M7GL%)_#S:$N(NP57&-H=1;[6*8S>MMM.':*T&K.%U$_3W8=_%==$`5E[$: M;\8?Q6^>=1-=KDJ?R">W1F\/]@6\CECU4(VC@-LM+=.]1+GNPC^N[25\%%73Q-\-V#_4) MS^OBP;['[R)I`11C%=Y`Q\\EG?DCH&N%TASM=U`YSU!+P:MOA#H#N4=N6?UZX+17(4WV!=,]_Y#M'_/ MR.$=TR9^<>W+*@0A#.)L-ASI*Z,=D*:\)Y$Q>UMUFB1]IZ]8D%1TJR&P-V27 MLTS+V2[15DO@+%GX.%:20=D4R$W!YZY,"C79ULKAU(_]$/OQ61)%?OH-+1X$ MN0%%G8#BZ3#@0#J[Y4*ZWN,R?I<+`:9EL!X'8&<`UV%)H`Q!E?O;B8E ME1-%W1C8VB_;HX2$&Q.?[@)I2'+!$PJ7$3E/;5Y1-T]6ZU*$R_PI2?%?*/Q. MCOMIXR!/TRYD)ZLJJ_Y-B@-T2VM9*CT0&OSCP)X$ML9PM&L?S!@N&&^?.LOD MSY2Z6Q\+;I^L=E("3'_X:;B^>_Z.,FJ>B4/JG@G(C_<)_54C2U_QMX*/=$4H ME@4E?08E#-B7HJ7KT(PRMFK#3@3&DM'D5M/@0J--2BYGV7+1,,)T7:B[?PC8 MI]-W4>X%W%A0ETWAT'W2-L`8`L>;E&2CL4S*OI++"LTE?!G7XFN$H-V@=)ZD M"UK00V]9,/0MZ(?@/=.7#,$/5Y_]=$LOJ5U%6EMB>)508?3@('O.)DYQ30'7)WDNYE6@+;S$>1;<=$? MURUSBB6^MJ;@,A3\^IB\O`L1+F5&?M@6%?F5=X4>_>@\SBE2MA>.T@C=%5@P#[&1R,4<"&Q)&#(MFX2VF6 M*DK;?;*V(E\D:5$[4FDRFAC>L>R4AJ&[F^-((74ES.QU)X%EI2)+/YH]1/BQ M$,L%S@(_^A^B7-_\?)F2);_:#I3-[+W&=23Q95^,[DZ\1NX]F`DVA@Q\FR/6 M^7R.@KPND$P(O"4G-9J,(0YPA`N)=7!PZ0_K8@:_GGC'$518^?Z+W9T`/R7' M\Q79\6F8C]J=1FT$8&]`-P51AC:2P+H*+X5**,9Y=VV0#`&?(YK0$K9C'@B41GT0T#``30710M5_7?E2 M:D-,=HQ\W1:@'FMMP;_+_4=$=B:4/J-1]!=7DR@'<7=3UCJ8?C+H/[G-6Z'W0AK"BZ3&&)9< M,7MQG7EXX`B.W@\-H M)GE"3O&'N^<(ZSUBVND->JWM(%..ST$)Z"ANM=^2&*V^^>F?*+]8QF$V+=TK MA%_%2T.!-DAZ@MY?C6F"'.08E@5Z>1<%!Y$_@UXHC8ESC60,U8[8E9W4IZ]2 M?Z!(^`&DK@(5N@"2*+!=2`;7:`:>DV.(_QPRQ1;#C8O)?U<34;`="GTLCRANAH">R6EF-ME[6NR(0T%E\<_TE*F`L%MJW[,.\MKJ!&H#ZR"I7?)=KQ[1,ZD+<#G/ M'EE=&H8G5].Z],S!WTBV?[V4G!J-?PNZ,BA'(SCJ,P1Z4ZO[,TIQ0M-.I3E0 M_$-/[A06T^PROBF`#*B$[0]!%QS=JP;N0A_).U^Z.U]FV;**8BX!EJ5VFM;Y MJJJ.4+^T!_..8$U1>CK4"=Z`,>`.K5$723I'."^2BQ=%:W#Y-&%M5$`=;XW@?](ZL*SLYU$HG8D&E:A\! M[ZB#*=LZ4&<_BL;ZF'=D24KDX96,![]2L$]`&^I@RE5?H?:C7NS/>4?6Y5H> M2L'X#*A4[//85.R4%IJ+HGVI&/MSWL02!\#P*L9G0*5B7\:F8IM;T'YTC/,] M;^*`KV!P#FP,MF-3,WN._1,'7`+#LZ#6M-Z^@6@Z M%8F>[ID";^*2'V)_/*DUN;?WPGXO:Z;E`AQ*G\U1X4W&Y-4PRY=:K]U^5=F; M:Q5CP-5:BQ!OXH`?!8XUM7+_W&X6J:,3Z$C2BRYO\A.Y;WISJIX)`SR-M<6R MT%&;( M>2DYB_EY(Y3Z`:DA9';_(^DDL[H?<,Z"/C)K8H!-<:DK M--*KVU1K]`3.:=!+<"T4L)DNI\;!4'BR5!TOEP5)YL%0"62KK+4G91KG;PR7K))-ZJ^V2-<7*%LG='B[9(IG4 MVVV%W)"L;G]D]7')\LBAWU*;XS;1%\E29G'D=W'"WB@DWYBU<6`IX1?=V;3I M`FQ3["BE)OG&TK@,*Z4[_*HII+H'L$FOFXR:U!M+!U+^JP1S4[06>7[+CR;2$PESUA M:&,$BK0/Y\U.T$D:N]HDV@C,I2`8VC"!TQSIKX.M;M`Y#;O:)[8QF'MM/TQ@ MU/<8YR@L?`*95G`4KR-TFD"]""D1"G,/RMV,D[(E%5^'.A:`D5+6/;F#R$=K M7?34D3C8Q#3Z\<1,]<\_*`SF&^Q;-B;A&TP'F>A'4LSBIP_XTT M@`/4XP"HEDY?(:^3`Q<3?A:?1'[PYUWP1#JL&]&+!V'&MR1$T>$E\B&^[Q#? M=RB3?BB3+I+/H4SZH4SZH4SZH4RZRT:AG@8]2]+,Z=OS`,NF`YM2+GR<_NY' M2S3-LN6BNNT_HX`.6\&L(TXKJMX%#%-GZ8MC0HL&+G]OVQV+4 M+<[^O$@1NB176J(C^3X5EO5M6UZ`[UMA.;P8D:'0]-3^/2&781SA?`6QR+:_ M;M^3]/TNLSO<&%$5WBXF4Q&OJ&7T2*:N@WP4.GQ76TT'XX*Q=P^P1NEI&.*2 M[LMXGJ2+8OR#R?E@_)5[+9_`P]Y#0OR[^69-^[0\$R)9,1 M91*#M.((CIBKU=&,7N[2Y^O*8P`;PC5DVEDIP-_#FUKKZ\U8:J'=:0ML3->2 M$F]QWX5D7X*#R(_7QN8I6=%"NJK)PI^Y78`MZSUDIH#,=4-N\(3"940.,.>+ MYRA9(72'TA<<(,Z5-RIH(3_-YKFA8Y@/0KL5]J!G;`T?C)UNGX.^HABE?D2VHVFX MP#&FM\((DS>12(4G]@U\!PHF>KFBI/W-:B)[C_#6;+O.G)*5'QR'B&GC? M@LZVE:OT]NEFGP1/28:/HBB0NK.U>^@C[0>3LT!"E!`1U> MQ$_=X6=/S?7H/IGF-+KC)"$KSS>$Q)'YS_\MHC=]85N#]!]EOHJ&_^CB^(H!F\1E!]U)X8"_C+$^710"T>I@] M]Y:A_"U!L'S'D0"BXYGT5.2>K/Z!PD=R+2S\`%2UGO#SR>HR)H)!&Y5>>]A/ M5JS!Z$,Z6>3]_H@`BNKOK@^<)6*O'+,AHB%#P:^/RW4\V$5@PC2R!)H5 MRL&`>3!@'@R8UMJ9RF1@50[Q\KW;+*7_TL/8R8JF#I,<+%6'L,>(*3EHZ@!R M/)6&&"H%*L\7I3@$M)E12ZI=%*,-U0:[2(\4*\5V):_%U6@&G0E"2SAL^6[# ML?.86U4[%RS-[(;0>1ZD"S"?;+`D#TI2X*Z1O*90>1,$#)9)8D.X=7?Q4S_V M0^S'9TD4^;(<0ZS&4/D*A%QF"H1#/.A"9=K+H M_F.V_JNVAUTR'/2S;P-ZH8`0.KR>%4Y:6RE#]OJTGY6^^R^(=&3570 MSE^?<5I(ZHQ=2%*QIS>QQ2`C$KX&F#%$WE;HKI/\#N5YA,J\&32;59W791-< M)U@.]`;R)K:$X:@L!/K8QN`LVV=0]@0V@D=/'710&3-O&+:JL[:V\OK(MR7R M^W@36^Q0(ODIP8`]V>L);"LCE_Y9SMC8WL06&U9'!="':RS3F15FZ"OL/]`" MU9B9LU/8WIO88B)36;RY$(QE!@.49Y$`N%S+SI8T]*I,.55F(+U&/XH_B=/E MJPS@36PQP*E(7!V3L8Q<9M?^FS0)$`JS"\*(PL,?!V45XBKE,SEQS.;K'*/\ M95YO&._8%@N=?$771U9)^LOX)GMQ&^DQU]O]O6.7+'G*D#8F&KNF>AG6TPZ? MI771N).:U\$[=L'2)L=0"PHFT+N7*:WA)TI*FJ>+9!FSA"GIX1T[9#H3@:C% M.4!E@OT]2IYF&*TGRURH]6=*4J9QR*!FFP3>@^6^0UKRLKFG5)A+;R^FV!#T.\;'T"9$TQ;V MX=7TS_=JNM:?DU7]XS\P2@G\I]45>D&1).10;0"@]]3FYX@V;,=C>&IP:SX5 MOHM=Q-*01JUQ@%]JJ\M6HAN*6&W8(0UHR&7\O"0G#\J?(^DK&4$OX-?@VM*3 M*`$3X`@"A5@`)YWD/K'BQ?F`3HD"S(Z_EV;-GQIBIX/A5F_H1_**4E0_##+P MC>0,V%Q"ZYFBOC<(ND,_E5>5H\:5@('0SM?5G9;&*\&;#Q/#0KVM-[];F.+& M&,)):;0L@4[_H0Z_%S]JG<:4@HR5QX!Z_&],X.S%1@O_"&ZB&U?BQL,QWXW@ M6BF%K(F'@$U2,)C&Z,`?PQ5V`VW'7=9PDUTCEAM4>PS83`I[T!D%_(-=?_?G MSF<>X8;/,:[^60W7O?Z@9ASV1%.6BS)]W/<,A??)&2("71!MVZP[Z^QR0B^] MYCB6N.8[<9UY5M3';\/]^`[R.+C>?W;7>U'\62&79*L=J".]MYKS(#GN M))>6_LYXM;\WC(C#F\B/E=(##?$Y8)?[CD*P]68@Y#9LCCTC_-?S3FIJW6T, M[&X?2J0XWO3"MHO MW6:^0$#FG]=KA=NV,1.AH.[&CR@61*"'(5G^`6'*`YO MV3G_=(>`=95VE3%[==#!/()UG@675C"_2!&J"I!TT!+6$%#Y[/>E)3S,8XB\ M$,V*WY.(B)+&F?183MJ#0&7-W_>"LHMZ5`\.&(CO"2,[J@CM"I6Q?]^*46$= M+#9T?P$X=7J]3<[M^^1FF09/?H8::9R,AM^H?E0C^$9W2*W0FP$-S+R0''DG M2^)O.C!>Q_I\"+4!-#4?XFH.<36#^$)A,Y#KZ+H*%L<#;AC4"F[H-M;B`C*0'(^E/ M:22](ZPJGM?,5FB^Q]DS"HHRXO)GA+P^P$91 MKH@X$A7`L&&7Z2[4FR+!!KJ)_*#@AS2&EMT!^H&?2#YLD7)QV&E/O4[BAS3Y M$Z7MXC02XZJP%["E54-F:F#LN58?C*X'HZM%A=/<-+^J8AN!#;8L.U;5"R0X MB\?HW!)=*MU4IB0CU67FJ8:9A/$.YCR.S13D+1LH_K>$JTQS13";/W8]>)SD2 M9^T4]+'$^:7/2N:4$0.UP2@Y1M>7$N\/GB]W/5_@FR?+3),Z2"(>D6RRQ MO+*;`SFS6*QBK2ED[-72HY@JV\HI+$F='U-R*\PRB[C0"(E+I!N2`4I66E'BP;('\!8_> MHFY2LK$%!3/#?R[+0#?9RB?N!^1U4EX"I=2#)1_C^P917MG,9/[`[99`CB%5 M:;#H-7:%-\;_T^+NAV,ROQ?E6BS?@@1]@/PUJC(14V[LNFY0.K$?^B?+#,VAG8>B!G.6D6Y,.R,XKNCL/QH[>,XDMUX6:VATA=VEQ$7AH6FB1:I6N*I M8-D:"*LFG0T*V-@*?I[9.1E/=9%C-8;*UM==0CP48PB!T$QE#YE/K].YL$6[ MXQ5!.J2MAXT\;3-?(*`-N3;X3?>=!WT"&RFZ+0&VG'9('D'8[]WR(<,A]M/5 MG1^AV;Q\\RJY,//Z>!/(\(9NEV81%L=K?#00T9IAL_D].5YE?N%4D-^@I9V] M"6QHIUAT''$KH7)[!;Z\F4E7W[J--P&VAZ@)A"W-%@KKC"';T>(_RNL-:?F; MW'TI[NE-@(TD7:2F@^KD;>'C`G.0F'\35L*0')F9[;P)LZ9$*B2U<+ABWCT:-&'_I MFKS3UIO`OF#FRX0M0R8`M^5W4]&H)D)6<>PUAO==5`*QKZ83*TT.PQAF]Z<=#`!:.: MPSN&-?SHB+6S8FR@NGTG.4.%I0N_R/W2VTV]8]A('3TIL27-PN2Z0$L2;]$+ MBI=H2@^3CX41A;)*LM;+.WO'D*4Z.RWS:J#`PO?W(7;IXJ[2W3N&M2`IRK&+ M$FP`6N>'HW[B(,5EO5!9/.5N6^\8UF"DS'?6F9R#Q^T%^@+'?AR0.X9D+6ZU M\][#F)AZ++L[]#O^,*?&(UU,MUIZ[V'-4+N"D`AL0[9UJ^%]BOW\*4KB.Y3G MDQ'L/ M8Y#J$_VL!:[2AL_NJX-TD=UM[+V'#2O2E)5,M:='<)MTX$IP]8]O:^:N&]A[74:#"^1;/C@734*'499WFZI)NVU/2R MW=A[[Z"IA06B$N.7,8B1QA(JF%/87;SWT"84IGQ4A-D&8=UJ>(=BG*2%Y1>% MITG\@M(<$UVE2BLUF\C[>N^AS2@"63!-)VJ8K)/CQE'>1Z):HW@?8,-WM&6K MCF`2%*A5<@2FDTX)*3?9I5F9;OGN.L*B>AD)O[X-]UI>V)-G'($5HIG92 M,O1#8C#=`S.=_!^(_C\*I^1K_B/2KYA@;&SO@WUA0R*M,`H_#6;+O.G),5_;:I+L/8IT]_R M/MCW]$UI5QN"$;#Y=/A/F"ZJN^L#";Y'65Y71"1?YTQ^17O@WVYE^1J8IP%@U4CVO>.]2!GR@.' M*>NC(;UY*F[V1[(];;_4>!]@S*%&=KW]L\I8;"ETH=V2#3>1'Y^_4O:QJDB) M.W@?[0MD4[8",-$8"VN#7M"ZK/(7/DZ+>L+3+%LNJDGRC`(R,\[P"PY1'-[Z MN5!/AOZV]]&^O%Z#'M%U&&,L9&@LVGN+LS\O4H0N8X*('%[VJ;VL;WL?[;.9 M[UU[>8PQ%EDP9NW]1LXEBR6K#NJ^2?`^.NH"V"-_S/F31JW393)34)TN2?`^ MNN7`@.!/K=,PC@X+=;HZCOV>1&28B#H5][]2"XGP/KKE6X'A4*W9/Z4#1H-E M^UVOA41X'W\RETTG#M6:[7)QA#VP#%:EO8]N^9[VS)I:B6'<5\#>!A&O!G,J M2#_J?73+#[8?CM2:ZKQ?K,NL+EW/EX0_*+R,N5[90;[C?738EV62";4*.N^F M*K&=+=/:\UQBOD8_BC^)$UVK#.!]?JV.$:T&EZ0B!%.VGA2- MO$\.^XIJ!+7L>GMU0&57U?:](&RBBNG'P298B;)*(%)I7^^3FWX5)6"U`O1V MC,`J0+EK91=)^CTF@'[0K&[QHSSV0-S1^^2F&T*.:A,./!:Y7R#A;KW5TOOD MIC&>`:,696^;.:@HF<'N^N]-^@SG?7+3DMT5:ZTYO6W2IM\B;>]=!,#W&`L> M&/$Z>)_<,N'*T=1"ZVUN-2TT)4&UX;AEDV0CJ`72VW1H?A:1J4_N;;*ITVCE M?7++YL:!4,NDMY%L#RO;IO0)O9M-X[!:JW56.^X@WB>WK%;=$-8"[VV2LN\0 M5#^DJK-5G_I1A,*35=_SD/K(WFJY;9]JX)&.%?FAZ1O$VA]D>RI M]CN@-YG]VTD^FCK/4$RI;&W7,V?J7PG\LL+W(J)V+KF%I' M[[-;IC%U5+4PW;:+":WX91J@C*"B9L$Z)=!F5>SJ_)`.['UVTZ[6'_7FX;/3 M>G5+Q$98_D1.86?H!47)E_< MLBYI`:L5P&T#TP[6Z2)9QGDW!=CNZWUQTTRD!&R3+\VVE7N6/Z%T&K[0@$'N M8MULY'UQRW##1E`+Q-$B(ASC9&'I[A'/WN[O?7'+PJ,-KM8"MZT]0DOU-""\ MRXK*`)UM_,TQO"]NVH.T`-:*X;B!:!-`>HN>EVGPY&>MX(IBOXK#\A>(K(W2 M`/IN(WI?'#4K=8=;JQ"4Q,&M5@3)^#7\FZ;<+[0SA?7'+QM8%7ZT5;D>YE<6(KI+XD;YJ+DH0 MB11@M[5'8T4I'ZQ*.=#W#Q4I'WZD4KO&'O'J&)G,\:HU# M&.B6>;`[REI-K`LQ6Y^9-T&Y$EL\ISU!Z9;-3XZFEMD`AKYW32X1,O_2^E'*,T2,]M$*%'K^@>(EHJ-!7WBLY;EL/QGO1 M;5+NTMZ_B%L_"7*/_^P5Y!KQ@SVX/3P87X*.B.0(C-4WV_^9_]1_QKD?$52S M9Y3Z-&_(566@+*^H6:-RS>PAPH_%9^GUI]$&Z"I0D)HI'/W;#0]'?<7IL<.V MG^-H?XU^5$H_?<6B+6>KI2.'^EVJH>3%W6+^ARRV65DXG;NI--H`'[\9#&7M M(6V"K>/Y%B\3^Y)HX+< M3"(29FN@0["R2'A$&RN"#1R`D=+'H/3%<7V*:N1BE6PO"KUM.4!+MAPU),9D M#G-ND(#DSEZM_AY,((VF(#MI00W0NJUQE@>GI!T._.@.I2\X0--'LF()I:K8 MTX.)2E"&-`?]/@-Z_N&Y<3T[H7B M`".K;EP",C>YE14N9%KC'.YKBE-)EZL_QW7N)DW"99#/TLKV+7'8,IH[".MD<[WSL9* MY^./S%HK+;G9L<2D:ZVT,*+HAKKA+R7K:+,1<)R0D+FLA7.+=DL%@)4D@*T( MY^DH`FP^3,>T$!2E@.V(PNDJ!SR:6)O+.$@6:&-\HU^B,A"?'`2]7(F^D4`8 MIUBE9PAA/^BP')G(M`2]@>2V7>3.CQ#_-0FCE7<$:_R0RX-S)FQ#<%QJRX<, MA]A/5Q16E6U:WD--PW7B*[]!?GQ/O7CS`^45EUY M9^\(V!LN%!U_PLI167>;^!KYK\G=`N=/_T6:RZ)/F*V](V`#BAKG60=<+A[K MY+3QV/)&NH_PNWA%D?F`5]K/$)L9C ML\2H/X7L'QT$Q^[I32!3_AJ0'Q^6?5:XB]"?/C^GR0L*+^,0EUKK*3`'+4$T`M/()-5GT0;P(<%:.S^>K!,G9H-2WDHMK%;+ZN M;XK)>;Q1S6J:$3TM8EL;>6*XHM8?RIL`Q^"H"[P;N$KLUE5=/W]]QBFM7<." MPY6PL)=W#!S(HRY,*8Y*;@.4=!KZ^5CI6[_W7Q%4'N>:`JUW8()>6J^^^*'O MP1,*EU$QB1G:.B\&/R@N,`TP=V:W)NB5;QGGZ9&1CX MJ9B8\;O#:;S^1R12]-+1;+(R*;<%^C=F#EYB?5`A'L4)4C.UI02 M?-,L0WFV28N49-FIGZ:K>9+^\-.0FJ91EN-`L-AU&`WHO9J6H-GWU&Y@?S:M MN4A2A!]%IBS]P4`3>.]+9S98QV'YU(!N1EE`K7*2431QR",EOP1K0>`LI\^]QBOP(_X7"TV5*E[D5/>0RXUNT MQX!ZL3F$-H@P5JKQV;8BG"7PV?STB:;_OXS+Q';GL4_/)&MF"++ZJ?2&>KK9 M_VBFBJZ2[A?;3F85@C6Q)1":6CU_$@3E"GM!/>$T)DTNJHT5QS8Q-N\&HJO2 M5CNHMYG]3]:[.&KA.)A8<]G1PC6[I2+FV-CA5W8%57:#B`5QV=4J1N?T< MO08V7>9/28KSE5("D.T.EO@YY<)BGR:YH,8F7,4T(+M=@/-F\@6D*E![$V?> MI>L3DQK@CHM)(BY91^!H7.TSZ>[&;`V<-E-70CP,UKH0+_`K M"J=Q>$EX&S_2P.C2IBI[/B[L!IQH4U=H4C#0KD6N]/[AIXLDQG\5'%;:R;@] MH+-RZ@I-",3:5QB-^VEY8:UNJ1O[Q)4T^%AG$%O\/+K7\VY(H<^?`SD"OZ;D MQ*WC]2LZP+I_M$6GZ.RKH8TS7'@WIJ'T:8JLQ>J#P/J0AE()(=S^2X*5\2#7 M2$LC2'-8I]10LE\#&_"*NG\GU>3@I&KKC-@5U6[FGL-IAWX;/`\9"GY]3%[> MA0B7>D1^V%8?\BOOBJR*T7F<\[U'C%:@+J-==K>%PJ:7*Y-AV5O2P'7=;#%I\#&5^QY/VQPSE80T/9X6)MI>OZ:1F1>; MK6QUJW"2:6_3;IT(UN^^RVH,LLH]NVUM]9EPQ,%&8%\2UR)#R>J,$"E,7]YN M!OJ"1[;A<`@&R\2JP'I)UO'MAJ!O:789*V9_3;)U"]+_(#\EOWXO68O:S6"? ML[#8RF+_+LVVBUUY^;;I+GF MOW577[7U?U*OI0Y=?1LTU_RW[>Y[K&9XJYI!5>OIM/XW:*[Y;\_E=_.:4_V] MP=4F?PCD)5C-\R$6&\+OX4.9[X=;"VJKS8S:U[+B!)=\$#85]P'*-$F5K`^FX/6U\1<(0DPF%? M%%WSH%T?PMY.0W*%*`B[C,G5<%$=Z=736R@/9DD1$OEQI1=$Z#NU7/Z<&8M,C`Q,C$R,S$N>'-D550)``-3W%E14]Q9475X M"P`!!"4.```$.0$``.U=6W/C-K)^WZK]#SQ^.=FJU=BR,TEF*I,M^99UK6UY M;4V2?=J"24C"&0I00-*6\NM/`[P+#9*2/#-0Y*I41B:Z@?ZZ<>L&V/SQ'XM9 MZ#U1&3'!/QSTWQP=>)3[(F!\\N'@X^BR]\/!/W[ZZU]^_)]>[[?3^VOO7/C) MC/+8NP&:,:.!]\SBJ7?Q1^\B8+&0WB]I71Y4]>;XS3OO<>F=DYB,)/$_11X4 MW`@>D.7?O<%3YY(^0$2([ZA[_=7#]H\?(J0\8_ MU:@7CS+,Z4\.5?$CB6A.KDJ#N&"H$K\]3`L+TK"AWM^NH>)JI:R!F/$H)MPO MA3"$SB#VW[U[=ZA+<(U)]*@YL@*M M[MY1OU:1#08\I_T;[!5I*10!&I:R;@R$HRCK+`;O4]"/PGM M#1S65+V![A]`>CW_#\>7C,-^4A&J:]1ZFE,;1WBB_JH-,!:D&[@C,OO&4Q@QD2)7?D197_DEW MY7O?U"K\V]X8H]*[KV`_-Z.#,*829E;V1(W^;U+@BO^V2?%%`>SRQMYP3J6& MMS_]OZ+0,Q)-+T/Q'%WQ@,$2&!LJ-REPE;_MKG)5I:?KW$>5/TQAH$]%&(#_ MHB%_REK[G^]M,&] M,=JMB&DT$L6B6ZKF9P%N)ZC-AWGHG$5^**)$TA%=Q*V(3#7L@G/![XV@4#_=Q!S_89<'0U3L=: M69V7U[AX=SO4_)UX3* M$U1Y_2.C,RH>3\SW:[MC'^KGX%$_Z7WD%8]BJ3W3"-;3?])@`J-TX$,1(*'1 M!G/\5G7C]NROVK-LPZLT\FK8Z)(P^0L)$UJJJ_L"T,R,F^9XU32J$D_7XMU0 MHA[NEVW,?6HV;9G/<8V>&)-7A7/OMJ+W@(!(?PH3R#E]HJ&8J^Z4JM12AJOU MVU6UYMPZ(E?AWQO5YML0<*/24`"?7,.(I>!/S5BL1VU]O])$B"O]K6T7HW1> M5.;IVKQ*=?MC@Q(SJ!<\&J4/RM4..0_#V0EPG7]GZ+RL0NN]5LG>:#H-#(S( M(M=L]0&N20 M(HY5]AQ7LN&;UMPK[YN4>7\4^GE\H:II/FL+J)&/#1\:][E>K=W1?^IFSBY5 MX/8R?&2+([9_!C,]K]JL9RO%U6SXNYAWMG\ZQEVQJIX;*7!=&YZPS67;/WUW M<,FJRN].CEO"<)X[^G'[9YB*5U$U@/D85[3A,%==COW39JF*ZLGA(`BTD"0T M+VRMP8!;P'"?:X>-\'=96?4"E_?-.8T)"_?2.(VN6R=K;5`#;C[#9V]S`%\- MBCJ&V3\_2]`;#3YRV-Y4BN]"PB\65/HL4C/2%3\CG`2,\',1AD1&J>I,M_)% M:L4-;WK^VBD=YDYI_B-KV].->Z,IK1%Z2@:O(@1T"2\7P\OD\&`=]3Z^>]Y5[JN^M@U9'XH*I*SD7BSF3-%#[#?DK,)ZI"W]A2(,[R80O%S)VV[VD!]KT;H%LFFY&;B'$3FE&0 MF@E?]U28!T,8OQ91-.1HS-;P7UK(<<,8(1-;U%95[ZGZU0M_.-$^CJ%2=WA@ MO8LOLP8G;D0CVF(QXNLP0^R6WH^\9N21A?K@(PM^!X.X"*X/^3U5;QS"<@'K M"C/&WD9UX+8T`CK6L'S:Z&&EU9P@\$A;#C6;& MB-`SG+P5K]*,%PLO;\A+6TKW/OL]`KL:!'G/<-M*;">L#;RX`8U0S.805]GV983V2N=T"`]>5V7M:(E[:RCP.NP\FMNL\IB1\G)!P^AFR2OM2K;XL6-#7K MOG"=N-&-*$_G(^-*VUZE<1UUKQ"^]@;4Y#=[! MK!LRX^8T`DF-M\A?C8C>`*G9!WF.J]X(_]3O@(#K+T#I(4L5/!SKD#B8YY'! M&ED>35U2V!JI%T;!6'=2/#%]U;!2F7=/8KJ/LZAIB;[-1'V+C5KNZ5PFL7IL M&NZ)RN6KRA7V8YO*CRTJ-T(M=>U6^K4.:Y^!:[?T+H5\)C)(-P^W@O?NZ3CA M07:R7^PUXW*O^6H=A?W$9IT3BW4:WY7Y\R\/ZG\J>R!T+T^GY7NO06G)`\K@L'6&CH'A+HV^LB61D.+XOG M,$_A![_*Q'Y0`%"$C#UN9!1MRIB9)B.]%KZNIH%%_=7+^7KJ4:]_W#OIOUE$ M02K8&NT7B-9L/^=;KWT\"VG'EG,&U>3;#HTUY@*UM*G;0QD/:1A'^9->6557 MU`TI.9MD0=BRWUO(@&4Y[2)$E2__8QLQL*2IG>2H,A9_;2&)D5JUBQ0%D_ZU M1>MFQM4NS9=6<&Z`JQF<.W2?,ZC?FS3]&I>UTYMYTSZUWJMM^45[C(9 MA5+6N-2,]$Y-@OWOMI&@XU18:3W>MN7FU+A=I:G6$@EHG:CFHJV/\Q$8PT M7Y#(["X&9V&H//&<-DJ`F<6)*OU9BF2>-\*@>H#K&7C5+39U06Y,80D+=&SY MB@>)3RM7ZE*$;9153#,!,P.12PS5F(11"ZRT[#'-$ M&JF%T'5(4XD-GE92QV%=B@19V]LH70<%&_N.H"J4CH-Z8(MNF"J$KD.B3Y1W M!%4E=1S6!9M,D4U"*ZE#L`;!_R51EAU'E`?8=X0%*C>!OMZF=__Z+G(MW+`V M:RVFHI]MZ)&^@..@+KLK.]&@UOFT5!<+?TKXA`['PV>^DN(XK0N.\LN^ZY&Z'..'>@#S0-VALJ)RMQU@[4NS"D&_X1*%V9'`,YBU]#I>#0,QASJBDM)2" MP\_L^+T!]$;LCJG@++M8J&H>+%A]-V24?>&Y)HC?!VRF/AHJ=("I%<&YCD79 M,.2E#H6O1`$NCE.&H#9:=U"-@:68O1VUN;L+NYM.L$ MU[;%/"O\\A/%%#BEGSQ2ZT11%?.:<4T8V7!4"-RQPC:YF)L[Y3;UN:.?AV0V M@WW]<-S\G:+5_KL6FXL]NQL`M,^OS>J.M?/E(_M^SO)T>9:^KF';QU@(7=[4 MV#) MICM=EB1W9*D>#=2+VD:^[RN>!HYJ:O@,M;L4BMH27B6767[*IA-EOZ0*[6UL MJW;'Z:DK//GFQ ML@M%[SNWDCJTQ<-E1>\\MY*Z#PN_]]R!V"%H+[CG&_"@\HVDV\1P5#YW4^[L M,E>_:-,TL#$BASK(JI1-@QDC!QH(H00`U4#H&Y)\M/X@EV M^@]SZL<"V=K8*!P"<0I;1PX2GB91!*Z+9,@;VC82AV#<@:\%?Q'UXL%(Q"1, M7:[A.(VBZ!N]*G5\Z:'5.MP&W+58C>+^:J&:U/ML^`11EGVEBZ M5#MYNE.%7-W>_WH'.\*G--`9)/.L)<-Q9:]_2^/A^&*A-HWU#>6ZG#NPM\1> MV#X346VEL-/L`,#M/O[OFL;!^+>[HXE;P1RD^45G?)YC>0`NA2XY! MJ?'<,B/HG997V.LD5^UNW$G"$@XF$A*\0/>-DJ'0&FW'USCF/IZW!<)="SG\$VD M#L$"7S[W]Y%%S"QT2/0S_2%0QJ'_S-*1@8Z?1C*GX'`2D#P+^IF0!J"FT_C M.+3LUQN('((R7+#?$W08K)8X)/39(W+CLO+0(5$?*&="/J@XOGI##J86&3/U M=AMX/%C/[T+N$+PRSK,FT#49'8*S\,1.;:3NA/+0 MBPF5P/G*'85[JDR0IFK34B8D5)':]LL.&]7I4OBW>G4[BU?K&RH=;GI;R;/N M[*M>\3+^BKUBRQ@:G4CI_&R2TFS`[<^;*#L M0+YR!H\T,II>C(K,D&E14!MX7SO_A=%![F3V'68M626I_+Y9R_%?R>!A26/ZBFM-TJUD:RSV?7E\-9[:F- M\^/N3(S9P#+R^-2?;SG+O.#FI?;A)$3@^@5<1^9%RR%7IY,PEY1?_1IY+5A0 M>[X#O3[=P5;6%;,_64EV`![^S8A;6NMQ#40[`/$_('MD)K:M/7;(Y[ZF432: M$O7%%_CDD"_$` M,__T7R&:1LM"X!"$J/DY:$[]NN'7X=L"@ MV8E5Y>I*]<6\"$RGW8&*2XV'6(:VB]JE7@IY3_5K9,OAN+`1%M1H9=F!Z0QF MG!GA5'UA6ET@IBLG/6CQ#L!*NQZ,PZFZK7/%T_C3!2?*;EEWK`>JNC'L$/1, MZ!202LVI#NTPR!;"'8!:'8`K8]0HV@$XYC M[RN1Q9D.KJ.Y'3IQ.`2RS%^L4EIA+V)CY0X!&/@^<`9YUC'D.`DG<`C")5OH M[-%7/(8U2'D+::(D)`;30ND0J'\2">L,^T-7:!LP#40.0:DL*NDJDR\M95(0 MU!58C\\=GZ"0VUAN5TM<7%0S7Q,9//4"ASI8YA33!_4E0.QM6:38(?%UM&-Y M#L*M'LRLEKAX^E+*:!ZWF&4.J5U=.SH^ZG]K=IC5$O>$?FL5^JVS0A\CF1%6 M2]P3^M@J]+&[0I]8A3YQ5VCK0#QV=R`>6P?BL<,#\3NKT-^Y*_3W5J&_=U?H M'ZQ"_^"NT.^L0K]S5N@3)$O*:HE[0EM7Q!-W5\2^M4_WW>W3?6N?[KO;IX^M M??K8X3YMW3"=N+AA*B.JC1$()^,,*\'MAKCW;MR4+@\C*I&?AB,+D\K%>$I^ MAJ^B#TDLEH74EM2#3:0.#9PL&M2`QD;A$`CD-H4U?(01.02E,AC*\&@/3:W< M%FQ=@]^=R;!V'08%EA9D)OLJ=^(.(Y6/E_STU[_\/U!+`0(>`Q0````(`*QY M@4(NT4:H)`L!`,$A$P`2`!@```````$```"D@0````!A9&AX9BTR,#$R,3(S M,2YX;6Q55`4``U/<65%U>`L``00E#@``!#D!``!02P$"'@,4````"`"L>8%" M].+\>%0)```E=P``%@`8```````!````I(%P"P$`861H>&8M,C`Q,C$R,S%? M8V%L+GAM;%54!0`#4]Q9475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*QY M@4*Y;R1DVD,``!2B!``6`!@```````$```"D@105`0!A9&AX9BTR,#$R,3(S M,5]D968N>&UL550%``-3W%E1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` MK'F!0L[:K_*\>@``&9L'`!8`&````````0```*2!/ED!`&%D:'AF+3(P,3(Q M,C,Q7VQA8BYX;6Q55`4``U/<65%U>`L``00E#@``!#D!``!02P$"'@,4```` M"`"L>8%"#U!JH[E+```]8@4`%@`8```````!````I(%*U`$`861H>&8M,C`Q M,C$R,S%?<')E+GAM;%54!0`#4]Q9475X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`*QY@4*?^[ADH!<``+X9`0`2`!@```````$```"D@5,@`@!A9&AX9BTR M,#$R,3(S,2YX`L``00E#@``!#D!``!02P4&``````8` ,!@`@`@``/S@"```` ` end XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2012
Income Tax Disclosure [Abstract]  
Reconciliation of the combined income tax rate
A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows:

 

    Year Ended
December 31,		     Year Ended
December 31,		  
    2012     2011  
Domestic loss     (4,397 )     5,623  
Foreign loss     (766 )     (938 )
Loss before income taxes     (5,163 )     4,685  
                 
Expected statutory rate (recovery)     26.50 %     28.25 %
Expected provision for (recovery of) income tax     (1,368 )     1,324  
Permanent differences     489       (2,209 )
Change in valuation allowance     2,467       (589 )
Non-refundable investment tax credits     0       157  
Effect of foreign exchange rate differences     (245 )     (204 )
Effect of change in future enacted tax rates     (1,378 )     (77 )
Effect of tax rate changes and other     36       1,599  
Provision for income taxes   $ -     $ -  

 
Primary temporary differences future income taxe

The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2012, December 31, 2011:

 

    December 31,
2012		     December 31,
2011		  
Future tax assets:                
SR&ED expenditures     2,195       2,071  
Income tax loss carryforwards     21,783       19,635  
Non-refundable investment tax credits     1,719       1,719  
Share issue costs     25       84  
Accrued expenses     -       -  
Fixed and intangible assets     970       685  
Harmonization credit     248       280  
      26,940       24,193  
Less: valuation allowance     (26,940 )     (24,193 )
Net future tax assets   $ -     $ -  

 
Unclaimed amounts and their expiry dates
The unclaimed amounts and their expiry dates are as listed below:

 

    Federal     Province/
State		  
SR&ED expenditures (no expiry)   $ 8,283     $ -  
Income tax loss carryforwards (expiry date):                
2014     6,089       6,089  
2015     11,499       11,499  
2021     26       -  
2022     233       -  
2023     133       -  
2024     1,536       1,455  
2025     4,795       4,768  
2026     20,562       20,496  
2027     8,340       8,320  
2028     10,840       10,823  
2029     8,502       8,502  
2030     2,608       2,607  
2031     3,377       3,377  
2032     3,660       3,660  
Investment tax credits (expiry date):            
2018     10        
2019     8          
2020     96          
2021     55          
2022     548          
2023     399          
2024     178          
2025     199          
2026     86          
2027     90          
2028     50          

 

XML 17 R42.htm IDEA: XBRL DOCUMENT v2.4.0.6
Capital and Operating Lease Commitments - Additional Information (Details) (USD $)
In Thousands, unless otherwise specified
 1 Months Ended
Feb. 28, 2013
Sep. 30, 2002
Dec. 31, 2012
Dec. 31, 2011
Total     $ 457 $ 457
Expected Future Contract Payments $ 0 $ 100    
XML 18 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details)
 12 Months Ended 12 Months Ended
Dec. 31, 2012
Aug. 25, 2011
May 20, 2007
Jul. 20, 2005
Dec. 31, 2012
Investor warrants expiring April 30, 2015 [Member]
Dec. 31, 2011
Investor warrants expiring April 30, 2015 [Member]
Dec. 31, 2012
Investor warrants expiring March 29, 2016 [Member]
Dec. 31, 2011
Investor warrants expiring March 29, 2016 [Member]
Class of Warrant or Right [Line Items]                
Common shares issuable upon exercise of outstanding warrants 18,035       13,337 [1] 13,337 4,698 [2] 4,698
Exercise Price In CAD Dollars   1.44 2.05 1.75 1.44 [1] 1.44 1.44 [2] 1.44
Expiration Date         Apr. 30, 2015   Mar. 29, 2016  
[1] (1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement ("Private Placement") of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
[2] (2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
XML 19 R47.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes - Additional Information (Details)
 12 Months Ended
Dec. 31, 2011
Canadian Statutoy Income Tax [Member]
  
Income Taxes Disclosure - Additional Information [Line Items]  
Income Tax Rate 28.25%
Federal Income Tax [Member]
  
Income Taxes Disclosure - Additional Information [Line Items]  
Income Tax Rate 16.50%
Provincial Income Tax [Member]
  
Income Taxes Disclosure - Additional Information [Line Items]  
Income Tax Rate 11.75%
XML 20 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Capital Assets
 12 Months Ended
Dec. 31, 2012
Property, Plant and Equipment [Abstract]  
Capital Assets

 3.         Capital Assets

 

At December 31, 2012 and December 31, 2011, the Company determined the carrying values of its capital assets to be nil. 
EXCEL 21 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B8S9F M,&8P93@W93DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=? M4&]L:6-I93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-A<&ET86Q?07-S971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-H87)E:&]L9&5R#I7;W)K M#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-I M9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I93$\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O&5S7U1A8FQE#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=O:6YG7T-O;F-E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I93(\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-A<&ET86Q?86YD7T]P97)A=&EN9U],96%S95]#;S,\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I7;W)K#I7 M;W)K%], M;W-S7T,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T M&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B8S9F,&8P93@W93D-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F)F-6$Q9&)?9#1B,5\T,&0Q M7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O'0^,3`M2SQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^041(6$8\2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!6;VQU;G1A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B8S9F,&8P M93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F)F-6$Q9&)? M9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'!E;G-E M*3H\+W-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQAF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D(&9O65E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&-E<'0@4VAA&EQ=6%N="!;365M8F5R73QB65E M2`R,#`W($9I;F%N8VEN9R!;365M8F5R73QB M&EQ=6%N="!;365M8F5R73QB2`R,#`T(%!L86-E;65N="!;365M8F5R73QB2`R,#`U(%!L86-E M;65N="!;365M8F5R73QB2!;365M8F5R73QB2!;365M8F5R73QB2`R,#`W($9I;F%N M8VEN9R!;365M8F5R73QB2!;365M8F5R73QB2!;365M8F5R73QB2!;365M8F5R73QB2`R,#`T(%!L86-E;65N="!;365M8F5R73QB2!;365M8F5R73QB2`R,#`V(%!L86-E M;65N="!;365M8F5R73QB2!;365M8F5R73QB&EQ=6%N="!;365M8F5R73QB65E6%B;&4@6TUE;6)E M6%B;&4@6TUE;6)E2`R,#`U(%!L86-E;65N="!;365M8F5R73QB2`R,#`W($9I;F%N8VEN9R!;365M8F5R73QB2`R,#`T(%!L86-E;65N="!;365M8F5R M73QB2`R,#`V(%!L86-E;65N="!;365M8F5R73QB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!C M;VUP;VYE;G0@;V8@8V]N=F5R=&EB;&4@;F]T97,\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B8S9F M,&8P93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F)F-6$Q M9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B M;&%C:SLG/CQB/C$N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[1V]I;F<@0V]N8V5R;CPO8CX\+V9O;G0^ M/"]P/@T*/'`@3L@=&5X="UI M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE"!496-H;F]L;V=I97,@26YC+B`H)B,X,C(P.T%D:&5R97@F(S@R M,C$[*2P@82!"2!O=VYE9"!S=6)S:61I87)I97,@3WAI<75A;G0L M($EN8RX@*"8C.#(R,#M/>&EQ=6%N="8C.#(R,3LI(&%N9"!!9&AE2PF(S@R,C$[(&ES(&$@9&5V96QO M<&UE;G0@2!W:71H(&$@ M<&]R=&9O;&EO(&]F('!R;V1U8W0@8V%N9&ED871E#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R M.B!B;&%C:SLG/E1H92!#;VUP86YY(&ES(&$@9&5V96QO<&UE;G0@2!A;F0@9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q M+"`R,#$R+"!I;F-U'!E2=S(&]P97)A=&EN9R!L;W-S97,@#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE2P@ M=&AE('5S92!O9B!A8V-O=6YT:6YG('!R:6YC:7!L97,@87!P;&EC86)L92!T M;R!A(&=O:6YG(&-O;F-E2P@9&5B="!O3L@=&5X="UI;F1E;G0Z(#`N M-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6EN9R!V86QU M97,@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'`@#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\ M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG M/E1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@:6YC;'5D M92!T:&4@86-C;W5N=',@;V8@061H97)E>"!A;F0@;V8@86QL(&ET2!T M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($%U9W5S="`Q,"P@ M,C`Q,2P@=&AE($)O87)D(&]F($1I28C.#(Q-SMS(&-O;6UO M;B!S:&%R97,L('-T;V-K(&]P=&EO;G,@86YD('=A7,@8F5E;B!P6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/E5S92!O9B!E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R M.B!B;&%C:SLG/E1H92!P3L@=&5X="UI;F1E;G0Z(#`N M-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE2!L M:7%U:60@:6YV97-T;65N=',@=VET:"!O#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!P M;&%C97,@:71S(&-A2!M87)K970@ M:6YV97-T;65N=',@='EP:6-A;&QY(&AA=F4@;6EN:6UA;"!R:7-K.R!H;W=E M=F5R+"!I;B!R96-E;G0@>65A6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D9I M;F%N8VEA;"!I;G-TF5D(&]N('1H92!B86QA;F-E M('-H965T2P@ M87!P2XF(S$V,#M4:&4@0V]M<&%N>2!D M;V5S(&YO="!H;VQD(&]R(&ES3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!I2XF(S$V,#M396-U3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!R:7-K2!C;W-T(&]F('1H92!C;VYS97)V871I=F4@;F%T=7)E M(&]F('1H92!A;&QO=V%B;&4@:6YV97-T;65N=',N)B,Q-C`[07,@=&AE(&UA M:6X@<'5R<&]S92!O9B!T:&4@0V]M<&%N>2!I6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C M:SLG/CQB/D-O;6UO;B!S=&]C:R!A;F0@=V%R6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D%T M($1E8V5M8F5R(#,Q+"`R,#`W+"!T:&4@0V]M<&%N>2!H860@=V%R28C.#(Q-SMS(%4N4RX@9&]L;&%R(&9U;F-T:6]N86P@ M8W5R6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE&5D('1O(&%N M($5N=&ET>2=S($]W;B!3=&]C:R8C.#(R,3L@*"8C.#(R,#M%251&(#`W+34F M(S@R,C$[*2P@8V]D:69I960@87,@05-#(#@Q-2TT,"XF(S$V,#LF(S$V,#M) M;B!*=6YE(#(P,#@L(&]N92!O9B!T:&4@8V]N8VQU2UL:6YK960@9FEN86YC:6%L(&EN2!O=&AE3L@28C M.#(Q-SMS(&]U='-T86YD:6YG('=A2!T:&4@2!T:&%T(&ES(&)O=&@@*&$I(&EN9&5X960@=&\@:71S(&]W;B!S=&]C M:R!A;F0@*&(I(&-L87-S:69I960@:6X@65A2!W:&EC:"!IF5D(&QO3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE M/3-$)V-O;&]R.B!B;&%C:SLG/DYO;BUR969U;F1A8FQE('5P+69R;VYT('!A M>6UE;G1S(')E8V5I=F5D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&1E=F5L M;W!M96YT(&%N9"!L:6-E;G-E(&%GF5D(&]N(&$@2!A2!D;V5S(&YO="!H879E(&%N>2!R979E;G5E+CPO9F]N=#X\+W`^#0H\ M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE"!C#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE65E(&-O;7!E;G-A=&EO;BP@;&%B;W)A=&]R>2!F965S+"!L M86(@'!E;G-E9"!A M3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/B8C M,38P.SPO8CX\+V9O;G0^/"]P/@T*/&1I=B!S='EL93TS1"=M87)G:6XZ(#!P M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/E1H M92!#;VUP86YY(&%C8V]U;G1S(&9O"!A'!E8W1E9"!F=71U2!P M3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/E1H92!#;VUP86YY(&%C M8V]U;G1S(&9O2!I;B!I;F-O;64@=&%X97,@8GD@9F]L M;&]W:6YG('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A MF5D(&EN(&%N(&5N=&5R<')I"!P;W-I M=&EO;G,@'!E8W1E9"!T;R!B92!T86ME;B!I M;B!T:&4@8V]U2UT:&%N+6YO="8C.#(R,3L@=&AR97-H;VQD(&]F M(&)E:6YG('-U2!T:&4@87!P;&EC86)L92!T87@@875T:&]R M:71Y+B8C,38P.U1A>"!B96YE9FET"!P;W-I=&EO M;G,@;F]T(&1E96UE9"!T;R!M965T('1H92`F(S@R,C`[;6]R92UL:6ME;'DM M=&AA;BUN;W0F(S@R,C$[('1HF5D(&EN('1H92!F:6YA;F-I86P@2!H87,@96QE8W1E9"!A;B!A8V-O=6YT:6YG('!O;&EC>2!T:&%T(&-O;G1I M;G5E2!A8V-R=65D(&EN=&5R97-T(&%N9"!P96YA;'1I M97,@&5S(&EN M(&EN8V]M92!T87@@97AP96YS92X\+V9O;G0^/"]P/@T*/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/D9O6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE2!T6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/D5A6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\ M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE2!D:79I9&EN9R!N970@96%R;FEN9W,O*&QO&-E<'0@=&AE('=E:6=H=&5D(&%V M97)A9V4@;G5M8F5R('-H87)E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/DYE=VQY M(&%D;W!T960@86-C;W5N=&EN9R!P6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C M:SLG/D]N($UA>2`Q,BP@,C`Q,2P@=&AE($9!4T(@:7-S=65D($%352`R,#$Q M+3`T("8C.#(R,#M&86ER(%9A;'5E($UE87-U2!T;R!D:7-C;&]S92!S97!A6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/B8C,38P.SPO8CX\+V9O;G0^ M/"]P/@T*/'`@6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG2!T;R!N970@:6YC;VUE+"!A;B!E;G1I M='D@;6%Y(&-R;W-S(')E9F5R96YC92!T;R!T:&4@2!I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'`@3L@=&5X="UI;F1E M;G0Z(#!P>#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!D971E6EN9R!V M86QU97,@;V8@:71S(&-A<&ET86P@87-S971S('1O(&)E(&YI;"XF(S$V,#L\ M+V9O;G0^/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'`@#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE28C.#(Q-SMS(&%N;G5A M;"!M965T:6YG+"!S:&%R96AO;&1E6EN9R!S:&%R97,@;VX@=&AE(&1A=&4@;V8@9W)A;G0N)B,Q-C`[ M06QL(&]P=&EO;G,@=F5S="!W:71H:6X@=&AR964@>65A2!O9B!T:&4@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R M.B!B;&%C:SLG/E1H92!F;VQL;W=I;F<@;W!T:6]N3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@=&5X M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE6QE M/3-$)W9E'0M86QI9VXZ(&-E;G1E'0M M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG6QE/3-$)V-O M;&]R.B!B;&%C:SLG/D]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$P M/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^/&9O M;G0@F4Z(#$P<'0[)SXP M+C8S+34X+C4P/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@,3(E.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)V-O;&]R.B!B;&%C:SLG/D=R86YT960\+V9O;G0^ M/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@F4Z(#$P<'0[)SXP+C4T+3`N.#$\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Q,'!T.R<^4F5I;G-T871E9#QS=7`^*#$I/"]S=7`^/"]F;VYT M/CPO=&0^#0H\=&0^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@F4Z(#$P<'0[)SXU+C`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`F(S@R M,3$[-3@N-3`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG M/D]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]F;VYT/CPO=&0^ M#0H\=&0^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@F4Z(#$P<'0[)SXP+C4T+3`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`N-30M M,"XX,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE/3-$)V-O;&]R.B!B;&%C:SLG/B0\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/"]T#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B@Q*3PO9F]N M=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/DEN M8VQU9&5S(#$P(&]P=&EO;G,@2!P97(@#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\=&%B;&4@6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O65A6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M,S`E.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`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`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O&5R8VES928C,38P.U!R:6-E M)B,Q-C`[:6XF(S$V,#M5+E,N)B,Q-C`[1&]L;&%R6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&IU6QE/3-$)V-O;&]R M.B!B;&%C:SLG/C6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I M9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@,3(E.R<^/&9O;G0@F4Z(#$P<'0[)SXD(#$N.#`@+2`R-"XS,#PO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$R)3LG/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SLG/CDN.3`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`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`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`Q,'!T.R<^)"`U+C`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`^#0H\<"!S='EL93TS1"=T97AT M+6EN9&5N=#H@,'!X.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E7!E.B!!6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)VUA"`P<'0@,3DN-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B,F(S$V,#M/=71S=&%N9&EN9R8C,38P.V%T(#QB'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`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`N,C`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`\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R.B!B;&%C:SLG/B0\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`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`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`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`^#0H\<"!S='EL M93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE2`S+"`R,#$P(&9O2!T:&4@0V]M<&%N M>2!O;B!!<')I;"`R,"P@,C`Q,"X@3VX@075G=7-T(#$X+"`R,#$P+&5A8V@@ M;V8@1'(N(%!O6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE&5R8VES92!P6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)V-O M;&]R.B!B;&%C:SLG/E-T;V-K(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O2XF(S$V,#LF(S$V M,#M4:&5S92!A;6]U;G1S(&AA=F4@8F5E;B!I;F-L=61E9"!I;B!T:&4@9V5N M97)A;"!A;F0@861M:6YI6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N M=#H@,"XU:6X[(&UA#L@9F]N=#H@,3!P="!T:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`V M-"4[)SX\9F]N="!S='EL93TS1"=C;VQO'!E8W1E9"!D M:79I9&5N9#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@,34E.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B4\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SX\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R.B!B;&%C:SLG/E)I6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@F4Z(#$P<'0[)SXQ+C`Y+3$N,C8\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO M6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="US:7IE.B`Q,'!T.R<^,2XX-2TR+C4\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/D5X<&5C=&5D('9O;&%T M:6QI='D\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`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`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE2!U28C.#(Q-SMS('-H87)E('!R:6-E+CPO9F]N=#X\+W`^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q M7S0P9#%?8F1B9%]B8S9F,&8P93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO8F)F-6$Q9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y M+U=O'0O M:'1M;#L@8VAA6QE M/3-$)W1E>'0M:6YD96YT.B`P<'@[(&UA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SQS=')O;F<^-2XF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M$97)I=F%T:79E($EN6QE/3-$)W1E>'0M M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$ M)V)A8VMG2`Q M+"`R,#`Y+"!T:&4@0V]M<&%N>2!A9&]P=&5D($%30R!4;W!I8R`X,34M-#`L M(")$97)I=F%T:79E2=S(&]W;B!S=&]C:R!I9B!T:&4@2X@5&AE(&-O;F-L=7-I;VX@2=S(&]W;B!S=&]C:SL@86YD("AB*2!C;&%S&5D('1O(&ET&5R8VES92!P2!A2=S(&9U;F-T M:6]N86P@8W5R#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/E1H92!# M;VUP86YY)W,@9&5R:79A=&EV92!I;G-T&5R8VES92!P M6QE/3-$)W=I9'1H.B`P+C(U:6X[)SX\+W1D/@T*/'1D M('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[)SX\9F]N="!S='EL93TS1"=C;VQO M3H@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V)A8VMG6QE/3-$)W9E#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R M.B!W:&ET93L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E2!A="!E86-H('-U8G-E<75E;G0@8F%L86YC M92!S:&5E="!D871E+B!!;GD@8VAA;F=E(&EN('9A;'5E(&)E='=E96X@F5D M(&=A:6XO*&QO&5R8VES960@;W(@97AP:7)E+B!4:&4@9F%I6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M&5R8VES92!A="!T:&4@8W5R&-H M86YG92!R871E(&%T('1H92!T:6UE(&]F(&5X97)C:7-E+CPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W=I9'1H.B`X-24[(&)O6QE/3-$)V9O;G0M M6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=C;VQOF4Z(#EP=#L@9F]N M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@F4Z(#EP=#LG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Y<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO6QE/3-$)V)A8VMGF4Z(#EP=#L@9F]N="UW96EG:'0Z(&)O;&0[ M)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R!F;VYT M+7-I>F4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S='EL93TS1"=C;VQOF4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T M6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Y<'0[)SY787)R86YT(&5X<&ER:6YG($UAF4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!C;VQOF4Z M(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!C;VQOF4Z(#EP=#LG M/B@U,#<\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!C;VQOF4Z(#EP=#LG/BD\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=C;VQOF4Z M(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X-"CPO='(^#0H\='(@6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SY2:6=H M=',@;V9F97)I;F<@9&5R:79A=&EV93PO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S='EL M93TS1"=C;VQOF4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z(&)L M86-K.R!F;VYT+7-I>F4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B M;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXM/"]F;VYT/CPO=&0^#0H\=&0@F4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=C M;VQOF4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B M;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@F4Z(#EP=#L@9F]N M="UW96EG:'0Z(&)O;&0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Y<'0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXH,S`\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C M;VQOF4Z(#EP=#LG/BD\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"=C;VQOF4Z(#EP=#LG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S M='EL93TS1"=C;VQOF4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T MF4Z(#EP=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D M('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^/&9O;G0@F4Z(#EP=#LG/E1O=&%L/"]F;VYT/CPO=&0^#0H\=&0@F4Z(#EP=#L@9F]N="UW96EG:'0Z M(&)O;&0[)SX\9F]N="!S='EL93TS1"=C;VQOF4Z(#EP=#LG M/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO M6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#EP=#L@9F]N="UW M96EG:'0Z(&)O;&0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\+W1A8FQE/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6QE/3-$)V)A8VMG2`R,#$Q+"!T:&4@0V]M<&%N M>2!F:6QE9"!A(&9I;F%L('-H;W)T(&9O'!I6QE/3-$ M)V)A8VMG2!R96-O9VYI>F5D(&$@9&5R:79A=&EV92!F:6YA;F-I86P@ M;&EA8FEL:71Y(&]F("0Q+C(U(&UI;&QI;VX@87-S;V-I871E9"!W:71H('1H M92!#;VUP86YY)B,X,C$W.W,@;V)L:6=A=&EO;B!T;R!C87)R>2!O=70@=&AE M(')I9VAT2!O9B!T:&4@=V%R M65AF5D(&1E6QE/3-$)V)A8VMG#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/E5N9&5R('1H92!T97)M&5D+B!%86-H(&AO;&1E2X@5&AE28C.#(Q-SMS('-H87)E:&]L9&5R M2!M96%S=7)E9"!A="!F86ER('9A;'5E+CPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)V)A8VMG2!T:&4@0V]M<&%N>2!R96-O'!E;G-E2`D,S`P(&%N9"!W97)E(&5X<&5N M#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CPO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG M/D1U65E&-E<'1I;VX@97AI'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!E6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT M+6EN9&5N=#H@,'!X.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE#L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)W1E>'0M:6YD96YT.B`P<'@[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'@[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W`^#0H\=&%B;&4@6QE/3-$)W9E6QE/3-$)V-O;&]R.B!B;&%C:SLG/E%U;W1E9"!06QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B M;&%C:SL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="UW96EG:'0Z(&)O M;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W9E6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/F9O6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="UW96EG M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]B6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="UW M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W9E6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="UW96EG:'0Z M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R M87`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`Q)3L@8V]L;W(Z(&)L86-K.R<^ M/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#$R)3L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^ M/&9O;G0@6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&-O;&]R.B!B;&%C:SLG/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`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`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`@3PO8CX\+V9O M;G0^/"]P/@T*/'`@3L@=&5X M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UEF5D(&-A<&ET86P@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($%U9W5S="`\9F]N M="!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!T97AT+75N9&5R;&EN M92US='EL93H@;F]N93LG/C$P+"`\+V9O;G0^,C`Q,2P@=&AE($)O87)D(&]F M($1I28C.#(Q-SMS(&-O;6UO;B!S:&%R97,L('-T;V-K(&]P M=&EO;G,@86YD('=A2!H87,@/&9O;G0@ M3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C M:SLG/D]N($IU;F4@-2P@,C`P,2P@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&%N M($E03R!I6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($1E8V5M M8F5R(#$Y+"`R,#`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`\+V9O;G0^<&5R('5N:70\9F]N="!S='EL93TS M1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!T97AT+75N9&5R;&EN92US='EL93H@ M;F]N93LG/BX@16%C:#PO9F]N=#X@=6YI="`\9F]N="!S='EL93TS1"=F;VYT M+7=E:6=H=#H@;F]R;6%L.R!T97AT+75N9&5R;&EN92US='EL93H@;F]N93LG M/F-O;G-I6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^+"!A;F0L(&%T('1H870@=&EM92P@ M96%C:#PO9F]N=#X@=VAO;&4@=V%R2`R,"P@,C`P-2P@=&AE M($-O;7!A;GD@8V]M<&QE=&5D(&$@<')I=F%T92!P;&%C96UE;G0@;V8@97%U M:71Y('-E8W5R:71I97,@9F]R(&=R;W-S('!R;V-E961S(&]F("0X+#4Q,"`\ M9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!T97AT+75N9&5R M;&EN92US='EL93H@;F]N93LG/F%N9"!I6QE/3-$)V9O;G0M=V5I9VAT M.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^,2XT,#PO M9F]N=#X@<&5R('5N:70L('!R;W9I9&EN9R!N970@<')O8V5E9',@;V8@)#@L M,3,T(&%F=&5R(&1E9'5C=&EN9R!B6QE/3-$)V9O M;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE M.R<^,S,W(#PO9F]N=#YS:&%R97,@;V8@8V]M;6]N('-T;V-K(&]N(&$@<&]S M="`F(S@R,3$[8V]N"!C;VUM;VX@6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD97)L M:6YE+7-T>6QE.B!N;VYE.R<^070@=&AA="!T:6UE+"!E86-H/"]F;VYT/B!W M:&]L92!I;G9E"!A="!A;B!E>&5R8VES92!P"!C;VUM;VX@6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD M97)L:6YE+7-T>6QE.B!N;VYE.R<^,2XW-2`\+V9O;G0^9F]R(&$@<&5R:6]D M(&]F('1W;R!Y96%R&5R8VES M960@;VX@2G5L>2`R,"P@,C`P-R!A;F0@,C`P."P@2!S96-U'!E;G-E"!C;VUM;VX@6QE M/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE M.B!N;VYE.R<^070@=&AA="!T:6UE+"!E86-H/"]F;VYT/B!W:&]L92!I;G9E M65A M6QE/3-$)V9O;G0M=V5I9VAT.B!N M;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^96YT:71L960\ M+V9O;G0^('1H92!H;VQD97(@=&\@86-Q=6ER92!O;F4@"!C;VUM;VX@6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD97)L M:6YE+7-T>6QE.B!N;VYE.R<^,"XY-SPO9F]N=#X@<&5R('-H87)E(&9O65A'!I2`W+"`R,#`X+B!4:&4@=V%R3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($9E8G)U87)Y(#(Q+"`R,#`W+"!T M:&4@0V]M<&%N>2!C;VUP;&5T960@=&AE('-A;&4@;V8@97%U:71Y('-E8W5R M:71I97,@<')O=FED:6YG(&=R;W-S('!R;V-E961S(&]F("0R-2PP,#`@9F]R M(#QF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD M97)L:6YE+7-T>6QE.B!N;VYE.R<^-S4L-S4Y(#PO9F]N=#YU;FET"!C;VUM;VX@6QE/3-$)V9O;G0M=V5I9VAT M.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^070@=&AA M="!T:6UE+"!E86-H/"]F;VYT/B!W:&]L92!I;G9E&5R8VES92!P M&5R M8VES92!P&5R8VES960@<&]R=&EO;B!O9B!W:&EC:"!E>'!I3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG M/D1U'!I2`R,2P@,C`Q,"X@ M5&AE('=A2!A="!A('!U&5R8VES M92!P6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R M.B!B;&%C:SLG/CQB/E-P96-I86P@=V%R6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE2`R,#`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`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE&5R8VES M960@;VX@4V5P=&5M8F5R(#,L(#(P,#$N/"]F;VYT/CPO<#X-"CQP('-T>6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C M:SLG/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]P/@T*/'`@6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG M/D]N($%P2!C;VUP;&5T960@82!F M:7)S="!C;&]S:6YG(&]F(&$@;F]N+6)R;VME65A28C.#(Q-SMS(&9U;F-T:6]N86P@8W5R M2!D:7-T2!S=6-H('-H87)E:&]L M9&5R)B,Q-C`[;VX@36%R8V@@,BP@,C`Q,2P@=&AE(')E8V]R9"!D871E(&9O M&5R8VES86)L92!F;W(@;VYE M('5N:70@=VAI8V@@8V]N2!A="!A('!U&-H86YG92!#;VUM:7-S:6]N('1O(')E9VES=&5R('1H92!R:6=H=',@ M86YD('5N9&5R;'EI;F<@2!T:6UE(&]N($UA2!H860@&EM M871E;'D@)#(N-2!M:6QL:6]N+CPO9F]N=#X\+V1I=CX-"CQP('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]P M/@T*/'`@3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!E;G1E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!W:&EC:"!H96QD(&-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[ M('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^=&\@<'5R8VAA&5R8VES92!P M'!I2`R,"P@,C`P-R!A;F0@ M:6YT6QE/3-$)V9O;G0M=V5I M9VAT.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^=&\@ M<'5R8VAA&5R8VES92!P&5R8VES960@;VX@3F]V96UB M97(@,C`L(#(P,#6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!F M;W(@;F]N+6-A;F-E2UO=VYE9"!S=6)S:61I87)Y(&]F($%D:&5R97@@870@=&AE M('1I;64L(&EN(')E='5R;B!F;W(@0VQA3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2`D.2PT.#DL(&EN(&]R9&5R('1O(&-O M;7!L>2!W:71H('1H92!R97%U:7)E;65N=',@;V8@4V5C=&EO;B`T,B!O9B!T M:&4@0T)#02X@5&AE($-O;7!A;GD@9&5C6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/DEN($9E8G)U87)Y(#(P,#0L('1H92!#;VUP86YY M(&%N9"!#0DD@8F5C86UE(&EN=F]L=F5D(&EN(&QI=&EG871I;VXN($]N($1E M8V5M8F5R(#,L(#(P,#0L('1H92!#;VUP86YY(&%N9"!#0DD@2X@07,@ M<&%R="!O9B!T:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!I6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/B8C,38P M.SPO8CX\+V9O;G0^/"]P/@T*/'`@6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($IU;F4@,C,L(#(P,#,L M('1H92!#;VUP86YY(&ES&5R8VES92!P'!I65A&5R8VES960@;VX@2G5N92`R M,RP@,C`P-2X\+V9O;G0^/"]P/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/D]N($1E8V5M8F5R(#,L(#(P,#,L('1H92!#;VUP M86YY(&ES2!F=6YD M(')A:7-I;F<@6QE/3-$)V9O;G0M=V5I M9VAT.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^870@ M=&AA="!T:6UE+"`\+V9O;G0^:6YV97-T;W)S(')E8V5I=F5D('=A6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD M97)L:6YE+7-T>6QE.B!N;VYE.R<^=&\@<'5R8VAA65A65A6QE/3-$)V9O;G0M=V5I M9VAT.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^,BXQ M-2`\+V9O;G0^<&5R('-H87)E('=H:6-H(&5X<&ER960@=6YE>&5R8VES960@ M;VX@1&5C96UB97(@,RP@,C`P-2X\+V9O;G0^/"]P/@T*/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($1E8V5M8F5R(#$Y M+"`R,#`S+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@86X@97%U:71Y(&9I;F%N M8VEN9R!R97-U;'1I;F<@:6X@=&AE(&-O;G9E6QE/3-$)V9O M;G0M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE M.R<^,34V(#PO9F]N=#YS:&%R97,@;V8@8V]M;6]N('-T;V-K(&]N(&$@<&]S M="UC;VYS;VQI9&%T:6]N(&)A6EN9R!V86QU92!O M9B`D,2PW.#4@8W)E9&ET960@=&\@8V]M;6]N('-T;V-K+B`\9F]N="!S='EL M93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!T97AT+75N9&5R;&EN92US='EL M93H@;F]N93LG/D%T('1H870@=&EM93PO9F]N=#XL('1H92!#;VUP86YY(&ES M6QE/3-$)V9O;G0M M=V5I9VAT.B!N;W)M86P[('1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE.R<^ M+"!S:&%R97,@;V8@/"]F;VYT/F-O;6UO;B!S=&]C:R!W:71H(&%N(&5X97)C M:7-E('!R:6-E(&]F($-!1"0\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!T97AT+75N9&5R;&EN92US='EL93H@;F]N93LG/C(N,34\+V9O M;G0^('!E'!I#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M M8V]L;&%P6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)R!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O M;&]R.B!B;&%C:SLG/D-O;6UO;B8C,38P.U-H87)E&5R8VES928C,38P.V]F)B,Q-C`[3W5T6QE/3-$)W!A M9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/D%P6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R.B!B M;&%C:SLG/C0L-CDX/"]F;VYT/CPO=&0^#0H\=&0@6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@ M,7!T.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)V-O M;&]R.B!B;&%C:SLG/DUA6QE/3-$)V)A8VMG'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO'0M86QI9VXZ(')I9VAT.R<^ M/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T2!A;FYO=6YC960@=&AA="!I="!H860@8V]M<&QE=&5D M(&$@9FER65A6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="UW96EG:'0Z(&YO2!A="!A('!U3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B8S9F M,&8P93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F)F-6$Q M9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/C@N M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[4F5S96%R8V@@86YD($1E=F5L;W!M96YT/"]B/CPO9F]N=#X\ M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN M9&5N=#H@,"XU:6X[(&UA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE"!C'!E;F1I='5R M97,@86YD(&=O=F5R;FUE;G0@9W)A;G1S(&AA=F4@8F5E;B!A<'!L:65D('1O M(')E9'5C92!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,@87,@ M9F]L;&]W3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W=I9'1H.B`Q,#`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`Q)3LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C8W M+#,S.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T#L@9F]N=#H@,3!P="!T:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C M:SLG/E=E(&AA9"!N;R!M871E'!E;G-E'1E;F1I;F<@8F5Y;VYD('1H M6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)V)O6QE/3-$)V-O;&]R.B!B;&%C:SLG/C$M,R`\8G(@("\^>65A6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/"]T6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/D]#5"!#;&EN:6-A;"!397)V:6-E($%G6QE/3-$)V-O;&]R.B!B;&%C:SLG/C0P,CPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R<^ M/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`^#0H\=&%B;&4@6QE/3-$)W9E6QE/3-$)V9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$ M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!H879E(&)E8V]M92!R97-P M;VYS:6)L92!F;W(@82!P87EM96YT('1O($](4U4@;V8@=7`@=&\@)#`N-2!M M:6QL:6]N('5P;VX@=&AE('-U8V-E6%L='D@<&%Y;65N=',L('=H:6-H(&%R92!C;VYT:6YG96YT(&]N M('-A;&5S+"!A#LG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B M;&4@6QE/3-$)W9E2!I7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/'`@#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/'`@6QE/3-$)V-O;&]R M.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/CPO M8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/'`@3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($9E8G)U87)Y(#(P+"`R,#$S+"!! M9&AE&-L=7-I=F4@;&EC96YS92!A M9W)E96UE;G0@=VET:"!/2`H)B,X,C(P.T](4U4F(S@R,C$[*2!F;W(@97AC;'5S:79E('=O M2!D;W=N(&%N9"!A(#4F(S$V,#MP97)C96YT(')O>6%L='D@;VX@86YY M(&-O;G-I9&5R871I;VX@6UE M;G0@9F5E6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]N($9E8G)U87)Y(#(P+"`R,#$S+"!! M9&AE&EQ=6%N="!A('=H;VQL>2!O=VYE9"!S=6)S M:61I87)Y(&]F($%D:&5R97@L(&1A=&5D(%-E<'1E;6)E&EQ=6%N="!I;G1O M(#(Q+#(U,"!S:&%R97,@;V8@061H97)E>"!C;VUM;VX@"!C;VUM;VX@ M6UE;G1S('=E&EQ=6%N="!W87,@=&\@8F4@;&EA8FQE M(&9O2!/2!A(#(N-24@2!O;B!N M970@2!C;VYS:61E6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^/"]F;VYT M/CPO9&EV/@T*/'`@"P@=6YL97-S(&5A2!M971H;V1S(&]F('5S92!P871E;G1S('1H870@=&AE($-O;7!A;GD@97AC M;'5S:79E;'D@;&EC96YS960@9G)O;2!/2%-5('1H870@97AP:7)E(&EN($5U M2!E:71H97(@061H97)E>"!O2!I;B!T:&4@979E;G0@;V8@82!M871E M2!E:71H97(@<&%R='D@ M869T97(@-#4@9&%Y"!H M87,@=&AE(')I9VAT('1O('1E2!T:6UE('5P;VX@-C`@9&%Y6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/'`@ M3L@=&5X="UI;F1E;G0Z(#`N M-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/D=L M87AO4VUI=&A+;&EN93PO8CX\+V9O;G0^/"]P/@T*/&1I=CX\9F]N="!S='EL M93TS1"=C;VQO6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E'!I2UB86-K(&%N9"!A6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/D]N($UA2!P=7)C:&%S960@ M86QL(&]F($=32R8C.#(Q-SMS(')E;6%I;FEN9R!B=7DM8F%C:R!O<'1I;VYS M(&9O"!N;W<@;6%Y(&)E(')E<75I2!'4TL@9&5V96QO M<&UE;G0@86YD('-A;&5S(&UI;&5S=&]N97,@86YD(')O>6%L=&EE2!D979E;&]P;65N="!M:6QE2!B92!R97%U:7)E9"!T;R!P87D@=7`@=&\@86X@ M861D:71I;VYA;"`D-S`N,"!M:6QL:6]N(&EN(&1E=F5L;W!M96YT(&%N9"!S M86QE2!T:&4@8G)E86-H M:6YG('!A7,@<')I;W(@=W)I='1E;B!N;W1I8V4N M/"]F;VYT/CPO<#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO'0^/'`@&5S/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE"!J=7)I28C.#(Q-SMS(&5F9F5C=&EV92!T M87@@6QE/3-$)W=I9'1H.B`Y M,B4[(&)O6QE/3-$)W9E6QE/3-$)W9E6QE M/3-$)V-O;&]R.B!B;&%C:SLG/C(P,3(\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=C;VQO'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)V-O;&]R.B!B;&%C:SLG/D1O;65S=&EC(&QO6QE/3-$)V-O;&]R.B!B;&%C:SLG/B@T+#,Y-SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!C;VUE('1A>"!R871E(&]F M(#(X+C(U)B,Q-C`[<&5R8V5N="!I&EM871E;'D@,38N-28C,38P.W!E"!A="!A<'!R;WAI;6%T96QY(#$Q M+C6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!T96UP;W)A6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\=&%B;&4@86QI9VX],T1C96YT97(@6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T M6QE/3-$)W=I9'1H.B`V M-"4[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=C;VQO'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE&5S(&5X M<&5C=&5D('1O(&)E(&]W960@:6X@=&AE(&YE87(@=&5R;2X\+V9O;G0^/"]P M/@T*/'`@'!E'!E;F1I='5R97,L(&EN8V]M92!T M87@@;&]S2!F;W)W87)D6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^ M#0H\=&%B;&4@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO M6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B;&%C:SLG/D9E9&5R86P\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$U)3LG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/C@L,C@S/"]F;VYT/CPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`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`X/"]F;VYT M/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B!B;&%C:SLG/C(L-C`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`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`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`M,"XR-6EN.R!P861D:6YG M+6QE9G0Z(#`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/C(P,C@\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'`@#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE2!H87,@ M2!A9&IU6QE/3-$)V-O;&]R.B!B M;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\ M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/'`@6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M'!E M;G-E(&1U2!A;F0@=&AE M('9A;'5E(&]F('-T;V-K(&)A6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T* M/'`@6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D-A6QE/3-$)W1E M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!P;&%C97,@:71S(&-A2!F:6YA;F-I86P@ M:6YS=&ET=71I;VYS(&EN(&%C8V]R9&%N8V4@=VET:"!I=',@:6YV97-T;65N M="!P;VQI8WD@9&5S:6=N960@=&\@<')O=&5C="!T:&4@<')I;F-I<&%L(&EN M=F5S=&UE;G0N)B,Q-C`[070@1&5C96UB97(@,S$L(#(P,3(L('1H92!#;VUP M86YY(&AA9"`D,BPS,#,@:6X@8V%S:"!A8V-O=6YT2!M87)K970@:6YV97-T;65N=',@='EP:6-A;&QY(&AA M=F4@;6EN:6UA;"!R:7-K.R!H;W=E=F5R+"!I;B!R96-E;G0@>65A6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D9I;F%N8VEA M;"!I;G-TF5D(&]N('1H92!B86QA;F-E('-H965T M2P@87!P2XF(S$V,#M4:&4@0V]M<&%N>2!D;V5S(&YO M="!H;VQD(&]R(&ES3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!I2XF(S$V,#M396-U3L@ M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!R:7-K2!C;W-T(&]F('1H92!C;VYS97)V871I=F4@;F%T=7)E(&]F('1H M92!A;&QO=V%B;&4@:6YV97-T;65N=',N)B,Q-C`[07,@=&AE(&UA:6X@<'5R M<&]S92!O9B!T:&4@0V]M<&%N>2!I6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/D-O;6UO;B!S=&]C:R!A M;F0@=V%R6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/D%T($1E8V5M8F5R(#,Q+"`R,#`W+"!T M:&4@0V]M<&%N>2!H860@=V%R28C.#(Q-SMS M(%4N4RX@9&]L;&%R(&9U;F-T:6]N86P@8W5R6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE&5D('1O(&%N($5N=&ET>2=S($]W;B!3=&]C:R8C M.#(R,3L@*"8C.#(R,#M%251&(#`W+34F(S@R,C$[*2P@8V]D:69I960@87,@ M05-#(#@Q-2TT,"XF(S$V,#LF(S$V,#M);B!*=6YE(#(P,#@L(&]N92!O9B!T M:&4@8V]N8VQU2UL:6YK960@9FEN86YC:6%L(&EN M2!O=&AE3L@28C.#(Q-SMS(&]U='-T86YD:6YG('=A M2!T:&4@2!T:&%T(&ES(&)O=&@@*&$I M(&EN9&5X960@=&\@:71S(&]W;B!S=&]C:R!A;F0@*&(I(&-L87-S:69I960@ M:6X@65A2!W:&EC:"!I MF5D(&QO6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/'`@ M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W`^#0H\9&EV/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C M:SLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O M;G0^/"]F;VYT/CPO9&EV/@T*/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE M/3-$)V-O;&]R.B!B;&%C:SLG/E1H92!#;VUP86YY(')E8V]R9',@2!R979E;G5E(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@8V]N=')A8W0@=&5R M;7,@;VYC92!I="!C86X@8F4@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^#0H\9&EV/CQF;VYT M('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/'`@2!D;V5S(&YO="!H879E M(&%N>2!R979E;G5E+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/E(\8CYE3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE'!E;G-E9"!A2!E>'!E;G-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`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`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/E1H92!#;VUP86YY(&%C8V]U;G1S M(&9O"!A'!E M8W1E9"!F=71U6EN9R!A;6]U;G1S(&%N9"!T87@@8F%S:7,@;V8@87-S971S(&%N9"!L:6%B M:6QI=&EE2!P3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`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`F(S@R,C`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`@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\9&EV/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^ M/"]F;VYT/CPO9&EV/@T*/'`@2!T:&4@=V5I9VAT960@879E2!M971H;V0N/"]F M;VYT/CPO<#X\'0^/&1I=CX\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B M;&%C:SLG/CQB/DYE=VQY(&%D;W!T960@86-C;W5N=&EN9R!P6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W`^#0H\9&EV/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^ M/"]F;VYT/CPO9&EV/@T*/'`@2!O;B!A(&=R;W-S(&)A6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W`^ M#0H\9&EV/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO M9&EV/@T*/'`@2!T;R!P2P@:6X@1&5C96UB97(@,C`Q,2P@=&AE($9!4T(@:7-S=65D($%3 M52`R,#$Q+3$R('=H:6-H(&1E9F5R'0^/&1I=CX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/E)E8V5N="!A M8V-O=6YT:6YG('!R;VYO=6YC96UE;G1S/"]B/CPO9F]N=#X\+W`^#0H\9&EV M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/CQB/CPO8CX\+V9O;G0^/"]F;VYT/CPO9&EV/@T* M/'`@#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V)A M8VMG2!T;R!N970@:6YC;VUE+"!A;B!E;G1I='D@;6%Y(&-R;W-S(')E9F5R96YC M92!T;R!T:&4@2!I'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'`@ M65A3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B;&%C M:SLG/EEE87(F(S$V,#M%;F1E9#QB6QE/3-$)W!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R M.B!B;&%C:SLG/C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=C;VQO6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`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`Q,'!T.R<^-R!Y96%R6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO3L@=&5X="UI;F1E;G0Z(#`N-6EN M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE2P@0V%N861I M86X@1&]L;&%R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P M6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/D5X97)C:7-E)B,Q-C`[4')I M8V4F(S$V,#MI;B8C,38P.T-A;F%D:6%N(#QB6QE/3-$)W9E6QE/3-$)V-O M;&]R.B!B;&%C:SLG/DYU;6)E6QE/3-$)V-O;&]R.B!B;&%C:SLG/E)A;F=E/"]F;VYT M/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/E=E:6=H=&5D+2`\8G(@ M("\^879E6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/"]T6QE/3-$)W=I9'1H.B`Q M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@,3(E.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Q,'!T.R<^,"XV,RTU."XU,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`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`Q,'!T.R<^,"XU-"TP+C@Q M/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`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`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`Q,'!T.R<^ M,S4N,3`@)B,X,C$Q.S4X+C4P/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@ M6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C0L,36QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,'!T.R<^,"XU-"TP+C@Q/"]F M;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`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`R,#$R/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R M.B!B;&%C:SLG/C0L,36QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,'!T M.R<^)"`P+C4T+3`N.#$\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S M='EL93TS1"=C;VQO'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`N-S@\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@ M,BXU<'0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Q+C5P=#LG/CPO=&0^#0H\=&0@6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A M9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)V)O65A M6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@,S`E.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`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`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T#L@9F]N=#H@,3!P="!T:6UE'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`@&5R8VES86)L92!I;B!5+E,N(&1O M;&QA6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE6QE M/3-$)W9E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ M(&-E;G1E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R.B!B;&%C:SLG/D]U='-T86YD:6YG(&%T($1E M8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Q,'!T.R<^)"`Q+C@P("T@,C0N,S`\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)V)A8VMG3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/D=R86YT960\+V9O M;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@F4Z(#$P<'0[)SXP+C4P+3`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`Q,'!T.R<^)"`U+C`T+3(Q M+C8P/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=C;VQO'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@F4Z(#$P<'0[)SXD(#`N-3`@ M+2`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`Q,'!T.R<^,"XQ-2TP+C4V M/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`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`N-C<\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU M<'0[)SX\9F]N="!S='EL93TS1"=C;VQO#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E2!P97(@'0^ M/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P6QE/3-$)V-O;&]R.B!B;&%C:SLG M/E!R:6-E)B,Q-C`[:6XF(S$V,#M54R8C,38P.T1O;&QA'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B;&%C:SLG/E)E M;6%I;FEN9R8C,38P.VQI9F4@/&)R("`O/BAY96%R6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B0\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#(S)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`N M,34\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C,S/"]F;VYT M/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,C(E.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`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`N-3`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`Y<'0[)SY'86EN M+RA,;W-S*28C,38P.V]N)B,Q-C`[1&5R:79A=&EV928C,38P.TENF4Z(#EP=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4Z M(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@ M8V]L6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SY4=V5L=F4F(S$V,#MM;VYT M:',F(S$V,#ME;F1E9"8C,38P.T1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=C;VQOF4Z(#EP=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<@8V]L6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SY4=V5L=F4F(S$V,#MM M;VYT:',F(S$V,#ME;F1E9"8C,38P.T1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[ M,C`Q,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Y<'0[)SY787)R86YT(&5X<&ER:6YG($%PF4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L M;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#(P M)3L@8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#EP=#LG/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXH,2PP,C8\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T M:#H@,24[(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)W=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K M.R!F;VYT+7-I>F4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&-O;&]R.B!B M;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V)A8VMGF4Z(#EP=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@F4Z(#EP=#LG/E=A6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S='EL93TS1"=C;VQOF4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#EP M=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y M<'0[)SXV-#,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!C;VQOF4Z(#EP=#LG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/"]TF4Z(#EP=#L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^/&9O;G0@F4Z M(#EP=#LG/E)I9VATF4Z(#EP=#LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!C;VQOF4Z(#EP=#LG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!C;VQOF4Z(#EP=#LG/BT\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQOF4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N M="!S='EL93TS1"=C;VQOF4Z(#EP=#LG/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8V]L M;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXV,3,\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQOF4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SY/<'1I;VYS('1O(&-O;G1R M86-T;W)S/"]F;VYT/CPO=&0^#0H\=&0@F4Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQOF4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!C;VQOF4Z M(#EP=#LG/B@S,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N M="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Y<'0[)SX\9F]N="!S='EL93TS1"=C;VQOF4Z(#EP M=#LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#EP=#LG/CQF M;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXS M-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SX\9F]N="!S='EL93TS M1"=C;VQO6QE/3-$)V)A8VMGF4Z M(#EP=#L@9F]N="UW96EG:'0Z(&)O;&0[)SX\9F]N="!S='EL93TS1"=C;VQO M6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z M(&)L86-K.R!F;VYT+7-I>F4Z(#EP=#L@9F]N="UW96EG:'0Z(&)O;&0[)SX\ M9F]N="!S='EL93TS1"=C;VQOF4Z(#EP=#L@9F]N="UW96EG M:'0Z(&)O;&0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M/&9O;G0@F4Z(#EP=#LG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@F4Z(#EP=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!C;VQO6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)SXX+#`W,3PO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@F4Z(#EP=#LG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/"]T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B8F8U83%D M8E]D-&(Q7S0P9#%?8F1B9%]B8S9F,&8P93@W93D-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8F)F-6$Q9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F M,&4X-V4Y+U=O'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6QE/3-$)W1E>'0M:6YD96YT.B`P<'@[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQB/D%S#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="UW96EG:'0Z(&)O;&0[)R!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O M;&]R.B!B;&%C:SLG/E-I9VYI9FEC86YT/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="UW96EG:'0Z M(&)O;&0[)R!N;W=R87`],T1N;W=R87`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`],T1N;W=R87`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`T,"4[(&-O;&]R M.B!B;&%C:SLG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/D-A6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R!C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R!C;VQO6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$R)3L@8V]L;W(Z(&)L86-K M.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`@ M("`\=&%B;&4@8VQA'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&5R8VES92!P6QE/3-$)V)O6QE/3-$)V-O;&]R M.B!B;&%C:SLG/CQB/E=A6QE/3-$)V-O;&]R.B!B;&%C:SLG/D5X M97)C:7-E)B,Q-C`[4')I8V4F(S$V,#MI;B8C,38P.T-A;F%D:6%N/&)R("`O M/D1O;&QA6QE/3-$)V-O M;&]R.B!B;&%C:SLG/D5X<&ER871I;VXF(S$V,#M$871E/"]F;VYT/CPO=&0^ M#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG#L@=VED=&@Z(#4U M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/DEN=F5S=&]R(%=A M6QE/3-$)W=I9'1H.B`Q M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@,3(E.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E M.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`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`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`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA"!C3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE6QE/3-$)W=I9'1H.B`Q,#`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`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`R+C5P="!D;W5B;&4[('1E>'0M86QI M9VXZ(')I9VAT.R<^/&9O;G0@'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O M;&]R.B!B;&%C:SLG/C8W+#,S.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/"]T#L@9F]N=#H@,3!P="!T:6UE'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/&1I=CY4:&4@9F]L;&]W:6YG('1A8FQE(')E<')E M6QE/3-$)W=I9'1H.B`Y,"4[(&)O6QE/3-$)W9E'0M86QI9VXZ M(&-E;G1E6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$ M)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`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`R+C5P M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@6QE/3-$)W1E M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H M.B`V)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6QE/3-$)W=I9'1H.B`Y-"4[)SX-"CQP/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6UE M;G1S(&]V97(@=&AE(&-O=7)S92!O9B!O=7(@4&AA2!A;65N9&5D('1H92!A9W)E96UE;G0@:6X@ M2G5N92`R,#$R(&9O2!/0U0N($EN(&%D9&ET:6]N M+"!T:&4@0V]M<&%N>2!A;65N9&5D('1H92!A9W)E96UE;G0@;VX@3V-T;V)E M6UE;G0@=&\@3TA352!O M9B!U<"!T;R`D,"XU(&UI;&QI;VX@=7!O;B!T:&4@2`R,"P@,C`Q,RX@4F]Y86QT>2!P87EM96YT6QE/3-$)VUA6QE/3-$)W=I9'1H.B`V)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W=I9'1H.B`Y M-"4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!M97-S86=E('!L871F;W)M+CPO9F]N M=#X\+W1D/@T*/"]T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B M8S9F,&8P93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F)F M-6$Q9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV/D$@"!R871E('=I M=&@@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W`^#0H\=&%B;&4@6QE/3-$)V-O;&]R.B!B M;&%C:SLG/EEE87(F(S$V,#M%;F1E9"`\8G(@("\^1&5C96UB97(F(S$V,#LS M,2P\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L M9#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R M.B!B;&%C:SLG/EEE87(F(S$V,#M%;F1E9"`\8G(@("\^1&5C96UB97(F(S$V M,#LS,2P\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@ M8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=C;VQO'0M M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R<^/&9O;G0@6QE/3-$ M)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@,34E.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)V)O6QE M/3-$)V-O;&]R.B!B;&%C:SLG/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@6QE/3-$)V-O M;&]R.B!B;&%C:SLG/B@Y,S@\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@ M6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B@U+#$V,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R M.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/"]T6QE/3-$)V-O;&]R M.B!B;&%C:SLG/D5X<&5C=&5D('-T871U=&]R>2!R871E("AR96-O=F5R>2D\ M+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=C;VQO6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=C;VQO'!E8W1E9"!P2!O9BD@:6YC;VUE('1A>#PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C M;VQO6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B@Q+#,V.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^/&9O;G0@6QE/3-$)V)A8VMG6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C M,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/B@R+#(P.3PO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R.B!B;&%C:SLG/D-H M86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]F;VYT/CPO=&0^#0H\=&0^ M/&9O;G0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)V-O;&]R.B!B M;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V)A8VMG6QE/3-$)V-O;&]R.B!B;&%C:SLG/C`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$ M)V-O;&]R.B!B;&%C:SLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT.R<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)V-O;&]R.B!B;&%C M:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V-O;&]R.B!B;&%C M:SLG/CPO9F]N=#XF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!D:69F M97)E;F-E&4\+W1D/@T*("`@("`@("`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`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`^#0H\=&%B;&4@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B;&%C M:SLG/D9E9&5R86P\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/CQF;VYT('-T>6QE M/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`Q)3LG M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B0\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$U M)3LG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/C@L,C@S/"]F;VYT M/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R<^/&9O;G0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-T M>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`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`X/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO M9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)V-O;&]R.B!B;&%C:SLG/C(L-C`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`M,"XR-6EN.R!P861D:6YG+6QE M9G0Z(#`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`M,"XR M-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/CQF;VYT('-T>6QE/3-$)V-O M;&]R.B!B;&%C:SLG/C(P,C@\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL M93TS1"=C;VQO6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=C;VQO6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%? M8F1B9%]B8S9F,&8P93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8F)F-6$Q9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@ M8VAA'0^ M,2UF;W(M,3@\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&EM=6T@6TUE M;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M&5R M8VES960@3G5M8F5R(&]F($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES960@4F%N9V4\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!P97(@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$65A M65A'0^-"!Y96%R2!#86YA9&EA;B!$;VQL87(@6TUE;6)E'0^-"!Y96%R3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%? M8F1B9%]B8S9F,&8P93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8F)F-6$Q9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^-B!Y M96%R&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S65A65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S65A&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S65A7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S65A&5R8VES86)L M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S65A&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,B!Y96%R65A65A7,\'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$65A65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,2!Y M96%R(#,@;6]N=&AS(#(Y(&1A>7,\65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA65A'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ,3@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ,S,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\2!3:&%R M92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!''0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B M9%]B8S9F,&8P93@W93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8F)F-6$Q9&)?9#1B,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B8S9F,&8P93@W M93D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F)F-6$Q9&)?9#1B M,5\T,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2`R,"P@,C`P-SQB'!I'!I'!I&5R8VES92!O9B!O=71S=&%N9&EN9R!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&0@ M8V]L2!A="!A('!U65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&EM=6T@6TUE;6)E'!E8W1E9"!V;VQA=&EL:71Y(')A M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A65A65A7,\7,\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2`H5V%R2`R,"P@,C`P-SQB'!I'!I2!A;FYO=6YC960@ M=&AA="!I="!H860@8V]M<&QE=&5D(&$@9FER65A2!A;FYO M=6YC960@=&AA="!I="!H860@8V]M<&QE=&5D(&$@;F]N+6)R;VME'1087)T7V)B9C5A,61B7V0T8C%?-#!D,5]B9&)D7V)C-F8P9C!E.#=E.0T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B8F8U83%D8E]D-&(Q7S0P M9#%?8F1B9%]B8S9F,&8P93@W93DO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H5V%R2`R,"P@,C`P-SQB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S&5R8VES M92!0'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R65A'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2`M($%D M9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;',I/&)R/DEN(%1H;W5S86YD M2`R,"P@,C`P-SQB&EQ=6%N="!;365M8F5R73QB2`P."P@,C`P-CQB2`P."P@,C`P-CQB M2`R,"P@ M,C`P-#QB&EM=6T@6TUE;6)E'0^,2UF;W(M,3@\'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!R M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-R!Y96%R65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6UE;G1S(&9O'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!787)R86YT'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'!E;G-E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!I2!H879E M(&)E8V]M92!R97-P;VYS:6)L92!F;W(@82!P87EM96YT('1O($](4U4@;V8@ M=7`@=&\@)#`N-2!M:6QL:6]N('5P;VX@=&AE('-U8V-E6%L='D@<&%Y;65N=',L('=H:6-H(&%R92!C M;VYT:6YG96YT(&]N('-A;&5S+"!A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'!E8W1E9"!&=71U'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P9#%?8F1B9%]B8S9F,&8P93@W93D- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F)F-6$Q9&)?9#1B,5\T M,&0Q7V)D8F1?8F,V9C!F,&4X-V4Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!097)C96YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6UE;G0@1F5E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6UE;G0@1F5E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@1F5E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S6%L='D@4&5R8V5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!2871E M(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E8W1E9"!S=&%T=71O"!R871E&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA"!A"!A&5S($9U='5R92!296-O=F5R>2!$:7-C;&]S=7)E(%M, M:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$"!L;W-S M(&-A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$"!A&5S($9U='5R92!296-O=F5R>2!$:7-C M;&]S=7)E(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F%T M:6]N(&-R961I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"!A'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!&;W)W87)D"!;3&EN92!)=&5M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$69O"!; M3&EN92!)=&5M"!L;W-S(&-A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$69O"!C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$69O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$69O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$69O"!C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$"!;3&EN92!)=&5M"!L;W-S(&-A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S"!C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$69O"!;3&EN92!)=&5M"!L;W-S(&-A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!;3&EN92!) M=&5M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!;3&EN92!) M=&5M"!L;W-S(&-A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$69O'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$"!;3&EN92!)=&5M"!L;W-S(&-A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$69O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$69O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$69O"!;3&EN92!)=&5M"!L;W-S(&-A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S"!;3&EN92!)=&5M"!L;W-S(&-A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!2871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XR."XR-24\"!;365M8F5R73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!2871E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ-BXU,"4\"!;365M M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!2871E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ,2XW-24\&UL/@T*+2TM+2TM/5].97AT4&%R=%]B8F8U83%D8E]D-&(Q7S0P 89#%?8F1B9%]B8S9F,&8P93@W93DM+0T* ` end XML 22 R43.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies - Additional Information (Details) (USD $)
 1 Months Ended 12 Months Ended
Oct. 31, 2006
Dec. 31, 2012
Royalty Percent   0.15%
Milestone Payment Fees   $ 100,000
Issue Of Convertible Common Stock As Per Licence Agreement   13,902
Expired Convertible Common Stock   21,250
Development Milestone [Member]
    
Milestone Payment Fees   5,000,000
Development and Sale Milestone [Member]
    
Milestone Payment Fees   70,000,000
Fda Approved Indication [Member]
    
Milestone Payment Fees   15,000,000
Glaxo Smith Kline [Member]
    
Sale of Stock, Consideration Received on Transaction 3,000,000 1,000,000
Sales [Member]
    
Milestone Payment Fees   250,000
Phase I [Member]
    
Milestone Payment Fees   50,000
Phase Ii [Member]
    
Milestone Payment Fees   200,000
Phase Iii [Member]
    
Milestone Payment Fees   0
Licensed Product [Member]
    
Royalty Percent   2.50%
Discount On Royalty Percent   1.00%
Minimum Amount To Be Bought To Get Disount On Royalty   $ 150,000
Sublicensed Technology [Member]
    
Royalty Percent   5.00%
XML 23 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock options (Price In Canadian Dollars) (Details)
 12 Months Ended
Dec. 31, 2012
Price In Canadian Dollars 0.54 [Member]
  
Outstanding and exercisable 88
Remaining life (years) 5 years 3 months 4 days
Price In Canadian Dollars 0.63 [Member]
  
Outstanding and exercisable 303
Remaining life (years) 5 years 5 months 1 day
Price In Canadian Dollars 0.81 [Member]
  
Outstanding and exercisable 3,780
Remaining life (years) 4 years 7 months 21 days
Currency Canadian Dollar [Member]
  
Outstanding and exercisable 4,171
Remaining life (years) 4 years 8 months 12 days
XML 24 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details)
 12 Months Ended
Dec. 31, 2012
Stock Option In Canadian Dollars [Member]
USD ($)
Dec. 31, 2012
Stock Option In Canadian Dollars [Member]
CAD
Dec. 31, 2011
Stock Option In Canadian Dollars [Member]
CAD
Dec. 31, 2012
Stock Option In Us Dollars [Member]
USD ($)
Dec. 31, 2011
Stock Option In Us Dollars [Member]
USD ($)
Dec. 31, 2012
Minimum [Member]
Stock Option In Canadian Dollars [Member]
Dec. 31, 2011
Minimum [Member]
Stock Option In Canadian Dollars [Member]
Dec. 31, 2012
Minimum [Member]
Stock Option In Us Dollars [Member]
Dec. 31, 2011
Minimum [Member]
Stock Option In Us Dollars [Member]
Dec. 31, 2012
Maximum [Member]
Stock Option In Canadian Dollars [Member]
Dec. 31, 2011
Maximum [Member]
Stock Option In Canadian Dollars [Member]
Dec. 31, 2012
Maximum [Member]
Stock Option In Us Dollars [Member]
Dec. 31, 2011
Maximum [Member]
Stock Option In Us Dollars [Member]
Outstanding Number of Options 4,171 4,171 3,901 963 721                
Granted Number of Options 0 0 310 1,137 138                
Exercised Number of Options 0 0 0 0 0                
Cancelled Number of Options 0 0 (50) (773)                  
Reinstated (1) Number?of Options 0 0 10 [1] 0 104 [2]                
Outstanding Number?of Options 4,171 4,171 4,171 1,327 963                
Outstanding Range           0.54 0.63 0.50 1.80 0.81 58.50 24.30 24.30
Granted Range           0 0.54 0.15 0.50 0 0.81 0.56 0.63
Exercised Range     0     0 0 0 0 0 0 0 0
Cancelled Range           0 35.10 5.04   0 58.50 24.30  
Reinstated (1) Range           0 5.04 [1] 0 5.04 [2] 0 35.10 [1] 0 21.60 [2]
Outstanding Range           0.54 0.54 0.15 0.50 0.81 0.81 11.34 24.30
Outstanding Weighted- average   0.78 1.26 $ 8.51 $ 9.90                
Granted Weighted- average   0 0.62 $ 0.32 $ 0.54                
Exercised Weighted- average   0 0 $ 0 $ 0                
Cancelled Weighted- average   0 49.39 $ 9.92 $ 0                
Reinstated (1) Weighted- average $ 0   8.93 [1] $ 0 $ 9.15 [2]                
Outstanding Weighted- average   0.78 0.78 $ 0.67 $ 8.51                
[1] Includes 10 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which had either expired and or were cancelled prior to the agreed severance agreement
[2] Includes104 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which were cancelled in error in 2010.
XML 25 R44.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Reconciliation Of The Combined Canadian Federal And Provincial Income Tax Rate) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Schedule Of Effective Tax Rate [Line Items]    
Domestic loss $ (4,397) $ 5,623
Foreign loss (766) (938)
Loss before income taxes (5,163) 4,685
Expected statutory rate (recovery) 26.50% 28.25%
Expected provision for (recovery of) income tax (1,368) 1,324
Permanent differences 489 (2,209)
Change in valuation allowance 2,467 (589)
Non-refundable investment tax credits 0 157
Effect of foreign exchange rate differences (245) (204)
Effect of change in future enacted tax rates (1,378) (77)
Effect of tax rate changes and other 36 1,599
Provision for income taxes $ 0 $ 0
XML 26 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock Options (Price In US Dollars) (Details)
 12 Months Ended
Dec. 31, 2012
PriceIn Us Dollars 0.15 [Member]
  
Outstanding 33
Exercisable 33
Remaining life (years) 6 years 7 months 13 days
Price In Us Dollars 0.18 [Member]
  
Outstanding 61
Exercisable 61
Remaining life (years) 6 years 4 months 17 days
Price In Us Dollars 0.20 [Member]
  
Outstanding 254
Exercisable 254
Remaining life (years) 6 years 3 months
Price In Us Dollars 0.35 [Member]
  
Outstanding 689
Exercisable 689
Remaining life (years) 6 years 10 months 21 days
Price In Us Dollars 0.50 [Member]
  
Outstanding 94
Exercisable 94
Remaining life (years) 6 years 1 month 6 days
Price In Us Dollars 0.56 [Member]
  
Outstanding 100
Exercisable 100
Remaining life (years) 6 years 11 months 19 days
Price In Us Dollars 0.63 [Member]
  
Outstanding 45
Exercisable 45
Remaining life (years) 5 years 7 months 21 days
Price In Us Dollars 1.80 [Member]
  
Outstanding 4
Exercisable 4
Remaining life (years) 2 years 8 months 16 days
Price In Us Dollars 5.04 [Member]
  
Outstanding 7
Exercisable 7
Remaining life (years) 1 year 11 months 1 day
Price In Us Dollars 5.22 [Member]
  
Outstanding 2
Exercisable 2
Remaining life (years) 2 years 4 months 28 days
Price In Us Dollars 7.20 [Member]
  
Outstanding 2
Exercisable 2
Remaining life (years) 1 year 8 months 12 days
Price In Us Dollars 10.26 [Member]
  
Outstanding 23
Exercisable 23
Remaining life (years) 1 year 4 months 13 days
Price In Us Dollars 11.34 [Member]
  
Outstanding 13
Exercisable 13
Remaining life (years) 1 year 3 months 29 days
Currency United States Dollar [Member]
  
Outstanding 1,327
Exercisable 1,327
Remaining life (years) 6 years 5 months 8 days
XML 27 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Expected dividend 0.00% 0.00%
Expected life 7 years 7 years
Minimum [Member]
    
Risk-free interest rate 1.09% 1.85%
Expected volatility 118.00% 121.00%
Maximum [Member]
    
Risk-free interest rate 126.00% 2.50%
Expected volatility 133.00% 132.00%
XML 28 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2012
Significant Accounting Policies [Abstract]  
Significant Accounting Policies

2.         Significant Accounting Policies

 

Basis of presentation

 

The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation.

 

On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “Share Consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).

 

Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.

 

The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2012, the Company had $2,303 in cash accounts (2011- $5,297). Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments. The Company has not experienced any loss or write-down of its money market investments. 

 

Financial instruments

 

Financial instruments recognized on the balance sheets at December 31, 2012 and December 31, 2011 consist of cash and cash equivalents, accounts payable and derivative warrant liability, the carrying value of which, with the exception of the derivative warrant liability, approximates fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading.

 

The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.

 

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature.

 

Common stock and warrants

 

At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company’s U.S. dollar functional currency.

 

In November 2007, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF No. 07-5, Issue Summary No.1 “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock” (“EITF 07-5”), codified as ASC 815-40.  In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock. This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company’s outstanding warrants to purchase common stock that were denominated in Canadian dollars. This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”), codified as ASC 815-10. SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133. As a result, the Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. ITF 07-05 is effective for financial statements for fiscal years beginning after December 15, 2008 and earlier adoption is not permitted. Since the warrants to purchase common stock that are denominated in Canadian dollars expired on December 19, 2008, EITF 07-5 did not have a material impact on the Company’s financial statements through 2008. However, the Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this results in warrants shown as a liability which is marked to market as at December 31, 2012 and December 31, 2011. At December 31, 2012, the derivative liabilitieswere valued at $6,640 (2011: $5,077) and the unrealized loss on the value of the underlying securities was $1,563 (2011: gain$8,071) for the year ended December 31, 2012.

 

Revenue recognition

 

Non-refundable up-front payments received in conjunction with the development and license agreement, including license fees and milestones, are deferred and recognized on a straight-line basis over the relevant periods.

 

The Company records royalty revenue in accordance with the contract terms once it can be reliably measured and the collection is reasonably assured.

 

At this time, the Company does not have any revenue.

 

Research and development costs and investment tax credits

 

Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.

 

Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.

 

Income taxes

 

The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities. The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized.

 

The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (‘‘FIN 48’’), codified as ASC 740-10-25, ‘‘Accounting for Uncertainty in Income Taxes – an Interpretation of SFAS No. 109.’’ FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, ‘‘Accounting for Income Taxes.’, codified as ASC 740-10. FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a “more-likely-than-not” threshold of being sustained by the applicable tax authority. Tax benefits related to tax positions not deemed to meet the “more-likely-than-not” threshold are not permitted to be recognized in the financial statements. Upon adoption of FIN 48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense.

 

Foreign currency translation

 

The U.S. dollar is the functional currency for the Company’s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations.

 

Earnings/(Loss) per share

 

Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the treasury method.

 

Newly adopted accounting pronouncements

 

On May 12, 2011, the FASB issued ASU 2011-04 “Fair Value Measurement Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. Specifically, this update will require (a) an entity to disclose separately the amounts of significant transfers into and out of Level 1 and 2 fair value measurements and to describe the reasons for the transfers; and (b) information about purchases, sales, issuances, and settlements to be presented separately on a gross basis in the reconciliation of Level 3 fair value measurements. Level 3 reconciliation disclosures are effective for annual and interim periods beginning after December 15, 2011. The adoption of the guidance to has not had a significant impact on the Company’s consolidated financial position and results of operations.

 

In June 2011, the FASB released ASU 2011-05, “Comprehensive Income (Topic 220) – Presentation of Comprehensive Income”. This update requires and entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income in either a single continuous statement or two separate but consecutive statements. This guidance does not change the items that must be reported in other comprehensive income. Subsequently, in December 2011, the FASB issued ASU 2011-12 which deferred some aspects of the June guidance that relate to the presentation of reclassification adjustments. ASU 2011-05 is now effective for fiscal years and interim periods within those years, beginning after December 15, 2012. The adoption of this standard to has not had a significant impact on the Company’s consolidated financial position or results of operations.

 

Recent accounting pronouncements

 

In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company is required to adopt this ASU in the first quarter for fiscal 2013.
XML 29 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock options - Additional Information (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended
Jun. 24, 2010
Dec. 31, 2011
Aug. 18, 2010
Raykov and Spector [Member]
Aug. 19, 2010
Raykov and Spector [Member]
Aug. 31, 2011
Raykov and Spector [Member]
Aug. 18, 2010
Breen and Bussandri [Member]
Aug. 19, 2010
Breen and Bussandri [Member]
Aug. 31, 2011
Breen and Bussandri [Member]
Dec. 31, 2012
General and Administrative Expense [Member]
Dec. 31, 2011
General and Administrative Expense [Member]
Dec. 31, 2012
Stock Option [Member]
Dec. 31, 2011
Stock Option [Member]
Jun. 24, 2010
Stock Option [Member]
Jun. 24, 2010
Plan Maximum Amendment [Member]
Shares issuable under Stock Option Plan                         20,000 6,290
Percentage Of Total Number Of Share Issued and Outstanding 25.00%       5.00%     1.33%            
Cash Compensation To Attend Board Meeting   $ 1,500                        
Non Cash Compensation To Purchase Shares   5,000                        
Allocated Share-based Compensation Expense                 326 250        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value                     $ 0.29 $ 0.56    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value                       $ 0    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     971,885 51,152   255,759 16,369              
XML 30 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
Research and Development (Investment Tax Credits Earned) (Details) (USD $)
In Thousands, unless otherwise specified
 1 Months Ended 12 Months Ended 196 Months Ended
Dec. 19, 2003
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Research and development $ 1,045 $ 2,075 $ 1,494 $ 69,168
Investment tax credits   0 0 (1,632)
National Research Council grants   0 0 (197)
Research and Development Net   $ 2,075 $ 1,494 $ 67,339
XML 31 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2012
Dec. 31, 2011
Current assets    
Cash and cash equivalents $ 2,303 $ 5,297
Prepaid expense 56 35
Other current assets 6 19
Total assets 2,365 5,351
Current liabilities    
Accounts payable 259 342
Accrued liabilities 423 52
Derivative liabilities 6,640 5,077
Total current liabilities 7,322 5,471
Total liabilities 7,322 5,471
Commitments and contingencies (Note 10 and 11)      
Stockholders' (deficit) equity    
Common stock, no par value; unlimited shares authorized; (2012 - 25,158, 2011 - 25,158 shares issued and outstanding) 65,952 65,952
Additional paid-in capital 38,391 38,065
Deficit accumulated during development stage (110,543) (105,380)
Accumulated other comprehensive income 1,243 1,243
Total stockholders' (deficit) equity (4,957) (120)
Total liabilities and stockholders' (deficit) equity $ 2,365 $ 5,351
XML 32 R45.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Future Income Taxes (Recovery) (Details) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2012
Dec. 31, 2011
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross $ 26,940 $ 24,193
Less: valuation allowance (26,940) (24,193)
Net future tax assets 0 0
SR&ED expenditures
    
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross 2,195 2,071
Income tax loss carryforwards
    
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross 21,783 19,635
Non-refundable investment tax credits
    
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross 1,719 1,719
Share issue costs
    
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross 25 84
Accrued expenses
    
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross 0 0
Fixed and intangible assets
    
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross 970 685
Harmonization credit
    
Income Taxes Future Recovery Disclosure [Line Items]    
Future tax assets gross $ 248 $ 280
XML 33 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Stockholders' Equity (USD $)
In Thousands, except Share data
Total
February 2007 Financing [Member]
April 2010 Financing [Member]
Warrant [Member]
Settlement of Advances [Member]
Initial Public Offering [Member]
Other [Member]
Series A Special Warrants [Member]
Rights [Member]
Oxiquant [Member]
Consultants [Member]
Financing Warrant [Member]
Convertible Notes Payable [Member]
June 2004 Convertible Notes [Member]
Convertible Notes Payable [Member]
December 2004 Convertible Notes [Member]
Nonredeemable Preferred Stock [Member]
Private Placement [Member]
Private Placement [Member]
December 2004 Placement [Member]
Private Placement [Member]
May 2004 Placement [Member]
Private Placement [Member]
July 2005 Placement [Member]
Private Placement [Member]
May 2006 Placement [Member]
Employees [Member]
Cadherin Biomedical Inc. [Member]
Common Stock [Member]
Common Stock [Member]
February 2007 Financing [Member]
Common Stock [Member]
April 2010 Financing [Member]
Common Stock [Member]
Warrant [Member]
Common Stock [Member]
Settlement of Advances [Member]
Common Stock [Member]
Initial Public Offering [Member]
Common Stock [Member]
Other [Member]
Common Stock [Member]
Series A Special Warrants [Member]
Common Stock [Member]
Rights [Member]
Common Stock [Member]
Oxiquant [Member]
Common Stock [Member]
Consultants [Member]
Common Stock [Member]
Financing Warrant [Member]
Common Stock [Member]
Convertible Notes Payable [Member]
June 2004 Convertible Notes [Member]
Common Stock [Member]
Convertible Notes Payable [Member]
December 2004 Convertible Notes [Member]
Common Stock [Member]
Nonredeemable Preferred Stock [Member]
Common Stock [Member]
Private Placement [Member]
December 2004 Placement [Member]
Common Stock [Member]
Private Placement [Member]
May 2004 Placement [Member]
Common Stock [Member]
Private Placement [Member]
July 2005 Placement [Member]
Common Stock [Member]
Private Placement [Member]
May 2006 Placement [Member]
Common Stock [Member]
Employees [Member]
Common Stock [Member]
Cadherin Biomedical Inc. [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
February 2007 Financing [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
April 2010 Financing [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Warrant [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Settlement of Advances [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Initial Public Offering [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Other [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Series A Special Warrants [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Rights [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Oxiquant [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Consultants [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Financing Warrant [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Convertible Notes Payable [Member]
June 2004 Convertible Notes [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Convertible Notes Payable [Member]
December 2004 Convertible Notes [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Nonredeemable Preferred Stock [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Private Placement [Member]
December 2004 Placement [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Private Placement [Member]
May 2004 Placement [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Private Placement [Member]
July 2005 Placement [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Private Placement [Member]
May 2006 Placement [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Employees [Member]
Non-redeemable Preferred Stock of Subsidiary [Member]
Cadherin Biomedical Inc. [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
February 2007 Financing [Member]
Additional Paid-in Capital [Member]
April 2010 Financing [Member]
Additional Paid-in Capital [Member]
Warrant [Member]
Additional Paid-in Capital [Member]
Settlement of Advances [Member]
Additional Paid-in Capital [Member]
Initial Public Offering [Member]
Additional Paid-in Capital [Member]
Other [Member]
Additional Paid-in Capital [Member]
Series A Special Warrants [Member]
Additional Paid-in Capital [Member]
Rights [Member]
Additional Paid-in Capital [Member]
Oxiquant [Member]
Additional Paid-in Capital [Member]
Consultants [Member]
Additional Paid-in Capital [Member]
Financing Warrant [Member]
Additional Paid-in Capital [Member]
Convertible Notes Payable [Member]
June 2004 Convertible Notes [Member]
Additional Paid-in Capital [Member]
Convertible Notes Payable [Member]
December 2004 Convertible Notes [Member]
Additional Paid-in Capital [Member]
Nonredeemable Preferred Stock [Member]
Additional Paid-in Capital [Member]
Private Placement [Member]
December 2004 Placement [Member]
Additional Paid-in Capital [Member]
Private Placement [Member]
May 2004 Placement [Member]
Additional Paid-in Capital [Member]
Private Placement [Member]
July 2005 Placement [Member]
Additional Paid-in Capital [Member]
Private Placement [Member]
May 2006 Placement [Member]
Additional Paid-in Capital [Member]
Employees [Member]
Additional Paid-in Capital [Member]
Cadherin Biomedical Inc. [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income [Member]
February 2007 Financing [Member]
Accumulated Other Comprehensive Income [Member]
April 2010 Financing [Member]
Accumulated Other Comprehensive Income [Member]
Warrant [Member]
Accumulated Other Comprehensive Income [Member]
Settlement of Advances [Member]
Accumulated Other Comprehensive Income [Member]
Initial Public Offering [Member]
Accumulated Other Comprehensive Income [Member]
Other [Member]
Accumulated Other Comprehensive Income [Member]
Series A Special Warrants [Member]
Accumulated Other Comprehensive Income [Member]
Rights [Member]
Accumulated Other Comprehensive Income [Member]
Oxiquant [Member]
Accumulated Other Comprehensive Income [Member]
Consultants [Member]
Accumulated Other Comprehensive Income [Member]
Financing Warrant [Member]
Accumulated Other Comprehensive Income [Member]
Convertible Notes Payable [Member]
June 2004 Convertible Notes [Member]
Accumulated Other Comprehensive Income [Member]
Convertible Notes Payable [Member]
December 2004 Convertible Notes [Member]
Accumulated Other Comprehensive Income [Member]
Nonredeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income [Member]
Private Placement [Member]
December 2004 Placement [Member]
Accumulated Other Comprehensive Income [Member]
Private Placement [Member]
May 2004 Placement [Member]
Accumulated Other Comprehensive Income [Member]
Private Placement [Member]
July 2005 Placement [Member]
Accumulated Other Comprehensive Income [Member]
Private Placement [Member]
May 2006 Placement [Member]
Accumulated Other Comprehensive Income [Member]
Employees [Member]
Accumulated Other Comprehensive Income [Member]
Cadherin Biomedical Inc. [Member]
Deficit Accumulated During Development Stage [Member]
Deficit Accumulated During Development Stage [Member]
February 2007 Financing [Member]
Deficit Accumulated During Development Stage [Member]
April 2010 Financing [Member]
Deficit Accumulated During Development Stage [Member]
Warrant [Member]
Deficit Accumulated During Development Stage [Member]
Settlement of Advances [Member]
Deficit Accumulated During Development Stage [Member]
Initial Public Offering [Member]
Deficit Accumulated During Development Stage [Member]
Other [Member]
Deficit Accumulated During Development Stage [Member]
Series A Special Warrants [Member]
Deficit Accumulated During Development Stage [Member]
Rights [Member]
Deficit Accumulated During Development Stage [Member]
Oxiquant [Member]
Deficit Accumulated During Development Stage [Member]
Consultants [Member]
Deficit Accumulated During Development Stage [Member]
Financing Warrant [Member]
Deficit Accumulated During Development Stage [Member]
Convertible Notes Payable [Member]
June 2004 Convertible Notes [Member]
Deficit Accumulated During Development Stage [Member]
Convertible Notes Payable [Member]
December 2004 Convertible Notes [Member]
Deficit Accumulated During Development Stage [Member]
Nonredeemable Preferred Stock [Member]
Deficit Accumulated During Development Stage [Member]
Private Placement [Member]
December 2004 Placement [Member]
Deficit Accumulated During Development Stage [Member]
Private Placement [Member]
May 2004 Placement [Member]
Deficit Accumulated During Development Stage [Member]
Private Placement [Member]
July 2005 Placement [Member]
Deficit Accumulated During Development Stage [Member]
Private Placement [Member]
May 2006 Placement [Member]
Deficit Accumulated During Development Stage [Member]
Employees [Member]
Deficit Accumulated During Development Stage [Member]
Cadherin Biomedical Inc. [Member]
Beginning Balance at Sep. 02, 1996 $ 0                                           $ 0                                         $ 0                                         $ 0                                         $ 0                                         $ 0                                        
Beginning Balance (in shares) at Sep. 02, 1996                                             0                                                                                                                                                                                                                
Issuance of stock (in shares)                                             89,000                                                                                                                                                                                                                
Issuance of stock 0                                           0                                         0                                         0                                         0                                         0                                        
Net (loss) income (37)                                           0                                         0                                         0                                         0                                         (37)                                        
Ending Balance at Jun. 23, 1997 (37)                                           0                                         0                                         0                                         0                                         (37)                                        
Ending Balance (in shares) at Jun. 23, 1997                                             89,000                                                                                                                                                                                                                
Beginning Balance at Jun. 30, 1997 (37)                                           0                                         0                                         0                                         0                                         (37)                                        
Beginning Balance (in shares) at Jun. 30, 1997                                             89,000                                                                                                                                                                                                                
Net (loss) income (398)                                           0                                         0                                         0                                         0                                         (398)                                        
Ending Balance at Jun. 30, 1998 (435)                                           0                                         0                                         0                                         0                                         (435)                                        
Ending Balance (in shares) at Jun. 30, 1998                                             89,000                                                                                                                                                                                                                
Exchange of Adherex Inc. shares for Adherex Technologies Inc. shares (in shares)                                             89,000                                                                                                                                                                                                                
Exchange of Adherex Inc. shares for Adherex Technologies Inc. shares 0                                           0                                         0                                         0                                         0                                         0                                        
Issuance of stock (in shares)                                             239,000                                                                                                                                                                                                                
Issuance of stock                                             1,615                                         0                                         0                                         0                                         0                                        
Cumulative translation adjustment 20                                           0                                         0                                         0                                         20                                         0                                        
Net (loss) income (958)                                           0                                         0                                         0                                         0                                         (958)                                        
Ending Balance at Jun. 30, 1999 242                                           1,615                                         0                                         0                                         20                                         (1,393)                                        
Ending Balance (in shares) at Jun. 30, 1999                                             239,000                                                                                                                                                                                                                
Issuance of warrants (in shares)                                                   0                                                                                                                                                                                                          
Issuance of warrants       255                                           0                                         0                                         255                                         0                                         0                                  
Issuance of stock (in shares)                                             16,000       16,000                                                                                                                                                                                                        
Issuance of stock         175                                   793       175                                 0       0                                 0       0                                 0       0                                 0       0                                
Issuance of equity rights 171                                           0                                         0                                         171                                         0                                         0                                        
Cancellation of common stock (in shares)                                                     (7,000)                                                                                                                                                                                                        
Cancellation of common stock         0                                           0                                         0                                         0                                         0                                         0                                
Cumulative translation adjustment 16                                           0                                         0                                         0                                         16                                         0                                        
Net (loss) income (1,605)                                           0                                         0                                         0                                         0                                         (1,605)                                        
Ending Balance at Jun. 30, 2000 47                                           2,583                                         0                                         426                                         36                                         (2,998)                                        
Ending Balance (in shares) at Jun. 30, 2000                                             264,000                                                                                                                                                                                                                
Issuance of warrants (in shares)                                                           0                                                                                                                                                                                                  
Issuance of warrants       1,722       4,335                                   0       0                                 0       0                                 1,722       4,335                                 0       0                                 0       0                          
Other (in shares)                                                         5,000                                                                                                                                                                                                    
Other             341                                           341                                         0                                         0                                         0                                         0                            
Issuance of stock (in shares)                                                       74,000                                                                                                                                                                                                      
Issuance of stock           5,689                                           5,727                                         0                                         0                                         0                                         (38)                              
Conversion of convertible securities (in shares)                                                   30,000       69,000 4,000                                                                                                                                                                                                
Conversion of convertible securities       0       0 0                                 1,977       4,335 171                               0       0 0                               (1,977)       (4,335) (171)                               0       0 0                               0       0 0                        
Cumulative translation adjustment 182                                           0                                         0                                         0                                         182                                         0                                        
Net (loss) income (2,524)                                           0                                         0                                         0                                         0                                         (2,524)                                        
Ending Balance at Jun. 30, 2001 9,792                                           15,134                                         0                                         0                                         218                                         (5,560)                                        
Ending Balance (in shares) at Jun. 30, 2001                                             446,000                                                                                                                                                                                                                
Cumulative translation adjustment 11                                           0                                         0                                         0                                         11                                         0                                        
Net (loss) income (3,732)                                           0                                         0                                         0                                                                                   (3,732)                                        
Ending Balance at Jun. 30, 2002 6,071                                           15,134                                         0                                         0                                         229                                         (9,292)                                        
Ending Balance (in shares) at Jun. 30, 2002                                             446,000                                                                                                                                                                                                                
Issuance of warrants (in shares)                                                                   0                                                                                                                                                                                          
Issuance of warrants                       53                                           0                                         0                                         53                                         0                                         0                  
Stock options issued                     4                                           0                                         0                                         4                                         0                                         0                    
Stock Issued for Acquisitions (in shares)                                                               446,000                                                                                                                                                                                              
Stock Issued for Acquisitions                   11,620                                           11,077                                         0                                         543                                         0                                         0                      
Equity component of convertible notes 1,058                                           0                                         0                                         1,058                                         0                                         0                                        
Exercise of stock options (in shares)                                             1,000                                                                                                                                                                                                                
Exercise of stock options 4                                           4                                         0                                         0                                         0                                         0                                        
Distribution to shareholders (158)                                           0                                         0                                         0                                         0                                         (158)                                        
Stated capital reduction 0                                           (9,489)                                         0                                         9,489                                         0                                         0                                        
Cumulative translation adjustment (159)                                           0                                         0                                         0                                         (159)                                         0                                        
Net (loss) income (17,795)                                           0                                         0                                         0                                         0                                         (17,795)                                        
Ending Balance at Jun. 30, 2003 698                                           16,726                                         0                                         11,147                                         70                                         (27,245)                                        
Ending Balance (in shares) at Jun. 30, 2003                                             893,000                                                                                                                                                                                                                
Repricing of warrants related to financing (in shares)                                             0                                                                                                                                                                                                                
Repricing of warrants related to financing 18                                           0                                         0                                         18                                         0                                         0                                        
Issuance of warrants (in shares)                                                                   0                                                                                                                                                                                          
Issuance of warrants                       54                                           0                                         0                                         54                                         0                                         0                  
Stock options issued                     148                                           0                                         0                                         148                                         0                                         0                    
Equity component of convertible notes 1,983                                           0                                         0                                         1,983                                         0                                         0                                        
Issuance of stock (in shares)                                                                         0 640,000 259,000                                                                                                                                                                                
Issuance of stock                             1,045   13,830 8,474                                     0 8,053 6,356                                     1,045 0 0                                     0 5,777 2,118                                     0 0 0                                     0 0 0        
Conversion of convertible securities (in shares)                                                                     96,000 60,000                                                                                                                                                                                      
Conversion of convertible securities                         1,123 171                                         1,216 569                                       0 0                                       (93) (398)                                       0 0                                       0 0              
Exercise of stock options (in shares)                                             1,000                                                                                                                                                                                                                
Exercise of stock options 23                                           23                                         0                                         0                                         0                                         0                                        
Amalgamation of 2037357 Ontario Inc. (22)                                           660                                         (1,045)                                         363                                         0                                         0                                        
Amalgamation of 2037357 Ontario Inc., shares                                             44,000                                                                                                                                                                                                                
Cumulative translation adjustment (219)                                           0                                         0                                         0                                         (219)                                         0                                        
Net (loss) income (6,872)                                           0                                         0                                         0                                         0                                         (6,872)                                        
Ending Balance at Jun. 30, 2004 20,454                                           33,603                                         0                                         21,117                                         (149)                                         (34,117)                                        
Ending Balance (in shares) at Jun. 30, 2004                                             1,993,000                                                                                                                                                                                                                
Cost related to SEC registration (493)                                           (493)                                         0                                         0                                         0                                         0                                        
Stock options issued                     39                   604                       0                 0                       0                 0                       39                 604                       0                 0                       0                 0  
Stock Issued for Acquisitions (in shares)                                                                                     37,000                                                                                                                                                                        
Stock Issued for Acquisitions                                           1,252                                         1,252                                         0                                         0                                         0                                         0
Cumulative translation adjustment 1,392                                           0                                         0                                         0                                         1,392                                         0                                        
Net (loss) income (6,594)                                           0                                         0                                         0                                         0                                         (6,594)                                        
Ending Balance at Dec. 31, 2004 16,654                                           34,362                                         0                                         21,760                                         1,243                                         (40,711)                                        
Ending Balance (in shares) at Dec. 31, 2004                                             2,030,000                                                                                                                                                                                                                
Financing costs (in shares)                                             0                                                                                                                                                                                                                
Financing costs (141)                                           (141)                                         0                                         0                                         0                                         0                                        
Stock options issued                     276                                           0                                         0                                         276                                         0                                         0                    
Issuance of stock (in shares)                                                                               337,000                                                                                                                                                                              
Issuance of stock                                     8,134                                         7,060                                         0                                         1,074                                         0                                         0      
Exercise of stock options (in shares)                                             1,000                                                                                                                                                                                                                
Exercise of stock options 25                                           25                                         0                                         0                                         0                                         0                                        
Net (loss) income (13,871)                                           0                                         0                                         0                                         0                                         (13,871)                                        
Ending Balance at Dec. 31, 2005 11,077                                           41,306                                         0                                         23,110                                         1,243                                         (54,582)                                        
Ending Balance (in shares) at Dec. 31, 2005                                             2,368,000                                                                                                                                                                                                                
Stock options issued                     100                   491                       0                 0                       0                 0                       100                 491                       0                 0                       0                 0  
Issuance of stock (in shares)                                                                                 431,000                                                                                                                                                                            
Issuance of stock                                       6,040                                         5,218                                         0                                         822                                         0                                         0    
Net (loss) income (16,440)                                           0                                         0                                         0                                         0                                         (16,440)                                        
Ending Balance at Dec. 31, 2006 1,268                                           46,524                                         0                                         24,523                                         1,243                                         (71,022)                                        
Ending Balance (in shares) at Dec. 31, 2006                                             2,799,000                                                                                                                                                                                                                
Exercise of warrants (in shares)                                             116,000                                                                                                                                                                                                                
Exercise of warrants 694                                           563                                         0                                         131                                         0                                         0                                        
Stock options issued                     59                   2,263                       0                 0                       0                 0                       59                 2,263                       0                 0                       0                 0  
Issuance of stock (in shares)                                               4,209,000                                                                                                                                                                                                              
Issuance of stock   23,221                                           17,842                                         0                                         5,379                                         0                                         0                                      
Net (loss) income (13,357)                                           0                                         0                                         0                                         0                                         (13,357)                                        
Ending Balance at Dec. 31, 2007 14,148                                           64,929                                         0                                         32,355                                         1,243                                         (84,379)                                        
Ending Balance (in shares) at Dec. 31, 2007                                             7,124,000                                                                                                                                                                                                                
Stock options issued                     88                   2,417                       0                 0                       0                 0                       88                 2,417                       0                 0                       0                 0  
Net (loss) income (13,600)                                           0                                         0                                         0                                         0                                         (13,600)                                        
Ending Balance at Dec. 31, 2008 3,053                                           64,929                                         0                                         34,860                                         1,243                                         (97,979)                                        
Ending Balance (in shares) at Dec. 31, 2008                                             7,124,000                                                                                                                                                                                                                
Stock options issued                     10                   355                       0                 0                       0                 0                       10                 355                       0                 0                       0                 0  
Net (loss) income (3,012)                                           0                                         0                                         0                                         0                                         (3,012)                                        
Ending Balance at Dec. 31, 2009 406                                           64,929                                         0                                         35,225                                         1,243                                         (100,991)                                        
Ending Balance (in shares) at Dec. 31, 2009                                             7,124                                                                                                                                                                                                                
Stock options issued                     53                   2,439                       0                 0                       0                 0       (100,991)               53                 2,439                                         0                                         0  
Issuance of stock (in shares)                                                 13,337                                                                                                                                                                                                            
Issuance of stock                                                 0                                         0                                         0                                         0                                         0                                    
Net (loss) income (5,163)                                           0                                         0                                         0                                         0                                         (7,824)                                        
Ending Balance at Dec. 31, 2010 (4,924)                                           64,929                                         0                                         37,717                                         1,243                                         (108,815)                                        
Ending Balance (in shares) at Dec. 31, 2010                                             20,461,000                                                                                                                                                                                                                
Stock options issued                     20                   129                       0                 0                       0                 0                       20                 129                       0                 0                       0                 0  
Issuance of stock (in shares)                                                             4,697,000                                                                                                                                                                                                
Issuance of stock                 (28)                                           1,023                                         0                                         199                                         0                                         (1,250)                        
Net (loss) income 4,685                                           0                                         0                                         0                                         0                                         4,685                                        
Ending Balance at Dec. 31, 2011 (120)                                           65,952                                         0                                         38,065                                         1,243                                         (105,380)                                        
Ending Balance (in shares) at Dec. 31, 2011                                             25,158                                                                                                                                                                                                                
Stock options issued                     152                   2,439                       0                 0                       0                 0                       152                 174                       0                 0                       0                 0  
Issuance of stock     0                                   174                                                                                                                                                                                                                    
Net (loss) income (5,163)                                           0                                                                                   38,065                                                                                   (5,163)                                        
Ending Balance at Dec. 31, 2012 $ (4,957)                                           $ 65,952                                         $ 0                                         $ 37,717                                         $ 1,243                                         $ (110,543)                                        
Ending Balance (in shares) at Dec. 31, 2012                                             25,158                                                                                                                                                                                                                
XML 34 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) (Fair Value, Measurements, Recurring, USD $)
In Thousands, unless otherwise specified
Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]  
Cash equivalents $ 2,241
Derivative liabilities 6,640
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]
  
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]  
Cash equivalents 0
Derivative liabilities 0
Significant Other Observable Inputs Level 2 [Member]
  
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]  
Cash equivalents 2,241
Derivative liabilities 6,640
Significant Unobservable Inputs Level 3 [Member]
  
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]  
Cash equivalents 0
Derivative liabilities $ 0
XML 35 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Shareholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2012
Warrants Outstanding to Purchase Common Stock

At December 31, 2012, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years: 

 

Warrant Description
(Warrants in thousands)		   Common Shares Issuable Upon
Exercise of Outstanding
Warrants at December 31, 2012		     Exercise Price in Canadian
Dollars		     Expiration Date
Investor Warrants (1)     13,337     $ 1.44     April 30, 2015
Investor Warrants (2)     4,698     $ 1.44     March 29, 2016
      18,035              

 

(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

 

(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
XML 36 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements - Additional Information (Details)
 12 Months Ended
Dec. 31, 2011
Warrant [Member]
Dec. 31, 2012
Warrant [Member]
Minimum [Member]
Dec. 31, 2012
Warrant [Member]
Maximum [Member]
Dec. 31, 2011
Options [Member]
Dec. 31, 2012
Options [Member]
Minimum [Member]
Dec. 31, 2012
Options [Member]
Maximum [Member]
Assumptions used to Determine Fair Value Options [Line Items]            
Expected dividend rate 0.00%     0.00%    
Risk free interest rate   1.15% 1.36%   1.37% 1.41%
Expected volatility rate   146.00% 155.00%   140.00% 145.00%
Expected life   2 years 3 months 18 days 3 years 2 months 12 days   4 years 10 months 24 days 5 years 4 months 24 days
XML 37 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Capital and Operating Lease Commitments (Tables)
 12 Months Ended
Dec. 31, 2012
Leases [Abstract]  
Contractual Obligations And Commitments
The following table represents our contractual obligations and commitments at December 31, 2012 (in thousands of U.S. dollars):

 

    Less than
1 year		     1-3
years		     Total  
OCT Clinical Service Agreement (1)     402       -       402  
Oregon Health & Science University (2), excluding potential royalty payments     -       -       -  
Life Sci Advisors, LLC (3)     55       -       55  
Total   $ 457     $ -     $ 457  

 

(1)

Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia.  The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients.  The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled.
(2) Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million.  Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included.

 

(3) Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of the agreement.  Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.
XML 38 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 39 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Going Concern
 12 Months Ended
Dec. 31, 2012
Going Concern [Abstract]  
Going Concern

1.         Going Concern

 

Adherex Technologies Inc. (“Adherex”), a British Columbia corporation together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company,” is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. With the exception of Adherex Inc., all subsidiaries are inactive.

 

These consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) of America that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

 

The Company is a development stage company and during the year ended December 31, 2012, incurred a loss from operations of $3,620. At December 31, 2012, it had an accumulated deficit of$110,543, and had experienced negative cash flows from operating activities since inception in the amount of $85,037. In addition, it had a deficiency in working capital at December 31, 2012 and the Company's operating losses since inception.

 

These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance our business strategy, operations and growth through the issuance of equity, debt or collaboration. If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing.

 

These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.
XML 40 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (Parenthetical) (USD $)
Dec. 31, 2012
Dec. 31, 2011
Common stock, no par value      
Common stock, shares issued 25,158 25,158
Common stock, shares outstanding 25,158 25,158
XML 41 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes
 12 Months Ended
Dec. 31, 2012
Income Tax Disclosure [Abstract]  
Income Taxes

11.      Income Taxes

 

The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows:

 

    Year Ended
December 31,		     Year Ended
December 31,		  
    2012     2011  
Domestic loss     (4,397 )     5,623  
Foreign loss     (766 )     (938 )
Loss before income taxes     (5,163 )     4,685  
                 
Expected statutory rate (recovery)     26.50 %     28.25 %
Expected provision for (recovery of) income tax     (1,368 )     1,324  
Permanent differences     489       (2,209 )
Change in valuation allowance     2,467       (589 )
Non-refundable investment tax credits     0       157  
Effect of foreign exchange rate differences     (245 )     (204 )
Effect of change in future enacted tax rates     (1,378 )     (77 )
Effect of tax rate changes and other     36       1,599  
Provision for income taxes   $ -     $ -  

 

The Canadian statutory come tax rate of 28.25 percent is comprised of federal income tax at approximately 16.5 percent and provincial income tax at approximately 11.75 percent.

 

The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2012, December 31, 2011:

 

    December 31,
2012		     December 31,
2011		  
Future tax assets:                
SR&ED expenditures     2,195       2,071  
Income tax loss carryforwards     21,783       19,635  
Non-refundable investment tax credits     1,719       1,719  
Share issue costs     25       84  
Accrued expenses     -       -  
Fixed and intangible assets     970       685  
Harmonization credit     248       280  
      26,940       24,193  
Less: valuation allowance     (26,940 )     (24,193 )
Net future tax assets   $ -     $ -  

 

There are no current income taxes owed, nor are any income taxes expected to be owed in the near term.

 

At December 31, 2012 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below:

 

    Federal     Province/
State		  
SR&ED expenditures (no expiry)   $ 8,283     $ -  
Income tax loss carryforwards (expiry date):                
2014     6,089       6,089  
2015     11,499       11,499  
2021     26       -  
2022     233       -  
2023     133       -  
2024     1,536       1,455  
2025     4,795       4,768  
2026     20,562       20,496  
2027     8,340       8,320  
2028     10,840       10,823  
2029     8,502       8,502  
2030     2,608       2,607  
2031     3,377       3,377  
2032     3,660       3,660  
Investment tax credits (expiry date):            
2018     10        
2019     8          
2020     96          
2021     55          
2022     548          
2023     399          
2024     178          
2025     199          
2026     86          
2027     90          
2028     50          

 
XML 42 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information (USD $)
 12 Months Ended
Dec. 31, 2012
Mar. 16, 2013
Jun. 30, 2012
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2012    
Document Fiscal Year Focus 2012    
Document Fiscal Period Focus FY    
Trading Symbol ADHXF    
Entity Registrant Name ADHEREX TECHNOLOGIES INC    
Entity Central Index Key 0001211583    
Current Fiscal Year End Date --12-31    
Entity Well-Known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Smaller Reporting Company    
Entity Common Stock Shares Outstanding   25,157,618  
Entity Public Float     $ 1,401,073
XML 43 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2012
Significant Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

 

The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation.

 

On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “Share Consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).
Use of estimates

Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation. Actual results could differ from those estimates.
Cash and cash equivalents

Cash and Cash Equivalents

 

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.

 

The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2012, the Company had $2,303 in cash accounts (2011- $5,297). Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments. The Company has not experienced any loss or write-down of its money market investments. 
Financial instruments

Financial instruments

 

Financial instruments recognized on the balance sheets at December 31, 2012 and December 31, 2011 consist of cash and cash equivalents, accounts payable and derivative warrant liability, the carrying value of which, with the exception of the derivative warrant liability, approximates fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading.

 

The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.

 

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature.
Common stock and warrants

Common stock and warrants

 

At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company’s U.S. dollar functional currency.

 

In November 2007, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF No. 07-5, Issue Summary No.1 “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock” (“EITF 07-5”), codified as ASC 815-40.  In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock. This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company’s outstanding warrants to purchase common stock that were denominated in Canadian dollars. This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”), codified as ASC 815-10. SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133. As a result, the Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. ITF 07-05 is effective for financial statements for fiscal years beginning after December 15, 2008 and earlier adoption is not permitted. Since the warrants to purchase common stock that are denominated in Canadian dollars expired on December 19, 2008, EITF 07-5 did not have a material impact on the Company’s financial statements through 2008. However, the Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this results in warrants shown as a liability which is marked to market as at December 31, 2012 and December 31, 2011. At December 31, 2012, the derivative liabilitieswere valued at $6,640 (2011: $5,077) and the unrealized loss on the value of the underlying securities was $1,563 (2011: gain$8,071) for the year ended December 31, 2012.
Revenue recognition

Revenue recognition

 

Non-refundable up-front payments received in conjunction with the development and license agreement, including license fees and milestones, are deferred and recognized on a straight-line basis over the relevant periods.

 

The Company records royalty revenue in accordance with the contract terms once it can be reliably measured and the collection is reasonably assured.

 

At this time, the Company does not have any revenue.
Research and development costs and investment tax credits

Research and development costs and investment tax credits

 

Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.

 

Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.
Income taxes

Income taxes

 

The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities. The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized.

 

The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (‘‘FIN 48’’), codified as ASC 740-10-25, ‘‘Accounting for Uncertainty in Income Taxes – an Interpretation of SFAS No. 109.’’ FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, ‘‘Accounting for Income Taxes.’, codified as ASC 740-10. FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a “more-likely-than-not” threshold of being sustained by the applicable tax authority. Tax benefits related to tax positions not deemed to meet the “more-likely-than-not” threshold are not permitted to be recognized in the financial statements. Upon adoption of FIN 48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense.
Foreign currency translation

Foreign currency translation

 

The U.S. dollar is the functional currency for the Company’s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations.
Earnings/(Loss) per share

Earnings/(Loss) per share

 

Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the treasury method.
Newly adopted accounting pronouncements

Newly adopted accounting pronouncements

 

On May 12, 2011, the FASB issued ASU 2011-04 “Fair Value Measurement Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. Specifically, this update will require (a) an entity to disclose separately the amounts of significant transfers into and out of Level 1 and 2 fair value measurements and to describe the reasons for the transfers; and (b) information about purchases, sales, issuances, and settlements to be presented separately on a gross basis in the reconciliation of Level 3 fair value measurements. Level 3 reconciliation disclosures are effective for annual and interim periods beginning after December 15, 2011. The adoption of the guidance to has not had a significant impact on the Company’s consolidated financial position and results of operations.

 

In June 2011, the FASB released ASU 2011-05, “Comprehensive Income (Topic 220) – Presentation of Comprehensive Income”. This update requires and entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income in either a single continuous statement or two separate but consecutive statements. This guidance does not change the items that must be reported in other comprehensive income. Subsequently, in December 2011, the FASB issued ASU 2011-12 which deferred some aspects of the June guidance that relate to the presentation of reclassification adjustments. ASU 2011-05 is now effective for fiscal years and interim periods within those years, beginning after December 15, 2012. The adoption of this standard to has not had a significant impact on the Company’s consolidated financial position or results of operations.
Recent accounting pronouncements

Recent accounting pronouncements

 

In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company is required to adopt this ASU in the first quarter for fiscal 2013.
XML 44 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended 196 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Revenue $ 0 $ 0 $ 0
Operating expenses:      
Research and development 2,075 1,494 69,168
Impairment of capital assets 0 0 386
Gain on deferred lease inducements 0 0 (497)
Acquired in-process research and development 0 0 13,094
General and administration 1,545 1,944 32,094
Loss from operations (3,620) (3,438) (114,245)
Other income (expense):      
(Loss)/Gain on derivative warrants (1,563) 8,071 3,257
Settlement of Cadherin Biomedical Inc. litigation 0 0 (1,283)
Interest expense 0 0 (19)
Other income/(expense) (5) 9 259
Interest income 25 43 2,897
Total other (expense)/ income (1,543) 8,123 5,111
Net (loss)/income and total comprehensive loss $ (5,163) $ 4,685 $ (109,134)
(Loss)/earnings per share of common stock, basic (In dollars per share) $ (0.21) $ 0.20  
(loss)/earnings per share of common stock, diluted (In dollars per share) $ (0.21) $ 0.19  
Weighted-average number of shares of common stock outstanding, basic (in shares) 25,158 23,983  
Weighted-average number of shares of common stock outstanding, diluted (In shares) 25,158 24,050  
XML 45 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements
 12 Months Ended
Dec. 31, 2012
Fair Value Disclosures [Abstract]  
Fair Value Measurements

6.         Fair Value Measurements

 

The Company has adopted Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

Assets/Liabilities Measured at Fair Value on a Recurring Basis

 

Fair Value Measurement at December 31, 2012

 

    Quoted Pricein Active Markets     Significant Other     Significant        
    for IdenticalInstruments     Observable Inputs     Unobservable Inputs        
    Level 1     Level 2     Level 3     Total  
Assets                                
Cash equivalents   $ -     $ 2,241     $ -     $ 2,241  
Liabilities                                
Derivative liabilities     -       6,640       -       6,640  

  

The Company's financial instruments include cash equivalents and derivatives. Only cash equivalents and derivatives are carried at their fair value. The derivative liabilities include warrants denominated in a currency other than the Company’s functional currency and options issued to contractors in a currency other than the functional currency of the Company. The warrants are carried at fair value and calculated using the Black-Scholes option pricing model using the following assumptions; expected dividend 0%; risk-free interest rate of 1.15%-1.36%; expected volatility of 146% - 155%; and a 2.3 or 3.2 year remaining life. The options also use the Black Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 1.37%-1.41% expected volatility of 140%- 145%; and a 4.9-5.4 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument.
XML 46 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Derivative Instruments
 12 Months Ended
Dec. 31, 2012
Derivative Instruments [Abstract]  
Derivative Instruments

 5.      Derivative Instruments

 

Effective January 1, 2009, the Company adopted ASC Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in shareholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' deficiency.

 

The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:

· Warrants to purchase 13,337 shares at CAD$1.44 per whole share that expire on April 30, 2015; and
· Warrants to purchase 4,698 shares exercisable at CAD$1.44 per whole share that expire on March 29, 2016.

 

These warrants have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.

 

As of December 31, 2012, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $4,698 and $1,847, respectively (December 31, 2011 – warrants expiring April 30, 2015, fair value of $3,672, March 29, 2016, fair value of $1,340), and the loss on these warrants for the twelve months ended December 31, 2012 was $1,026 and $507, respectively (December 31, 2011 - warrants expiring April 30, 2015, gain of $6,778; March 29,2016, gain of $643). There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.

 

Gain/(Loss) on Derivative Instruments   Twelve months ended December 31, 2012     Twelve months ended December 31, 2011  
Warrant expiring April 15, 2015     (1,026 )     6,778  
Warrant expiring March 29, 2016     (507 )     643  
Rights offering derivative     -       613  
Options to contractors     (30 )     37  
Total     (1,563 )     8,071  

 

In February 2011, the Company filed a final short form prospectus for a rights offering. In accordance with the terms of the rights offering, each shareholder of record on March 2, 2011 received one right for each common share held. Every right held entitled the holder thereof to purchase for CAD $0.03, or USD $0.0303 at the shareholder’s option, a unit consisting of one common share along with one warrant to purchase a common share of the Company at CAD $0.08. The rights began trading on March 2, 2011 on the TSX and on the Pink Sheets and expired on March 29, 2011.

 

On March 2, 2011, the Company recognized a derivative financial liability of $1.25 million associated with the Company’s obligation to carry out the rights offering. The deficit was adjusted by a corresponding amount. The derivative financial liability will be adjusted to fair value at each quarter end with changes being recognized in earnings until the expiry of the warrants. During the year ended December 31, 2011, the Company recognized a realized derivative gain of $613. The rights expired on March 29, 2011.

 

Under the terms of the rights offering, the monetary amount to be received by the Company upon the exercise of rights was not fixed. Each holder of rights could elect either the $0.03 CAD or USD$0.0303 subscription price. Furthermore, the CAD $0.03 subscription price was not denominated in the Company’s U.S. dollar functional currency. Therefore, the pro rata distribution of rights to the Company’s shareholders was accounted for as a derivative financial liability measured at fair value.

 

Upon the closing of the rights offering in March 2011, the Company issued a total of 84,559 units for total net proceeds of $2,566. Accordingly the Company recorded an increase in Common stock of $1,023 (4,697 shares). Expenses and fees relating to the rights offering totaled approximately $300 and were expensed since it was uncertain as to whether any shares would be issued.

 

During the fiscal year ended December 31, 2011, the Company issued 108 optionsto contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13, no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise.
XML 47 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Research and Development (Tables)
 12 Months Ended
Dec. 31, 2012
Research and Development [Abstract]  
Research and Development

Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows:

 

    Year Ended
December 31,		     Year Ended
December 31,		     Cumulative
FromSeptember 3,1996 to
December 31,		  
    2012     2011     2012  
Research and development   $ 2,075     $ 1,494     $ 69,168  
Investment tax credits     -       -       (1,632 )
National Research Council grants     -       -       (197 )
    $ 2,075     $ 1,494     $ 67,339  

 
XML 48 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock options (Tables)
 12 Months Ended
Dec. 31, 2012
Fair values of options granted using weighted average assumptions

The fair values of options granted in fiscal years ended December 31, 2012 and 2011 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions:

 

    Year Ended
December 31,
2012		     Year Ended
December 31,
2011		  
Expected dividend     0 %     0 %
Risk-free interest rate     1.09-1.26 %     1.85-2.5 %
Expected volatility     118-133 %     121-132 %
Expected life     7 years       7 years  

 
Currency, Canadian Dollar [Member]
  
Options granted under the stock option plan are exercisable

The following options granted under the stock option plan are exercisable in Canadian dollars:

 

          Exercise Price in Canadian
Dollars		  
    Number of
Options		     Range     Weighted-
average		  
Outstanding at December 31, 2010     3,901       0.63-58.50     $ 1.26  
Granted     310       0.54-0.81       0.62  
Reinstated(1)     10       5.04-35.10       8.93  
Exercised     -       -       -  
Cancelled     (50 )     35.10 –58.50       49.39  
Outstanding at December 31, 2011     4,171       0.54-0.81       0.78  
Granted     -       -       -  
Exercised     -       -       -  
Cancelled     -       -       -  
Outstanding at December 31, 2012     4,171       $ 0.54-0.81     $ 0.78  

 

(1) Includes 10 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which had either expired and or were cancelled prior to the agreed severance agreement.
Options reinstated agreement either expired and cancelled prior to the agreed severance
Price in Canadian Dollars     # outstanding and
exercisable at
December 31, 2012		     Weighted average remaining life (years)  
$ 0.54       88       5.26  
$ 0.63       303       5.42  
$ 0.81       3,780       4.64  
TOTAL       4,171       4.70  

 
Currency, U.S. Dollar [Member]
  
Options granted under the stock option plan are exercisable

The following options granted under the stock option plan are exercisable in U.S. dollars:

 

          Exercise Price in U.S. Dollars  
    Number of
Options		     Range     Weighted-
average		  
Outstanding at December 31, 2010     721       $ 1.80 - 24.30     $ 9.90  
Granted     138       0.50-0.63       0.54  
Exercised     -       -       -  
Reinstated(1)     104       $ 5.04-21.60       9.15  
Outstanding at December 31, 2011     963       $ 0.50 - 24.30     $ 8.51  
Granted     1,137       0.15-0.56       0.32  
Exercised     -       -       -  
Cancelled     (773 )     $ 5.04-24.30       9.92  
Outstanding at December 31, 2012     1,327       $ $0.15-11.34       0.67  

 

(1) Includes104 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which were cancelled in error in 2010.
Options reinstated agreement either expired and cancelled prior to the agreed severance
Price in US Dollars     # Outstanding at
December 31, 2012		     # Exercisable at
December 31, 2012		     Remaining life
(years)		  
$ 0.15       33       33       6.62  
$ 0.18       61       61       6.38  
$ 0.20       254       254       6.25  
$ 0.35       689       689       6.89  
$ 0.50       94       94       6.10  
$ 0.56       100       100       6.97  
$ 0.63       45       45       5.64  
$ 1.80       4       4       2.71  
$ 5.04       7       7       1.92  
$ 5.22       2       2       2.41  
$ 7.20       2       2       1.70  
$ 10.26       23       23       1.37  
$ 11.34       13       13       1.33  
          1,327       1,327       6.44  

 
XML 49 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Capital and Operating Lease Commitments
 12 Months Ended
Dec. 31, 2012
Leases [Abstract]  
Capital and Operating Lease Commitments

9.      Capital and Operating Lease Commitments

 

We had no material commitments for capital expenses or commitments extending beyond three years as of December 31, 2012.  The following table represents our contractual obligations and commitments at December 31, 2012 (in thousands of U.S. dollars):

 

    Less than
1 year		     1-3
years		     Total  
OCT Clinical Service Agreement (1)     402       -       402  
Oregon Health & Science University (2), excluding potential royalty payments     -       -       -  
Life Sci Advisors, LLC (3)     55       -       55  
Total   $ 457     $ -     $ 457  

 

(1)

Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia.  The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients.  The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled.
(2) Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million.  Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included.

 

(3) Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of the agreement.  Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.  
XML 50 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Shareholders' Equity
 12 Months Ended
Dec. 31, 2012
Stockholders' Equity [Abstract]  
Shareholders' Equity

7.         Shareholders’ Equity

 

Authorized capital stock

 

The Company’s authorized capital stock consists of an unlimited number of shares of no par common stock.

 

On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “share consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the share shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our 2011 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).

 

Equity financings

 

On June 5, 2001, the Company completed an IPO issuing 74 shares of common stock at a price of CAD$135 per share. Net proceeds of this offering credited to common stock amounted to $5,727 after deducting the underwriting fee of $501 and expenses of $354. As additional compensation in connection with the offering, the Company granted the underwriters non-assignable support warrants representing ten percent of the offered shares. At that time, each support warrant entitled the holder to purchase one share of common stock on or before June 5, 2003 at CAD$7.50.

 

On December 19, 2003, the Company completed a private placement of equity securities totaling $16,095, comprised of (i) $15,050 for 11,522 units, at a price of CAD$1.75 per unit. Each unit consisted of one share of common stock and one-half of a common stock purchase warrant in Adherex with an exercise price of CAD$2.15 per share, which expired unexercised on December 19, 2008 (on a post-consolidation basis, 640 shares of common stock were issued), and (ii) $1,045 for 800 Series 1 Preferred Shares and warrants to purchase 400 Series 1 Preferred Shares of 2037357 Ontario Inc. The $5,777 estimated fair value of the warrants has been allocated to additional paid-in capital and the balance of $8,053 has been credited to common stock. At that time, the non-redeemable Series 1 Preferred Shares of 2037357 Ontario Inc. (“Preferred Shares”) were exchangeable into 800 shares of common stock of Adherex (44 shares of common stock on a post-consolidation basis). Upon such an exchange, all of the then outstanding warrants to purchase the Preferred Shares would be exchanged for an equal number of warrants to purchase Adherex common stock, which warrants expired on December 19, 2008. The $1,045 was to be spent on specific research and development projects in Ontario, Canada as designated by Adherex. Adherex could compel the exchange of the Preferred Shares into common stock and warrants for common stock of Adherex at any time after January 3, 2005. 2037357 Ontario Inc. has been accounted for in accordance with the substance of the transaction. The $1,045 has been recorded as non-redeemable Preferred Shares and the amounts expended were recorded as expenses in the relevant periods. On June 14, 2004, the preferred shares and warrants were exchanged for 44 shares of Adherex common stock on a post-consolidation basis, and warrants to purchase shares of Adherex common stock, all of which warrants expired on December 19, 2008. In June 2004, 2037357 Ontario Inc. became a wholly owned subsidiary of the Company and was amalgamated with Adherex Technologies Inc. The investment has been split between the estimated fair value of the warrants of $363, which has been included in additional paid-in capital, and the remainder of $660, which has been recorded in common stock. On May 20, 2004, the Company completed equity financings with total gross proceeds of $9,029 less $555 of issuance costs and issued4,669 units at a purchase price of CAD$2.65 per unit. Each unit consisted of one share of common stock and one-half of a common stock purchase warrant, and, at that time, each whole warrant entitled the holder to acquire one additional share of common stock at an exercise price of CAD$3.50, all of which expired unexercised on May 19, 2007. The financing resulted in the issuance of an aggregate of 259 shares of common stock on a post-consolidation basis. The $2,118 value of the warrants has been allocated to additional paid-in capital and the balance of $6,356 has been credited to common stock.

 

On July 20, 2005, the Company completed a private placement of equity securities for gross proceeds of $8,510 and issued 6,079 units at a price of $1.40 per unit, providing net proceeds of $8,134 after deducting broker fees and other expenses of $376. At the time, each unit consisted of one common share and 0.30 of a common share purchase warrant and the private placement resulted in the issuance of an aggregate of337 shares of common stock on a post –consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. At that time, each whole investor warrant entitled the holder to acquire one additional share of common stock of Adherex at an exercise price of $1.75 per share for a period of three years and each whole broker warrant entitled the holder to acquire one share of Adherex common stock at an exercise price of $1.75 for a period of two years, all of which expired unexercised on July 20, 2007 and 2008, respectively. The warrants, with a value of $1,074 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $7,060 has been credited to common stock.

 

On May 8, 2006, the Company completed a private placement of equity securities for gross proceeds of $6,512 and issued 7,753 units at a price of $0.84 per unit providing net proceeds of $6,040 after deducting broker fees and certain other expenses. Each unit consisted of one common share and 0.30 of a common share purchase warrant, and the private placement resulted in the issuance of an aggregate of 431 shares of common stock on a post-consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. At that time, each whole investor warrant entitled the holder to acquire one additional share of Adherex common stock at an exercise price of $0.97 per share for a period of four years, and each whole broker warrant entitled the holder to acquire one share of Adherex common stock at an exercise price of $0.97 per share for a period of two years, all of which expired unexercised on May 7, 2008. The warrants, with a value of $822 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $5,218 has been credited to common stock.

 

On February 21, 2007, the Company completed the sale of equity securities providing gross proceeds of $25,000 for 75,759 units at a price of $0.33 per unit providing net proceeds of $23,221 after deducting broker fees and other expenses. Each unit consisted of one common share and one-half of a common share purchase warrant. The offering resulted in the issuance of an aggregate of4,209 shares of common stock on a post-consolidation basis, along with investor warrants and broker warrants to acquire additional shares of Adherex common stock. At that time, each whole investor warrant entitled the holder to acquire one additional share of Adherex common stock at an exercise price of $0.40 per share for a period of three years, and each whole broker warrant entitled the holder to acquire one additional unit at an exercise price of $0.33 per unit for a period of two years, the unexercised portion of which expired on February 21, 2009. The warrants, with a value of $5,379 based on the Black-Scholes option pricing model, have been allocated to additional paid-in-capital and the remaining balance of $17,842 has been included in common stock.

 

During the second quarter of fiscal 2007, the Company received gross proceeds of $694 related to the exercise of warrants and issued 116 shares of common stock on a post-consolidation basis and additional investor warrants, which expired on February 21, 2010. The warrants, with a value of $131 based on the Black-Scholes option pricing model, have been allocated to additional paid-in capital and the remaining balance of $563 has been included in common stock.

 

On April 30, 2010, the Company completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066,664 units, at a price of CAD$0.03 per unit for net proceeds of CAD$7.2 million. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). At that time, each Warrant entitled the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. As a result of the Share Consolidation on August 25, 2011, the number of sharesand warrants issued upon exercise of the units consists of 13,337,037 shares and warrants to purchase 13,337,037 shares of common stock at the exercise price of CAD $1.44 per whole share.

 

Special warrants

 

From May 2000 through November 2000, the Company issued special warrants. At that time, each special warrant was sold for CAD$25.00 and entitled the holder thereof to acquire, for no additional consideration, four shares of common stock of the Company. The special warrants also included a price protection adjustment determined by dividing CAD$32.50 by the initial public offering (“IPO”) price of CAD$7.50.

 

During the year ended June 30, 2000, 16 of 126 special warrants were issued, with the balance of110 issued in the year ended June 30, 2001. Upon completion of the IPO, on June 5, 2001, these special warrants were converted to 30 shares of common stock, which included 2 shares of common stock issued under the price protection adjustment (such shares are presented on a post-consolidation basis).

 

Special A warrants

 

During October 2000, the Company issued Series A special warrants. At that time, each Series A special warrant was sold at CAD$6.25 and entitled the holder to acquire, for no additional consideration, one share of common stock of the Company. At that time, the Series A special warrants also included a price protection adjustment determined by dividing CAD$8.125 by the IPO price.

 

Upon completion of the IPO, on June 5, 2001, these Series A special warrants were converted to 69 shares of common stock, which included 5 shares of common stock issued under the price protection adjustment (such shares are presented on a post-consolidation basis).

 

In addition, each Series A special warrant included a share purchase warrant entitling the holder to purchase an additional share of common stock at the IPO price, which was also subject to the price protection adjustment. These share purchase warrants expired unexercised on September 3, 2001.

 

2010 Private Placement Warrants

 

On April 30, 2010, the Company completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066,664 units, at a price of CAD$0.03 per unit for net proceeds of CAD$7,202. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). At that time, each Warrant entitled the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. As the exercise price is denominated in a currency other than the company’s functional currency, these warrants are treated as a derivative instrument. (Note 5) As a result of the Share Consolidation on August 25, 2011, the number of shares issuable upon the exercise of the warrants issued in connection with the April 2010 Private Placement consists of 13,337,037 shares of common stock at the exercise price of CAD $1.44 per whole share.

 

Equity rights

 

On September 28, 1999, University Medical Discoveries Inc. (“UMDI”) invested $171 for equity of the Company. The form of this equity was to be the same as the first class of securities to raise greater than $683 subsequent to the date of the investment. The date of conversion was dependent on certain milestones being met under a specific research project. On August 24, 2000, the Company and UMDI agreed to convert UMDI’s $171 investment into 3 shares of common stock of the Company.

 

The Company a rights offering to its shareholders on March 2, 2011, the record date for the rights offering (the "Rights Offering"). Pursuant to the terms of the Rights Offering, the Company distributed rights to subscribe for up to 425,000,000 Units at a price of CAD$0.03 per unit, for gross proceeds of up to CAD$12,750,000, to the shareholders on the basis of one right per each share of common stock held by such shareholder on March 2, 2011, the record date for the Rights Offering.  Purchasers of units in the Company's April 2010 Private Placement described above that owned common stock as of the record date for the Rights Offering agreed not to participate in the Rights Offering. Each right was exercisable for one unit which consisted of one common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one common share of the Company at a purchase price of CAD$0.08 per share for a period of five years from the issue date. Adherex filed a short-form prospectus for the Rights Offering with the securities regulatory authorities in Canada to qualify the distribution of the rights in Canada on February 11, 2011 and a Form S-1 registration statement with the Securities and Exchange Commission to register the rights and underlying securities in the United States, which registration statement was declared effective on February 11, 2011. As of 5:00 pm New York City time on March 29, 2011, the expiration date for the Rights Offering, the Company had received subscriptions for an aggregate of 84,559,178 Units, representing estimated aggregate gross proceeds of approximately $2.5 million.

 

Triathlon settlement

 

During fiscal 2000, other advances totaling $175 were settled by the issuance to Triathlon Limited of 16 shares of common stock of the Company. The number of shares issued was determined with reference to the fair value at the time the advances were made.

 

Shire BioChem Inc. agreement

 

On August 17, 2000, the Company entered into a subscription agreement and a license agreement with Shire BioChem Inc. (“BioChem”). Under the subscription agreement, BioChem purchased 5 shares of common stock of the Company for $341. Pursuant to a price protection clause in the agreement, an additional eight shares of common stock were issued on completion of the Company’s IPO on June 5, 2001.

 

Acquisitions

 

On November 20, 2002, the Company issued 446 shares of commons stock to acquire all of the issued and outstanding securities of Oxiquant, a holding company which held certain intellectual property rights, including rights to sodium thiosulfate.

 

In connection with the acquisition of the intellectual property of Oxiquant in November 2002, the Company issued warrants to purchase shares of common stock with an exercise price of CAD$3.585 that expired unexercised on May 20, 2007 and introduction warrants to purchase shares of common stock with an exercise price of CAD$2.05 that expired unexercised on November 20, 2007.

 

As a prerequisite of the Oxiquant transaction, Adherex licensed all of its Cadherin-related intellectual property for non-cancer applications and transferred $158 in cash to Cadherin Biomedical Inc. or CBI, a wholly-owned subsidiary of Adherex at the time, in return for Class A Preferred Shares of CBI. These CBI Class A Preferred Shares were then distributed to all of the Adherex shareholders of record by way of special dividend, effecting a “spin out” of CBI and the non-cancer assets from Adherex.

 

In order to effect such a distribution under Section 42 of the Canada Business Corporations Act (“CBCA”), the Company was legally required to reduce its stated capital so that the aggregate amount of its liabilities and stated capital did not exceed the realizable value of Adherex’s assets. Management determined that the stated capital needed to be reduced by $9,489, in order to comply with the requirements of Section 42 of the CBCA. The Company decreased common stock and increased additional paid-in capital by $9,489.

 

In February 2004, the Company and CBI became involved in litigation. On December 3, 2004, the Company and CBI settled the litigation and the Company agreed to acquire all of the issued and outstanding shares of CBI and reacquire the non-cancer rights to the cadherin-based intellectual property. As part of the agreement, the Company issued 37 common shares valued at $1,252, net of transaction costs.

 

Convertible note warrants

 

On June 23, 2003, the Company issued senior secured convertible notes with a face value totaling $2,219. These notes were convertible into common stock and warrants to acquire common stock of the Company upon completion of an equity fund raising round. At that time, investors also received warrants to purchase shares of common stock of the Company with an exercise price of CAD$2.75 per share that expired unexercised on June 23, 2007. The notes bore interest at an annual rate of eight percent compounded semi-annually, and matured one year from issue but were renewable for one additional year at the option of the Company. In connection with this issuance, at that time, the Company issued broker warrants to purchase shares of common stock exercisable at a price of CAD$2.35 per share, which expired unexercised on June 23, 2005.

 

On December 3, 2003, the Company issued additional senior secured convertible notes with a face value totaling CAD$1,458. These notes were convertible into common stock and warrants to acquire common stock of the Company upon completion of an equity fund raising round. Also, at that time, investors received warrants to purchase shares of common stock exercisable at a price of CAD$2.15 per share which expired unexercised on December 3, 2007.The notes bore interest at an annual rate of eight percent compounded semi-annually, and matured one year from issue but were renewable for one additional year at the option of the Company. At that time, the Company also issued broker warrants to purchase shares of common stock exercisable at a price of CAD$2.15 per share which expired unexercised on December 3, 2005.

 

On December 19, 2003, the Company completed an equity financing resulting in the conversion of the June and the December notes into 156 shares of common stock on a post-consolidation basis with a carrying value of $1,785 credited to common stock. At that time, the Company issued warrants to purchase, shares of common stock with an exercise price of CAD$2.15 per share which expired unexercised on December 19, 2008.

 

Warrants to Purchase Common Stock

 

At December 31, 2012, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years: 

 

Warrant Description
(Warrants in thousands)		   Common Shares Issuable Upon
Exercise of Outstanding
Warrants at December 31, 2012		     Exercise Price in Canadian
Dollars		     Expiration Date
Investor Warrants (1)     13,337     $ 1.44     April 30, 2015
Investor Warrants (2)     4,698     $ 1.44     March 29, 2016
      18,035              

 

(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

 

(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
XML 51 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Research and Development
 12 Months Ended
Dec. 31, 2012
Research and Development [Abstract]  
Research and Development

8.         Research and Development

 

Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows:

 

    Year Ended
December 31,		     Year Ended
December 31,		     Cumulative
FromSeptember 3,1996 to
December 31,		  
    2012     2011     2012  
Research and development   $ 2,075     $ 1,494     $ 69,168  
Investment tax credits     -       -       (1,632 )
National Research Council grants     -       -       (197 )
    $ 2,075     $ 1,494     $ 67,339  

 
XML 52 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2012
Commitments [Abstract]  
Commitments and Contingencies

10.      Commitments and Contingencies

 

Oregon Health & Science University agreement

 

On February 20, 2013, Adherex entered into a new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, a 2.5 percent royalty on net sales for licensed products which can be reduced to 1.0 percent upon a $150,000 buy down and a 5 percent royalty on any consideration received from sublicensing of the licensed technology. Milestone payment fees payable to OHSU include $100,000 upon first commercial sale for any licensed product.

 

On February 20, 2013, Adherex terminated the previous exclusive license agreement with Oregon Health & Science University and Oxiquant a wholly owned subsidiary of Adherex, dated September 26, 2002(the "Previous OHSU Agreement"). Pursuant to the Previous OHSU Agreement, OHSU granted Oxiquant an exclusive worldwide license to intellectual property directed to thiol-based compounds including STS and their use in oncology. In consideration, Oregon Health & Science University was issued 13,902 shares of common stock of Oxiquant that were subsequently converted upon the acquisition of Oxiquant into 21,250 shares of Adherex common stock, and warrants to purchase shares of Adherex common stock that subsequently expired in 2007. In addition under the Previous OHSU Agreement, the following milestone payments were included in the agreement: (i) $50,000 upon completion of Phase I clinical trials, (ii) $200,000 upon completion of Phase II clinical trials, (iii) $500,000 upon completion of Phase III clinical trials. Also, Oxiquant was to be liable for an additional milestone payment of $250,000 upon the first commercial sale for any licensed product. Further, the Previous OHSU Agreement required Adherex to pay Oregon Health & Science University a 2.5% royalty on net sales of any licensed products and a 15% royalty on any consideration received from sublicensing of the licensed technology.

 

The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Adherex, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Adherex or Oregon Health & Science University in the event of a material breach of the agreement by either party after 45 days prior written notice. Adherex has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

 

GlaxoSmithKline

 

On July 14, 2005, Adherex entered into a development and license agreement with GlaxoSmithKline, or GSK. The agreement included the in-license by the Company of GSK’s oncology product, Eniluracil, and an option for GSK to license ADH-1.  As part of the transaction, GSK invested $3.0 million in the Company's common stock. On October 11, 2006, the GSK option to license ADH-1 expired unexercised. Under the terms of the agreement relating to Eniluracil, Adherex received an exclusive license to develop Eniluracil for all indications and GSK retained options to buy-back and assume development of the compound at various points in time.

 

On March 1, 2007, the GSK agreement was amended and the Company purchased all of GSK’s remaining buy-back options for a fee of $1.0 million.  As a result of the amendment to the GSK agreement, Adherex now may be required to pay GSK development and sales milestones and royalties. Specifically, if Adherex files a New Drug Application, or NDA, with the Food and Drug Administration, or FDA, Adherex may be required to pay development milestones of $5.0 million to GSK. Additionally, depending upon whether the NDA is approved by the FDA and whether Eniluracil becomes a commercial success, the Company may be required to pay up to an additional $70.0 million in development and sales milestones for the initially approved indication, plus royalties in the low-double digit range based on annual net sales. If the Company pursues other indications, it may also be required to pay up to an additional $15 million to GSK for each FDA-approved indication. The GSK agreement continues until the earliest of (i) the licensed patents expire or (ii) is terminated by either party in the event of an uncured breach by the breaching party after 60 days prior written notice.
XML 53 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
Derivative Instruments - Additional Information (Details)
 10 Months Ended 12 Months Ended 196 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended
Jun. 23, 1997
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2012
USD ($)
Aug. 25, 2011
May 20, 2007
Jul. 20, 2005
Dec. 31, 2011
Issued In Quarter [Member]
USD ($)
Dec. 31, 2011
Reclassified [Member]
USD ($)
Dec. 31, 2012
Investor warrants expiring April 30, 2015 [Member]
USD ($)
Dec. 31, 2011
Investor warrants expiring April 30, 2015 [Member]
USD ($)
Dec. 31, 2012
Investor warrants expiring April 30, 2015 [Member]
Dec. 31, 2011
Investor warrants expiring April 30, 2015 [Member]
Mar. 31, 2011
Investor warrants expiring March 29, 2016 [Member]
USD ($)
Dec. 31, 2012
Investor warrants expiring March 29, 2016 [Member]
USD ($)
Dec. 31, 2011
Investor warrants expiring March 29, 2016 [Member]
USD ($)
Dec. 31, 2012
Investor warrants expiring March 29, 2016 [Member]
Dec. 31, 2011
Investor warrants expiring March 29, 2016 [Member]
Mar. 31, 2011
Investor warrants expiring March 29, 2016 [Member]
Rights [Member]
USD ($)
Dec. 31, 2012
Rights Offering Derivative [Member]
USD ($)
Dec. 31, 2011
Rights Offering Derivative [Member]
USD ($)
Mar. 02, 2011
Rights Offering Derivative [Member]
USD ($)
Dec. 31, 2011
Rights Offering Derivative [Member]
Canadian Dollar [Member]
Dec. 31, 2012
Options to Contractors [Member]
USD ($)
Dec. 31, 2011
Options to Contractors [Member]
USD ($)
Derivative [Line Items]                                                  
Common shares issuable upon exercise of outstanding warrants   18,035   18,035           13,337 [1] 13,337       4,698 [2] 4,698                  
Warrant exercise price         1.44 2.05 1.75         1.44 [1] 1.44       1.44 [2] 1.44     0.0303   0.03    
Expiration Date                   Apr. 30, 2015         Mar. 29, 2016                    
Fair value of warrants                   $ 4,697,000 $ 3,672,000       $ 1,847,000 $ 1,340,000                  
Gain/(Loss) on Derivative Instruments   (1,563,000) 8,071,000 3,257,000           1,026,000 6,778,000       (507,000) 643,000       0 613,000     0 37,000
Rights offered for each common shares held                                                 108
Weighted average exercise price of warrants                                         0.08        
Derivative financial liability                                           1,250,000      
Issuance of stock (in shares)                           84,559         4,697            
Issuance of units, net of issue costs                           2,566,000                      
Issuance of stock 0                                   1,023,000            
Rights offering, issuance costs                                     300,000            
Derivative, Notional Amount               $ 49,000 $ 53,000                                
[1] (1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement ("Private Placement") of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
[2] (2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
XML 54 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2012
Fair Value Disclosures [Abstract]  
Assets/Liabilities Measured at Fair Value on Recurring Basis

Assets/Liabilities Measured at Fair Value on a Recurring Basis

 

Fair Value Measurement at December 31, 2012

 

    Quoted Pricein Active Markets     Significant Other     Significant        
    for IdenticalInstruments     Observable Inputs     Unobservable Inputs        
    Level 1     Level 2     Level 3     Total  
Assets                                
Cash equivalents   $ -     $ 2,241     $ -     $ 2,241  
Liabilities                                
Derivative liabilities     -       6,640       -       6,640  

 
XML 55 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Going Concern - Additional Information (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 196 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Going Concern [Line Items]      
Disposal Group, Including Discontinued Operation, Operating Income (Loss) $ 3,620    
Net cash used in operating activities 2,994 3,226 85,037
Deficit accumulated during development stage $ 110,543 $ 105,380 $ 110,543
XML 56 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
Capital and Operating Lease Commitments (Contractual Obligations And Commitments) (Details) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2012
Dec. 31, 2011
Total $ 457 $ 457
Otc Clinical Service Agreement [Member]
    
Total 402 [1]  
Database Integration Service Agreement [Member]
    
Total 0 [2]  
Drug Purchase Commitment [Member]
    
Total 55 [3]  
Less than 1 year [Member]
    
Total 457  
Less than 1 year [Member] | Otc Clinical Service Agreement [Member]
    
Total 402 [1]  
Less than 1 year [Member] | Database Integration Service Agreement [Member]
    
Total 0 [2]  
Less than 1 year [Member] | Drug Purchase Commitment [Member]
    
Total 55 [3]  
1-3 years [Member]
    
Total 0  
1-3 years [Member] | Otc Clinical Service Agreement [Member]
    
Total 0 [1]  
1-3 years [Member] | Database Integration Service Agreement [Member]
    
Total 0 [2]  
1-3 years [Member] | Drug Purchase Commitment [Member]
    
Total $ 0 [3]  
[1] (1) Under the service agreement with OCT Group LLC entered in August 2010, the Company is required to make several payments over the course of our Phase II clinical trial in Russia. The payments will be made upon the fulfillment of several milestones during the planned clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients. The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. Further, the Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled.
[2] (2) Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million. Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments, which are contingent on sales, are not included.
[3] (3) Under the service agreement with LifeSci Advisors, LLC, the Company is required to make several payments over the course of the agreement. Life SciAdvisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.
XML 57 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 196 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Operating activities:      
Net (loss)/income $ (5,163) $ 4,685 $ (109,134)
Adjustments for non-cash items:      
Loss/(gain) on derivative warrants 1,563 (8,071) (3,257)
Depreciation and amortization 0 0 1,404
Non-cash Cadherin Biomedical Inc. litigation expense 0 0 1,187
Unrealized foreign exchange (gain)/loss 0 (9) 36
Loss on impairment of capital assets 0 0 386
Amortization of and gain on lease inducements 0 0 (412)
Non-cash severance expense 0 0 168
Stock options issued to consultants 152 121 1,048
Stock options issued to employees 174 129 10,269
Acquired in-process research and development 0 0 13,094
Changes in non-cash working capital 280 (81) 174
Net cash used in operating activities (2,994) (3,226) (85,037)
Investing activities:      
Purchase of capital assets 0 0 (1,440)
Disposal of capital assets 0 0 115
Proceeds from sale of assets 0 0 24
Release of restricted cash 0 0 190
Restricted cash 0 0 (209)
Purchase of short-term investments 0 0 (22,148)
Redemption of short-term investments 0 0 22,791
Investment in Cadherin Biomedical Inc. 0 0 (166)
Acquired intellectual property rights 0 0 (640)
Net cash used in investing activities 0 0 (1,483)
Financing activities:      
Conversion of long-term debt to equity 0 0 68
Long-term debt repayments 0 0 (65)
Capital lease repayments 0 0 (8)
Issuance of common stock 0 2,566 86,443
Registration expense 0 0 (465)
Financing expenses 0 0 (544)
Proceeds from convertible note 0 0 3,017
Other liability repayments 0 0 (87)
Security deposits received 0 0 35
Proceeds from exercise of stock options 0 0 51
Net cash provided from financing activities 0 2,566 88,445
Effect of exchange rate changes on cash and cash equivalents 0 10 378
Net change in cash and cash equivalents (2,994) (650) 2,303
Cash and cash equivalents - Beginning of period 5,297 5,947 0
Cash and cash equivalents - End of period $ 2,303 $ 5,297 $ 2,303
XML 58 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock options
 12 Months Ended
Dec. 31, 2012
Stock Options Abstract  
Stock options

4.        Stock options

 

The Compensation Committee of the Board of Directors administers the Company’s stock option plan.  The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the Stock Option Plan from a fixed number of 20,000 to the number of shares that represent twenty five percent (25%) of the total number of all issued and outstanding shares of common stock from time to time. Based upon the current shares outstanding, a maximum of 6,290 options are authorized for issuance under the plan.  The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years from the date of grant.  The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2012 is below.

 

The following options granted under the stock option plan are exercisable in Canadian dollars:

 

          Exercise Price in Canadian
Dollars		  
    Number of
Options		     Range     Weighted-
average		  
Outstanding at December 31, 2010     3,901       0.63-58.50     $ 1.26  
Granted     310       0.54-0.81       0.62  
Reinstated(1)     10       5.04-35.10       8.93  
Exercised     -       -       -  
Cancelled     (50 )     35.10 –58.50       49.39  
Outstanding at December 31, 2011     4,171       0.54-0.81       0.78  
Granted     -       -       -  
Exercised     -       -       -  
Cancelled     -       -       -  
Outstanding at December 31, 2012     4,171       $ 0.54-0.81     $ 0.78  

 

(1) Includes 10 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which had either expired and or were cancelled prior to the agreed severance agreement.

 

Price in Canadian Dollars     # outstanding and
exercisable at
December 31, 2012		     Weighted average remaining life (years)  
$ 0.54       88       5.26  
$ 0.63       303       5.42  
$ 0.81       3,780       4.64  
TOTAL       4,171       4.70  

 

The following options granted under the stock option plan are exercisable in U.S. dollars:

 

          Exercise Price in U.S. Dollars  
    Number of
Options		     Range     Weighted-
average		  
Outstanding at December 31, 2010     721       $ 1.80 - 24.30     $ 9.90  
Granted     138       0.50-0.63       0.54  
Exercised     -       -       -  
Reinstated(1)     104       $ 5.04-21.60       9.15  
Outstanding at December 31, 2011     963       $ 0.50 - 24.30     $ 8.51  
Granted     1,137       0.15-0.56       0.32  
Exercised     -       -       -  
Cancelled     (773 )     $ 5.04-24.30       9.92  
Outstanding at December 31, 2012     1,327       $ $0.15-11.34       0.67  

 

(1) Includes104 options reinstated to D.Scott Murray per severance agreement on March 8, 2011 which were cancelled in error in 2010.

 

F-14
 

 

Price in US Dollars     # Outstanding at
December 31, 2012		     # Exercisable at
December 31, 2012		     Remaining life
(years)		  
$ 0.15       33       33       6.62  
$ 0.18       61       61       6.38  
$ 0.20       254       254       6.25  
$ 0.35       689       689       6.89  
$ 0.50       94       94       6.10  
$ 0.56       100       100       6.97  
$ 0.63       45       45       5.64  
$ 1.80       4       4       2.71  
$ 5.04       7       7       1.92  
$ 5.22       2       2       2.41  
$ 7.20       2       2       1.70  
$ 10.26       23       23       1.37  
$ 11.34       13       13       1.33  
          1,327       1,327       6.44  

 

Pursuant to employment agreements dated May 3, 2010 between the Company and each of Robert Andrade, Rostislav Raykov and Thomas Spector (collectively Messrs. Andrade, Raykov and Spector) and conditional upon the approval of the amended Stock Option Plan, the Board approved the grant to each, Messrs. Andrade, Raykov and Spector an option to purchase up to 5.0% of Adherex’s common stock estimated by the Company to be outstanding upon completion of the proposed rights offering announced by the Company on April 20, 2010.On August 18, 2010, Messrs. Andrade, Raykov and Spector were each granted 971,885 options and on August 19, 2011 Messrs. Andrade, Raykov and Spector were each granted 51,152 options.

 

Pursuant to Independent Director Agreements dated May 3, 2010 for each of Dr. Porter and Messrs. Breen and Bussandri and conditional upon the approval of the amended Stock Option Plan, the Board approved the grant to each Dr. Porter and Messrs. Breen and Bussandri an option to purchase up to 1.33% of Adherex’s common stock estimated by the Company to be outstanding upon completion of the proposed rights offering announced by the Company on April 20, 2010. On August 18, 2010,each of Dr. Porter and Messrs. Breen and Bussandri were granted 255,759 options and on August 19, 2011,each of Dr. Porter and Messrs. Breen and Bussandri were granted 16,369 options.

 

Effective upon the Continuance, Chris A. Rallis and Steven D. Skolsky were appointed as members of the Board of Directors and Dr. Arthur T. Porter, William G. Breen and Claudio F. Bussandri resigned from the Board of Directors. In addition, each of the new directors has entered into an Independent Director Agreement with the Company, dated as of August 25, 2011, which provides for (i) cash compensation in the form of $ 1,500 per board meeting attended, and (ii) non-cash compensation in the form of a grant of options to purchase shares of the Company’s common stock having an aggregate value equal to $5,000 (with price per share and exercise price based on the value of the Company’s common stock as of the date of grant) per board meeting attended. The options immediately vested when granted and are otherwise subject to the terms and conditions of the Company’s stock option plan, as amended. The Independent Director Agreement also provides for the reimbursement of such director’s reasonable travel and related expenses incurred in the course of attending board meetings.

 

Stock compensation expense for the fiscal years ended December 31, 2012 and 2011 was $326 and $250 respectively.  These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted during the fiscal years ended December 31, 2012 and 2011 was $0.29 and $0.56, respectively. The intrinsic value (being the difference between the share price as at December 31, 2012 and exercise price) of stock options outstanding at December 31, 2012 was NIL.

 

The fair values of options granted in fiscal years ended December 31, 2012 and 2011 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions:

 

    Year Ended
December 31,
2012		     Year Ended
December 31,
2011		  
Expected dividend     0 %     0 %
Risk-free interest rate     1.09-1.26 %     1.85-2.5 %
Expected volatility     118-133 %     121-132 %
Expected life     7 years       7 years  

 

The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price.
XML 59 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Accounting Policies - Additional Information (Details) (USD $)
In Thousands, unless otherwise specified
 1 Months Ended 12 Months Ended 196 Months Ended
Aug. 25, 2011
Aug. 10, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2010
Sep. 02, 1996
Summary Of Significant Accounting Policies [Line Items]              
Reverse stock split ratio 1-for-18 1-for-18          
Cash and cash equivalents - Beginning of period     $ 2,303 $ 5,297 $ 2,303 $ 5,947 $ 0
Derivative liability     6,640 5,077 6,640    
(Loss)/Gain on derivative warrants     $ (1,563) $ 8,071 $ 3,257    
XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 733 253 1 true 136 0 false 8 false false R1.htm 001 - Document - Document and Entity Information Sheet http://adherex.com/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://adherex.com/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://adherex.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 004 - Statement - Consolidated Statements of Operations Sheet http://adherex.com/role/StatementOfIncomeAlternative Consolidated Statements of Operations false false R5.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://adherex.com/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows false false R6.htm 006 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://adherex.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statements of Stockholders' Equity false false R7.htm 007 - Disclosure - Going Concern Sheet http://adherex.com/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock Going Concern false false R8.htm 008 - Disclosure - Significant Accounting Policies Sheet http://adherex.com/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies false false R9.htm 009 - Disclosure - Capital Assets Sheet http://adherex.com/role/CapitalAssets Capital Assets false false R10.htm 010 - Disclosure - Stock options Sheet http://adherex.com/role/StockOptions Stock options false false R11.htm 011 - Disclosure - Derivative Instruments Sheet http://adherex.com/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Derivative Instruments false false R12.htm 012 - Disclosure - Fair Value Measurements Sheet http://adherex.com/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R13.htm 013 - Disclosure - Shareholders' Equity Sheet http://adherex.com/role/ShareholdersEquity Shareholders' Equity false false R14.htm 014 - Disclosure - Research and Development Sheet http://adherex.com/role/ResearchAndDevelopment Research and Development false false R15.htm 015 - Disclosure - Capital and Operating Lease Commitments Sheet http://adherex.com/role/CapitalAndOperatingLeaseCommitments Capital and Operating Lease Commitments false false R16.htm 016 - Disclosure - Commitments and Contingencies Sheet http://adherex.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R17.htm 017 - Disclosure - Income Taxes Sheet http://adherex.com/role/IncomeTaxes Income Taxes false false R18.htm 018 - Disclosure - Significant Accounting Policies (Policies) Sheet http://adherex.com/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Significant Accounting Policies (Policies) false false R19.htm 019 - Disclosure - Stock options (Tables) Sheet http://adherex.com/role/StockOptionsTables Stock options (Tables) false false R20.htm 020 - Disclosure - Derivative Instruments (Tables) Sheet http://adherex.com/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables Derivative Instruments (Tables) false false R21.htm 021 - Disclosure - Fair Value Measurements (Tables) Sheet http://adherex.com/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) false false R22.htm 022 - Disclosure - Shareholders' Equity (Tables) Sheet http://adherex.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) false false R23.htm 023 - Disclosure - Research and Development (Tables) Sheet http://adherex.com/role/ResearchAndDevelopmentTables Research and Development (Tables) false false R24.htm 024 - Disclosure - Capital and Operating Lease Commitments (Tables) Sheet http://adherex.com/role/CapitalAndOperatingLeaseCommitmentsTables Capital and Operating Lease Commitments (Tables) false false R25.htm 025 - Disclosure - Income Taxes (Tables) Sheet http://adherex.com/role/IncomeTaxesTables Income Taxes (Tables) false false R26.htm 026 - Disclosure - Going Concern - Additional Information (Details) Sheet http://adherex.com/role/DisclosureGoingConcernAdditionalInformation Going Concern - Additional Information (Details) false false R27.htm 027 - Disclosure - Significant Accounting Policies - Additional Information (Details) Sheet http://adherex.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformation Significant Accounting Policies - Additional Information (Details) false false R28.htm 028 - Disclosure - Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details) Sheet http://adherex.com/role/StockOptionsOptionsGrantedUnderStockOptionPlanExercisableInCanadianDollarsDetail Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details) false false R29.htm 029 - Disclosure - Stock options (Price In Canadian Dollars) (Details) Sheet http://adherex.com/role/StockOptionsReinstatedToEitherExpiredAndOrWereCancelledPriorToAgreedSeveranceAgreementDetail Stock options (Price In Canadian Dollars) (Details) false false R30.htm 030 - Disclosure - Stock Options (Price In US Dollars) (Details) Sheet http://adherex.com/role/StockOptionsPriceInUsDollarsDetails Stock Options (Price In US Dollars) (Details) false false R31.htm 031 - Disclosure - Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details) Sheet http://adherex.com/role/StockOptionsOptionsWereGrantedBasedOnBlackScholesOptionPricingModelDetail Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details) false false R32.htm 032 - Disclosure - Stock options - Additional Information (Details) Sheet http://adherex.com/role/StockOptionsAdditionalInformationDetail Stock options - Additional Information (Details) false false R33.htm 033 - Disclosure - Derivative Instruments (Gain Loss on Derivative Instruments) (Details) Sheet http://adherex.com/role/DisclosureGainLossOnDerivativeInstruments Derivative Instruments (Gain Loss on Derivative Instruments) (Details) false false R34.htm 034 - Disclosure - Derivative Instruments - Additional Information (Details) Sheet http://adherex.com/role/DisclosureDerivativeInstrumentsAdditionalInformation Derivative Instruments - Additional Information (Details) false false R35.htm 035 - Disclosure - Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) Sheet http://adherex.com/role/DisclosureAssetsLiabilitiesMeasuredAtFairValueOnRecurringBasis Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) false false R36.htm 036 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://adherex.com/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Details) false false R37.htm 037 - Disclosure - Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details) Sheet http://adherex.com/role/DisclosureWarrantsOutstandingToPurchaseCommonStock Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details) false false R38.htm 038 - Disclosure - Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details) Sheet http://adherex.com/role/DisclosureWarrantsOutstandingToPurchaseCommonStockParenthetical Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details) false false R39.htm 039 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://adherex.com/role/ShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) false false R40.htm 040 - Disclosure - Research and Development (Investment Tax Credits Earned) (Details) Sheet http://adherex.com/role/ResearchAndDevelopmentInvestmentTaxCreditsEarnedDetails Research and Development (Investment Tax Credits Earned) (Details) false false R41.htm 041 - Disclosure - Capital and Operating Lease Commitments (Contractual Obligations And Commitments) (Details) Sheet http://adherex.com/role/CapitalAndOperatingLeaseCommitmentsContractualObligationsAndCommitmentsDetails Capital and Operating Lease Commitments (Contractual Obligations And Commitments) (Details) false false R42.htm 042 - Disclosure - Capital and Operating Lease Commitments - Additional Information (Details) Sheet http://adherex.com/role/CapitalAndOperatingLeaseCommitmentsAdditionalInformationDetails Capital and Operating Lease Commitments - Additional Information (Details) false false R43.htm 043 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://adherex.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) false false R44.htm 044 - Disclosure - Income Taxes (Reconciliation Of The Combined Canadian Federal And Provincial Income Tax Rate) (Details) Sheet http://adherex.com/role/IncomeTaxesDetails Income Taxes (Reconciliation Of The Combined Canadian Federal And Provincial Income Tax Rate) (Details) false false R45.htm 045 - Disclosure - Income Taxes (Future Income Taxes (Recovery) (Details) Sheet http://adherex.com/role/IncomeTaxesDetails1 Income Taxes (Future Income Taxes (Recovery) (Details) false false R46.htm 046 - Disclosure - Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) Sheet http://adherex.com/role/IncomeTaxesDetails2 Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) false false R47.htm 047 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://adherex.com/role/IncomeTaxesDetails3 Income Taxes - Additional Information (Details) false false All Reports Book All Reports Element adhxf_ExpectedFutureContractPayments had a mix of decimals attribute values: -5 -3. Element adhxf_MilestonePaymentFees had a mix of decimals attribute values: -5 -3. Element adhxf_PercentageOfTotalNumberOfShareIssuedAndOutstanding had a mix of decimals attribute values: 2 4. Element adhxf_ProceedsFromUnits had a mix of decimals attribute values: -5 -3. Element adhxf_RoyaltyPercent had a mix of decimals attribute values: 3 4. Element us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights had a mix of decimals attribute values: 2 3 4. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate had a mix of decimals attribute values: 3 4. Element us-gaap_SharesOutstanding had a mix of decimals attribute values: -3 0. Element us-gaap_StockIssuedDuringPeriodSharesAcquisitions had a mix of decimals attribute values: -3 0. Element us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities had a mix of decimals attribute values: -3 0. Element us-gaap_StockIssuedDuringPeriodSharesNewIssues had a mix of decimals attribute values: -3 0. Element us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '034 - Disclosure - Derivative Instruments - Additional Information (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '043 - Disclosure - Commitments and Contingencies - Additional Information (Details)' had a mix of different decimal attribute values. Process Flow-Through: 002 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: Removing column 'Dec. 31, 2005' Process Flow-Through: Removing column 'Dec. 31, 2004' Process Flow-Through: Removing column 'Jun. 30, 2004' Process Flow-Through: Removing column 'Jun. 30, 2003' Process Flow-Through: Removing column 'Jun. 30, 2002' Process Flow-Through: Removing column 'Jun. 30, 2001' Process Flow-Through: Removing column 'Jun. 30, 2000' Process Flow-Through: Removing column 'Jun. 30, 1999' Process Flow-Through: Removing column 'Jun. 30, 1998' Process Flow-Through: Removing column 'Jun. 30, 1997' Process Flow-Through: Removing column 'Jun. 23, 1997' Process Flow-Through: Removing column 'Sep. 02, 1996' Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 004 - Statement - Consolidated Statements of Operations Process Flow-Through: Removing column '6 Months Ended Dec. 31, 2004' Process Flow-Through: Removing column '10 Months Ended Jun. 23, 1997' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2006' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2005' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2004' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2003' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2002' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2001' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2000' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 1999' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 1998' Process Flow-Through: 005 - Statement - Consolidated Statements of Cash Flows adhxf-20121231.xml adhxf-20121231.xsd adhxf-20121231_cal.xml adhxf-20121231_def.xml adhxf-20121231_lab.xml adhxf-20121231_pre.xml true true XML 61 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details)
In Thousands, except Share data, unless otherwise specified
 10 Months Ended 1 Months Ended 1 Months Ended
Jun. 23, 1997
USD ($)
Dec. 31, 2012
Aug. 25, 2011
May 20, 2007
Jul. 20, 2005
Apr. 30, 2010
Private Placement [Member]
USD ($)
Apr. 30, 2010
Private Placement [Member]
CAD
Dec. 31, 2011
Private Placement [Member]
Mar. 29, 2011
Non-Broker Rights Offering [Member]
USD ($)
Mar. 29, 2011
Non-Broker Rights Offering [Member]
CAD
Dec. 31, 2011
Non-Broker Rights Offering [Member]
Class of Warrant or Right [Line Items]                      
Issuance of stock $ 0         $ 240,066     $ 84,559    
Issuance of stock, price per share             0.03     0.03  
Proceeds from issuance of unit             7,200   $ 2,547    
Common shares issuable upon exercise of outstanding warrants   18,035           18     18
Warrants, exercise Price     1.44 2.05 1.75     1.44     1.44
Warrants, term           5 years 5 years       5 years
XML 62 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Derivative Instruments (Tables)
 12 Months Ended
Dec. 31, 2012
Derivative Instruments [Abstract]  
Gain Loss on Derivative Instruments
Gain/(Loss) on Derivative Instruments   Twelve months ended December 31, 2012     Twelve months ended December 31, 2011  
Warrant expiring April 15, 2015     (1,026 )     6,778  
Warrant expiring March 29, 2016     (507 )     643  
Rights offering derivative     -       613  
Options to contractors     (30 )     37  
Total     (1,563 )     8,071